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Abstract 
The cyclin dependent kinase inhibitor p27 is one of the most frequently 
dysregulated tumour suppressor protein in human cancers. A reduction in the level 
of cellular p27 is frequently due to increased proteasome-dependent degradation. 
Recently, studies show that the macrocyclic octapeptide argyrin A induced an 
increase in cellular p27 levels by preventing the turnover of the protein via 
inhibition of proteasome function. 
In order to investigate this interesting biological property, this project embarked on 
the total synthesis of argyrin A, a naturally occurring macrocyclic peptide 
originally isolated from myxobacteria Archangium gephyra. Argyrin A is a non-
ribosomal octapeptide containing four standard amino acids and three unusual 
amino acid-based subunits.   
The synthesis of these three unusual amino acid components was established. In 
particular, a novel generic synthetic route to access the optically pure N-Fmoc-4-
methoxy-tryptophan and analogues thereof was developed. Key features of the 
synthetic route include the use of chiral Strecker amino acid synthesis and mild 
conditions to hydrolysHĮ-DPLQRQLWULOHWRĮ-amino acid.  
Furthermore, the total synthesis of argyrin A and analogues was accomplished by 
the application of modern solid-phase chemistry and macrocyclisation strategies. 
This platform technology will enable the robust total chemical synthesis of a 
focused library of argyrin analogues, which will facilitate a comprehensive SAR 
study. 
Additionally, the synthesised argyrin A and analogues thereof comprising unique 
tryptophan analogues were tested in a cytotoxicity assay against HCT-117 human 
colon cell line. The results showed that all synthetic argyrin derivatives display 
growth inhibitory effects at nanomolar concentrations. The best result was obtained 
for the argyrin A and (5-methoxy-Trp4)argyrin with GI50 value at 1.8 and 3.8 nM, 
respectively. In summary, it became apparent that the methoxy group at 4- or 5-
position of tryptophan-5 residue is essential for the biological activity of argyrin.
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MS Mass spectrometry 
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M.W. Microwave irradiation 
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SKP2 S-phase kinase-associated protein 2 
SPPS Solid phase peptide synthesis 
TFA Trifluoroacetic acid 
TFAA Trifluoroacetic acid anhydride 
TGF-ȕ Transforming growth factor-beta 
THF Tetrahydrofuran 
TIPS Triisopropylsilane 
T-L Trypsin-like 
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Chapter 1  
Introduction 
The proteasome is responsible for the degradation of most intracellular proteins, 
including those crucial for the cell cycle regulation and induction of apoptosis. 
With the increasing understanding of the ubiqutin-proteasome pathway, the 
proteasome has become an attractive drug target for anti-cancer therapy. 
Several types of proteasome inhibitors have been developed. Bortezomib (13), 
currently as the first-line treatment of multiple myeloma, has demonstrated the 
clinical value of proteasome inhibition. There are currently five proteasome 
inhibitors in clinical development, belonging to three different structural classes.1  
Apart from those, recent studies have revealed that the cyclic octapeptide argyrin A, 
a secondary metabolite of myxobacteria, can be regarded as a potential alternative 
to bortezomib.2 Its anti-tumour activity is believed to depend on the stabilisation of 
the tumour suppressor p27.3 
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The major goal of this project is the total synthesis of the naturally occurring 
proteasome inhibitor argyrin A and analogues. This chapter outlines the rationales 
for targeting the proteasome in cancer therapy, followed by the literature review on 
the existing proteasome inhibitors.   
1.1 Cyclin-dependent kinase inhibitor p27 
As a cyclin-dependent kinase inhibitors (CKIs), p27 is a broad-spectrum inhibitor 
that binds and inhibits cyclinD-CDK4, cyclinE-CDK2, and cyclinA-CDK2, where 
the former two complexes are important for G1 progression and the latter is 
essential for the S phase (Figure 1-1). The CDK-inhibiting activity of p27 in the 
cell cycle can be explained by two aspects: its concentration and the 
phosphorylation status.4 
1.1.1   Cell cycle 
The cell cycle, also known as cell division cycle, is a process by which one cell 
divides into two daughter cells. In eukaryotic cells, the division frequency and the 
division time vary considerably according to cell types. For example, skin cells 
divide more frequently than liver cells. The latter only divide when damaged cells 
need to be repaired. In addition, specialised cell (e.g. nerve cells and muscle cells) 
cease to divide when the body reaches maturity.5 
The cell cycle consists of two phases, the interphase and the mitosis phase. Prior to 
the cycle, the cells stop dividing or they are at rest, which is called the quiescent 
state (G0). During the interphase, which accounts for ninety percent of the cycle 
duration, the cells grow, duplicate their DNA and accumulate nutrients needed for  
mitosis. Mitosis is a relatively short period of the cycle. During this time, the 
chromosomes separate into two identical sets, followed by division of the nuclei, 
cytoplasm and cell membranes into two identical cells.6  
The interphase can be divided into three distinct phases; the gap phase (G1), 
synthesis phase (S) and the second gap phase (G2) (Figure 1-1). Normally, a cell 
cycle begins with the G1 phase during which the cells increase in size.  Significant 
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biosynthesis of enzymes required for DNA replication also takes place during this 
phase. During the S phase, the chromosomal DNA and centrosome duplication are 
mediated by several enzymes. During the G2 phase, the cell continues to grow and 
prepares microtubules for mitosis.6 
 
Figure 1-1  p27 in cell cycle control. 
1.1.2   Cell cycle regulation 
To ensure a precise cell division, there are several sensoring mechanisms, known 
as the cell cycle checkpoints. There are three checkpoints that ensure genomic 
integrity, namely the G1, G2 and mitotic spindle checkpoi nts.7 They are regulated 
by several types of regulatory proteins cooperatively, such as cyclins, cyclin 
dependent kinases (CDKs) and cyclin dependent kinase inhibitors (CKIs).8 
The cyclins regulate the cell cycle via their cyclical increase and decrease in levels. 
Regulation is mediated by the phosphorylation of the substrates by the functional 
heterodimeric complexes formed by cyclins and CDKs. However, during the G1 
phase, the kinase activity of CDK is usually inactivated by CKI. For example, p27, 
one of the CKIs, can block the active site of cyclinE-CDK2 during the G1 phase. 
Once a cell progresses from the G1 to S phase, p27 is removed from cyclinE-
CDK2, releasing the kinase activity.9 
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The G1 check point, also known as the restriction point, is located at the end of the 
G1 phase to check if the DNA is undamaged.10 In response to DNA damages, the 
G1 checkpoint stops the cell cycle by increasing the level of two CKIs, p27 and 
p21. This inactivates the CDKs and prevents the cell from entering into the S phase.  
When the cell passes the G1 checkpoint, cyclinD-CDK4/6 complexes can 
inactivate the tumour suppressor retinoblastoma protein (Rb) by phosphorylation 
and partially release the transcription factor E2F (Figure 1-2).11 The partially 
released E2F induces the expression of cyclin E which forms a complex with 
CDK2. The cyclinE-CDK2 complex then fully releases E2F by further 
phosphorylation of Rb. The fully released E2F triggers the expression of 
dow nstream cyclins (e.g. cyclin A) and other proteins required for DNA synthesis 
in the S phase.12 
 
Figure 1-2 Regulation of G1 and the G1/S transition. (Adapted from Malumbres et al.)12 
The G2 checkpoi nt at the end of the G2 phase prevents a damaged genome from 
entering mitotic phase. Cyclin B-CDK1 complex is required for G2-M transition. 
In response to the damaged or unrepaired DNA, two kinases Myt1 and Wee1 
phosphorylate cyclin B-CDK1 complex, which results in deactivation of CDK1 
activity. During the mitosis transition, CDK1 is activated by the phosphatase cdc25, 
which then triggers the initiation of mitosis (Figure 1-3).13    
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Figure 1-3 The G2 checkpoint. 
The mitotic spindle checkpoint, the checkpoint at mitosis phase, ensures precise 
chromosome transmission. It stops the cell cycle progression if spindle damage and 
/or unattached kinetochores were present.14 Its signalling cascade is mediated by 
several cell cycle arrest proteins, including Bub3, Mad2, Mad3 and cdc20.15 In 
response to unattached kinetochores, the spindle checkpoint stops the cycle by 
inhibiting the anaphase-promoting complex (APC) of which the APC activator 
cdc20 is further blocked by the interaction of Bub3, Mad2 and Mad3 (Figure 1-4). 
When the last kinetochore is attached to the microtubules of the spindle, Bub3,  
Mad2 and Mad3 dissociate from APC, activating APC-cdc20 for the anaphase. 
 
Figure 1-4 Inhibition of APC-cdc20 complex by combined action of Bub3, Mad2 and Mad3. 
(Adapted from Hardwick et al.)15 
Chapter 1  Introduction 
-6- 
 
1.1.3   Cyclin dependent kinase inhibitors (CKIs) 
The cyclin and CDK themselves do not have kinase activity unless they bind to 
each other by forming non-covalent complexes. Cyclin-CDK complexes are 
essential for regulating and timing the cell cycle progressions from one phase to the 
next. The activation of a cyclin-CDK is a two-step process.16 In the first step, the 
CDK is bound by cyclin with the assistance of the cyclin-binding motif, resulting 
in it an active configuration. In the second step, the CDK is phosphorylated at Thr-
160 by CDK-activating kinase (CAK), which further change the CDK 
conformation that allows cyclin-CDK to bi nd its substrates.17 
The activity of cyclin-CDK complexes can be controlled in several ways. They can 
be directly inhibited by the phosphorylation of their CDK catalytic sites. 
Alternatively, one can control the abundance of cyclin-CDK through the expression 
and de gradation of cyclins since the concentration of CDKs do not fluctuate during 
the cell cycle.18  
Recent studies have found that the activity of cyclin-CDK is also constrained by 
cyclin dependent kinase inhibitors (CKIs), which regulate the cell cycle especially 
during phase transitions. The effectiveness of CKIs are controlled by three ways; 
their concentrations, the distribution of bound- and unbound-CDK complexes and 
their subcellular localisation.19 
In mammalian cells, CKIs are grouped into two families based on their sequence 
alignments and the specificity of cyclin-CDK targets. One family is the inhibitors 
of cyclin-dependent kinase 4 family (INK4) that are named for their specific ability 
to inhibit the catalytic sites of CDK4 and CDK6. The proteins of this family, 
including p15INK4B, MTS2, p16INK4, MTS1, p18INK4c and p19INK4D act as tumour 
suppressor proteins during the G1 phase.20 In particular, they are induced by the 
extracellular anti-proliferative signals such as growth factors (TGF-ȕ DQG
hor mones, and hence block the active subunit of cyclinD-CDK4. The cell cycle 
then arrests at the G1 phase. Interestingly, it has been found that the INK4 tumour 
suppressor protein is mutated in a wide range of human cancers.21 
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The other family of CKIs is the Kip/Cip family, including p27kip1, p21cip1, WAF-1, 
and p57kip2. They are able to bind to and hence inhibit various classes of cyclin-
CDK complexes such as cyclinD-CDK4/6 and cylcinE-CDK2 complexes at the G1 
phase, cyclinA-CDK2 complex at the S phase and cyclinA-CDK1 at the G2 
phase.22-24 Therefore, cyclin-CDK complexes are activated and phase transitions 
can occur when CKIs are effectively removed through the ubiquitin-proteasome 
degradation process. For example, p27 reaches its highest level during the G0 and 
early G1 phase. During late G1 and S phases the level rapidly declines due to its 
degradation by the proteasome.  
Unlike INK4, the genes of those proteins in the Kip/Cip family are rarely mutated, 
but their levels are reduced in many cancer cells due to the over-degradation or the 
relocation from nucleus to the cytoplasm.25 Therefore, one of the possible cancer 
therapies, on which is this thesis focus, is to stabilise Kip/Cip protein levels.  
1.1.4    p27, a multifunctional CKI 
As one of Kip/Cip inhibitors, p27 governs the transition from the G0 to G1 and the 
G1 to S phase. It was discovered in 1994. Thus, the treatment of the mink lung cell 
with the anti-proliferative signal, transforming growth factor (TGF-ȕ, triggered the 
accumulation of p27 and consequently induced cell cycle arrest.22 This indicates 
that it is the extracellular proliferative signals that are responsible for the reduction 
of p27, although the signalling pathway was not elucidated. Moreover, throughout 
the cell cycle, the p27 mRNA level remained constant while the p27 level varied, 
impl ying that the level of p27 is modulated through translational and 
posttranslational regulations. 
Figure 1-5 illustrates the level of p27 during the cell cycle. During the G0 phase 
when the p27 level is high, the activities of CDKs are low. However, during the 
transitions from the G0 to G1 phase and from the G1 to S phase, the p27 level 
decreases and the CDK activity is increased.4  
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Figure 1-5  p27 levels and regulation during G0/G1 to S phase. (Reproduced from Hardwick 
et al.)4 
1.1.4.1  The role of p27 in the G0/G1 transition 
During the G0 to early G1 phase, most p27 binds to the cyclinE-CDK2 complex 
and inhibits its activity. During the G1 phase, the growth factors, such as fibroblast 
growth factors (FGFs), trigger the phosphorylation of p27 at Ser10 by kinases-
interacting stathmin (KIS) or the arginine-directed serine/threonine kinase 
Mirk/DYRK (Figure 1-6 (a)).26, 27 The phosphorylated S10-p27 is recognised by 
the expor tin CRM1 which then targets and interacts with nuclear export signal 
(NES). This enables the dissociation of p27 from the cyclinE-CDK2 and for the 
nuclear exportation. The expor tation begins with the binding of the transport 
protein RanGTP to the expor tin CRM1,  forming a RanGTP-exportin-p27 complex. 
28
 This ternary complex is then transported to cytoplasm through the nuclear pore 
embedded in the nuclear envelope. In the cytoplasm, RanGTP is hydrolysed to 
RanGDP by Ran GTPase activating protein, changing the exportin’s conformation 
to dissociate from p27. 
The monomeric p27 in the cytoplasm has two destinations that depend on the 
concentration of mitogenic signals (Figure 1-6 (b)); In the absence of the signals, 
p27 is directly ubiquitinated by the ubiquitin ligase KPC (kip1 ubiquitylation 
promoting complex).29 This leads to the degradation of p27 by the 26S proteasome 
(see Section 1.2.3 for details). With the presence of the signals, p27 is 
phosphorylated at both T157 and T198 by AGC kinase. This results in the 
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promotion of the assembly the p27-cyclinD-CDK complexes but without activating 
it.30, 31 
 
Figure 1-6  Model of signalling pathway that regulate p27. (Modified from Chu et al.)4 
1.1.4.2   The role of the p27 in the G1/S transition 
The p27-cyclinD-CDK4/6 complex is essential for the cell progressing from the G1 
to S phase (Figure 1-6 (c)).32,33 The assembly process is triggered by extracellular 
mitogen via the Ras-MEK-MAPK signal pathway.34 Generally, the Ras signal 
firstly promotes the expression of cyclin D. p27 then binds to both cyclin D and 
CDK4/6, acting as an assembly factor for cyclinD-CDK4/6. However, the nature of 
this ternary-complex interaction remains unclear.   
In order to activate the cyclinD-CDK4/6, the complex is transported to the nucleus 
and the p27 has to be removed from the active sites of cyclinD-CDK4/6. Studies 
have shown that the phosphorylation of p27 at the key tyrosine residue at position 
88 (Y88) involves two kinases, the Src and Bcr-abl kinase.35, 36 This results in the 
inhibitory domain 310-helix of p27 to be ejected from the ATP-binding pocket of 
CDK4/6 (see Figure 1-7).37 38 
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Figure 1-7  p27 binding to cyclin D-CDK4/6 complexes. (Adapted from Kaldis et al.)38 
To start the importation of p27-cyclinD-CDK4 into the nucleus, the phosphorylated 
residues T157, T198 and S10 of p27 need to be dephosphorylated (Figure 1-6 (c)), 
though the mechanism is poorly understood.39 The p27-cyclinD-CDK4 complex is 
imported to the nucleus during the late G1 phase (Figure 1-6 (d)). Similarly to its 
exportation in the early G1 phase, the p27 complex is recognised by an LPSRUWLQĮ 
and bound to the LPSRUWLQȕ through the nuclear localisation signal region (NLS).40     
Studies have shown that the nucleus p27-cyclinD-CDK4/6 are involved in two 
activities in the G1/S transition (see Figure 1-8).41 The first one is the 
phosphorylation of Rb, which triggers the two-step releasing of E2F after the G1 
checkpoints. This result in the E2F transcription of cyclin E and cyclin A as 
mentioned Section 1.1.2 (see also Figure 1-8 (a)). The second activity involves 
transferring p27 to cyclinE-CDK2 for its degradation (see Figure 1-8 (b)). However, 
the transferring mechanism is less understood.  
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Figure 1-8 Regulation of the G1/S transition. 
As a potent CDK2 inhibitor, the level of p27 in the nucleus needs to be reduced to 
enable the transition from the G1 to S phase. Unlike the  KPC-mediated proteolysis 
in the cytoplasm during the G0 to G1 phase, the degradation of p27  in the nucleus 
during the G1 to S phase is mediated by the SCFSkp2 (see Figure 1-6 (d)).42 
Specifically, SCFSkp2 only function in the nucleus and it requires the 
phosphorylation of the Thr 187 residue of cyclinE-CDK2-bound p27. The latter 
process generates a binding site for the SCF. This E3 ligase polyubiquitinates p27 
and targets it for the further degradation by the 26S proteasome.43 Recently, 
Nguyen et al. have also reported that even in the absence of cyclinE-CDK2, the 
Y88-phosphorylated p27 can still be phosphorylated on the Thr 187 for the SCF 
mediated ubiqutination.44  
1.1.5    p27 and cancer 
Following the above discussions, the tumour suppressor p27 is regarded as a 
possible candidate for chemotherapy development since (1) p27 is not a classic 
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tumour suppressor like p53, as it is rarely mutated or lost at the gene level;45 (2) the 
mislocated p27 can be targeted for translocation back to the nucleus;45, 46 (3) p27 
can be a powerful diagnostic marker since it indicates the involvement of different 
pathways  in the development of tumours.47 
In human tumour cells, it has been observed that p27 levels and its activity are 
decreased because of the anomalous increase in its degradation and cytoplasmic 
mislocalisation.48 Specifically, studies have shown that excessive level of SCFSkp2 
have been observed in human tumours and correlated with a wide range of 
malignancies.49 On the other hand, the p27 in the cytoplasm of colon, ovarian, 
breast and thyroid tumours is suggested to be mislocated from its nuclear cyclin-
CDK targets, though the mechanism is unknown.50, 51 The accelerated proteolysis 
and mislocation lead to the deregulation of its dow nstream substrates, such as 
cyclinE-CDK2 and cyclinD-CDK4, and consequently promote the cell cycle, i.e. 
the tumour cell proliferates.   
The project outlined in this thesis aimed to overcome the over-degradation of p27. 
Typically, it is well known that the ubiqutin-proteasome pathway accounts for the 
degradation of regulatory proteins. Hence the unregulated degradation of p27 is 
believed to be a result of the enhanced SCF-mediated proteasome pathway.  
1.2 The ubiquitin-proteasome pathway 
Cells have robust mechanisms in place to regulate their intracellular protein 
stability and degradation. Two major routes of protein degradation have been 
identified. One is through the endocytosis pathway by lysosomes. This is only 
involved in the degradation of membrane-associated proteins and extracellular 
proteins. The other channel, through which the majority of proteins are degraded, is 
the ubiquitin–proteasome (UP) pathway.52 
The ubiquitin-proteasome (UP) pathway, operating both in nucleus and cytosol, 
can be explained in two sequential steps: (1) A series of ubiquitin molecules are 
attached successively to a target protein via covalent bonding. (2) The proteasome 
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complex then degrades the polyubiquitylated protein and recycles the ubiquitins 
(see Figure 1-9).52 
 
Figure 1-9 Overview of the ubiquitin-proteasome pathway. 
The UP pathway is crucially related to the cell-cycle regulations. For example, the  
degradation of the key short-lived cellular processes such as the synchronised 
degradation of CKIs are mediated through the UP pathway.44 The turnover of a 
broad range of transcription factors that regulate the cell proliferation, VXFKDV,ț%, 
p53 and Bcl-2, have also been shown to be modulated by the UP pathway. 
Therefore, the idea of disrupting the UP pathway can profoundly influences both 
the aetiology and treatment of cancer.53 
1.2.1    The ubiquitin system 
In the UP pathway, the targeted proteins need to be firstly polyubiquitinated. This 
was discovered by Ciechanover, Hershko and Rose, who were awarded the 
Chemistry Nobel prize in 2004.54 Successive ubiquitination occurs through the 
sequential actions of three enzymes (see Figure 1-9). Initially, the ubiquitin-
activating enzyme (E1), consumes one ATP and forms a thioester bond between its 
active site of cysteine and the carboxyl terminal of ubiquitin. Then, the ubiquitin-
conjugating enzyme (E2) takes the ubiquitin with the high-energy thioester from 
E1 and transfers to an ubiquitin-protein ligase protein (E3) which is responsible for 
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determining the substrate specificity. There are two major types of E3:55 the 
unbound HECT-type E3, which will subsequently bind to the target protein, and  
the RING-type E3 which is already bound with the target protein. Both of these 
E3s will facilitate the attachment of the ubiquitin, by forming a covalent peptide 
bond with the Lys residue of the target protein. The iterative actions of E1, E2 and 
E3 finally results in a chain of (usually more than four) ubiquitin moieties. i.e. a 
polyubiquitin, being attached to the target protein. This allows the target protein to 
be recognised and degraded by the proteasome.54 
1.2.2   The proteasome: a proteolytic enzyme 
Proteasomes are highly conserved and compartmentalised protease complexes that 
can be found in the cytoplasm and nucleus of eukaryotic cells.56 The 26S 
proteasome is involved in ubiquitin-mediated protein degradation pathway. 
Specifically, although the X-ray crystallography of the entire 26S proteasome is 
still not available, its three-dimensional image has been generated by the cryo-
electron microscopy.57 As shown in Figure 1-10, the 26S proteasome consists of a 
barrel-shaped 20S protease core particle (720 kDa) and two 19S caps  as regulatory 
particles (890 kDa).58 
 
Figure 1-10 The proteasome multi-enzyme complex. (Reproduced from Adams et al.) 58 
The hollow cylindrical shape of the 20S core particle is comprised of four stacked 
KHSWDPHULF ULQJV WZR LQQHU ULQJV RI ȕ- VXEXQLWV DQG WZR RXWHU ULQJV RI Į-7 
subunits. The two 19S regulatory particles contain two different subunits, the lid 
and the base. The lid firstly controls the access of substrates to the 20S core by 
recognising and cleaving of the polyubiquitin chains. The base then is responsible 
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for unfolding the substrate and opening the tunnel of WKHĮ-ring. This then allows 
the substrates to access into the proteolytic pocket of 20S core.59 
1.2.3    Important proteasome-targeted proteins 
The ubiquitin-proteasome system was first described in 198960 and cyclins were the 
substrates of the proteasome.61 Since then, extensive studies have shown that the 
UP pathway is responsible for degrading intracellular proteins involved in various 
cellular functions such as cell cycle progression, oncogenesis, apoptosis, regulation 
of gene expressions, inflammation and DNA repair (see Table 1-1). The ubiquitin-
proteasome system therefore maintains the hoemeostasis of protein levels for 
molecular signalling and cellular survival. 
Table 1-1 Selected substrates of ubiquitin-proteasome pathway 
Function Substrate 
Cell cycle progression p27Kip1, p21, cyclins 
Oncogenesis p53, p27Kip1, bax, Iț% 
Apoptosis Bcl-2, cIAP, XIAP 
Regulation of gene expression c-Jun, E2F1, Iț%ȕ-catenin 
Inflammation Iț%, p105 precursor of NF-ț% 
  
(1) Cell cycle progression 
The proteasome-mediated proteolysis of cell-cycle regulatory proteins functions as 
a major regulatory mechanism for the cell cycle progression. Cyclins A, B, D and 
E,62 cyclin-dependent kinase inhibitor p27 (as described in Chapter 1.1.4) and p21, 
transcription factor E2F, Rb and the tumour suppressor p53 have all been show n as 
the substrates for the UP pathway.63 Inhibiting their degradation processes can 
sensitise the cell to apoptosis.64 
(2) Iț% 
The nuclear factor ț% inhibitor (Iț%) is also a substrate for the UP pathway.65 Its 
substrate, the nuclear factor ț%(NF-ț%), is a transcription factor that regulates the 
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expression of numerous genes involved in immune response, cellular proliferation, 
apoptosis and cell migration.66  
Specifically, NF-ț% is inactivated and sequestered in the cytoplasm by Iț% during 
the resting state. The presence of stimuli such as reactive oxygen species (ROS) 
and tumour necrosis IDFWRU DOSKD 71)Į, can activate NF-ț% through the 
phosphorylation, ubiquitylation and subsequent proteasomal degradation of Iț%. 
The activated NF-ț% is then transpor ted into the nucleus to bind to the specific 
sequences in the promoter regions of the target genes. This results in an increased 
expression of the genes including the anti-apoptotic genes (Bcl-2, IAP), cell-
proliferated genes (interleukins)  and angiogenesis genes.67 
The growth-promoting and anti-apoptotic property of NF-ț% PDNHV it a target for  
cancer chemotherapy. Since the UP pathway is responsible for the Iț% degradation, 
perturbing the proteasomal activity may help stabilise the levels of Iț% and 
consequently inhibits the transcriptional activity of NF-ț%.  
1.2.4   The ubiquitin proteasome pathway in cancer 
The proteasomal degradation of tumour suppressor and pro-apoptotic proteins are 
found to be deregulated in many human malignancies.68, 69 Table 1-2 shows the 
examples of the UP pathway dysregulation for some important proteins.  
Table 1-2  The UP pathway in cancer  
Substrate Proteolysis 
degradation 
Functional effect Biological effect Tumour type 
p27 increased p27 inactivation tumour 
progression 
lung, colon, prostate, 
ovary, colorectal 
carcinomas,70 breast 
cancer
71
 
p53 increased p53 inactivation transformation ovarian,72 gastric cancer68 
Cyclin D, 
B1 and E 
decreased Cyclin D, B and 
E over-expression 
tumour 
progression 
many common tumours73, 
74
 
,ț% increased increasing the 
NF-ț%DFWLYDWLRQ 
resistance to TNF-
ĮNLOOLQJ 
lung cancer75 
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As mentioned before, the deregulation of p27 is believed to occur at the post-
tranlational stage. It has been found that the oncogenic signals can accelerate the 
activation of several protein kinases that ubiquitinate p27, resulting in the p27 
proteolysis.76, 77 It is worth noting that although p21 belongs to the same family of 
CKI, i t is mostly regulated at the transcriptional level.  
Another tumour suppressor, p53, regulates the surveillance of DNA damage, 
cellular stress and deregulated oncogenic expression. In tumour cells, p53 tends to 
be excessively ubiquitinated, because it is targeted by an over-expressed oncogenic 
E3 ligase, murine double minute 2 (Mdm2). This results in the proteasomal 
degradation of p53.78 Cyclin B1, D1 and E are frequently over-expressed in many 
common tumours. Study have shown that this results from the reduced proteasomal 
degradation.79  
Finally, cancer cells require high levels of the NF-ț% to suppress apoptosis and 
express the genes involved in tumour metastasis and angiogenesis. The increased 
levels is attributed to an increased phosphorylation and degradation of Iț%.80 
1.2.5   Targeting the proteasome for cancer therapy 
As a promising cancer therapy, the UP pathway is difficult to target due to a lack of 
specificity. Nevertheless, recent experiments have demonstrated that many types of 
proliferating malignant cells are more susceptible to the UP pathway inhibition 
than the normal cells.81-83 Most malignant cells exploit the UP pa thway to promote 
proliferation and to suppress the apoptotic pathway. The excessive demand for 
protein synthesis makes those highly proliferative cells vulnerable to the UP 
pathway inhibition.   
Targeting specific enzymes involved in the UP pathway makes it possible to 
control specific proteins turnover and the resulting cellular responses. Those target 
enzymes can be categorised into three groups, based on the sequential steps of the 
UP pathway: (1) kinases activity, (2) ubiquitination system and (3) proteasome 
activities. 
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It has been known that many proteins need to be phosphorylated before they enter 
the ubiquitin proteasome pathway. These phosphorylations at the serine or 
threonine residues of the substrates form the binding sites for the ubiquitin ligases 
of which the F-box domains can promote the ubiquitination.84 Accordingly, 
targeting those kinases involved in the phosphorylation could mod ulate the 
degradation of specific proteins, such as p27, p53 and Iț% and leave others 
unaltered. However, studies have also shown that disrupting this kinase activity can 
also stimulate their degradations by ER stress.85 
Developing inhibitors of ubiquitination enzymes can be another way for  
pharmacological interventions since the ubiquitin proteasome pathway is initiated 
by ubiquitination. The ubiqutin ligation enzymes E2 and E3 and deubiquitylation 
enzymes (DUBs) are of particular focus.86 The specificity of E3s to their 
downstream substrates enables their corresponding inhibitors to selectively perturb 
ubiquitination and hence degradation process. These inhibitors can be selectively 
designed to target their phosphorylation recognition sites, the protein-protein 
interaction site, E2-E3 interaction site and the ligation active site. Figure 1-11 (a) 
lists some small-molecule inhibitors of ubiquitin ligases. 
 
Figure 1-11 Small-molecule inhibitors of UP pathway. (a) Ubiquitin ligases, E2 and E3.  
(b) DUBs. (Adapted from Edelmann et al.)86 
On the other hand, DUBs that are ubiquitin-specific can trim the corresponding 
ubiquitin from the tagged substrates. Accordingly, their inhibitors are developed to 
promote degradations of tumourigenic proteins such as cyclins from 
deubiquitylation.87 The two best-characterised DUBs are ubiquitin-specific 
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proteases (USPs) and ubiquitin C-terminal hydroylases (UCHs). The design of 
these inhibitors have been challenging because of the structural similarities of  
DUBs and the complexity of protein-protein interactions.88 In addition, depleting 
the ubiquitin pool is another side effect.86 Therefore, clinical use of DUB inhibitors 
requires further investigations. Figure 1-11 (b) lists some small-molecule inhibitors 
of DUBs.  
The last step of the UP pathway is the proteolytic degradation by 26S proteasome. 
The 26S proteasome is currently the mos t promising target in the drug development 
and its protein degradation function has been extensively studied in the past 15 
years.  
1.2.6   Active sites of 20S proteasome 
As mentioned in Section 1.2.2, the 20S proteasome subunit is responsible for 
proteolytic activities. The 20S core consists of four heptameric rings. The outer 
rings are composed of VHYHQGLIIHUHQWĮVXEXQLWV Į1-Į7, while the inner rings are 
FRPSRVHG RI VHYHQ GLIIHUHQW ȕ VXEXQLWV ȕ1-ȕ7.89 These four rings form three 
continuous proteolytic active sites in the middle (Figure 1-12).90 The one near the 
ȕ5 subunits, called the “chymotrypsin-like” (CT-L) pocket, cleaves after the C-
terminal of hydrophobic residues. The one near the ȕ2 subunits is called the 
“trypsin-like” (T-L) pocket that cleaves after basic residues. The active site near the 
ȕ1 subunits cleaves after acidic residues is called the “caspase-like” (C-L) pocket.  
 
Figure 1-12  Active sites of eukaryotic 20S proteasome. 
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The three pockets jointly exhibit the overall proteolytic activity of 20S proteasome. 
Unlike other cellular proteases that utilise an internal residue to cleave amide bonds, 
studies have revealed that the proteasome utilises the side chain of the amino-
terminal threonine RIWKHȕ-subunits as the catalytic nucleophile.91, 92 
The proteolytic mechanism of proteasome was initially understood by utilising 
protease inhibitors. Peptide aldehydes are well-characterised inhibitors on the 
hydroxyl groups of serine for proteases. By applying them to the proteasome, the 
X-ray diffraction studies showed similar inhibiting functions. The hemiacetal bond 
formed with the N-terminal threonine RIȕ-subunits of the proteasome resembles its 
transition state of the proteolytic reaction.98 Furthermore, the three N-terminal 
threonines of each of the subunits were proven as the active sites of the 
proteasome.93 Thus, development of proteasome inhibitors that can impede activity 
of proteasome makes them feasible candidates for therapeutic intervention.   
1.3 Proteasome inhibitors 
Initially, proteasome inhibitors were used only as biological research tools due to 
their high toxicity.94 Later, several studies showed that proliferating malignant cells 
are more susceptible to proteasome blockade than normal cells when treated with  
proteasome inhibitors PSI (4), LLnV81 and lactacystin (20).95 Other studies  
targeting the proteasome by using small molecule inhibitors resulted in positive 
therapeutic outcomes in 60 different cancer cell lines.96 Moreover, no mutations of 
proteasomes in malignancies have been found as cancer cells are shown to utilise 
this system.97 In 2003, bortezomib, the first proteasome inhibitor drug was 
approved by FDA for treatment of multiple myeloma. This opens a new window 
for cancer therapeutics and a series of proteasome inhibitors are being developed.  
In general, developing proteasome inhibitors is aimed to stabilise several 
dysreguated proteins, triggering further signal pathway to suppress cell 
proliferation.98, 99 Many types of synthetic as well as naturally occurring 
proteasome inhibitors have been developed for clinical and preclinical use.      
Chapter 1  Introduction 
-21- 
 
1.3.1    Cell death mechanisms induced by proteasome inhibitors 
Several pathways have been proposed to explain the antitumor activity of 
proteasome inhibitors for different types of cancers. Most of them serve to stabilise  
proapoptoic regulatory proteins.100 Figure 1-13 illustrates some know n mechanisms.  
 
Figure 1-13 Mechanisms of induction of apoptosis by proteasome inhibitors 
There are two most prevailent pathways for the proteasome inhibition induced 
apoptosis: (1) The accumulation of both tumour suppressor proteins (p27, p53), and 
cell death signal proteins (Bcl-2), and (2) the inhibition of survival signals (NF-ț%).  
As discussed in Section 1.1.5, the tumour suppressor proteins are over-degraded in 
many cancer cells. When proteasome inhibitors are used and hence the UP pathway 
is perturbed, the cancer cells are observed to undergo apoptosis predominately in 
the G1 phase.99 Proteasome inhibitions are found helpful to stabilise and 
accumulate p53 and p27.100 The stabilisation of p53 enabled cell cycle arrest in the 
G1-phase and promotes the cell apoptosis by inducting the pro-apoptotic protein 
called Bcl-2 gene family bax. The stabilisation of p27 has also been shown to result 
in cell apoptosis, though this mechanism is still unclear. Moreover, as a substrate of 
the proteasome, the pro-apoptosis factors, like Bax and Noxa, can also be 
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accumulated by proteasome inhibition. This also increases their relative level to 
anti-apoptotic Bcl-2 proteins, which help cell apoptosis. To sum up, proteasome 
inhibitors cause the stabilisation of p27, p53 and Bax levels, which leads to the cell 
cycle arrest and eventually the cancer cell apoptosis.  
Another impor tant pathway is to inhibit the transcriptional activity of NF-ț% by 
stabilising the level of Iț%see Section 1.2.3). Both in vitro and in vivo studies of 
proteasome inhibitors have shown that the growth arrest and apoptosis of 
pancreatic and colorectal cancer cell lines are NF-ț% GHSHQGHQW101, 102  Tumour 
metastasis and angiogenesis are suppressed because of the reduced gene 
expressions for the growth factors, adhesion molecules, anti-apoptosis and 
angiogenesis signals  
Clearly, several apoptotic pathways are induced by proteasome inhibitors. However, 
having wide range of effects on cells also makes it difficult to identify one specific 
pathway responsible for their antitumor activities. Hence, the specificity and exact 
mechanism of action of each proteasome inhibitors are still open for further 
exploration. 
1.3.2    Design of proteasome inhibitors 
As show n in Figure 1-10, proteasome consists of a 20S core particle and two 19S 
regulatory caps. Based on X-ray crystallography, the crystal structure of the 
eukaryotic 20S subunit has been elucidated. Most proteasome inhibitors are 
designed to reversibly or irreversibly block the 20S active sites.103  On the contrary, 
the mechanism of recognition, unfolding and translocation of substrates by the 19S 
are still poorly understood. 
To measure the potency of  20S proteasome inhibitors, specific fluorogenic peptide 
substrates can be designed and introduced to target on particular active sites of the 
proteasome.104 These engineered substrates penetrate cell membranes and are 
rapidly hydrolysed by the corresponding active sites. Specifically, these substrates 
are short peptides incorporating a fluorogenic group at the C-terminal, which can 
be selectively cleaved in the active pockets of the proteasome and release a highly 
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fluorogenic product. Thus, measuring the intensity of the resulting fluorescence 
enables quantitative evaluation of the proteasomal activity.   
Studies found that the chymotrypsin-like (CT-L) pockets of the 20S proteasome are 
more sensitive to most inhibitors than the other two.105, 106  In the following 
sections, eight major classes of proteasome inhibitors and their inhibitory 
mechanism are discussed.  
1.3.3   Major classes of proteasome inhibitors 
Based on the chemical structure of the pharmacophores, eight major classes of 
proteasome inhibitors have been identified: peptide aldehyde, peptide vinyl 
sulfones, peptide epoxyketones, ȕ-lactones, macrocyclic vinyl ketones, flavonoids, 
peptide boronates and cyclic peptides. The former six classes are covalent 
inhibitors, and the later two classes are non-covalent inhibitors. In general, the 
reversible non-covalent inhibitors are pharmacological preferred due to their 
greater specificity and stability. 
Table 1-3 summarises the inhibitory activities of various proteasome inhibitors. 
Activities are reported for the three proteolytic sites of proteasome, the CT-L, T-L 
and C-L pockets. Lower values of Ki, IC50 or higher Kobs/[I]  indicate higher 
effectiveness of a compound in inhibiting proteolytic functions. It is worth noting 
that inter-study comparison of inhibitor potency may not be appropriate since each 
study may differ in cell lines, assays, protocols or experimental conditions. The 
detailed inhibitory properties and their mechanisms are discussed in the following 
sections. 
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Table 1-3 Difference classes of proteasome inhibitors and their selective representatives107 
Cl
as
s 
Compounds Origin 
Inhibition of 20S active sites a 
Ki ȝ0RU IC50 ȝ0RU.obs/[I] (M-1 s-1)  20S source 
CT-L T-L C-L 
Pe
pt
id
e a
ld
eh
yd
e 
Leupetin (1) 
 
Natural 
product 
- Ki = 1.2 - Bovine 
pituitary 
Calpain inhibitor 
I (2) 
Synthetic Ki = 5.7 Ki = 50 IC50 = 205 Bovine 
pituitary 
IC50 = 6.6 IC50 = 6 IC50 = 21 Human 
leukemia 
Calpain inhibitor 
II (3) 
Synthetic Ki = 33 Ki = 186 IC50 = 280 Bovine 
pituitary 
PSI (4) Synthetic IC50 = 0.25 - - Bovine 
pituitary 
MG132 (5) Synthetic IC50 = 0.024 IC50 = 9.215 IC50 = 
2.288 
Human red 
blood 
Tyropeptin  Natural 
product 
IC50 = 0.14 IC50 = 5 IC50 = 68 Human HL60 
TP-110 (7) Synthetic IC50 = 0.027 IC50 > 100 IC50 > 100 Human HL60 
Fellutamide B 
(6) 
Natural 
product 
IC50 = 0.0094 IC50 = 2 IC50 = 1.2 mammalian 
Pe
pt
id
e 
v
in
yl
 
su
lfo
n
es
 
ZLVS (11) Synthetic Kobs/[I] = 29 Kobs/[I] = 8 Kobs/[I] = 
5 
Human 
U373MG 
NLVS (10) Synthetic Kobs/[I] = 6790 Kobs/[I] = 5.3 Kobs/[I] = 
6.4 
Bovine red 
blood 
Kobs/[I] = 5000 Kobs/[I] = 3.4 Kobs/[I] = 
4 
Bovine 
reticulocyte 
Pe
pt
id
e 
bo
ro
n
at
es
 
MG262 (12) Synthetic Ki = 0.00003  - - Rabbit muscle 
P341 
(Bortezomib) 
(13) 
Synthetic Ki = 0.62 - - Rabbit muscle 
IC50 = 0.0038 - - Human red 
blood 
MLN9708 (14) Synthetic IC50 = 0.0034 IC50 = 3.5 IC50 = 
0.031 
 
CEP-18770 (15) Synthetic IC50 = 0.0038 - - Human red 
blood 
Pe
pt
id
e 
ep
ox
yk
et
o
n
es
 Epoxomicin (16) Natural 
product 
Kobs/[I] = 
10000 
Kobs/[I] = 80 Kobs/[I] = 
21 
Rabbit muscle 
Ki = 0.007 Ki = 0.35 Ki = 2.6 Bovine red 
blood 
Carfilzomib (18) Synthetic Kinact/Ki =  
33000 b 
Kinact/Ki < 
100 
Kinact/Ki < 
100 
Human red 
blood 
ȕ-l
a
ct
o
ne
s 
Latacystin (20) Natural 
product 
Kobs/[I] = 1500 Kobs/[I] = 110 Kobs/[I] = 
17 
Rabbit muscle 
IC50 = 0.259 - - Human red 
blood 
Omuralide (21) Natural 
product 
Kobs/[I] = 8530 Kobs/[I] = 253 Kobs/[I] = 
37  
Bovine red 
blood 
Salinosporamide 
A (22) 
Natural 
product 
IC50 = 0.0035 IC50 = 0.028 IC50 = 
0.43 
Human red 
blood 
Antiprotealide 
(24) 
Natural 
product 
IC50 = 0.038 - - yeast 
Cinnabaramide 
A (25) 
Natural 
product 
IC50 = 0.001 - - Human red 
blood 
Belactosin A 
(23) 
Natural 
product 
IC50 = 0.21 - - Rabbit 
IC50 = 0.82 IC50 = 4.9 IC50 =2 Human red 
blood 
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Table 1-3 Continued 
Cl
aa
ss
 Compounds Origin 
 
Inhibition of 20S active sites a 
Ki ȝ0RU,&50 ȝ0RU.obs/[I] (M-1 s-1) 
20S source 
CT-L T-L C-L 
Sy
rb
ac
tin
s Syringolin A 
(26) 
Natural 
product 
Kobs/[I] = 863 Kobs/[I] = 94 Kobs/[I] = 
6 
Human red 
blood 
Glidobactin A 
(27) 
Natural 
product 
Kobs/[I] = 3377 Kobs/[I] = 141 - Human red 
blood 
Fl
av
o
no
id
s EGCG (28) Natural 
product 
IC50 = 0.68 - - Rabbit 
Genistein (29) Natural 
product 
IC50 = 26 - - Rabbit 
Cy
cl
ic
 P
ep
tid
es
 TMC-95A (30) Natural 
product 
IC50 = 0.0054 IC50 = 0.2 IC50 = 
0.06 
Human 
leukemia 
Ki = 0.0011 Ki = 0.043 Ki = 0.65 yeast 
Linear TMC-
95A (31) 
Synthetic Ki = 0.85 Ki >> 100 Ki = 0.98 Rabbit 
reticulocyte 
Argyrin A (32) Natural 
product 
Ki = 0.076 Ki = 0.112 Ki = 
0.081 
Human red 
blood 
a
 Ki (Inhibition constant) is the binding affinity of the proteasome inhibitors,  IC50 value is the 50 % 
inhibitory concentration of the proteasome inhibitors, Kobs (Observed rate of proteasome inhibition) 
/[I] (Inhibitor concentration) is the second-order rate constant. b Kinact (the rate constant of 
proteasome inactivation )/Ki (Inhibition constant between proteasome and inhibitors ) is equivalent 
to the second-order rate constant Kobs/[I]. 
1.3.3.1     Peptide aldehydes 
Peptide aldehydes are the earliest developed proteasome inhibitors, inspired by the 
observation that the natural compound leupetin (1) has inhibitory effects on the T-L 
activity of the proteasome.108 Calpain inhibitor I (2) and calpain inhibitor II (3) 
were first synthesised and shown to inhibit the CT-L pocket.109 Since then, many 
aldehyde-based molecules with higher potency and selectivity, such as PSI (4) and 
MG132 (5) have been developed. Two naturally occurring molecules, fellutamide 
B (6) and tyropetin A analogy (TP110) (7) that were recently identified in this class 
have been shown to potently inhibit the CT-L activity with IC50 values below 100 
nM.110, 111 
The inhibitory mechanism of peptide aldehydes relies on the formation of a 
reversible hemiacetal adduct. Specifically, the aldehyde covalently binds to the 
hydroxyl group of the Thr1 LQ WKHȕVXEXQLWVRIWKH6proteasome (Figure 1-14), 
resulting in the proteasome inhibition. However, due to the instability of its 
functional group and its insufficient specificity to the proteasome, peptide aldehyde 
is less considered as a potential therapeutic.  
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Figure 1-14 Mechanism of proteasome inhibition by peptide aldehyde. 
1.3.3.2     Peptide vinyl sulfones 
To address the limitations of the peptide aldehydes, non-aldehyde peptide 
proteasome inhibitors were synthesised. Examples include peptide benzamide 
(8),112 SHSWLGHĮ-ketoamide (9)113 and peptide vinyl sulfones. ZLVS (Z-Leu3-VS) 
(11), a vinyl sulfone analogue of MG132 (5), is a synthetic irreversible proteasome 
inhibitor firstly reported in 1997.114 Its inhibition mechanism is via the formation of 
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an irreversible ether bond, i.e. the hydroxyl group of the Thr1 covalently adds to 
the vinyl group via a Michael addition pathway (Figure 1-15).  
Several radioiodine-coordinated vinyl sulfones have been described to label 
proteasome since this class of inhibitors are relatively easy to synthesise.115 Their 
irreversible binding specificity WR WKHȕ-subunits of proteasome makes them ideal 
proteasome probes. Specifically, the incubation of radio-iodinated inhibitors with 
cellular extracts leads to their covalent binding with ȕ-subunits of proteasomes. 
The resulting radio-labelled proteasome can be isolated and visualised in two-
dimensional isoelectric focusing SDS/PAGE.114 For example, NLVS (10) which is 
modified from ZLVS (11) is widely used as a proteasome probe. However, the low 
potency of these inhibitors is a major limitation to be considered as potential 
therapeutic drug.  
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Figure 1-15 Mechanism of proteasome inhibition by peptide vinyl sulfones. 
1.3.3.3     Peptide boronates 
Various aldehyde replacements were examined in attempt to enhance the inhibitory 
activity. The breakthrough was achieved by the replacement of an aldehyde with a 
boronic acid, forming the peptide boronates.116  It had been well documented that 
peptidyl boronic acid is a potent serine protease inhibitor before it was applied to 
proteasome.117 The availability of an empty p-orbital on a boron atom is 
appropriate to accept the lone pair from the oxygen in serine. Accordingly, the 
formation of the stable tetrahedral borane complex with the Thr1 of proteasome 
was anticipated to increase the binding affinity. With a boron-derived modification, 
MG262 (12) was proved to be more than a 100-fold more potent than its parent 
compound MG132 (5).116 Further structure simplifications of MG262 (12) gave  
rise to the nanomolar dipeptide boronic acid proteasome inhibitor PS341 (13).  
PS341 (Bortezomib or Velcade®) is the first and has been so far the only 
proteasome inhibitor in clinical use. Its mechanism relies on the property that a 
peptide boronate is able to form a reversible non-covalent tetrahedral complex. 
Specifically, an X-ray di ffraction study showed that the boronate group forms a 
tetrahedral adduct with the K\GUR[\OJURXSRIWKH7KU LQWKHȕVXEXQLWVFigure 1-
16). The stable tetrahedral borane complex effectively slows the dissociation rate 
of the boronate-proteasome adduct and yields a low Ki value.118 Studies on the 
mode of action also showed that the peptide boronate exhibits a very high 
selectivity to proteasome over many common serine proteases. Moreover, 
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bortezomib, at therapeutic concentrations, was demonstrated to bind exclusively to 
ȕDQGȕRIthe S20 subunit, i.e. it mainly inhibits the CT-L and C-L activities.119   
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Figure 1-16 Mechanism of proteasome inhibition by peptide boronates. 
Bortezomib initially was approved for the treatment of multiple myeloma (MM) 
and mantle lymphoma. Later, studies showed that it also has significant antitumour 
activities against various other malignancies, such as breast, brain, colorectal, lung, 
ovarian and pancreatic cancers.58 Several preclinical studies on bortezomib showed 
that it can induce apoptosis in tumour cells via the NF-ț% pathway58 and the 
endoplasmic reticulum (ER) stress response pathway.120As described in Section 
1.2.3, inhibiting the former pathway by stabilising the Iț% reduces the expressions 
of growth-promoting and anti-apoptotic genes. On the other hand, the protein 
aggregation raised by proteasome inhibition can disrupt protein folding in the ER, 
triggering a stress signal pathway known as unfolded protein response pathway 
(UPR). The activation of UPR induces the cell cycle arrest and eventually 
apoptosis.121 Since proteasome inhibition by bortezomib can trigger various cell 
death mechanisms, the effective pathways on different types of cancers still need 
further clarification.  
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The adverse-effects122 and the emergence of drug resistance123 motivated the 
development of second-generation peptide boronates. MLN2238 (14)124 and CEP-
18770 (15)125 are the two successful examples under clinical trials for the treatment 
of MM. Similarly to bortezomib (13), MLN2238 and CEP18870 interact with the 
CT-L and C-L active sites. Although the two new generation boronates exhibit less 
potency than bortezomib, they have significantly lower toxicities. Moreover, 
MLN2238 and CEP18870 are orally bio-available when they are formulated as a 
boronic ester pro-drug.126  
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1.3.3.4     Peptide epoxyketones 
The class of peptide epoxyketones as proteasome inhibitors were identified from 
microbial antitumour activity screens in the late 1990s.127 Two natural products, 
epoxomycin (16) and eponemycin (17) were found to irreversibly bind the CT-L 
active site of the proteasome. Apart from the high selectivity, this specificity is the 
unique feature of peptide epoxyketone inhibitors due to its distinctive inhibition 
mechanism.128  
As revealed by the epoxomycin co-crystallisation with the yeast 20S proteasome, 
the epoxomycin forms a six-membered morpholino ring (19) with the Thr1 of the 
20S proteasome (Figure 1-17). This is achieved by a two-step reaction. Firstly, the 
carbonyl group of the epoxyketone is nucleophilically attacked by the hydroxyl 
group of the Thr1, forming a hemiacetal, similarly to the mechanism for peptide 
aldehyde. Then, the free amine of the Thr1 N-terminal attacks the epoxide ring to 
afford the morpholino adduct (Figure 1-17). Consequently, the participation of both 
WKH ȕ-hydroxyl DQG Į-amino groups of the Thr1 residue results in high binding 
affinity. 
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Figure 1-17 Mechanism of proteasome inhibition by peptide epoxyketones. 
By utilising the specificity of the epoxyketones, hundreds of peptide epoxyketone 
analogues have been synthesised. A large proportion of them are developed as site-
selective proteasome probes.129 In comparison with the clinically-used bortezomib, 
carfilzomib (18) exhibited higher potency of inhibiting the CT-L proteolytic 
activity in phase I trials in patients with the chronic hematologic malignancies.130 
In phase II trials, carfilzomib has achieved an extraordinary 24 % partial response 
rate in heavily pre-treated MM patients. Their phase III trial for MM is being 
undertaken. 
1.3.3.5     ȕ-Lactones 
Unlike the previous classHVȕ-lactones are non-peptide, small size nature products. 
For example, lactacystin (20), originally isolated from a microbial metabolite in 
1991, was found to induce neurite growth in a mouse neuroblastoma cell line.131 
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Corey et al. achieved the total synthesis and found that it irreversibly blocks the ȕ
subunit of mammalian proteasome.132 Thus, lactacystin is regarded as a proteasome 
inhibitor targeting the CT-L pocket. 
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The inhibition mechanism of lactacystin can be divided into two consecutive steps 
(Figure 1-18 (a)).93 Firstly, in the aqueous solution lactacystin is spontaneously 
hydrolysed into clasto-lactacystin-ȕ-lactone (21) termed omuralide and N-
acetylcysteine. Secondly, the carbonyl group in thLVȕ-lactone ring is opened by the 
ȕ-hydroxyl group of Thr1 to form a ester bond. However, this ester bond can be 
slowly hydrolysed, hence reducing the inhibition potency. To overcome this 
problem, several alternative ȕ-lactone proteasome inhibitors have been discovered.  
Salinosporamide A (22), also known as NPI0052 or marizomib, is a secondary 
metabolite of marine actinomycete Salinispora tropica.133 It is currently 
undergoing clinical trials for MM. Sharing similar chemical structure to omuralide 
(21), salinosporamide A possesses a unique chlorine moiety that enhances the 
potency. In addition to forming  a ester bond to the Thr1 of proteasome, the carbon 
near chloride is further nucleophilic attacked by the neighbouring hydroxyl group, 
forming a tetrahydrofuran ring (Figure 1-18 (b)).134 This tetrahydrofuran ring 
blocks the access site of Thr1 from deacylation, and hence increases inhibition 
stability 2WKHUȕ-lactone analogues, such as belactosins (23), anti-protealide (24) 
and cinnabaramide (25) also show high potency with IC50 in nanomolar ranges.107 
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Figure 1-18 Mechanism of proteasome inhibition by (a) lactacystin, (b) Salinosoporamide A. 
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Several reports have demonstrated that lactacystin is around five-fold less potent 
than epoxomycin (16) and it also inhibits other cellular proteases.135 Moreover, 
their complex structures tend to hamper WKH GHYHORSPHQW RI ȕ-lactone-based 
therapeutic agents.133 
1.3.3.6     Macrocyclic vinyl ketones (syrbactins) 
Syrbactins are 12–PHPEHUHGODFWDPQDWXUDOSURGXFWVFRQWDLQLQJDQĮȕ-unsaturated 
amide moiety and recently have been shown to be useful proteasome inhibitors. 
Syringolin A (26) and glidobactin A (27), are two examples isolated respectively 
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from Pseudomonas synringae pv Syringae136 and Polyangium brachyspomm.137 
Studies have show n that these two compounds and their analogues can inhibit 
proliferation and induce apoptosis in neuroblastoma and ovarian cells.138 The 
crystal structure of the syrbactins in complex with the yeast proteasome showed 
that syrbactins covalently bind to WKH ȕ VXEXQLW RI WKH SURWHDVRPH, with the 
mechanism similar to the peptide vinyl sulfones (Section 1.3.3.2).138 Specifically, 
the hydroxyl group of Thr1 undergoes 1,4-addition to the double bond of the 
syrbactins and forms an irreversible ether bond (Figure 1-19).135 Although 
syrbactins exhibit proteasome inhibition and apoptotic properties, few studies apply 
it as a research tool or a therapeutic agent. 
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Figure 1-19 Mechanism of proteasome inhibition by syrbactins. 
1.3.3.7     Flavonoids 
The origins of this class are mainly from food. Epidemiological studies suggest that 
polyphenols in green tea are associated with anticancer effects.139 In particular, 
epigallocatechin-gallate (EGCG) (28),  representing the largest proportion of the 
polyphenols, has been shown for proteasome inhibition.140 In vitro and in vivo 
studies showed that EGCG mainly inhibits the CT-L active site of the proteasome. 
Based on computational docking studies, the inhibition undergoes via the acylation 
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of the hydroxyl group of Thr1 by the ester group of EGCG.141 EGCG is unstable 
under physiological conditions, thus further developments aims to a pro-drug form.   
Epidemiological studies also showed that high soy consumption is associated with 
less occurrence of cancers including breast, colon and prostate cancers.142 
Genistein (29), one of the bioactive isoflavones found in soybean, has been shown 
mainly to inhibit the proteasomal CT-L activity, though the binding mode to the 
CT-L active site has not yet been elucidated. Moreover, in vitro and in vivo studies 
suggested that genistein is a weaker proteasome inhibitor than EGCG from green 
tea.143 
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1.3.3.8     Cyclic peptides 
Apart from the covalent inhibitors mentioned above, some inhibitors utilise 
hydrogen bonds, van der Walls forces and hydrophilic/hydrophobic interactions 
and hence can target on very specific positions of the proteasome. From a clinical 
perspective, non-covalent inhibitors are anticipated to have less side-effect due to 
this higher selectivity. 
Cyclic peptides are one of the non-covalent proteasome inhibitors. TMC-95A (30) 
and its diastereoisomeric derivatives, originally isolated from Apiospora montagnei 
Sacc TC1093, were proven to be potent proteasome inhibitors with IC50 values in 
the nanomolar range.144 Their macrocyclic structure are characterised by (1) the 
cyclic tripeptide array containing a tyrosine, and an asparagine and an unusual 
oxidised tryptophan residue, (2) a (Z)-1-propenylamide subunit and (3) a 3-methyl-
2-oxopentanoic acid subunit. The total synthesis and X–ray co-crystal study have  
been reported respectively by Williams et al. and Groll et al.145, 146 Both works 
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have shown that TMC-95A interacts with the yeast 20S proteasome by forming 
five hydrogen bonds (Figure 1-20). These non-covalent interactions result in 
inhibition of CT-L, T-L, C-L proteolytic activities respectively with IC50 of 1.1 nM, 
43 nM and 650 nM. Further tests on the linear conformation of TMC-95A (31) 
suggest that the linear  tripeptide only retains 1/100 inhibitory activities, indicating 
the necessary structure  of constrained ring.147 Therefore, more SAR studies are 
needed to simplify the macrostructure of TMC-95A.       
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Figure 1-20  Interaction of TMC-95A to the active site of proteasome ȡ2 subunit. (Taken 
from Groll et al.)146 
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Since the recent discovery of proteasome inhibition activities for another cyclic 
peptide, argyrin A (32),148 an increasing number of researches have emerged 
focusing on its structural interaction with the proteasome three pockets.3 
1.4 Argyrins 
Argyrins were first isolated by Sasse et al. in 2002 from a myxobacterium strain 
Archamgium gephyra.148 The two major products isolated from the fermentation 
broth were named argyrin A (32) (fermentation yield 6 mg L-1) and argyrin B (33) 
(13 mg L-1). Another six derivatives were also found as minor products, named 
argyrin C-H. The structures of these eight argyrin analogues were further 
elucidated by NMR spectroscopy, chemical degradation and X-ray analysis.149 
Argyrin A, a cyclic octapeptide, was identified as a proteasome inhibitor by 
Nickeleit et al. in 2008.3 The study concluded two adva ntages. Firstly, argyrin A 
exhibits antitumour activity in many cancers by inducing apoptosis mainly via p27-
dependent mechanism. Secondly, argyrin A is capable of targeting the pre-existing 
tumour vessels directly by inhibiting angiogenesis.3 
The exploitation of the chemotherapeutic potential of argyrins and their derivatives 
is difficult because it requires laborious efforts to isolate sufficient amounts of the 
compounds from the microorganism. To overcome this difficulty, Ley et al. firstly 
described a total synthesis of argyrins in 2002,150 followed E\ %ȨORZ et al. in 
2010151 and Wu et al. in 2011.152 
1.4.1    Bioactivity of argyrin A  
All argyrins exhibit antibacterial activities and are able to inhibit the growth of 
mammalian cell cultures.148 More recently, high-throughput screening of p27 
expression in human cancer cells found that argyrin A stabilises the p27 levels in 
many human cancer cells, including human colon cancer cells (HCT116), human 
colon adenocarcinoma cells (SW480) and cervical cancer cells (HeLa).3 Since p27 
turnover mechanism are mediated by the 20S proteasome, further functional studies 
using purified human S20 proteasome established  that argyrin A mediate dose-
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dependent inhibition of CT-L, T-L and C-L proteolytic activities (Figure 1-21).3 
Furthermore, the apoptosis potency across the cancer cell lines are comparable with 
clinically-used bortezomib (13). The accumulation of other proteasome substrates 
such as p53, Bax and Iț% were also observed following argyrin A treatment.3  
 
Figure 1-21 argyrin A and bortezomib dose-dependent inhibition of CT-L, C-L and T-L 
pockets. (Adapted from Nickeleit et al.)3 
In addition to apoptosis, stablisation of p27 level is also shown to suppress tumour 
blood vessel formation.3 Nickeleit and his co-workers observed that following 
treatment with argyrin A, tumour tissues exhibit a lower rate of endothelial cell 
focal adhesion in vitro. This can be explained by the p27 inhibition of RhoA, a 
GTPase promoting focal adhesion and stress fibre formation.153   
The antitumour activity of argyrin A has also been tested in vivo in mice with 
human colon-cancer-derived xenografts.3 The intraperitoneal injection of argyrin A 
can inhibit 20S proteasome activity, leading to a significant reduction in tumour 
size. More importantly, comparing with bortezomib, argyrin A treatment is better 
tolerated on animals. There were no discomforts and weight loss being reported in 
treatment with argyrin A.3  
1.4.2    Structure analysis of argyrins  
From the biosynthetic perspective, argyrins are non-ribosomally derived cyclic 
octapeptides containing unusual thiazole and tryptophan residues. Firstly, the 2-(1-
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amino)-thiazole-4-carboxylic acid in all argyrins can be formed by the cyclisation 
and dehydrogenation of an alanyl-cysteine depeptide. These thiazole-contained 
peptides can be widely found in microbial and marine natural products.154 Secondly, 
4-methoxytryptophan in argyrin A, B, F, G, H can be  derived from a tryptophan by 
hydroxylation and O-methylation.149   
Figure 1-22 (a) illustrates the structural analysis of argyrin A (32). It can be seen 
that argyrin A is a cyclic octapeptide containing a sarcosine (Sar8), a exocyclic 
double bond dehydroalanine (Dha7), a (R)-alanine ((R)-Ala6), a glycine (Gly5), a 
tryptophan derivative with a methoxy substituent at C-4 of the indole (4-MeO-
Trp4), a tryptophan (Trp3) and a dipeptide thiazole derivative of (R)-alanine ((R)-
Ala1-Thz2).  
 
Figure 1-22 Structure and configuration of the argyrin A. (a) Structure and configuration of 
the argyrin A. (b) Intramolecular hydrogen bonds of argyrin A. 
The backbone of argyrin A adopts a compact conformation with a dimension of 10 
× 6 × 5 Å3, and two constraints do minate the dynamics of this macrocycle.155 One 
is that the thiazole ring is coplanar with the adjacent peptide bonds. This 
arrangement results in a planar constraint. The other constraint is created from the 
alkene group in the exocyclic alkene (Dha7).155 The overall conformation is further 
stabilised by five intramolecular hydrogen bonds (Figure 1-22 (b)), of which three 
are within the macrocyclic ring and two are between the ring and the (4-MeO)-Trp4 
and Trp3 side chains respectively.155  
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1.4.3    SAR studies of argyrins as a potent proteasome inhibitor 
Stauch et al. proposed an argyrin A/proteasome model by molecular modelling.155  
The docking mode of argyrin A generated by the program GOLD is based on the 
three assumptions: (a) argyrin binds to the canonical catalytically active sites on the 
proteasome’s ȕ VXEXQLWs, motivated by the observations from MG-132 and 
bortezomib, (b) the bioactive conformation of argyrin remains similar after its 
interaction with the proteasome, and (c) the three binding pockets are inspired by a 
yeast proteasome and bortezomib, with the side chains replaced by human 
equilents. 
Three interactions can be found for all the pockets when argyrin A blocks the 
proteasome (Figure 1-23). Specifically, Thr21 in proteasome forms two hydrogen 
bonds between the NH and the carbonyl groups with their respective carbonyl and 
NH of Trp3 of the argyrin A. Another group of hydrogen bonds can be formed 
between the NH group in proteasome’s Gly47 and the carbonyl in (R)-Ala6 of 
argyrin. Moreover, the hydroxyl group and the positive-charged N-terminus of 
Thr1 can form hydrogen bond and polar interaction with the carbonyl groups of 
Gly5 and Dha7 respectively. 
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Figure 1-23 Binding poses of argyrin A with three active sites of proteasome. (a) A caspase-
like binding pocket. (b) A trypsin-like binding pocket. (c) A chymotrypsin-like binding pocket. 
(Reproduced from Stauch et al.)155 
(b) T-L  pocket
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In addition to those common patterns, distinct interactions can be found for each 
pocket. At the C-L pocket (Figure 1-23 (a)), argyrin Trp3 and Trp4 are respectively 
sandwiched between His116 Met94, and between His116 and Tyr114. The 
hydroxyl group of S118 also forms a hydrogen bond to the methoxy group of Trp4.  
At the T-L binding pocket (Figure 1-23 (b)), Trp4 and Trp3 are both located inside 
the hydrophobic side pocket containing Leu115, Ser20, Ala27, Cys31, Cys118 and 
Met120. It is worthy to note that there is no hydrogen bond between the poc ket and 
the methoxy group of Trp4, w hich is different from the other two poc kets.  
At the CT-L pocket (Figure 1-23 (c)), Trp4 is surrounded by the side pocket 
containing Asp114, Ala22, Ala27, Lys125 and Ser118. The hydroxyl group of 
Ser118 form a hydrogen bond to the methoxy group of Trp4, similarly to the C-L 
pocket. 
To provide argyrin derivatives for SAR study, Stauch et al. synthesised a series of 
argyrin derivatives and measured their activities using purified human 
proteasomes.155 The argyrin B, C, D and H were obtained by fermentation, and 
other derivatives shown in Table 1-4 were synthesised. Note that argyrin 6 has no 
exocyclic alkene, and Dha7 was replaced by Gly. The remaining 20S proteasome 
activities after inhibition were determined using CT-L, T-L and C-L fluorogenic 
substrates. Moreover, the cytotoxic IC50 values were obtained after incubation of 
colon carcinoma cells (SW480) with argyrin derivatives.  
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Table 1-4 SAR data of argyrins and synthetic derivatives.155 
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Argyrins a  
 
R1 
 
R2 
 
R3 
 
R4 
 
R5 
Proteasome remaining activity 
(%) b 
IC50 (nM) c 
SW-480 
C-L T-L CT-L 
Argyrin A 
(32) 
CH3 OCH3 CH3 H H 29 ± 5.2 45  ± 4.5 30 ± 6.0 3.8 ± 0.3 
Argyrin B 
(33)  
CH3 OCH3 CH2CH3 H H 52  ± 3.0 55 ± 8.5 58 ± 6.5 4.6 ± 0.6 
Argyrin C  
(34) 
CH3 OCH3 CH3 CH3 H 38  ± 8.3 40 ± 7.0 43 ± 5.5 1.5 ± 1.1 
Argyrin D 
(35) 
CH3 OCH3 CH2CH3 CH3 H 50  ± 6.0 62 ± 8.0 64 ± 5.2 3.6 ± 2.0 
Argyrin E 
(36)  
CH3 H CH3 H H 65  ± 4.0 70 ± 3.0 70 ± 5.5 520 ± 270 
Argyrin F 
(37) 
CH2OH OCH3 CH3 H H 35 ± 7.0 38  ± 6.5 28 ± 2.5 4.2 ± 0.4 
Argyrin G 
(38)  
CH2OH OCH3 CH2CH3 H H 60  ± 6.5 75  ± 3.0 65 ± 4.5 63 ± 55 
Argyrin H 
(39) 
H OCH3 CH3 H H 52  ± 5.5 60 ± 7.0 51 ± 8.0 30 ± 2 
Argyrin 1  CH2OH H CH2CH3 H (R)-
CH2
OH 
65 ± 7.0 70 ± 7.5 55 ± 3.5 1050 ± 180 
Argyrin 2  CH2OH H CH2CH3 H H 68  ± 4.6 75 ± 2.7 62 ± 19 3800 ± 43 
Argyrin 3  CH3 H CH2CH3 H H 72 ± 13.3 74 ± 2.9 92 ± 3.0 >4000 
Argyrin 4 
 
CH2OH OCH3 CH3 H (R)-
CH3 
54  ± 2.5 72 ± 4.5 50 ± 3.0 90 ± 0.2 
Argyrin 5 
 
CH2OH OCH3 CH3 H (S)-
CH3 
65 ± 3.0 89 ± 2.5 87 ± 2.5 2300 ± 180 
Argyrin 6 
 
CH3 OCH3 CH3 H H 100 ± 6.5 85 ± 6.5 87 ± 6.5 3600 ± 400 
a.
 Argryin A-H are naturally occurring analogues, and Argyrin 1-6 are synthetic analogues. 
b.
 3URWHDVRPHDFWLYLW\DVVD\VZHUHFDUULHGRXWLQDȝ/UHDFWLRQYROXPHFRQWDLQLQJ1.2 ȝ0$UJ\ULQ
ȝJKXPDQHU\WKURF\WH-derived 20S proteasomes, Tris/EDTA: 20mM Tris/HCL; 1mM EDTA ; pH 
7.8 and ȝM fluorogenic substrate  at 37 °C. 
c.
 The cytotoxicity of argyrins was measured by MTT assay after 5 days of incubation at 37 °C and 10 
% CO2. 
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Based on the SAR study, argyrin A and F are apparently the most potent 
derivatives. By comparing them with argyrin E, 1, 2 and 3, it can be seen that the 
methoxy group at R2 in Trp4 is essential for activity. This can be explained by the 
hydrogen bonds of the methoxy group to the hydroxyl group of S118 in the C-L 
and CT-L pockets. Moreover, the comparison with argyrin 6 shows that the 
absence of the exo-alkene group of Dha7 residue in argyrin also significantly 
reduce the activity. This suggests that the removal of structural constraint increases 
the flexibility of the macrocycle, which eventually reduces argyrin interaction 
capability with the three pockets. These two essential elements are consistent with 
the docking model. 
The activity of argyrin F is slightly higher than that of argyrin A, which can be 
explained by an enhanced stability of the complex. Specifically, the hydroxyl group 
of serine in argyrin F can form an additional hydrogen bond to the carbonyl group 
of the conserved residue Gly23.  
By comparing argyrin B with argyrin A, elongating the methyl side chain of (R)-
Ala6 by one carbon atom is well tolerated. For argyrin C and D, the additional 
methyl group at the C2 position of indole side chain of Trp4 is also tolerable, 
probably because this additional group can be readily accommodated without 
changing the conformation of Trp4. 
By comparing argyrin 4 and 5 with argyrin F, R5 is substituted by (R)-Ala and (S)-
Ala respectively. The former structure (pro-R) is tolerable while the later (pro-S) is 
detrimental. One possible explanation is that the steric hindrance between the 
methyl group of (S)-Ala and the carbonyl group of Trp4 would distort the 
conformation of the macrocycle, and this methyl group would also clash with the 
protein backbone at Thr 20 near the T-L and CT-L pockets. 
Based on an existing small library of argyrin analogues, it is unrealistic to draw any 
definitive SAR conclusion, apart from the apparent crucial requirement of MeO-
Trp4. To fully identify the optimal binding and proteasomal inhibition, unique 
analogues of argyrins are required. Thus, establishing a robust synthetic access to 
argyrins would allow for the construction of a wide range of analogues for detailed 
biological investigations. 
Chapter 1  Introduction 
-45- 
 
1.5 Aims and objectives 
While argyrins have been proven to inhibit proteasome function, its inhibition 
mechanism is still poorly understood.3 In order to further explore argyrin biological 
function, chemical syntheses are necessary for obtaining diverse analogues.  
The aim of the project is the total synthesis of argyrin A and analogues thereof, 
particularly with regards to the substituted tryptophan (Trp4(X)). A new 
methodology by adopting Fmoc solid-phase chemistry and macrocyclisation 
strategies is introduced. A new synthetic route providing access to a wide range of 
tryptophan derivatives is also established.   
The overall synthetic plan is outlined in Scheme 1-1. Among those seven amino 
acid building blocks, Fmoc-tryptophan derivatives (43), N-Boc-(R)-Ala-Thz-OH 
(44) and Fmoc-phenylselenocysteine (42) are not commercially available and 
hence synthesised. 
Chapter 1  Introduction 
-46- 
 
O
O
N
O
HN
O
NH
HN
O
O
NH
NH
O
HN
HN
O
N
S
BocHN
50 %(v/v) TFA/DCM, 1~2 h
N OH
O
Fmoc
Fmoc-Sar8-OH
Fmoc
H
N
OH
O
SePh
Se
Fmoc-Ph(Se)7-OH
Fmoc
H
N OH
O
Fmoc-(R)-Ala6-OH
Fmoc
H
N OH
O
Fmoc-Gly5-OH
Fmoc
H
N OH
O
NH
Fmoc-Trp3-OH
Boc
H
N
N
S
OH
O
Boc-(R)-Ala1-Thz2-OH
Fmoc solid phase 
peptide synthesis
2-Chlorotrityl 
chloride resin
ClCl
Fmoc
H
N OH
O
NH
Fmoc-Trp4(X)-OH
R
R
(41)
(43)
(42)
(40)
45
(44)
 
 
 
Chapter 1  Introduction 
-47- 
 
S
N
H
NO
N
O
HN
O
N
H
O HN
O
HN O
HN
O
N
H
NH
S
N
H
NO
N
O
HN
O
N
H
O HN
O
HN O
HN
O
N
H
NH
1. NaIO4, CH3CN/H2O
2. NaHCO3, CH3CN/H2O
OH
O
N
O
HN
Se
O
NH
HN
O
O
NH
NH
O
HN
HN
O
N
S
TFA
.
H2N
PyBOP, HOBt. DIPEA
     CH2Cl2   , r.t.
Se
R
R
R
46
47
48
1
2
3
4
5
6
7
8
 
Scheme 1-1 Retrosynthetic analysis of argyrin A and analogues thereof 
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Initially, attention is focused on synthesis of optically pure Fmoc-tryptophan 
derivatives (43). There are numerous reports on the synthesis of optically pure 
tryptophan derivatives. However, they are either restricted to substitution at 
specific positions or requiring reagents that are not affordable. Therefore, the 
retrosynthetic strategy for Fmoc-protected tryptophan derivatives (43) is illustrated 
in Scheme 1-2. The key step (step c) utilising diastereoselective Strecker synthesis 
is developed in this thesis. The detail of this new approach is discussed in Chapter 
2.  
N
H NH
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CN
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R R R
R R
R R
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c d
e f
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OH OH
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Scheme 1-2  Synthesis of Fmoc-tryptophan derivatives (43); Reagents and conditions: (a) POCl3, 
DMF, 0 °C then 45 °C; (b) i. Ph3PCH2OCH3, n-BuLi; ii. HCl, THF, reflux; (c) (R)-2-
Phenylglycinol, NaCN, AcOH, MeOH; (d) H2O2, Na2CO3, DMSO; (e) Recrystallisation or RP-
HPLC; (f) Pd/ C, NH4HCO2, MeOH, reflux; (g) 1 M HCl, reflux; (h) Fmoc-OSu, NaHCO3, 
THF/H2O. 
 
The second unusual building blocks (R)-Ala1-Thz2-OH (44) is prepared by four-
step synthesis, outlined in scheme 1-3. The crucial step (step c) involves two-step 
modified Hantzsch thiazole formation. In addition, another analogy of the thiazole-
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containg dipeptide, the oxazole dipeptide (63), is also synthesised. The synthetic 
scheme is shown in Scheme 1-4.  
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Scheme 1-3 Synthesis of Boc-(R)-Ala-thiazole (44); Reagents and conditions: (a) DCC, HOBt, 
NH3, CH2Cl2, 0 °C; (b) Lawesson’s reagent, THF, 0 °C; (c) i. BrCH2COCO2Et, KHCO3, DME, -15 °
C; ii. TFAA, 2,6-lutidine, DME, -15 °C; (d) LiOH, THF/H2O, room temp. 
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Scheme 1-4 Synthesis of  Boc-(R)-Ala-oxazole (63); Reagents and conditions: (a) DCC, HOBt, 
DIPEA, CH2Cl2, 0 °C; (b) Burgess reagent, microwave, 70 °C; (c) CuBr, PhCOOO-t-Bu, benzene, 
reflux; (d) LiOH, THF/MeOH/ H2O, room temp. 
 
As the third unusual building block dehydroalanine is unstable, the synthesis 
strategy involved the utilisation of a masked precursor, phenylselenocysteine, 
which is eventually converted at the final step to the desired dehydroalanine 
residue. To obtain the phenylselenocysteine, a four-step synthetic scheme based on 
a previous report is utilised, shown in Scheme 1-5. The detail of the thiazole- and 
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oxazole-containing dipeptide and the Fmoc-phenylselenocysteine (42) is discussed 
in Chapter 3.  
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Scheme 1-5 Synthesis of Fmoc-phenylselenocysteine (42); Reagents and conditions: (a) DEAD, 
PPh3, THF, -78 °C to room temp.; (b) PhSeSePh, NaBH(OMe)3, EtOH, room temp.; (c) 
THF/CH2Cl2, room temp.; (d) Fmoc-OSu, NaHCO3, THF/H2O, room temp. 
 
The prevailing method for chemical assembly of argyrin is solution-phase peptide 
synthesis. It was envisaged that Fmoc SPPS approach provides a much easier 
methodology for assembling the linear peptide. The macrocycle ring is installed 
using solution phase head-to-tail intramolecular cyclisation of the linear peptide. 
The oxidative removal of the phenylselenocysteine eventually completes the 
argyrin synthesis. The Fmoc solid phase peptide synthesis, macrocyclisation 
strategy and biological evaluation of synthesised argyrin analogues are discussed in 
Chapter 4.  
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Chapter 2  
Synthesis of Fmoc-(S)-
tryptophan derivatives 
As outlined in Section 1.5, an unusual amino acid building block of argyrin A is the 
(S)-tryptophan derivative (43). In fact, tryptophan is one of the essential amino acid 
with less than 1% abundance in nature. Although both stereo-isomers of tryptophan 
can be found in naturally occurring peptides, only the (S)-stereoisomer of 
tryptophan is utilised as the source of ribosomally-encoded proteins. A structural 
feature of tryptophan is the indole moiety, which largely affects the 
physicochemical properties of tryptophan. In general, the indole ring provides the 
molecule with amphipathicity, i.e. its N-H group can form hydrogen bonds and its 
aromaticity enables non-polar interactions.156 Moreover, biological activities of 
many tryptophan-contained natural products, particularly second metabolites, are 
related to specific substituents in the indole moiety. For example, rhopaladin 
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alkaloids containing 5-bromo- and 6-hydroxy-tryptophan are show n to be 
inhibitory to CDK4,157 mitragynine alkaloids containing 4-methoxy-tryptophan 
derivatives have antinociceptive activity,158  iotrochamides B containing 5-bromo-
tryptophan displayed antitrypanosomal activity159 and rebeccamycin having 7-
chloro-tryptophan derivatives have anticancer activity.160 Hence, tryptophan 
derivatives can be considered to be an active moiety for these natural products.  
A multitude of synthetic methods has been described in literatures in order to 
provide these building blocks. In this chapter, seven existing methods toward the 
synthesis of enanatiomerically pure tryptophan are reviewed, followed by 
developing of a novel route to access to a wide range of tryptophan derivatives. 
2.1 Existing methods 
Current methods  for  synthesising enantiomerically pure (S)-tryptophan derivatives 
rely on either enzymatic or chemical approaches. There are two types of enzymes 
being employed in the former approach. One approach adopts N-acylase and 
generally involved a final-step resolution of the racemates. The acylase resolution 
releases the desired (S)-tryptophan in a mixture containing the unprocessed N-
acetyl-(R)-tryptophan.150 Two examples are presented in Section 2.1.1 and 2.1.2. 
The other approach adopts purified tryptophan synthase that can directly alkylate 
serine with indole derivatives, which is reviewed in Section 2.1.3. In contrast, 
studies based on chemical synthesis required multi-step processes and are low 
yielding. However, these multi-step synthetic schemes allowed access to a wider 
range of indole-substituted tryptophan. The key challenges are the stability of 
intermediates and stereoselectivity of reactions. Therefore, specialised procedures 
and chiral auxiliaries are usually employed, as in those studies outlined in Section 
2.1.4 and 2.1.5. 
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2.1.1    Ley’s approach to the synthesis 4-methoxy-(S)-tryptophan 
In order to prepare the desired 4-methoxy-tryptophan for total synthesis of argyrin 
B, Ley et al. in 2002 developed a six-step synthetic route to N-Cbz-4-MeO-(S)-
tryptophan.150  
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Scheme 2-1 Synthesis of N-Cbz-4-MeO-(S)-tryptophan (70) by Ley’s group; Reagents and 
conditions: (a) CH2NMe2+I-, CH3CN, room temp.; (b) (C2H5O2C)2CHNHCOCH2Ph, EtONa Then 
68 and  Me2SO4, EtOH, room temp.; (c) i. NaOH, MeOH/dioxane, 50 °C; ii. Dioxane, 100 °C; iii. 
NaOH, MeOH/dioxane, 50 °C; (d) Immobilised penicillin G acylase, MeOH/H2O, room temp.; (e) 
Cbz-Cl, NaHCO3, THF/H2O, room temp.   
As shown in Scheme 2-1, the starting material 4-methoxyindole was subjected to 
aminoalkylation reaction, i.e. Mannich reaction, by treatment of Eschenmoser's salt. 
The gramine derivative 67 underwent alkylation using the enolate of malonic ester 
to give 68. Saponification of the diester followed by further acid- or base-mediated 
decarboxylation of the carboxylic acid gave racemic 4-methoxytryptophan 
derivatives 69. Finally, chiral resolution was performed by treatment with 
immobilised penicillin G acylase. This route utilised enzymatic kinetic resolution 
of the racemic precursors. In fact, the enzymatic optical resolution using acylase 
was based on the method used by Wade et.al for the synthesis of 5-bromo-(S)-
tryptophan in 1980.161 
The unreacted substrate was removed and the desired amino acid was N-protected 
with Cbz to provide optically pure N-Cbz-4-MeO-(S)-tryptophan 70 in 44% yield. 
Unfortunately, the penicillin G acylase used in the chiral resolution was no longer 
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commercially available. Another group reported that using other immobilised 
acylases resulted in poor conversion.151 
2.1.2    Konda-Yamada’s approach for the synthesis of 7- and 6-
bromo-(S)-tryptophans 
Another route that involved enzymatic hydrolysis of N-acyltryptophan was 
reported by Konda-Yamada in 2002 (Scheme 2-2).162 This synthetic route took 
advantage of the elegant construction of racemic tryptophan put forward by the 
Yokoyama’s group. 163 Tryptophan was synthesised directly from indole and serine. 
This one-step bio-mimetic synthesis is not only efficient (> 80 % yield), but also 
avoids the use of protection and deprotection steps in the synthetic route. Although 
this method is relatively straightforward, the two resulting isomers (71) require an 
additional chiral separation step. The enantiomeric specific separation was 
conveniently performed with (S)-aminoacylase and (R)-aminoacylase to give  
optically pure (S)-tryptophan and (R)-tryptophan, respectively. Further 
investigation by Sanderson et al. in 2008 successfully applied this route to a range 
of 5- and 6-substituted tryptophan derivatives.164 However, a number of factors 
affect the yields, including the substituents, aminoacylase sources, pH and 
temperature.164 Furthermore, applying this method to the indole system with bulky 
substituents, such as iodo or nitro, was found to be less efficient. It was envisaged 
that the poor efficiency was due to the limited accessibility to enzyme active site.  
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Scheme 2-2 Synthesis of 7-Br-(S)-tryptophan (72) by Konda-Yamada’s group; Reagents and 
conditions: (a) (S)-Serine, AcOH/Ac2O, 75 °C; (b) (S)-Aminoacylase, phosphate buffer pH = 7, 
CoCl2·6H2O.  
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2.1.3    Goss approach for the synthesis of (S)-halotryptophans 
Since tryptophan synthase was firstly used to synthesise 5-fluoro-tryptophan, 
several groups have utilised this strategy towards different tryptophan derivatives 
from 1974-2006.165 However, this biotransformation method was hampered by 
time-consuming purification of enzymes and the limited solubility of substrates. In 
2006, Goss’s group reported a scalable procedure to synthesise (S)-
halotryptophans.166 The procedure utilised the tryptophan synthase from the lysate 
of a commercially available microorganism, Salmonella enterica (Scheme 2-3(a)). 
In fact, this biotransformation was achieved by three sequential reactions (Scheme 
2-3(b)).  
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Scheme 2-3 Synthesis of (S)-halotryptophans by Goss’ group. (a) Overall enzymatic synthesis of 
(S)-halotryptophans. (b) Tryptophan synthase mediated conversion of serine and haloindoles to 
tryptophans with PLP. 
In the first step, serine was reacted with pyridoxal 5’-phosphate cofactor (PLP) (74) 
to form a Schiff’s base, followed by dehydration to give 75. In the second step, the 
indole derivative undergoes Michael addition with 75 to afford 76. Finally, 
hydrolysis of 76 releases PLP and the tryptophan derivatives. The yield of 
Chapter 2 Synthesis of  Fmoc-(S)-tryptophan derivatives 
-56- 
 
transformation after one cycle was nearly 50%. Although this enzymatic synthesis 
was readily accessible and environmentally friendly, applying this procedure to the 
indole ring system with various substitutions at 4-, 5-, 6- and 7-positions was not 
successful, especially with substitutions at the 4- or 7-positions. The specificity of 
the enzyme resulted in poor tolerance for bulky substituents and for substitutions at 
the 4- or 7-positions. 
2.1.4   Hengartner’s approach to synthesis of 6-methyl-(R)-
tryptophan 
As illustrated in Scheme 2-4, to prepare the sweetening agent 6-methy-(R)-
tryptophan 83, Hengartner’s group successfully introduced asymmetric catalytic 
hydrogenation of 79 to afford 6-methyl-(R)-tryptophan 83 in high enantiomeric 
excess (ee).167 The hydrogenation substrate 79 was prepared from 6-methyindole 
77 in three steps. The starting material 77 was subjected to Vilsmeier formylation 
to give aldehyde 78, which condensated with ethyl malonate to give a 5:1 mixture 
of two isomeric acetamidoacrylic esters 79 and 80. Saponification of the ester 79 
for ms 81 which is a better substrate for enantioselective catalytic hydrogenation. 
Various catalysts have been extensively studied, and the results showed that the 
phosphine ligand 84 in combination with [Rh (cod) Cl]2 gave the best yield (100 %) 
and ee (83 %). The hydrogenation product was identified as pure R configuration. 
Finally, N-acetyl group is carefully removed under mild conditions to afford 
enantiomerically pure 83. 
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Scheme 2-4 Synthesis of 6-methyl-(R)-tryptophan (83) by Hengartner’s group; Reagents and 
conditions: (a) POCl3, DMF, room temp.; (b) Ethyl acetamidomalonate, Ac2O, pyridine, room temp.; 
(c) NaOH, 70 °C; (d) H2, 84, [Rh(cod)Cl]2, MeOH, room temp.; (e) 2.5 M HCl, reflux. 
2.1.5   Synthetic approaches to 4-methoxy-tryptophan 
2.1.5.1 Nickeleit’s approach for the synthesis of 4-methoxy-(S)-
tryptophan 
A similar route using catalytic hydrogenation was recently developed by 
Nickeleit’s group in 2010.151 In order to prepare 4-methoxy-(S)-tryptophan, 
required for the total synthesis of argyrin F, a new catalyst was introduced to 
provide 4-methoxy-(S)-tryptophan 89 in excellent yield (99 %) and high ee (99 %). 
The seven-step synthesis is illustrated in Scheme 2-5. The initial three-step reaction 
gave the hydrogenation substrate 87. Thus, the starting material 4-methyoxyindole 
was subjected to Vilsmeier formylation to give aldehyde 85, followed by N-Boc 
protection of indole. Next, using phosphonoglycine and DBU, the Horner-
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Wadsworth-Emmons reaction was applied to convert indole-3-carboxaldehyde 86 
to (Z)-dehydrotryptophan 87 as a single isomer. It is worth noting that the (Z) 
geometric selectivity of this method is superior to Hengartner’s method outlined in 
Section 2.1.4.  
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Scheme 2-5 Synthesis of N-CBz-4-methoxy-(S)-tryptophan (89) by Nickeleit’s group; Reagents 
and conditions: (a) POCl3, DMF, 45 °C; (b) (Boc)2O, DMAP, DCM, room temp.; (c) (Z)-Į-
Phosphonoglycine trimethyl ester, DBU, DCM, room temp.; (d) H2, Rh(cod)2BF4, 90, MeOH, room 
temp.; (e) i. TFA, DCM, room temp.; ii. LiOH, THF/ MeOH/ H2O, room temp.  
The synthesised substrate 87 was then subjected to asymmetric hydrogenation. In 
fact, this specific strategy was first described by Moody et al. in 2004.168 Using the 
catalyst Rh(cod)2BF4, in combination with DuanPhos ligand 90 under 10 bar of 
hydrogen gave an enantiomerically pure tryptophan 88. Finally, the desired product 
89 was obtained by TFA-mediated acidolysis of the Boc group followed by 
saponification of the methyl ester. 
2.1.5.2 Cook’s approach for the synthesis of 4-methoxy-(R)-tryptophan 
In the course of a total synthesis of the indole alkaloids mitragynine, Cook and 
colleagues reported a new route for the synthesis of 4-methoxy-(R)-tryptophan in 
2009 (Scheme 2-6(b)).169 Unlike other methods which use indole derivatives as 
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starting materials, Cook employed Larock heteroannulation of iodide-substituted 
alanine 94 with the internal alkyne 93a directly to build the stereogenic centre of 
the tryptophan. The propargyl-substituted Schöllkopf chiral auxiliary 93a was 
prepared from the reagent 91, which can be obtained from (R)-valine and (S)-
glycine using standard four-step procedures.170 Thus, reaction of 91 with diphenyl 
(trimethylsilyl)propargyl phosphate 92 gave diastereoselective products 93a and 
93b in 46 : 1 ratio (Scheme 2-6 (a)). It is worth mentioning that the leaving group 
in 92 other than phosphate, such as bromo or O-tosyl, gave poorer 
diastereoselectivities.171  
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Scheme 2-6 Synthesis of 4-methoxy-(R)-tryptophan (97) by Cook’s group; Reagents and 
conditions: (a) n-BuLi, THF, -78 °C; (b) Pd(OAc)2, K2CO3, LiCl, DMF, 100 °C; (c) 2 M HCl, THF, 
room temp.; (d) NaOH, EtOH, room temp.   
Internal alkyne 93a was then used for the Larock heteroannulation (Scheme 2-6 (b), 
step b). Good regio- and stereo-selectivity were reported when TMS propargyl-
substituted Schöllkopf chiral auxiliary 93a was used. As show n in Figure 2-1, this 
selectivity was attributed to the steric interactions between the methoxy substituent 
and the TMS on the alkyne. The less sterically hindered intermediate 98 is more 
favoured than the intermediate 99. Thus, the corresponding product 95 was formed.  
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Next, the Schöllkopf chiral auxiliary and indole-2-silyl group in 95 were 
hydrolysed in 2 M aqueous HCl to afford 4-methoxy-(R)-tryptophan ethyl ester 96. 
Finally, saponification of the ethyl ester afforded 4-methoxy-(R)-tryptophan 97. In 
general, this method is a short synthetic process and gives good yield, but the 
general application is restricted by the regio-selectivity of annulation which relies 
on the presence of steric group at the aromatic ring.  
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Figure 2-1   Proposed steric effect for the Larock heteroannulation. 
2.1.5.3   Jiang’s approach for the synthesis of 4-methoxy-(S)-tryptophan 
In the course of a total synthesis of argyrin A, Jiang et al. successfully adopted a  
ligand-less palladium-catalysed one-pot annulation reaction previously established 
by Zhu in 2006.152, 172 The five-step synthesis is outlined in Scheme 2-7(a). Similar 
to Cook’s strategy (Section 2.1.6), the tryptophan derivatives were directly 
constructed from a heteroannulation reaction between an aldehyde 100 prepared 
from glutamic acid in three steps (Scheme 2-7(b)) and the aryl iodide 94.173 The 
glutamic acid was firstly converted to diester 103, followed by Boc protection of 
the amine. Then dimethyl N,N-di-Boc-glutamate 104 was then reduced with 
diisobutylaluminium hydride (DIBAL) under mild conditions to form the aldehyde 
100 in good yield. With the aldehyde 100 in hand, it was annulated to aryl iodide 
94 using Zhu’s conditions [Pd(OAc)2, DMF, DABCO, 85 °C] to afford the desired 
tryptophan derivative 101. Finally, selective deprotection of N-Boc and hydrolysis 
of the methyl ester 102 gave N-Boc-4-methoxy-(S)-tryptophan. So far, among these 
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established synthetic routes to prepare tryptophan derivatives, Jiang’s approach not 
only tolerates a wide range of substituent in the indole ring, but also afforded good 
yields. However, it is envisaged that the application of this strategy for the 
synthesis of halotryptophans would be drastically limited since aryl halides could 
interfere with the annulation reaction.  
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Scheme 2-7 Synthesis of 4-methoxy-(S)-tryptophan by Jiang’s group; Reagents and conditions: 
(a) Pd(OAc)2, DABCO, DMF, 85 °C; (b) BiBr3 (10 mol %), MeCN, room temp.; (c) LiOH, THF/ 
MeOH/ H2O, room temp.; (d) i. TMSCl, MeOH; ii. Boc2O, Et3N, MeOH; (e) Boc2O, DMAP, 
MeCN; (f) DIBAL, Et2O, -78 °C.  
2.2 Preparation of tryptophan analogues using new method 
exploiting Strecker condensation with (R)-2-phenylglycinol 
The literature methods  in Section 2.1 provide several possible methodologies for  
the preparation of tryptophan derivatives. However, most of these methods suffer 
from some limitations. For example, they might require reagents which are not 
economically viable or lack of generality. Therefore, an alternative route of 
accessing to a wide range of tryptophan derivatives was established as shown in 
Scheme 2-8. All desired Fmoc-tryptophan derivatives were synthesised from 
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corresponding indoles in seven steps. Briefly, inspired by the method established 
by Bayston et al. WKDW F\FORSURSDQHFDUER[DOGHK\GH UHDFWV ZLWK DQ Į-
alkylbenzylamine to give a mixture of two diastereomeric aminonitriles in 3.2 to 1 
ratio, the key step of the synthesis is the use of chiral auxiliary (R)-2-
phenylglycinol and mild conditions for hydrolysis of Į-DPLQR QLWULOHV WRĮ-amino 
acids (Scheme 2-8, steps c and d).174  
A detailed consideration of each step is disclosed in the following sections.  
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Scheme 2-8 Summary of a new method exploiting Strecker amino acid synthesis of (S)-
tryptophan analogues (43); Reagents and conditions: (a) POCl3, DMF, 0 °C then 45 °C; (b) i. 
Ph3PCH2OCH3, n-BuLi; ii. HCl, THF, reflux; (c) (R)-2-Phenylglycinol, NaCN, AcOH, MeOH; (d) 
H2O2, Na2CO3, DMSO; (e) Recrystallisation or RP-HPLC; (f) Pd/ C, NH4HCO2, MeOH, reflux; (g) 
1 M HCl, reflux; (h) Fmoc-OSu, NaHCO3, THF,/H2O. 
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2.2.1   Vilsmeier-Haack formylation  
N
H NH
H
O
R R
49 d-j 50 d-j
 
 d e f g h i j 
R = 6-F 7-Et 5-Me 5-MeO 4-MeO 1-Me 2-Me 
        
As show n in Scheme 2-8, the initial step in this synthesis is to install an aldehyde at 
the 3-position of the indole ring. Vilsmeier-Haack reaction is one of the most 
commonly used for formylation of electron-rich aromatic compounds to yield 
aromatic aldehydes.175 The Vilsmeier reagent is normally prepared in situ by the 
addition of a N,N-disubsituted formamide, such as DMF or N-methylformanilide to 
phosphorus oxychloride or phosgene. The heteroaromatic compounds, such as 
indole derivatives, undergo formlyations when treated with Vilsmeier reagents. 
Good regioselectivity at C-3 indole carbon can be achieved, as electron-rich C-3 of 
the indole system gives the lowest resonance transition state. The mechanism of the 
Vilsmeier formylation of indole derivatives is shown in Figure 2-2. 
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Figure 2-2 Proposed mechanism of Vilsmeier formylation. 
The first step is formation of the electrophilic iminium 105 which is prepared from 
DMF and POCl3. In practice, DMF was used as a reagent and as a solvent. The 
iminium intermediate 105 then underwent electrophilic substitution to the electron 
rich position of indole ring. The intermediates 106 are unstable and can be easily 
hydrolysed. Therefore, the next step is to hydrolyse 106 using Na2CO3(aq) to give 
indole-3-carboxaldehyde derivatives (50d-j). 
In theory, regardless of the R group in the indole ring, the formlyation takes place 
exclusively at C-3 position under controlled temperature. Initially, 3 equivalents of 
Vilsmeier reagent were used, following the literature conditions at 45 °C for 2 h.151 
The production of aldehydes 50d-j were confirmed by 1H NMR analysis, which 
revealed the appearance of a distinctive aldehyde singlet at į 10.02 ppm. Thus, 
most of the indole derivatives were successfully converted to the corresponding 
indole-3-carboxaldehydes in good yields. However, lower yields (50-60 %) were 
obtained for the methoxyindoles (49g and 49h), even though the starting material 
methoxyindoles had been completely consumed. Consequently, a number of 
reaction conditions were evaluated; including changes in the reaction temperature 
and duration. Surprisingly, increasing the reaction temperature from 45 to 100 °C 
resulted in formation of both 3-formylated and N-formylated products. Presumably, 
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the thermodynamic stable product, N-acylated indole, could be formed at the high 
temperature. Moreover, low yields were observed due to poor solubility of the 
methoxy-subs tituted product during the work-up procedure.    
2.2.2   Homologation of aldehyde via Wittig reaction 
N
H
H
O
N
H
H
O
R R
50a-j 51a-j
 
 a b c d e f g h i j 
R = H 5-Br 5-Cl 6-F 7-Et 5-Me 5-MeO 4-MeO 1-Me 2-Me 
           
In order to apply the Strecker amino acid synthesis strategy (Section 2.2.3) for the 
synthesis of tryptophan derivatives, the resultant aldehydes must be extended by 
one-carbon unit. This transformation is commonly known as a homologation 
reaction. Homologation of aldehydes has been extensively studied.176-178 However, 
conventional methods involving the reaction of the diazoalkane with aldehydes to 
produce ketones or alcohols is not applicable for Strecker amino acid synthesis.176, 
177
 Other than diazoalkane derived homologation, Wittig reagents are also 
employed in aldehyde homologations which produce a homologous aldehyde.  
Here, Wittig reaction was applied using (methoxymethyl)triphenylphosphonium 
chloride 107 to yield enol ethers which easily undergo acid-catalysed hydrolysis to 
the corresponding aldehydes.178 The mechanism of this two-step homologation is 
shown in Figure 2-3. 
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Figure 2-3 Mechanism of two-step aldehyde homologation (a) Wittig reaction. (b) Acid-
catalyst hydrolysis of enol ether.  
The reaction was initiated by the ylide formation (Figure 2-3(a)). Phosphonium 
ylide 107 was prepared in situ as a dark red solution in dry THF by stirring the 
phosphonium salt with a strong base, n-butyllithium. Next, 50d-j and commercially 
available aldehydes 50a-c were added dropwise to the mixture under a nitrogen 
atmosphere, and ylide 107 then readily underwent nucleophilic substitution at the 
carbonyl groups of the aldehydes to give the diionic betaines 108. The betaine 
intermediates were then converted to the lower energy state form, which is known 
as an oxaphosphetane 109. Finally, the formation of stable triphenylphosphine 
oxide drives the elimination to give the E- and Z-alkenes. As expected, a major 
spot and a minor spot were observed by TLC after work-up. Although other factors 
could affect the E/Z ratio, stabilised ylide was established to give the E-
configuration 110a-j as the major product, as the less crowded of trans-
oxaphosphetane was formed under thermodynamic control. Indeed, desired E/Z 
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enol ether formation was confirmed by 1H NMR analysis, which revealed the 
disappearance of the aldehyde proton (į = 10.5 ppm, s, CHO) in the starting 
material 50b and the appearance of the two pairs of alkene protons (į = 5.58, 6.19 
ppm, d, for E-isomer and į = 5.94, 7.03 ppm, d, for Z-isomer) in the enol ether 
110b (Figure 2-4). In addition, although the stereoselectivity outcome is an 
important concern for the Wittig reaction, it should not have an effect on the 
subsequent enol ether hydrolysis. Therefore, a mixture of two isomers was used 
directly in the next step of the reaction.  
 
 
Figure 2-4   1H NMR spectrum of 5-bromo-3-(2-methoxyvinyl)-1H-indole (110b). 
 
The enol ethers 110a-j are relatively unstable compounds. Consequently, 110a-j 
following a rapid silica gel chromatography to avoid decomposition were 
immediately subjected to acid-catalysed hydrolysis to the aldehydes. The 
mechanism of acid-catalysed hydrolysis of enol ether is shown in Figure 2-3(b). 
The delocalisation of the oxygen long pair led to the protonation of the alkenic 
carbon to produce oxonium intermediates 111. The unstable oxonium ions 111 
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were nucleophilically attacked by water to form hemiacetal intermediates 112, 
which subsequently yielded the desired aldehydes 51a-j. 
Initially, the acid hydrolysis of all enol ether derivatives was examined by refluxing 
in a mixture of 1 M aqueous HCl (12 mL) and THF (18 mL). This condition gave  
the homologated aldehydes in moderate yields when R = H (110a), halogens (110b, 
110c, 110d) and ethyl (110e) but less than 10 % yields when R = Me (110f) and 
MeO (110g and 110h). Under the standard acid-catalysed hydrolysis conditions, 
these indoles with an electron-donating subs tituent (110f, 110g, 110h) resulted in 
decomposition.  
Table 2-1 Optimisation of enol ether hydrolysis for 5-methoxy-(E/Z)-3-(2-methoxyvinyl)-1H-
indole (110g). 
 Temperature Solvent Acid Conc. Time 
( h ) 
Observation 
1 Reflux  THF/ H2O HCl 0.1 M 2 product (47 % crude yield ) 
and decomposition 
2 Reflux  Acetone/H2O HCl 0.1 M 2 product (43 % crude yield ) 
and decomposition 
3 Reflux  THF/ H2O HCl  0.4 M 2 product (9 % crude yield) 
and decomposition 
4 Room temp. THF/ H2O HCl 0.1 M 48 no reaction for 3 h, 
decomposition over 48 h 
5 Room temp. THF/ H2O acetic acid 3 eq. 5 starting material and trace 
amount of product 
6 Reflux THF/ H2O acetic acid 3 eq. 2 decomposition 
7 Room temp. THF/ H2O formic acid 3 eq. 5 starting material and trace 
amount of product 
8 Reflux THF/ H2O TsOH 3 eq. 3 decomposition 
9 Room temp. THF/ H2O Hg(OAc)2 1 eq. 3 decomposition 
 
To avoid decomposition of methoxy substituted analogues (110g, 110h), the 
hydrolysis of 110g was studied under various conditions. A systematic evaluation 
of a series of acids and at various concentrations took place. The result of this study, 
summarised in Table 2-1, indicates that heating is required since no hydrolysis 
occurred when the reaction was carried out at room temperature (entry 4). No 
improvement was obtained using acetone/H2O as the reaction solvent (entry 2). 
Moreover, replacing HCl with milder acids, such as acetic acid (entry 6), formic 
acid (entry 7) and toluenesulfonic acid (entry 8)179 also failed to give the product. 
Another attempt by treatment with Hg(OAc)2 followed by KI-induced elimination 
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also failed in this study (entry 9).180 These disappointing results led to the 
consideration of fine balance between the acid concentration and reaction 
temperature. Improved yield (47 %) was obtained by decreasing the HCl 
concentration (entry 1). Although decomposition of 110g cannot be avoided, the 
yield was nevertheless considered acceptable. 
The results of eight analogues are summarised in Table 2-2. To sum up, the 
efficiency of acid hydrolysis of the enol ethers 110a-j is dependent on the aryl 
substitution of the indole ring. Regardless of the substitution positions, indoles with 
an electron-donating substitution 110e-h are more labile to acid-mediated 
decomposition than their counterparts with electron-withdrawing groups 110b-d. 
Hence, the two-step homologation reaction was monitored carefully by TLC to 
avoid the decomposition of the indole subunit.  
Table 2-2 Hydrolysis of (E/Z)-3-(2-methoxyvinyl)-1H-indole (110a-j) 
N
H
N
H
H
O
R R
(E)-110a- j 51a- j
OCH3
H HCl, THF/ H2O
refluxingN
H
R
(Z)-110a- j
H
OCH3
+
 
Starting material 
(E/Z)-110a-j 
R Acid conc. 
(M) 
Reaction time 
(h) 
Crude yield of 
51a-j (%) 
110a H 0.4 2.5  69  
110b 5-Br 0.4 2  74  
110c 5-Cl 0.4 2  74  
110d 6-F 0.4 2  73  
110e 7-Et 0.4 2  65  
110f 5-Me 0.4 1.5  60  
110g 5-MeO 0.1 1.5 55  
110h 4-MeO 0.1 1.5  47  
110i 1-Me 0.4 2  76  
110j 2-Me 0.4 2  70  
 
It is also worth noting that 51a-j are unstable. In fact, the crude homologated 
aldehydes were initially yellow in EtOAc / hexane solution, but on removal of 
solvent the reaction mixtures were gradually decomposed to dark oils which were 
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no longer soluble in EtOAc. Consequently, the crude aldehydes 51a-j were directly 
subjected to Strecker amino acid synthesis.  
2.2.3   Strecker amino acid synthesis 
N
H
HN
CN
N
H
H
O
R R
OH
51a- j 52a- j
 
 a b c d e f g h i j 
R = H 5-Br 5-Cl 6-F 7-Et 5-Me 5-MeO 4-MeO 1-Me 2-Me 
The classical Strecker amino acid synthesis was developed over 160 years ago by 
Adolph Strecker.181 7KLVĮ-amino acid synthesis can be divided into two successive 
steps. The first step is condensation of an aldehyde with an amine in the presence 
of a cyanide salt to form an Į-amino nitrile. The second step is hydrolysis of Į-
amino nitrile to carboxylic acid. In the classical Strecker syQWKHVLV UDFHPLF Į-
amino acid was obtained. Hence, several asymmetric synthesis methods have been 
developed.  
In general, chiral auxiliary reagents for asymmetric Strecker synthesis can be 
divided into two classes. The first uses a chiral catalyst to facilitate an 
enantioselective product.  A number of metal-coordinated catalysts which consist 
of chiral ligands attached to metals such as Al, Ti and Zr have been described to 
provide enantioselective products in good yields.182-184 In addition to metal 
catalysts, several organo-catalysts which comprise a chiral diketopiperazine, 
guanidine or Schiff base have also been developed.185  
The second class uses D FKLUDO LQGXFLQJ DJHQW VXFK DV ȕ-amino alcohol,186, 187 
DPLQR GLROV Į-arylethylamines188-190 and their derivatives to give a 
diasteUHRVHOHFWLYH Į-amino nitrile at different level of chiral purity. The major 
advantages of this class of chiral auxiliaries are (1) most of them are inexpensive  
and easily accessible, (2) their removal can be achieved under mild conditions and 
(3) they tolerate broad range of substrates. Therefore, a chiral inducing auxiliary 
was chosen for the tryptophan derivative synthesis. 
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Initially, the simplest chiral inducing agent (S)-methylbenzylamine 115 was 
introduced in the asymmetric Strecker synthesis of Į-amino nitriles 117a-j. The 
mechanism of the first step condensation is shown in Figure 2-5. The reaction is 
initiated by protonation of the carbonyl oxygen of the aldehyde. The intermediate 
114 is then nucleophilically attacked by the amine 115 to form an imine 116. Next, 
cyanide ion attacks to the iminium carbon to afford aminonitriles 117a-j. In the 
process of nucleophilic addition, the cyano nucleophile is more favourable to attack 
from the less shielded diastereotopic face (re-face) therefore preferentially 
affording (S,S) isomer 117 a-j in excess. 
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Figure 2-5 Mechanism of amino nitrile formation. 
In practice, an one-SRW6WUHFNHUV\QWKHVLVRI WKH Į-amino nitriles was used. Thus, 
one equivalent of amine 115 was added to a mixture of the aldehydes 51a-j, 
sodium cyanide and acetic acid in methanol at 0 °C. The reaction mixtures were 
allowed to warm to room temperature and were stirred for 16 h. However, 
monitoring the progress of the reaction by TLC was found to be difficult since 
starting materials (51a-j) and products (117a-j) showed similar Rf values in many 
solvent pairs. The mixtures were stirred for 16 h, followed by an aqueous work-up. 
The desired products (S,S)-117a-j and (R,S)-117a-j were obtained in 30-70 %  
yield in a ratio of 3 : 1. The diastereomeric ratio of (S,S) and (R,S) was established 
by 1H NMR on the basis of the relative integration between two isomers. Figure 2-
6 illustrates the 1H NMR of crude amino nitrile 117a. The three to one ratio of the 
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two diastereomers was obtained by comparing the integration of the methyl signal 
at į = 1.35 ppm for (S,S)-117a and į = 1.39 ppm for (R,S)-117a. In addi tion, this 
diastereoselectivity was further confirmed by RP-HPLC analysis which is shown in 
Figure 2-7.  
 
 Figure  2-6    1H NMR spectrum of a mixture of amino nitriles (S,S)-117a and (R,S)-117a. 
 
 
 Name Retention time Area % Area Height 
1 (R,S)-117a 6.041 7961803 23.41 575107 
2 (S,S)-117a 7.177 26041955 76.59 2019790 
Figure 2-7  RP-HPLC trace of a mixture of the amino nitriles (S,S)-117a and (R,S)-117a. Peaks 
were identified using MS. The method used was 3-30 % B over 10 min at 3 mL/min (Onyx 
Monolithic C18, 100 x 4.6mm). Eluent detection was monitored by UV absorbance at 216 nm.  
In view of other chiral auxiliaries reported in the literature, which gave higher 
diastereomeric excess, another chiral auxiliary (R)-2-phenylglycinol 118 was 
applied to the asymmetric synthesis (Figure 2-8 (a)). According to the literature, 
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(R)-2-phenylglycinol 118 gave high diastereomeric excess in a broad range of 
substrates and the two diastereoisomers can be separated by column 
chromatography.187, 191, 192 In principle, the hydroxyl group in (R)-2-phenylglycinol  
not only stabilises the predominant reactive conformer 119 by forming a hydrogen 
bond to the imine (Figure 2-8(b)),187 but also facilitates interaction to silica gel 
leading to better chromatographic separation. However, in practice, no differences 
were observed between two chiral auxiliaries. The products were obtained as a 3:1 
mixture of two diastereomers.   
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Figure 2-8 (a) Strecker synthesis using 118 as a chiral auxiliary. (b) Proposed intermediate of 
(R)-2-phenylglycinol induced chiral selectivity.  
Unfortunately, confirmation of the absolute configuration by X-ray 
crystallographic analysis was not achieved since single crystals of neither amino 
nitriles 117a-j nor 52a-j could not be obtained. The major (S,R) configuration 
assigned was based on the literature precedents with simpler substrates.174, 193 
Several attempts also have been made to separate the two diastereisomers by 
fractional crystallisation. However, it was observed that only bromo-substituted 
analogy 52b barely gave crystals. Moreover, these two isomers only showed one 
spot in TLC analysis which suggested column chromatography separation would 
be difficult. Therefore, it was decided that the two diastereisomers would be 
separated at a later stage.    
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The second step of Strecker amino acid synthesis is to hydrolyse Į-aminonitriles to 
WKHLU FRUUHVSRQGLQJ Į-amino acids. Initial attempts to hydrolyse aminonitriles 
117a-j and 52a-j directly to amino acids 120a-j and 121a-j, respectively, were 
found to be difficult (Figure 2-9).  
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Figure 2-9 Hydrolysis of amino nitriles to amino acids. 
Specifically, initial experiments were focused on acid- or base-catalysed hydrolysis 
methods.194-196 The conversion of the aromatic nitrile to the corresponding 
carboxylic acid is a well-established procedure, but for the aliphatic nitrile it was 
not always straightforward. Typical acid- or base-catalysed hydrolysis methods  
require concentrated acid or strong alkali base at high temperatures. As was 
expected, these severe acidic conditions led to the decomposition of the Į-
aminonitriles, and only trace amount of Į-amino acid was detected (Table 2-3, 
entries 1-9).  
On the other hand, it was anticipated that base-catalysed hydrolysis could alleviate 
this problem. Unfortunately, no desired product was detected (entries 10 and 11). 
Moreover, alternative milder condition utilising sonochemistry in the presence of 
low concentration of aqueous HCl was employed (entry 12) .197 Again, no 
satisfactory result was obtained from the ultrasound-assisted hydrolysis. It can be 
concluded from these observations that the harsh acidic or basic conditions were 
detrimental to the indolyl subunit. Hence, alternative approaches were explored. 
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Table 2-3  Acid- and base-catalysed K\GURO\VLVRIWKHĮ-aminonitriles to the amino acids 
 
Acid/ Base Solvent Temp. Time Observation 
1 3 M HCl H2O/THF 69 °C 2 days trace amount of amino acid 
2 3 M HCl H2O/MeOH 70 °C 1 day decomposition, recovery tiny 
amount of starting materials 
3 4 M HCl H2O/THF 
2:1 
78 °C 1 day trace amount of amino acid 
4 6 M HCl H2O/MeOH r.t. 3.5 days decomposition, recovery tiny 
amount of starting materials 
5 6 M HCl H2O only 80 °C 2 days trace amount of amino acid 
6 6 M HCl MeOH 70 °C 1 day decomposition, recovery most 
of starting materials 
7 10 M HCl Dioxane 90 °C 17 h decomposition 
8 12 M HCl H2O 50 °C 3.5 days decomposition 
9 50 % H2SO4 H2O /DCM r.t. 3.5 days decomposition 
10 NaOH MeOH/ 
H2O 
60 °C 20 h decomposition 
11 Ba(OH)2  0.6eq THF/H2O 70 °C 2 days decomposition 
12 2 M HCl THF/H2O 70 °C )))) a 8 h trace amount of amino acid 
a.
 An ultrasonic horn operating at a frequency of 30 kHz was used.   
Another feasible method to convert aminonitriles to amino acids is enzyme-
catalysed hydrolysis. The major advantage of enzyme catalysing the conversion of 
nitrile substrates to its corresponding carboxylic acids is that the decomposition of 
labile functional groups in the subs trates could be avoided. Enzyme catalysis can 
be accomplished via single-step reaction by nitrilase or via two-step reaction by 
nitrile hydratases and amidases.198 There are several nitrilase-contained 
microorganisms which have been introduced to transform nitrile to its 
corresponding acid.198 However, there are few reports on producing amino acid by 
using nitrilase, and neither even mentioning the usage of indole analogy as 
substrate of nitrilase, nitrile hydratases and amidases. The reactivity of these 
enzymes depends on factors including the chemical structure of substrate, pH and 
temperature. Therefore, to identify a microorganism or a nitrilase which are 
capable of hydrolysing aminonitriles 117a-j or 52a-j, large scale screening of 
possible strains and appropriate conditions would be anticipated.   
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Kinetic studies of acid- and base-catalysed hydrolysis of nitrile showed that the key 
obstacle of  conversion of  nitrile to carboxylic acid is hydrolysis of nitrile to 
amide.199 Thus, alternative chemical transformation conditions were investigated 
for the preparation of amino acids 121a-j via amino a mides 53a-j (Figure 2-10). 
N
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R
OH
N
H
HN
COOH
R
OH
N
H
HN
CONH2
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OH
Slow Fast
52a- j 121a- j
53a- j
 
Figure 2-10 Hydrolysis of aminonitriles to acids via amino amides. 
2.2.4    Peroxide hydrolysis of Į-aminonitriles 
N
H
HN
CN
N
H
HN
NH2
O
R R
OH OH
52a- j 53a- j
 
 a b c d e f g h i j 
R = H 5-Br 5-Cl 6-F 7-Et 5-Me 5-MeO 4-MeO 1-Me 2-Me 
           
Thus, a peroxide-mediated method reported by Katritzky was employed.200 
Aminonitriles 52a-j were smoothly transformed into their corresponding amides 
53a-j by reacting with sodium peroxide in the presence of a mild base in dimethyl 
sulfoxide at room temperature. This method not only uses mild reaction conditions, 
but also possesses several advantages, including a short reaction time and ease of 
purification of the desired products.  
The mechanism and kinetics of the reaction was studied by Wiberg et al..201 
Although the stoichiometry of the reaction is normally written as an oxidation-
reduction of hydrogen peroxide with the nitrile, the mechanism of the reaction is 
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not so simple (Figure 2-11(a)). Its specific mechanism can be understood in four-
step sequence which is show n in Figure 2-11(b). The hydrogen peroxide first reacts 
with hydroxide anion to generate HOO
-
. The nucleophile HOO
-
 is added to the 
nitrile to form a peroxycarboximidic acid intermediate 122, which is believed to be 
the rate-determining step of the reaction. After a proton transfer, the 
peroxycarboximidic acid 123 undergoes oxidation-reduction with dimethyl 
sulfoxide (DMSO) to afford the amide and dimethyl sulfone (DMSO2). It is worth 
noting that in this reaction, adding DMSO as a solvent or as an additive 
significantly increases the reaction rate by several hundred times.201   
RCN + 2H2O2 RCONH2 + O2 + H2O
OH-
H2O2 +
-OH HOO- + H2O
RCN + HOO
- RC=N-
OOH
RC=N-
OOH
+ H2O RC=NH
OOH
+
-OH
RC=NH
OOH
+ DMSO RCONH2 + DMSO2
(a)
(b)
122
122
123
123
 
 
Figure 2-11 (a) Reaction of nitriles with alkaline hydrogen peroxide. (b) Proposed mechanism 
of peroxide hydrolysis of nitriles. 
In practice, the aminonitriles 52a-j were dissolved in a small amount of di methyl 
sulfoxide (DMSO) in the presence of a catalytic amount of potassium carbonate. 
The reaction conditions employed an excess of 30 % aqueous hydrogen peroxide at 
room temperature for 2 h. A further quantity of hydrogen peroxide solution was 
added to allow the completion of the reaction. The use of DMSO as the reaction 
solvent was found to be useful as it dissolves aminonitriles very well and is 
miscible with hydrogen peroxide solution. The reaction conversions were clean and 
fast. All aminonitriles 52a-j were converted to the corresponding amides 53a-j in 
50 - 80 % yields. The hydrolysis itself was highly selective, yielding the amide 
with no detectable further hydrolysis to acid. In addition, the 2-position of indole 
system was not oxidised during this treatment. Further optimisation of the yield 
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was achieved by modification of the work-up procedure. DMSO and by-product 
dimethyl sulfone were removed using a simple aqueous extraction without further 
purification. This hydrolysis procedure was subsequently carried out with a mixture 
of two diastereomers (R,R)-52a-j and (S,R)-52a-j to afford corresponding amides 
(R,R)-53 a-j and (S,R)-54a-j. It should be noted that all aminonitriles 52a-j and 
amino amides 53a-j are stable to store at room temperature without noticeable 
decomposition over at least several months. 
2.2.5    Separation of the two diastereoisomers 
N
H
HN
NH2
O
N
H
HN
NH2
O
R
R
OH OH
+
N
H
HN
NH2
O
R
OH
53a- j (R,R)-53a- j (S,R)-54a- j
 
 
 a b c d e f g h i j 
R = H 5-Br 5-Cl 6-F 7-Et 5-Me 5-MeO 4-MeO 1-Me 2-Me 
           
Having a mixture of two diastereomeric amides in hand,  separation of (R,R)-53a-j 
and (S,R)-54a-j was attempted at this stage. Initially, the diastereomeric amides 
were separated using classical recrystallisation methods. The recrystallisation was 
carried out in many different solvents and their combinations. However, very few 
crystals were obtained for mos t analogues. Again, it was observed that only bromo-
substituted (S,R)-53b gave crystals.    
However, it was found that two distinct spots were observed when analysed by 
TLC using CHCl3/MeOH = 6:1 was used as the mobile phase. This observation 
suggested that the two diastereoisomers could be separated by silica gel column 
chromatography. Indeed, the minor isomer (R,R)-53a-j eluted first, followed by the 
major isomer (S,R)-54a-j from a silica gel column using a chloroform-methanol  
(10:1) mixture as the eluent. The major (S,R) amino amides 54a-j were obtained as 
white foams, whereas the minor (R,R) amino amides 53a-j were obtained as yellow 
oils. The ratio of two separated amino amides was approximately 3:1. In addi tion, 
amino amides which were derived from chiral auxiliary 118 gave better separation 
than amino amides that were derivated form chiral auxiliary 115. This observation 
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could be explained by the fact that the hydroxyl group of (R,R)-53a-j and (S,R)-
54a-j makes impor tant interactions with silica gel.  
The 1H NMR of two purified amino amides (R,R)-53h and (S,R)-54h are shown in 
Figures 2-12 and 2-13, respectively. It has been observed in the two 1H NMR 
spectra that the two isomers gave distinct chemical shifts. However, confirmation 
of the absolute configuration by X-ray crystallographic analysis was unsuccessful 
since none of the amino amides could be obtained in a single crystal form. Hence, 
the absolute configuration would be confirmed at the last stage by conversion to 
(S)-tryptophan which can be used to compare with an authentic sample. 
 
Figure 2-12  1H NMR spectrum of (R,R)-53h. 
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Figure 2-13 1H NMR spectrum of (S,R)-54h. 
With the diastereomeric pure amino amides (S,R)-54a-j in hand, attention was 
turned towards hydrolysis of the amides to corresponding amino acids 121 (Figure 
2-14). Several conditions were attempted to hydrolyse 54a-j to the corresponding 
carboxylic acids 121. Besides typical acidic and basic conditions,202 nitrogen 
peroxide has also been examined.203 Although all condi tions gave the desired 
amino acids, the yields were very unsatisfactory (< 10 %). In most cases, the 
reaction led to inevitable decomposition products. Again, these results were 
attributed to the high susceptibility of the indole moiety to the acid treatment. Thus, 
in an attempt to avoid the decomposition problem, instead of converting amino 
amides 54a-j to amino acids 121, the chiral auxiliary of 54a-j was first 
debenzylated by hydrogenolysis to free amines 55a-j (Figure 2-14). 
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Figure 2-14 Hydrolysis of amino amides 54a-j to amino acids 56a-j via removal of the chiral 
auxiliary. 
2.2.6    Removal of the chiral auxiliary 
54a- j 55a- j
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 a b c d e f g h i j 
R = H 5-Br 5-Cl 6-F 7-Et 5-Me 5-MeO 4-MeO 1-Me 2-Me 
           
It is well know n that N-benzyl protecting group can be readily cleaved by catalytic 
hydrogenolysis.204 The debenzylation is generally achieved in the presence of a 
catalytic amount of transition metal catalysts, such as palladium, platinum or 
rhodium on activated carbon under a hydrogen atmosphere. Among these catalysts, 
5-10 % palladium on charcoal (Pd/C) is the most common catalyst to remove 
benzyl protecting groups.204 In some difficult debenzylation, a more reactive 
Pearlman catalyst Pd(OH)2/C can be used.205 The proposed mechanism of 
hydrogenolysis is illustrated in Figure 2-15. With the presence of Pd/C, hydrogen 
gas cleaves into two hydrogen radicals which are absorbed on the catalyst surface. 
The catalyst surface also coordinates the benzyl amine via electron-rich benzyl ring. 
Hydrogen radicals then transfer to the C-N bond of benzyl amine to form a free 
amine and a phenylethyl alcohol. 
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Figure 2-15 Mechanism of hydrogenolysis of modified benzyl amine. 
In practice, a series of hydrogenolytic conditions were examined, and the results of 
which are summarised in Table 2-4. Initial attempt using a catalytic amount of 10 
% Pd on activated carbon (20 % w/w) in MeOH under a balloon of hydrogen (1 
atm, 72 h) did not give the desired amine (entry 1). Pd(OH) has been recommended 
as a more reactive catalyst in the hydrogenolysis of N-benzyl group.205 However, 
even using more reactive and larger amount of catalysts failed to give desired 
amine (entries 2-4). Indeed, it has been reported in the literatures WKDWĮ-substitution 
in the benzyl group prevented debenzylation under standard conditions.206 
Therefore, more vigorous conditions, such as more active catalysts or higher 
pressure of hydrogen gas is required.  
Table 2-4 Catalytic hydrogenation removal of the chiral auxiliary 
Catalyst Solvent H2 source 
Time 
( h ) Result 
1 10 % Pd/ C, 
20 % w/w 
EtOH Balloon of 
H2 
72 Recovery of 
starting material 
2 20 %  Pd(OH)/C, 
20 % w/w 
EtOH/ AcOH = 
1:1 
Balloon of 
H2 
16  Recovery of 
starting material 
3 20 %  Pd(OH)/C,  
100 % w/w 
EtOH Balloon of 
H2 
18  Recovery of 
starting material 
4 20 %  Pd(OH)/C, 
50 % w/w 
EtOH/ AcOH = 
1:1 
Balloon of 
H2 
17  Recovery of 
starting material 
5 10 % Pd/ C, 
100 % w/w 
MeOH HCO2NH4 
5 eq. x 2 
16  65 % yield 
6 10 % Pd/ C, 
100 % w/w 
MeOH HCO2NH4 
2 eq. x 2 
16  Reaction not 
complete 
7 10 % Pd/ C, 
100 % w/w 
MeOH HCO2NH4 
large excess 
16  60 % yield 
8 10 % Pd/ C, 
45 % w/w 
MeOH HCO2NH4 
5 eq. x 2 
20  65 % yield 
9 10 % Pd/ C, 
10 % w/w 
MeOH HCO2NH4 
5 eq. x 2 
20  Reaction not 
complete 
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Several alternative metal catalysts were then considered. However, it has been 
repor ted that in the presence of certain catalysts, such as platinum, nickel, copper 
and palladium hydroxide-barium sulfate, the 2,3-double bond of the indole ring 
might also be reduced.207 Alternatively, catalytic transfer hydrogenation has been 
reported to promote N-debenzylation, in particular to the Į-substituted benzylamine 
(entry 5).208 
Catalytic transfer hydrogenation is typically carried out with a hydrogen source in 
the presence of a Pd/C. A large number of hydrogen donors have been used for 
catalytic transfer hydrogenation, including formic acid,209 cyclohexene, 
cyclohexadiene210 and ammonium formate.211 Among these hydrogen sources, 
ammonium formate is the most convenient and efficient.211 Thus, five equivalents 
of ammonium formate and catalytic amount of 10 % Pd/C were added to a solution 
of the N-benzyl amino amides 54a-j in MeOH. The reaction mixtures were stirred 
at refluxing solvent for 4 h. Monitoring the reactions by TLC after 4 h usually 
revealed the presence of some starting materials. Additional equivalents of 
ammonium formate were added and the reaction mixture were stirred under reflux 
for a further 16 h, after which time TLC analysis showed the absence of starting 
materials. The reaction mixtures were filtered through a pad of Celite, and the 
filtrates were acidified with a small amount of 1 M aqueous HCl. The phenylethyl 
alcohol by-product was removed by liquid-liquid extractions. All non-halogen-
substituted indole derivatives 54a, 54d, 54e, 54f, 54g, 54h, 54i, 54j were converted 
to the corresponding amines 55a, 55d, 55e, 55f, 55g, 55h, 55i, 55j in 50-80 % 
yields. The identity of the products was confirmed by mass spectrometry, 1H and 
13C NMR analysis. 
Studies were also carried out to determine the amount of catalysts and hydrogen 
donor required for optimum N-debenzylation. The results show that adding 5 eq. of 
ammonium formate twice in the presence of 45 % w/w catalyst was ideal (Table 2-
4, entries 5-7). The rate of the reaction decreases substantially when only 2 eq. of 
ammonium formate was added. On the other hand, a large excess of ammonium 
formate does not increase the reaction rate, but made the removal of excess 
ammonium formate rather cumbersome. Similarly, 30 - 50 % w/w of Pd/C is ideal 
for the reaction (entries 8 and 9).  
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Figure 2-16 Competitive dehalogenation by hydrogenolysis. 
However, limitations were encountered in the hydrogenolytic N-debenzylation of 
halogen-substituted indoles 54b and 54c. Hydrogenolysis of 54b and 54c led to 
concomitant dehalogenation, resulting in 54a as a major product (Figure 2-16).212 
Only fluoro-substituted analogy 54d gave desired product 55d without causing 
dehalogenation. In addition, an interesting observation was obtained during 
monitoring the reaction. As show n by 1H NMR and mass analysis, the mixture of a 
dehalogenated starting material 54a and a dehalogenated product 55a were formed 
during the reaction. This observation suggested that dehalogenation occurred prior 
to debenzylation. Although hydrogenolysis over a heterogeneous palladium 
catalyst for the N-Į-substituted benzyl group are well established, selective removal 
of the N-Į-subs tituted benzyl group in the presence of bromo- and chloro- 
substitution remains unexplored in literatures.  
Consequently, several attempts on the selective removal of N-benzyl group in the 
presence of aryl halide were outlined in Table 2-5. A similar problem has been 
reported for the selective hydrogenolysis of O-benzyl groups in the presence of an 
aryl chloride. Li et al. found that the use of chloride salt provided the desired 
selectivity.212 The reported conditions were evaluated; unfortunately, no desired 
products were observed by adding ammonium bromide and ammonium chloride 
for the debenzylation of 54b and 54c, respectively (entries 2 and 3). This result was 
attributed to the higher stability of benzyl amine. Moreover, an alternative 
approach utilising microwave irradiation in the presence of 1,4-cyclohexadiene 
with Pd/C was employed.213 Again, no satisfactory conversion was obtained (entry 
4). Another method reported by Srinivasa et al. to the hydrogenolysis of benzyl 
group tolerating halogen substituents was appl ied (entry 5).214 No conversion 
occurred during the process. Lastly, replacing the protic solvent MeOH by an 
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aprotic solvent EtOAc to suppress the dehalogenation was also unsuccessful (entry 
6).   It was concluded that the reductive removal of N-Į-substituted benzyl group in 
the presence of aryl halides (Br and Cl) was not feasible. Therefore, alternative 
methods for removal of N-Į-substituted be nzyl group need to be investigated.  
Table 2-5 Catalytic transfer hydrogenation of N-Į-substituted benzyl group 
54b, 54c
N
H
HN
CONH2
OH
X
N
H
NH2
CONH2
X
hydrogenolysis
55b, 55c
 
 X Catalyst Solvent H2 source Conditions Observation 
1 Cl Pd/ C (40 % 
w/w) 
MeOH HCOONH4 reflux, 26 h Dechlorinated 
product  
2 Cl Pd/ C (40 % 
w/w), NH4Cl 
MeOH HCOONH4 reflux, 20 h Dechlorinated 
product 
Br Pd/ C (40 % 
w/w), NH4Br 
MeOH HCOONH4 reflux, 20 h Debrominated 
product 
3 Cl Pd/C (10 % 
w/w), NH4Cl 
MeOH HCOONH4 M.W. (100W), 30 
min, 100 °C 
Dechlorinated 
product 
4 Cl Pd/C (10 % 
w/w) 
MeOH 1,4-
cyclohexadiene 
M.W. (100W), 30 
min, 100 °C 
Major spot is 
starting material 
5 Br Zn dust   1 eq. MeOH HCOONH4 reflux, 17 h No reaction 
6 Cl Pd/ C (40 % 
w/w) 
EtOAc HCOONH4 reflux, 26 h Major spot is 
starting material 
 
Because of the competing dehalogenation associated with the removal of the chiral 
auxiliary 118, an alternative chiral auxiliary (S)-4-methoxy-Į-methylbenzylamine 
(124) was employed. This chiral auxiliary provides advantages over the benzyl 
counterpart, since the N-4-methoxy-Į-methylbenzyl (N-PMB) group can be readily 
removed by reductive, oxidative, acidolytic and other methods .215  
H2N
OCH3
124
 
 
Initially, it was anticipated that the higher electronic density of the aromatic ring 
would accelerate the reaction rate of debenzylation by hydrogenolysis (Table 2-6, 
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entry 1). However, the result showed that dehalogenation problem remained the 
same. Hence, an oxidative approach using ceric ammonium nitrate (CAN) or 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) would be useful as an alternative 
method (entries 2 and 3).216 Unfortunately, the reaction was not as straightforward 
as suggested by the literatures,216, 217 since unreacted starting material and 
unidentified by-products were obtained.  
Table 2-6  Removal of the N-4-methoxy-Į-methylbenzyl group 
N
H
HN
CONH2
X
N
H
NH2
CONH2
X
OMeX = Br or Cl
125b, 125c
55b, 55c
 
 
 Catalyst H2 source Temp./ Time (h) Observations 
R
ed
uc
tiv
e 1 Pd/C 
20% w/w 
HCOONH4 reflux/ 23 Dehalogened starting material + 
dehalogened product 
O
x
id
at
iv
e 
 Oxidative 
reagent 
Solvent Temp./ Time (h) Result 
2 DDQ DCM/H2O 
5:1 
r.t./ 16  Starting material 
3 CAN MeCN/ H2O 
5:1 
r.t./ 16  Starting material 
A
ci
do
ly
sis
 
 Acid Scavenger Temp./ Time (h) Observations 
4 Neat TFA - r.t. / 17  No reaction, but no decomposition 
5 Neat TFA - 70 °C/ 24  Starting material and tiny product  
6 Formic acid Et3SiH 90 °C/ 1  Starting material and  product 
7 Neat TFA iPr3SiH r.t. / 24  Starting material and  tiny product 
8 Neat TFA iPr3SiH 60 °C/ 24  Product + tiny amount of starting 
material 
9 Neat TFA iPr3SiH 60 °C/ 41  Product  
  
Since both the reductive and oxidative approaches were unsuccessful, the 
acidolysis approach was investigated.218 Initially, no product was detected by 
treatment of 125b with trifluoroacetic acid at ambient temperature (entry 4). Hence, 
the reaction mixture was heated to 70 °C for 24 h. Gratifyingly, the mass spectrum 
of crude mixture showed formation of the desired product. Several reaction 
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conditions including the acid reagents, reaction time and the use of scavengers 
were evaluated (entries 6 - 9).219 It was clear that the best result was obtained by 
heating 125b with TFA at 60 °C in the presence of triisopropylsilane (TIPS) for 41 
h. Notably, the addition of TIPS, which is capable of irreversibly scanverging the 
reactive 4-methoxy-Į-methylbenzyl cation is required. After TFA was removed in 
vacuo, the by-product was removed by trituration to afford amino amide as a 
trifluoroacetate salt in more than 90 % crude yield. Having established suitable 
reaction conditions, the other halogen analogue 125c was also acidolysed to 55c. 
ES-MS and 1H NMR revealed the presence of the desired free amines 55b and 55c. 
In summary, catalytic transfer hydrogenation has been demonstrated to be an 
effective method for the removal of N-Į-substituted benzyl group. Selective 
removal of N-benzyl groups in the presence of an aryl halide required introducing 
4-methoxy-Į-methylbenzylamine as a chiral auxiliary. By employing a TFA-
mediate acidolysis procedure, it was established that PMB group could be 
efficiently deprotected to give the free amines in good yields.  
2.2.7    +\GURO\VLVRIĮ-DPLQRDPLGHVWRĮ-amino acids 
N
H
NH2
COOH
N
H
NH2
NH2
O
R R
55a- j 56a- j
 
 a b c d e f g h i j 
R = H 5-Br 5-Cl 6-F 7-Et 5-Me 5-MeO 4-MeO 1-Me 2-Me 
           
In order to find the appropriate reaction conditions for the hydrolysis of Į-amino 
amides 55a-j without causing decomposition, the first attempt was to use a very 
mild condition in aqueous solution of sodium peroxide.220 MS analysis after 3 h 
reaction time revealed the presence of desired amino acids 56a-j. However, the 
reaction only gave the desired products in low yields. In addition, large amount of 
salts produced from neutralising the basic reaction mixtures was found to be 
difficult to separate from the products. Hence, the focus of the studies was returned 
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to the classical acid-catalysed hydrolysis. The reaction mechanism was illustrated 
in Figure 2-17. Strong acid and heating are required for the efficient transformation.  
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Figure 2-17 Mechanism of acid-catalysed hydrolysis of amides. 
Initially, 55a-j were treated with 5 M aqueous HCl under reflux. It was anticipated 
that high concentration of acid could result in decomposition of the starting 
materials. Surprisingly, TLC analysis after 2 h revealed the absence of starting 
materials (Rf = 0.7) and the presence of the products (Rf = 0.5), and some 
impurities. It is noteworthy to mention that the reactions were monitored by both 
silica TLC and neutral alumina TLC. The plates were eluted with a mixture of n-
butanol: acetic acid: water, 3: 1: 1 v/v followed by ninhydrin stain; the amino 
amides 55a-j appeared yellow colour whereas the resulting amino acids 56a-j 
appeared purple colour on TLC plates. Further optimising the conditions 
gratifyingly established that the hydrolysis of 55a-j were accomplished in good 
yields (> 95 %) by heating with 1 M hydrochloric acid for 5 h.  The reaction 
conversions were clean and no decomposition of 55a-j were observed.  
1H and 13C NMR (D2O) analyses of 55a-j revealed that no differences were 
observed between the amides and carboxylic acids. Since the starting materials and 
the products displayed almos t identical chemical shifts in NMR spectroscopy, the 
identity of the desired products was confirmed by mass spectrometry. Moreover, 
MS analysis of the products needs to be careful, as the m/z of the acids are only 1 
mass less than the amide counterparts. For example, the successful conversion of 
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55e to 56e was confirmed by disappearance of the amide (m/z = 232.1390) and the 
presence of a molecular ion at m/z = 233.1174 accounting for the acid 56e.  
2.2.8    Fmoc-protection of tryptophan derivatives 
N
H
NH2
COOH
N
H
NHFmoc
COOH
R R
56a-k 43a-k
 
 a b c d e f g h i j k 
R = H 5-Br 5-Cl 6-F 7-Et 5-Me 5-MeO 4-MeO 1-Me 2-Me 5-F 
The final step i n the synthesis of tryptophan-based building blocks is the protection 
RI WKH Į-amino group with Fmoc. The Fmoc (fluorenylmethoxy carbonyl) 
protection group is required for the solid-phase peptide synthesis of argyrin and 
analogues thereof. Typically, Fmoc-protection is carried out by reaction with a 
stoichiometric amount of Fmoc-OSu or Fmoc-Cl under basic conditions. The 
reaction mechanism is illustrated in Figure 2-18.221 
N
H
NH2
R
O
O-
+ OO
O
NO O
N
H
HN
R
O
O-
O-
O
O
N O
O
N
H
HN
R
O
O-
O
O
N
OH
O
O
56
43
 
Figure 2-18 Mechanism of N-Fmoc protection using Fmoc-OSu. 
One major advantage of the Fmoc group is its stability towards acidic conditions, 
allowing selective removal of acid-labile protection groups like Boc and t-butyl 
groups.222 The advantage of using Fmoc-OSu rather than Fmoc-Cl is that Fmoc-
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OSu eliminates the possibility of the formation of undesired anhydride side-product 
during the acylation reaction. 221 
Hence, tryptophan hydrochloric salts 56a-k were dissolved in THF or acetone 
depending on their solubility. Two equivalents of aqueous sodium carbonate 
solution and one equivalent of Fmoc-OSu in THF were added. The solution was 
then stirred vigorously at room temperature for 2 -16 h. Subsequently, the reaction 
mixtures were subjected to an aqueous work-up followed by acidification to afford 
the final product 43a-k. The yields of eleven analogues 43a-k are listed in Table 2-
7.  
Table 2-7   N-Fmoc protection of tryptophan derivatives 43a-k. 
Starting material Product Yield 
(%) 
Melting point 
(°C) 
>Į@D24 
(c 1.0,MeOH) 
56a Trp 43a Fmoc-Trp-OH 64 182-185 - 29 
56b 5-Br-Trp 43b Fmoc-5-Br-Trp-OH 20 130-132 - 23 
56c 5-Cl-Trp 43c Fmoc-5-Cl-Trp-OH 20 98-99 - 16 
56d 6-F-Trp 43d Fmoc-6-F-Trp-OH 50 102-104 - 19 
56e 7-Et-Trp 43e Fmoc-7-Et-Trp-OH 50 146-148 - 26 
56f 5-Me-trp 43f Fmoc-5-Me-trp-OH 66 178-179 - 15 
56g 5-MeO-Trp 43g Fmoc-5-MeO-Trp-OH 82 198-200 - 23 
56h 4-MeO-Trp 43h Fmoc-4-MeO-Trp-OH 62 168-171 - 27 
56i 1-Me-Trp 43i Fmoc-1-Me-Trp-OH 74 92-94 - 24 
56j 2-Me-Trp 43j Fmoc-2-Me-Trp-OH 40 182-185 - 15 
56k 5-F-(S/R)-Trp 43k Fmoc-5-F-(S/R)-Trp-OH 50 196-197 not applicable 
 
The purity of the final products was established using analytical RP-HPLC. For 
example, a one major peak observed at tR = 10.0 min by analytical RP-HPLC 
confirmed the purity of Fmoc-5-Cl-Trp-OH 43c (Figure 2-19). Additionally, the 
identity of the products was confirmed by mass spectrometry and 1H and 13C NMR 
analysis. The stereochemical-identity was confirmed by determination of specific 
optical rotation >Į@D (Table 2-7). All Fmoc-tryptophan analogues showed 
levorotations which corresponds to the (S)-configuration in the literature.164  
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 Retention time Area % Area Height 
1 7.838 546350 4.31 67652 
2 10.078 12137618 95.69 1950883 
Figure 2-19 Analytical HPLC of Fmoc-tryptophan derivative 43c. Analysed using 10-60 % B 
over 10 min at 3 mL/ min on an Onyx Monolithic C18 column (100 x 4.6 mm). Eluent detection was 
monitored by UV absorbance at 216 nm.  
The optical purity of 43a-j was established by their specific optical rotations.  The 
observed specific optical rotations >Į@24D -29°, -23° and -19° ( c = 1.0 in methanol) 
for N-Fmoc-(S)-tryptophan (43a), N-Fmoc-5-methoxy-(S)-tryptophan (43g) and N-
Fmoc-6-fouro-(S)-tryptophan (43d), respectively, are comparable to the values 
reported in the literature >Į@25D  -28°, -24.5° and -16.8° (c = 1.0 in methanol).164 
The closely matched optical rotations suggest that the obtain Fmoc-tryptophan 
derivatives are of good enantiomeric purity.  Moreover, this finding is in agreement 
with the hypothesis of the chiral induction described in Section 2.2.3 could install S 
configuration as the major product. The obtained Fmoc-protected tryptophan 
building blocks were used for the Fmoc solid phase peptide synthesis which will be 
discussed in Chapter 4.                     
2.3 Conclusion 
A novel eight-step synthetic route has been developed for the construction of 
tryptophan analogues with high enantiomeric purity. This synthetic route enabled 
the synthesis of N-Fmoc-(S)-tryptophan derivatives from the corresponding indoles. 
As a result, the synthesis of tryptophan derivatives with a wide range of functional 
groups at various positions of the indole moiety was achieved.  
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R   = H 5-Br 5-Cl 6-F 7-Et 5-Me 5-MeO 4-MeO 
R’  = OH H H OH OH OH OH OH 
R’’ = H OCH3 OCH3 H H H H H 
Figure 2-20 Synthesis Fmoc-tryptophan derivatives (43); Reagents and conditions: (a) POCl3, 
DMF, 0 °C then 45 °C; (b) i. Ph3PCH2OCH3, n-BuLi; ii. HCl, THF, reflux; (c) Chiral auxiliary, 
NaCN, AcOH, MeOH; (d) H2O2, Na2CO3, DMSO; (e) Recrystallisation or HPLC; (f 1) Pd/ C, 
NH4HCO2, MeOH, reflux; (f 2) TFA, TIPS, 60 °C; (g) 1 M HCl, reflux; (h) Fmoc-OSu, NaHCO3, 
THF,/H2O. 
As summerised in Figure 2-20, commercially available indoles were subjected to 
Vilsmeier formylation to give aldehydes 50a-j which were then homologated via 
Wittig reaction followed by acid hydrolysis of enol ether intermediates to afford 
aldehydes 51a-j. The diastereoselective Strecker amino acid synthesis was 
achieved by using (R)-2-phenylglycinol as chiral auxiliary to give a 
diastereoisomeric mixture of (S,R)- and (R,R)-Į-aminonitriles 52a,d-j in 3 : 1 ratio. 
The mild peroxide hydrolysis condition was employed for the conversion of acid 
ODELOH Į-aminonitriles 52a,d-j WR FRUUHVSRQGLQJ Į-amino amides 53a,d-j.  
Subsequent separation of the major (S,R Į-aminoa mides 54a,d-j were readily 
obtained by silica gel column chromatography. The removal of chiral auxiliary was 
carried out using the catalytic transfer hydrogenation to afford (S)-tryptophan 
amide derivatives 55a,d-j. In the case of the two halogen indole derivatives, 54b 
and 54c, N-debenzylation was accompanied by dehydrogenation. This problem was 
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overcome by introducing PMB as a chiral auxiliary (Figure 2-20, R’ = H, R’’ = 
OCH3). The removal of N-PMB was then carried out using TFA-mediated 
acidolysis. Subsequent hydrolysis of all (S)-tryptophan amide derivatives 55a-j to 
the corresponding (S)-tryptophan derivatives 56a-j was accomplished by refluxing 
in 1 M aqueous hydrochloric acid for 5 h without causing decomposition. Finally, 
the N-terminus of amino acids was protected with Fmoc to afford 43a-j which are 
suitable for the Fmoc solid phase peptide synthesis. All the intermediates reported 
are of good or reasonable purity and are fully characterised. The spectral data of all 
intermediates are in good agreement with the proposed structures. 
The characteristic data of the synthetic Fmoc-(S)-tryptophan and Fmoc-5-bromo-
(S)-tryptophan are consistent with the data reported in the literatures. The 
cumulative yields over this eight-step synthesis ranged from 2 to 5 %, due to the 
sensitivity of indole moiety, especially indoles with electron-donating groups. In 
comparison to literature synthesis, this route can be accessed with inexpensive 
commercially available reagents, and avoids using expensive chiral auxiliaries or 
resolving reagents.  
 
Chapter 3 Synthesis of two key building blocks of argyrin A 
-94- 
 
Chapter 3  
Synthesis of two key building 
blocks of argyrin A 
As outlined in Section 1.5, the other two unusual amino acid building block of 
argyrin A are the dipeptide (R)-2(1-tert-butoxycarbonylamino)ethyl)thiazole-4-
carboxylic acid and Įȕ-dehydroalanine. The aim of the research presented in this 
chapter is to synthesis thiazole- and oxazole-containing dipeptides and the 
SUHFXUVRURIWKHĮȕ-dehydroalanine analogues using existing procedures. 
3.1 Synthesis of (R)-2(1-tert-butoxycarbonylamino)ethyl)thiazole-
4-carboxylic acid 
(R)-2(1-tert-butoxycarbonylamino)ethyl)thiazole-4-carboxylic acid, or abbreviate 
as N-Boc-(R)-Ala-Thz-OH (44), is a thiazole-containing dipeptide. The thiazole 
ring, which is a member of the azole heterocycles, has great aromaticity due to the  
conjugated ʋ electron and a planar ring system. The thiazole moiety is abundantly 
found in secondary metabolic products of algae, fungi and marine organisms. In 
particular, a large number of these thiazole-containing secondary metabolites are 
peptide derivatives, many of which possess significant biological activities.223 For 
example, hectochlorin isolated from a marine organism showed cytotoxic activities 
and is able to promote actin polymerisation.224 The cyclic hexapeptide bistratamide 
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C and dolastatin 1 also exhibit cytotoxic activities.225 However, the biological 
mode-of-action of these thiazole-containing compounds are poorly understood.  
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The biosynthetic pathway of these thiazole-containing amino acids was believed to 
be derived from the condensation of peptide precursors with cysteine, followed by 
cyclisation and oxidation.226 Figure 3-1 shows biosynthetic pathway of the 
thiazole-containing amino acids derived from cysteine-containing peptidyl moiety. 
Cysteine side chain was reacted with preceding carbonyl group to generate 5-
membered heterocycle ring, followed by dehydration to give thiazoline. Oxidation 
of thiazoline resulted in the heteroaromatic thiazole system. In contrast to the 
biosynthesis, two chemical synthetic routes have been established and these are 
discussed in Sections 3.1.1 and 3.1.2.  
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Figure 3-1 Proposed biosynthetic pathway of thiazole-containing amino acids 
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3.1.1   Shioiri’s approach  
In the course of synthesis of cytotoxic cyclic peptides, Shioiri and colleagues in 
1987 reported a synthetic route towards optically pure thiazole amino acids.227 The 
five-step synthesis is outlined in Scheme 3-1. The synthesis is similar to the 
biosynthetic route, which uses cysteine and (R)-alanine as building blocks. The key 
feature of Shioiri’s approach is condensation of N-SURWHFWHGĮ-(R)-amino aldehyde 
128 with cysteine methyl ester forming thiazolidine derivative 129 (step d, Scheme 
3-1), followed by oxidative dehydrogenation of thiazolidine with manganese 
dioxide. 
126 127
128 129
130
H
N OH
O H
N OCH3
O H
N OH
H
N
O
S
N
H
CO2CH3
H
N
S
N
CO2CH3
H
N
O
O
O
O
O
O
O
O
O
O
O
O
a b
c d
e
 
Scheme 3-1 Synthesis of N-Boc-(R)-Ala-Thz-OEt (130) by Shioiri’s s group; Reagents and 
conditions: (a) CH3I, KHCO3, DMF; (b) NaBH4, LiCl, THF/EtOH; (c) DMSO, pyridine-SO3, Et3N; 
(d) (S)-Cys-OMe, benzene; (e) MnO2, benzene.  
Firstly, in order to prepare the N-SURWHFWHG Į-(R)-amino aldehyde 128, 
commercially available Boc-(R)-Ala-OH was converted to the corresponding 
methyl ester 126, which in turn was selectively reduced to the FRUUHVSRQGLQJĮ-(R)-
amino alcohol 127 under standard conditions. The transformation of (R)-amino 
alcohol 127 to N-SURWHFWHGĮ-(R)-amino aldehyde 128 was then achieved by Parikh-
Doering oxidation. The subsequent condensation of aldehyde 128 with cysteine 
methyl ester afforded the thiazolidine derivative 129 as a mixture of C-4 epimers. 
Finally, oxidation of thiazolidine derivative 129 to the N-Boc-(R)-Ala-Thz-OEt 130 
was accomplished by treatment with manganese dioxide. The cumulative yield of 
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this approach was around 50 % in high enantiomeric excess (> 99 %). In general, 
although this method gave products in good yield, it was later established that the 
manganese dioxide oxidation step was rather ineffective.228, 229  
3.1.2   Modified Hantzsch thiazole synthesis 
Another route for the preparation of thiazole-containing amino acid involved a 
modified Hantzsch thiazole synthesis. The Hantzsh condensation was first reported 
in 1889. Since then, this reaction has been widely used for the synthesis of 
thiazole-containing amino acid derivatives.230 However, this method only yields 
racemic thiazole amino acids, even when starting with chiral precursors. Later, 
Schmidt et al. successfully modified the Hantzsch synthesis to produce 
enantiomerically pure thiazole amino acids in satisfactory yield.231 
The four-step modified Hantzsch synthesis has become one of the most reliable 
route to thiazoles.230 The key feature of Hantzsch thiazole formation involved the 
treatment of thioamides with ethyl bromopyruvate, followed by aromatisation to 
afford thiazole amino acid derivatives (steps c and d, Scheme 3-2). The 
methodology of each step will be detailed in the following four sections.  
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Scheme 3-2 Synthesis of N-Boc-(R)-Ala-Thz-OH (44);  Reagents and conditions: (a) DCC, HOBt, 
NH3, CH2Cl2, 0 °C; (b) Lawesson’s reagent, THF, 0 °C; (c) i. BrCH2COCO2Et, KHCO3, DME, -15 °
C; ii.TFAA, 2, 6-lutidine, DME, -15 °C; (d) LiOH, THF/ MeOH/ H2O, room temp. 
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3.1.2.1 Preparation of N-Boc-(R)-Ala-NH2 
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The initial step was the amidation of N-Boc-(R)-Ala-OH. Į-Carbonyl was activated 
by using a mixture of N,N’-dicyclohexylcarbodiimide (DCC) (131) and 1-
hydoxybenzotriazole (HOBt) (132), to yield the reactive acylating agent for a 
further nucleophilic acyl subs titution with ammonia. The mechanism of amination 
is shown in Figure 3-2.  
O
H
N
O
O-
O
N C N O
H
N
O
O
O
C
NH
N
N
N
N
O-
O
H
N
O
O
O
N
NN
NH3
O
H
N
O
NH2
O
C
O H
N
H
N
131
132
133
57
H+
 
 
Figure 3-2 Mechanism of DCC and HOBt mediated amide formation 
DCC (131) is one of the carbodiimide reagents that has been commonly used in 
peptide synthesis since 1955.232 The auxiliary reagents, such as 1-hydroxy-7-
azabenzotriazole (HOAt) and 1-hydroxybenzotriazole (HOBt) (132), not only 
suppress racemisation, but also enhance the reactivity.233 The advantages of using 
DCC/HOBt coupling reagent are their relatively low prices and their by-product, 
urea (133) which is insoluble in most solvents and hence readily separable from the 
product. 
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Hence, DCC and HOBt were added to a solution of N-Boc-(R)-Ala-OH in DCM at 
0 °C. The solution was warmed to room temperature and stirred for 1 h. The 
solution was cooled to 0 °C again and then was mixed with a solution of 0.5 M 
ammonia in dioxane or methanol. The reaction mixture was stirred vigorously for 1 
h at room temperature. The suspension was filtered, and the filtrate was 
concentrated and purified to afford N-Boc-(R)-Ala-NH2 (57) in quantitative yield. 
This transformation was confirmed by 1H NMR analysis, which revealed the 
disappearance of the carboxylic acid proton (į = 12.01 ppm) in the starting material 
and the appearance of the NH2 protons (į = 6.07 and 6.56 ppm) in 57. 
3.1.2.2 Thionation of N-Boc-(R)-Ala-NH2 
O
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In the second step, a thionation reaction was carried out where the carbonyl (C=O) 
was converted to a thiocarbonyl (C=S) functionality. The thionation can be easily 
achieved by thionation reagent such as Belleau’s reagent,234 Lawesson’s reagent235 
and phosphorus pentasulfide.236 Among these thionation reagents, Lawesson's 
reagent (134) is one of the most convenient and cheap reagent for the conversion of 
ketones, esters, and amides to the corresponding thioketones, thioesters and 
thioamides.235 Indeed, better yield was obtained by using Lawesson's reagent (86 
%) than Belleau’s reagent (36 %). The mechanism of thionation with Lawesson’s 
reagent is shown in Figure 3-3. 
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Figure 3-3 Mechanism of thionation with Lawesson’s reagent 
In solution, Lawesson’s reagent (134) forms two reactive dithiophosphine ylides 
(135) which can react with electron rich carboxamide to give a thiaoxaphosphetane 
intermediate (136). The intermediate then undergoes spontaneous cycloreversion, 
resulting in the formation of the P=O bond and the thioamide 58. It is noteworthy 
to mention that this cycloreversion step resembles the final step of Wittig reaction 
which was described in Section 2.2.2.    
Hence, Lawesson’s reagent (0.6 eq.) was added to a solution of N-Boc-(R)-Ala-
NH2 (57) in THF at 0 °C. The mixture was stirred at room temperature for 40 min. 
Having largely removed the excess Lawesson’s reagent and by-product in an 
aqueous work-up, further purification afforded the desired thioamide 58 in 56-86 % 
yield (mp. 94-96 °C, literature 104-105 °C150). Successful thionation of 57 was 
further confirmed by FT-IR and 13C NMR analysis. Specifically, FT-IR with an 
absorption at 1241 cm-1 accounted for the distinct C=S stretching. Additionally, 13C 
NMR showed the disappearance of carbonyl group at į = 176.03 ppm in the 
starting material 57 and the appearance of thiocarbonyl group at į = 210.58 ppm in 
58. 
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3.1.2.3 Modified Hantzsch thiazole formation 
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The modi fied Hantzsch reaction is the key step for  the thiazole synthesis. A 
combination of the two-step reaction is required for the formation of the N-Boc-
(R)-Ala-Thz ethyl ester 59 from the N-Boc-(R)-Ala-thioamide 58. The mechanism 
of the two-step thiazole formation is shown in Figure 3-4. The reaction begins with 
condensation of thioamide 58 with ethyl bromopyruvate 137 in the presence of 
finely powdered KHCO3 to give hydroxythiazoline derivative 138. It has been 
shown that isolation or storage of hydroxythiazoline 138 leads to racemisation via 
an imine-enamine equilibration.237 Without isolating the intermediate 138, 
activation of the hydroxyl group of hydroxythiazoline with trifluoroacetic 
anhydride (TFAA) forms a good leaving group which could be eliminated to give 
the thiazole amino acid derivative 59. 
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Figure 3-4 Mechanism of Hantzsch thiazole formation from thioamide 
In order to prevent racemisation caused by the imine-enamine equilibration of 
thiazoline intermediate, various dehydration conditions were extensively 
investigated by other groups to suppress the tautomerisation. Mayers et al. 
established the best conditions which used a bulky base 2,6-lutidine and lowers the 
reaction temperature to -15 °C giving an ee > 99 %, in yield of 96 %.238 Hence, the 
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solution of N-Boc-(R)-Ala-thioamide 58 in dry dimethoxyethane (DME) was 
cooled to -15 ° C and was treated with ethyl bromopyruvate in the presence of 
excess of finely powdered potassium bicarbonate. The mixture was stirred 
vigorously for 5 min, and the solution of 2,6-lutidine and trifluoroacetic anhydride 
in DME was added in one portion at  -15 °C. After stirring at -15 °C for 1 h, TLC 
analysis revealed the absence of thiazoline intermediate 138. The mixture was 
subjected to an aqueous work-up and subsequent column chromatography gave the 
(R)-Ala-Thz ethyl ester 59 in an overall yield of 49 %. 
The identity of the product was confirmed by NMR analysis, mass spectrometry 
and melting point. Specifically, the distinctive singlet C5-H signal appearing at į = 
8.08 ppm in 1H NMR revealed the formation of the thiazole ring. MS (ESI+) 
detected a peak at m/z 323.1144 corresponding to the calculated value for the 
[M+Na]+ species of 59. However, the melting point obtained for 59 (mp = 80-82 
°C) was five degree lower than the value found in the literature (mp = 85-86 °C 150). 
The melting point depression can be attributed to amorphous solid or small 
impurities in the sample. The stereo-identity was confirmed by two independent 
methods: Determination of specific optical rotation >Į@D and using Mosher’s chiral 
derivatising agent. The details will be discussed in Section 3.2. 
3.1.2.4 Saponification of ester to carboxylic acid 
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The final step for the preparation of the Boc-(R)-Ala-Thz-OH is the hydrolysis of 
the ethyl ester. The thiazole amino acid 44 is required as a building block in SPPS 
of argyrin. Esters can undergo hydrolysis in both acidic and basic conditions. 
However, acid-catalysed hydrolysis is of limited use because of the protected N-
Boc would also be cleaved in acid conditions. Therefore, hydrolysis under basic 
conditions, also known as saponification, was chosen. Typically, saponification of 
ester is carried out in an aqueous alkali, such as sodium hydroxide or lithium 
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hydroxide, and is usually completed within few hours. The mechanism of base-
catalysed hydrolysis of the ester is illustrated in Figure 3-5.  
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Figure 3-5 Base-catalysed hydrolysis of ester 
Hence, (R)-Ala-Thz ethyl ester (59) and lithium hydroxide were dissolved in 
MeOH / H2O (1:1) mixture. As the thiazole ester 59 was poorly soluble in water, 
addition of MeOH was required. The solution was stirred for 18 h. TLC analysis 
revealed the absence of starting material and the presence of product at the baseline. 
Unexpectedly, an additional spot was observed in TLC, which was assumed to be 
the solvent-facilitated transesterfication by-product. This hypothesis was further 
confirmed by ES-MS and 1H NMR analysis. In order to avoid transesterfication 
during the hydrolysis, the MeOH / H2O mixture was replaced by THF / H2O. 
However, changing the solvent mixture resulted in lower reaction rates. By 
carefully adjusted solvent ratio of THF/H2O/MeOH to 15:13:10, the desired 
product 44 was obtained in 88 % yield.    
The purity of the final product was established using analytical RP-HPLC. The 
single peak observed in analytical HPLC confirmed the purity of the (R)-Ala-Thz-
OEt building block. MS (ESI+) detected a peak at m/z 295.0562 that corresponded 
to the calculated value for the [M+Na]+ species of 44. Furthermore, 1H and 13C 
NMR analysis confirmed the absence of ethyl ester signals and no methyl ester 
peak was detected. Therefore, the obtained dipeptide building block 44 was ready 
for the Fmoc solid phase peptide synthesis which will be discussed in Chapter 4.                     
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3.2 Determination of chiral purity by Mosher’s reagent 
Determination of chiral purity can be achieved by numerous methods. Before 1960, 
the chiral purity of molecules relied on the measurement of optical rotation of the 
sample.239 The value which was measured by a polarimeter under defined solvent, 
concentration and temperature can be compared to the optical rotation of the 
known enantiomerically pure sample. Today, measurement of optical rotation 
remains one of the most convenient methods for the indication of optical purity. 
However, there are two major limitations of this method. Firstly, the optical 
rotation is not perfect linear function of the enantiomeric composition. As a result, 
no accurate enantiomeric composition can be observed by this method. Secondly, 
the use of optical rotation for determination of chiral purity is subject to the some 
variability, including temperature, concentration and contamination. Given these 
two limitations, other independent methods have been developed to accurately 
determine the chiral purity.     
The two major independent methods have been widely used to determine the 
optical purity. One method is employing analytical chiral HPLC or GC containing 
the single enantiomer of a chiral compound in the stationary phase.240 The other 
method involves NMR analysis following derivatisation with a chiral reagent.241 
The principle of both methods is based on the formation of transient or permanent 
diastereoisomers. However, the former method is more expensive as the type of 
column used for separating a class of enantiomer is often specific and costly. On 
the contrary, the latter method is very convenient to determine both the optical 
purity and elucidate the absolute configuration of the chiral compounds. Hence, the 
derivatisation-NMR methodology was chosen to determine the optical purity of 
(R)-Ala-Thz-OEt (59). 
3.2.1   Mosher’s derivatising agents   
The determination of optical purity by derivatisation of enantiomer with an 
enantiomerically pure reagent, followed by NMR spectroscopy analysis was 
introduced by Raban and Mislow in 1965.241 Since then, a wide range of chiral 
derivatising agents have been reported, such as Pirkle’s reagent 140,242 
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chlorodioxaphospholane 141 243 and Mosher’s reagent 142 (Figure 3-6).244 Among 
these chiral derivatising agents, Į-methoxy-Į-(trifluoromethyl)phenylacetic acid 
142 (MTPA), also known as Mosher’s reagent,  is mos t commonly used.244  
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Figure 3-6 Chiral derivatising reagents 
The enantiomerically pure (R)-MTPA-Cl (143) or (S)-MTPA-Cl reacts readily with 
primary and secondary alcohols or amines to afford diastereomeric esters or amides, 
which can be analysed by 1H and 19F NMR. The chiral purity can be determined by 
the differences in chemical shift of the non-equivalent proton or fluorine. 
Additionally, the ratio of enantiomeric composition can be  established by the 
integration of those signals. Hence, to de termine the chiral purity of N-Boc-(R)-
Ala-Thz-OEt (59), (R)-MTPA-Cl was used as a derivatising reagent. 
3.2.2   NMR determination of enantiomeric purity of dipeptide 
Boc-(R)-Ala-Thz-OEt 
In order to forming diastereomeric (R)-MTPA-amide 145, the N-Boc of Boc-(R)-
Ala-Thz-OEt 59 was firstly removed by TFA-mediated acidolysis. The free (R)-
Ala-Thz-OEt 144 was subsequently used for the condensation with (R)-MTPA-Cl 
(143) to afford the diastereomeric (R)-MTPA-amide 145 (Figure 3-7). 
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Figure 3-7 Synthesis of diastereomeric (R)-MTPA-amide (145). 
Specifically, different ba tches of synthesised Boc-(R)-Ala-Thz-OEt were treated 
with 50 % v/v TFA in DCM at room temperature for 1 h to release the amine 
trifluoroacetate salt 144. The (R)-Ala-Thz-OEt 144 was then treated with a 
stoichiometric amount of (R)-MTPA-Cl (143) in the presence of DIPEA in dry 
DCM.  The reaction mixture was vigorously stirred under a nitrogen atmosphere 
for 1 h, after which the solvent was removed in vacuo and the residual material was 
subjected to an aqueous work-up to afford the diastereomeric (R)-MTPA-amides 
145. 
The 1H and 19F NMR assignments for the (R)-MTPA-amides 145 are listed in 
Table 3-1. Three different batches using modified Hantzsch thiazole formation 
without isolation of the hydroxythiazoline intermediate were examined (entries 1-
3). As expected, the results showed only single set of signals in both 1H and 19F 
NMR analysis (Figures 3-8 and 3-9). The evidence suggested that no racemisation 
occurred in these modified Hantzsch thiazole conditions and the obtained products 
were of high optical purity. The optical rotation obtained for N-Boc-(R)-Ala-Thz-
OEt 59  (>Į@21D = + 32 (c = 1.0 CHCl3)) was slightly lower than the value repor ted 
in the literature (>Į@25D = + 40.8 (c = 1.0 CHCl3)150); the variation is postulated to be 
due to the effect of temperature on the measurements. 
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Figure 3-8    1H NMR analysis of (R)-MTPA-amide 145. 
 
Figure 3-9    19F NMR spectrum of (R)-MTPA-amide 145. 
In contrast, two well-resolved sets of the chemical shifts in the 1H NMR spectrum 
ZHUH REVHUYHG ǻįH = 0.06 Hz) when the hydroxythiazoline intermediate was 
isolated in modified Hantzsch thiazole formation (Table 3-1, entry 4). In addition, 
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19F NMR spectrum also showed two distinguished signals at įF = - 68.94 ppm and 
įF = - 68.57 ppm. Moreover, the optical rotation observed (>Į@21D =  + 4 (c = 1.0 
CHCl3)) is much lower than the value repor ted in the literature.150 These results 
indicate that a racemic mixture was obtained, and are in agreement with the finding 
of the Meyers group.238     
Table 3-1  NMR analysis of diastereoisomeric (R)-MTPA-amide 145 and optical rotations of 
N-Boc-(R)-Ala-Thz-OEt.  
 Modified 
Hantzsch thiazole 
formation 
1H  NMR 
(R,R) : (S,R) 
19F  NMR 
į (-68.94:-
68.57) 
Diastereoisomeric 
ratio ( R:S ) 
>Į@21D 
(c =1.0 CHCl3) 
1 Step 1 for 2 min > 99:1 > 99:1 > 99:1 + 32.0 
2 Step 1 for 5 min > 99:1 > 99:1 > 99:1 + 32.3 
3 Step 1 for 10 min > 99:1 > 99:1 > 99:1 + 30.3 
4 Isolation of 
intermediate 50.3 : 49.7 50.7: 49.3 51:49 + 4.3 
 
In conclusion, Hantzsch thiazole formation without isolation of the intermediate 
resulted in desired product with high enantiomeric purity. Therefore, modified 
Hantzsch thiazole reaction is generally applicable for the synthesis of optically pure 
thiazole amino acids. On the basis of the spectroscopic features and optical rotation 
data, the quality of the synthesised N-Boc-(R)-Ala-Thz-OH 44 is suitable for the 
Fmoc solid phase peptide synthesis which is discussed in Chapter 4. 
3.3 Synthesis of Boc-(R)-Ala-oxazole-OH 
Having synthesised the required dipeptide Boc-(R)-Ala-Thz-OH building block, 
attention was then focused on the synthesis of Boc-(R)-Ala-oxazole-OH. Like 
thiazole ring, oxazole is also a member of azoles and abundantly found in marine 
organisms, many of which possess significant biological activities. For example, 
taxaline, a simple oxazole-containing alkaloid exhibited antituberculosis activity.245 
Bengazole A, isolated from a marine sponge, showed anti-proliferation of many 
human cell lines.246 Almazole D, a metabolite isolated from a red seaweed 
displayed anti-bacterial activities.247  
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Similar to the thiazole-containing peptide, the biosynthetic pathway of the oxazole-
containing amino acid was derived from the condensation of peptide precursors 
with threonine, followed by cyclisation and oxidation.248 Due to the interest of 
many active oxazole-containing natural products, new oxazole formation 
methodologies have been established. The three literature approaches were utilised 
and discussed in the following sections. 
3.3.1   Classical Hantzsch oxazole approach  
The initial strategy was carried out using the classical Hantzsch oxazole synthesis. 
Following the literature procedure outlined in Scheme 3-3, N-Boc-(R)-Ala-OH was 
first coupling with ammonia under standard conditions to give the amide 57.249 
Subsequent reaction with ethyl bromopyruvate in the presence of 3,4-
epoxycyclopentene afforded corresponding 4-hydroxyoxazoline, followed by 
dehydration to give the desired (R)-Ala-oxazole-OEt 146. It is worthwhile to note 
that the addition of a large excess of 3,4-epoxycyclopentene as an acid scavenger  
prevents acid-catalysed imine-enamine tautomerisation and hence suppresses the 
epimerisation of  4-hydroxyoxazoline. 249 
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Scheme 3-3 Classical Hantzsch synthesis of (R)-Ala-oxazole-OEt (146); Reagents and 
conditions: (a) DCC, HOBt, DIPEA, DCM; (b) i. BrCH2COCO2Et, 3,4-epoxycyclopentene, DME. 
ii.TFAA, 2,6-lutidine, DME, -15 °C.  
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Specifically, N-Boc-(R)-Ala-OH and ammonia in dioxane were reacted with DCC 
and HOBt in the presence of a slight excess of DIPEA. The urea by-product was 
removed by filtration and the filtrate was subjected to column chromatography to 
give the amide 57 in quantitative yield. The synthesised amide 57 was then 
employed for the Hantzsch oxazole synthesis. Similar to the thiazole synthesis 
described in Section 3.1.2.3,  the solution of amide 57  in dry DME was cooled to -
15 ° C and was treated with ethyl bromopyruvate in the presence of finely 
powdered potassium bicarbonate and 3,4-epoxycyclopentene. The mixture was 
stirred vigorously for 5 min. The solution of 2,6-lutidine and trifluoroacetic 
anhydride in DME was added in one portion at  -15 ° C. The reaction was left to 
stir at -15 °C for 1 h. Unexpectedly, TLC analysis indicated that no product was 
for med. After an aqueous work-up, MS and 1H NMR analysis showed only the 
starting material. It should be noted that no 4-hydroxyoxazoline intermediate 147 
was detected by TLC or in 1H NMR analysis. It was hypothesised that the lower 
electron density of oxygen may result in inefficiency of nucleophilic attack of the 
ethyl bromopyruvate 137 (Figure 3-10). Therefore, an alternative oxazole synthesis 
strategy was then investigated. 
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Figure 3-10 Proposed mechanism of Hantzsch oxazoline formation. 
3.3.2   Mitsunobu approach to synthesis of oxazole 
Another strategy for the construction of the oxazole ring was introduced by Wipf et 
al. in 1992, exploiting the intramolecular Mitsunobu reaction of serine-containing 
diepeptides.250 This method was further adopted by Yamada et al. for the synthesis 
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of Boc-(R)-Ala-oxazole building block.251  As shown in Scheme 3-4, the synthesis 
started with the coupling reaction of N-Boc-(R)-Ala-OH and serine ethyl ester 
using standard peptide coupling reagents. The dipeptide 148 was then cyclised to 
oxazoline 149 under Mitsunobu condition, followed by peroxide oxidation to 
provide the desired N-BOC-(R)-Ala-oxazole-OEt 146. The detail of Mitsunobu 
reaction will be discussed in Section 3.4.2.1. 
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Scheme 3-4  Synthesis of N-Boc-(R)-Ala-oxazole-OEt (146) via Mitsunobu reaction. Reagents 
and conditions: (a) DCC, HOBt, DIPEA, DCM; (b) Diisopropyl azodicarboxylate, Ph3P, THF, 0 °C. 
(c) i. KN(TMS)2, THF-toluene, then PhSeCl, -78 °C. ii 30 % H2O2, DCM, 0 °C. 
Thus, N-Boc-(R)-Ala-OH and serine ethyl ester were reacted with DCC and HOBt 
in the presence of a slight excess of DIPEA. The urea by-product was removed by 
filtration and the filtrate was subjected to column chromatography to afford the 
dipeptide 148 in quantitative yield. The resulting dipeptide 148 in dry THF was 
treated dropwise with 1.5 eq. of diisopropyl azodicarboxylate (DIAD) and 
triphenylphosphine over 5 min at 0 °C under a nitrogen atmosphere. After complete 
addition, the reaction mixture was warmed to room temperature and left to stir for 4 
h. Unfortunately, TLC analysis revealed that no product was formed. Subsequent 
work-up and purification of the crude reaction mixture gave the by-product 
triphenylphosphine oxide and the starting material, recovered in 40 % yield. The 
reaction was found to be unsuccessful with more vigorous stirring and increasing 
reaction time. 
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3.3.3   Burgess approach to synthesis of oxazole 
The key step of oxazole synthesis is the formation of oxazoline intermediate 149. 
In addition to intramolecular Mitsunobu cyclisation, one alternative method is 
utilising Burgess reagent. Wipf et al. later introduced methyl N-
(triethylammoniumsulphonyl)carbamate 150, also known as Burgess reagent, i n the 
preparation of oxazole-containing natural products.252 As shown in Scheme 3-5, the 
dipeptide 148 was cyclised with Burgess reagent 150 to give the oxazoline 149, 
followed by peroxide oxidation to afford oxazole dipeptide 146. The reaction 
details will be discussed in the following sections. 
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Scheme 3-5  Synthesis of Boc-(R)-Ala-oxazole-OEt (146) using Burgess reagent. Reagents and 
conditions: (a) THF, 70 °C; (b) PhCOOO-t-Bu, CuBr, benzene, reflux. 
3.3.3.1   Cyclisation of hydroxyl amino acids with Burgess reagent 
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Burgess reagent 150 is a mild and selective dehydrating agent which has been 
widely used for the cyclodehydration of hydroxyl amides or thioamides to afford 
the corresponding heterocycles.253 The mechanism of this type of oxazoline 
formation is outlined in Figure 3-11. The hydroxyl group of serine attacks the 
sulfonyl group of Burgess reagent to give the intermediate 151, followed by 
intramolecular cyclisation to afford the oxazoline 149. According to the literature, 
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epimerisDWLRQ LQ Į-carbon can be suppressed compared with other cyclisation 
methods.253 
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Figure 3-11 Mechanism of oxazoline formation by reaction of N-Boc-(R)-Ala-Ser-OEt with 
Burgess reagent. 
Initial attempts focused on using the condition as described in the literature.254 To a 
solution of the dipeptide 148 in THF was added 1.1 equivalents of Burgress reagent. 
The reaction mixture was then refluxed for 5 h, after which TLC analysis showed 
only starting material and decomposition of Burgress reagent. Several alternative 
conditions were also investigated. Table 3-2 outlines the conditions used for the 
synthesis of Boc-(R)-Ala-oxazoline 149. The first attempt was to increase the 
reaction temperature by the use of dioxane as a solvent (entry 2). However, no 
improvement was obtained and 40 % starting material was recovered. Another 
attempt to use dry THF gave the desired product but in a very low conversion 
(entry 3). It appeared that no satisfactory yield could be obtained in routine thermal 
conditions. Therefore, the reaction was conducted under microwave irradiation, as 
reported by Brain et al. (entry 4).255 Surprisingly, the yield was drastically 
improved to 64 - 81 %. No elimination by-product was detected under these 
conditions. 
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Table 3-2  Optimisation of oxazoline formation 
 Equivalent of 
Burgess reagent 
Solvent Temperature 
(°C) 
Time Result 
1 1.1 THF 66  5 h no reaction 
2 1.1 Dioxane 100  5 h no reaction 
3 1.1 dry THF 66  5 h 2 % yield 
4 1.1 THF M.W., 70  30 min 64 - 81% yield 
 
Thus, 1.1 eq. of Burgess reagent was added to a solution of dipeptide 148 in dry 
THF under a nitrogen atmosphere. The reaction mixture was irradiated for 30 min 
with a microwave power of 100 W. TLC analysis revealed the absence of dipeptide 
148 and the presence of the two new products. The mixture was subjected to an 
aqueous work-up and subsequent column chromatography gave the (R)-Ala-
oxazoline ethyl ester 149 in an overall yield of 64 - 81 %. It was ascertained that 
the product 149 was composed of two distinct spots by TLC analysis and it was 
proposed that these corresponded to diastereoisomers of the oxazoline. 1H NMR 
also showed two sets of doublet signals, assigned to the C-4H of the oxazoline ring. 
Although there is no stereoselectivity in this oxazoline formation, two 
diastereomeric oxazolines should oxidise to a single oxazole product in the next 
step. Therefore, a mixture of two isomers was used directly in the next step of the 
reaction.  
3.3.3.2   Peroxide oxidation of oxazoline to oxazole 
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Three methods have been reported for the oxidation of oxazolines to oxazoles: (1) 
NBS with either benzoyl peroxide or light, (2) BrCCl3/DBU reagent and (3) 
Kharasch-Sosnovsky reaction.256-259 The disadvantage of the first method is that a 
concomitant Į-bromination side product could be formed using NBS, with either 
benzoyl peroxide or light as the radical initiator.256 Both of the two remaining 
methods have been investigated for the synthesis of 2,4-disubstituted oxazoles and 
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thiazoles.257-259 Hence, Kharasch-Sosnovsky oxidation was firstly chosen in order 
to establish suitable reaction conditions.258 The proposed copper ion-catalysed 
radical mechanism is shown in Figure 3-12.  
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Figure 3-12 Oxidation of oxazoline (149) to oxazole (146) by two possible copper ion-catalysed 
mechanisms. 
The process begins with decomposition of peroxyester catalysed by Cu+, and the 
resulting oxidised Cu2+ then reacts with oxazoline 149 to generate a carbon radical, 
which could be either at 4- or 5-position of the oxazoline ring. In mechanistic 
pathway A, the intermediate Į-oxa radical is further oxidised by Cu2+ to form 
oxonium intermediate 152a, which rapidly loses a proton to give the oxazole 146. 
In path B, the more favourable captodative radical 153 is oxidised by Cu2+ to form 
oxonium intermediate 152b.260 152b is further attacked by benzoic acid anions, 
followed by syn-elimination to give the oxazole 146.256  
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Hence, 1.5 eq. of tert-butyl perbenzoate was added to a boiling solution of the 
oxazoline 149 and CuBr in benzene over 1 h. The reaction mixture was further 
refluxed for 1 h. TLC analysis revealed the absence of oxazoline 149 and the 
presence of the product along with some impurities. The mixture was subjected to 
an aqueous work-up and subsequent column chromatography afforded the (R)-Ala-
oxazole ethyl ester 146 in an overall yield of 60-72 %. 
Similar to the thiazole analogue describing in Section 3.1.2.3, the distinct singlet 
signal appearing at į = 8.18 ppm in the 1H NMR spectrum revealed the formation 
of the oxazole ring. Additionally, stereochemical-identity was confirmed by using 
Mosher’s chiral derivatising agent (Figure 3-13). 
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Figure 3-13  Synthesis of diastereomeric (R)-MTPA-amide 155. 
To determine the chiral purity of the oxazole derivative 146, N-Boc was firstly 
removed by TFA-mediated acidolysis. The free (R)-Ala-oxazole-OEt 154 was 
subsequently used for the condensation with (R)-MTPA-Cl (143) to afford the 
diastereomeric (R)-MTPA-amide 155. 1H and 19F NMR spectra of (R)-MTPA-
amide 155 are shown in Figures 3-14 and 3-15, respectively. Surprisingly, two 
well-resolved sets of the chemical shifts in 1H and 19F NMR were observed. The 
results indicated that a mixture of (R,R)-155 and (R,S)-155 was obtained. These 
results are in disagreement with the literature reported by Khapli  et al. and Brain et 
al.253,255 The evidence from 1H and 19F NMR spectra strongly suggests that 
epimerisation had occurred.  
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Figure 3-14  1H  NMR spectrum of the diastereomeric (R)-MTPA-amide 155. 
 
Figure 3-15  19F NMR spectrum of the diastereomeric (R)-MTPA-amide 155. 
The epimerisation was postulated to be due to the isolation of the oxazoline 
intermediate. The isolated oxazoline intermediate 149 can undergo an imine-
enamine tautomerization resulting in epimerisation as shown in Figure 3-16. 
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Therefore, the synthesised racemic N-Boc-(R)-Ala-oxazole 146 was not suitable for  
the Fmoc solid phase peptide synthesis. 
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Figure 3-16 Racemisation via an imine-enamine type equilibration. 
3.4 Synthesis of a dehydroalanine precursor 
Dehydroamino acids including dehydroalanine and dehydrobutyrine are important 
constituents of numerous naturally occurring peptides, many of which possess 
biological activities. For example, a cyclic peptide microcystin is a potent 
hepatotoxin.261 Another cyclic peptide thiostrepton shows antibiotic activity by 
inhibiting several biochemical pathways at the ribosomal GTPase centre.262  
The incorporation of dehydroamino acids into these cyclic peptides exert a 
conformational constrain, leading to an increase in the rigidity of structure, which 
is likely to be essential for the biological activities.263 Moreover, owing to the 
electrophilicity of dehydroamino acids, it has been shown that dehydroalanine 
allows access to a wide variety of unusual amino acids via nucleophilic Michael 
addition264 or acid-catalysed cross-coupling processes.265  
On the other hand, as a Michael acceptor, dehydroalanine readily react with a wide 
range of nucleophiles, including amines, nitrogen heterocycles and thiols, making it 
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incompatible with conventional methods of peptide synthesis.266, 267 Hence, the 
most common approach for the installing of dehydroalanine in peptides involves 
incorporation of a masked residue, which can be subsequently unmasked to the 
dehydroalanine at the final stage. In the following sections, three major methods 
for installing this functional residue into polypeptides are investigated.  
3.4.1   Previous reports for installing dehydroalanine in peptides 
The biosynthetic pathway of dehydroalanine and dehydrobutyrine are believed to 
be predominantly derived from the dehydration of serine and threonine residues, 
respectively. In contrast to the biosynthesis, several chemical synthetic routes have  
been described to install dehydroamino acid residues into polypeptides. However, 
GXHWRWKHUHDFWLYLW\RIĮȕ-unsaturated alkenes, most reported methodologies relied 
on the incorporation of a masked precursor at an early stage in peptide synthesis, 
followed by conversion to the Įȕ-unsaturated amino acid after the completion of 
peptide synthesis.  
A review of literature led to the identification of three strategies for the preparation 
of dehydroalanine precursor. These strategies include the activation and 
elimination of serine derivatives,268 oxidative elimination of S-alkyl or S-aryl 
protected cysteine derivatives269 and oxidative elimination of phenylselenocysteine 
derivatives.270 The latter two methodologies were applied, one of which resulted in 
the successful preparation of dehydroalanine precursor. The detail of the three 
strategies is discussed in the following sections. 
3.4.1.1 Serine approach 
The preparation of dehydroalanine residues was first achieved by Koshland et al. in 
1963. Koshland successfully converted the serine residue in chymotrypsin to 
dehydroalanine in the course of investigating the catalytic role of Ser195.271 As 
illustrated in Figure 3-17 (A), the hydroxyl group of a serine residue reacts readily 
with p-toluenesulfonyl chloride to form the O-tosylated serine derivative 156, and 
subsequent ȕ-elimination of O-tosylserine 156 under alkaline conditions provides 
dehydroalanine 157. However, Sakai et al. reported that the elimination of O-
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tosylated serine derivatives does not always produce the desired dehydroalanine; 
instead, aziridine derivatives 158 were obtained in high yield.272 Ranganathan et al. 
improved this method by reacting serine with oxalyl chloride in the presence of 
triethylamine (Figure 3-17(B)). However, the yield was strongly affected by the 
peptide length and the position of the dehydroalanine residue in the peptide 
chain.268 Therefore, a new approach utilising cysteine as a dehydroalanine 
precursor was studied. 
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Figure 3-17 Synthesis of dehydroalanine from serine. (A) Koshland’s approach. (B) 
Ranganathan’s approach. 
3.4.1.2  Attempted preparation of dehydroalanine precursor via 
cysteine 
An alternative method to prepare dehydroalanine is using S-alkyl or S-aryl 
protected cysteine derivative as a precursor. After completion of peptide synthesis, 
subsequent oxidative elimination reactions led to desired dehydroalanine residue.273 
As shown in Figure 3-18, commercially available N-Boc protected S-methyl 
cysteine 159 was incorporated during peptide synthesis. After completion of 
peptide synthesis, peptide 160 was allowed to convert to the dehydroalanine 162 by 
oxidation and elimination. This conversion involved formation of sulfoxide 161 
using sodium metaperiodate, followed by DBU-facilitated elimination under reflux 
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condition. This method was reported to be compatible with both Boc and Fmoc 
strategies. 
H
N
O
OHO
SO
Peptide synthesis H
N
O
NHRO
SO
H
N
O
NHR
O
SO O
H
N
O
NHRO
O
a
b
159
160
161 162
 
 
Figure 3-18 Synthesis of dehydroalanine from S-methyl cysteine; Reagents and conditions: (a) 
NaIO4, H2O, dioxane; (b) DBU, MeOH or dioxane, reflux. 
However, the WHPSHUDWXUH UHTXLUHG WR HIIHFW HOLPLQDWLRQ RI ȕ-methylsulfinyl 
derivatives was found to vary over a wide range (25-140 °C). In addition, the high 
temperature appeared to be too harsh for the synthesis of larger peptides, which 
typically denature at high temperatures. Furthermore, the synthesised 
dehydroalanine can readily undergo polymerisation at this high temperature.274 
Therefore, a lower temperature, solid-phase procedure was investigated by 
Yamada’s group. 275 
As shown in Figure 3-19, Yamada’s strategy involved a side-chain unprotected 
cysteine linking to the Merrifield resin (163), a commonly used chloromethylated 
polystyrene solid support for SPPS. After completion of peptide synthesis, desired 
peptides were released from the solid support via an S-oxidative eliminated to 
dehydroalanine, which is mediated by m-chloroperbenzoic acid (m-CPBA) and 1,8-
diazabicycloundec-7-ene (DBU). The resulting dehydroalanine-containing peptides 
could be obtained in good yields (75- 86 %) and purity (95- 98 %). 
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Figure 3-19 Solid-phase synthesis of dehydroalanine derivatives; Reagents and conditions: (a) 
DBU, DMF; (b) m-CPBA, DCM; (c) DBU, DCM. 
Thus, in order to establish suitable conditions, initial attempt was carried out using 
Yamada’s approach. Following the literature procedure, the first step in this 
synthesis requires attachment of cysteine to Merrifield resin (163) through 
nucleophilic substitution by the thiol side-chain functionality to produce 164. 
Hence, two equivalents  of DBU was added to a solution of unprotected cysteine in 
DMF under a nitrogen atmosphere,276 and was left to stir overnight. Determination 
of the loading efficiency was achieved through measuring UV absorbance of Fmoc 
attachment to the free N-terminal of cysteine. However, the best obtained loading 
was only 0.03 mmol g-1, which was substantially lower than what was reported in 
the literature (0.38 mmol g-1).276 The observed low loading was postulated to be 
due to the potential competing reaction of the N-terminal attachment to resin. 
Therefore, N-Boc-cysteine was used to enhance the loading efficiency. 
Unfortunately, the highest loading obtained from this study was 0.052 mmol g-1, 
even though the reaction was performed at high temperature (60 °C).  
Since monitoring the reaction was not practicable and the observed efficiency of 
the reaction was too low, an alternative approach for the synthesis of 
dehydroalanine peptides was sought. 
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3.4.2    Preparation of the dehydroalanine precursor, 
phenylselenocysteine 
Walter and co-worker found in 1971 that selenocysteine derivatives could be easily 
converted to dehydroalanine derivatives under mild oxidative elimination 
conditions.277 They observed that treatment with sodium metaperiodate or 
hydrogen peroxide, diphenylmethylselenocysteine was oxidised to the 
corresponding selenoxide derivative, which spontaneously eliminates to 
dehydroalanine derivative at room temperature (Figure 3-20). Hence, such 
advantageous have been exploited for the synthesis of selenocysteine derivatives as 
a dehydroalanine precursor. In particular, phenylselenocysteine was successfully 
adopted  by Shirahama et al. for the synthesis of dehydroamino acid-containing 
peptides.278 This approach is compatible with solution-phase and the standard 
solid-phase peptide synthesis. 
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Figure 3-20 Phenylselenocysteine as a dehydroalanine precursor. 
Thus, one of the earliest and most predominant methods for the preparation of 
optically pure phenylselenocysteine was developed by the same group.279 Van der 
Donk et al. further modified this strategy by introducing this mild, chemoselective 
method to standard Fmoc-SPPS.270 This approach for the synthesis of Fmoc-
phenylselenocysteine was achieved and outlined in Figure 3-21; these 
transformations are discussed in the following sections. 
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Figure 3-21  Synthesis of dehydroalanine precursor Fmoc-phenylselenocysteine (42). Reagents 
and conditions: (a) DEAD, PPh3, THF, -78 °C to room temp.; (b) PhSeSePh, NaBH(OMe)3, EtOH, 
room temp.; (c) TFA/DCM, room temp.; (d) Fmoc-OSu, NaHCO3, THF/H2O, room temp. 
3.4.2.1 6\QWKHVLVRIȕ-lactone ring via Misunobu reaction 
64
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N
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O
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The ILUVW VWHS LV WKH IR UPDWLRQ R I ȕ-lactone ring via intramolecular Mitsunobu 
reaction. Mitsunobu et al. first reported this type of reaction which has become a 
useful tool  in organic synthesis since its discovery in 1967 .280 In general, the 
reaction is a method for converting alcohols into various functional groups such as 
esters, aryl ethers and thioethers. The process involves activating an alcohol into a 
good leaving group, which then undergoes nucleophilic substitution (SN2) by 
nucleophiles, including carboxylic acids, phenols and diols. The reaction 
mechanism is illustrated in Figure 3-22.      
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Figure 3-22 Mechanism of intramolecular Misunobu reaction to form ȕ-lactone ring (64).  
Initially, an oxidising azo reagent, diethyl azodicarboxylate (DEAD) (165) or 
diisopropyl azodicarboxylate (DIAD), reacts with triphenylphosphine to form 
betaine intermediate 166 which is then protonated by carboxylic acid of serine to 
form the phosphonium salt 167. In the alcohol activation step, the resulting 
triphenylphosphine group of phosphonium salt 167 is transferred to the hydroxyl 
group of serine. Thus, alkoxyphosphonium salt 168 and hydrazine by-product 169 
are generated. Finally, the carboxylate group of serine undergoes an intramolecular 
nucleophilic substitution to afford the desired lactone ring 64 and by-product 
triphenylphosphine oxide.  
Thus, triphenylphosphine in dry THF under nitrogen atmosphere at -78 °C was 
treated with a stoichiometric amount of DEAD. A solution of Boc-(S)-serine in 
THF was then added dropwise to the mixture over 30 min. After completion of 
addi tion, the mixture was stirred at -78 °C for 20 min and the mixture was slowly 
warmed to room temperature over 2.5 h. After work-up and purification, the highly 
SXUHȕ-lactone product 64 was obtained in 38-45 % yield. Another commonly used 
oxidising azo reagent DIAD was also employed for this reaction. Unfortunately, no 
improvement in yields was observed. 
It was anticipated that the ring strain of 4-PHPEHUHG ȕ-lactone results in low 
reaction efficiency. Indeed, sWRUDJH RI WKH ȕ-lactone results in decomposition. 
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Therefore, the ȕ-lactone product 64 after purification was used immediately in the 
next step. The identity of the products was confirmed by mass spectrometry, NMR 
analysis and melting point. The observed data were in agreement with the values 
reported in the literature.150 
3.4.2.2 Ring opening of the ȕ-lactone  
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In the second step, WKHȕ-lactone 64 was reacted with phenyl selenide anion to form 
the phenylselenocysteine derivatives 65. In general, the benzeneselenolate anion is 
generated in situ via reduction of diphenyl diselenide with two equivalents of 
sodium trimethoxyborohydride.279 In order to avoid the reduction of the reactive 
lactone, reduction of diphenyl diselenide is conducted before a solution of the 
lactone is added. The reaction mechanism is illustrated in Figure 3-23. The 
reactivity R I WKH ȕ-lactone ring comes from the ring strain and the masked aldol 
functionality. Hence, substitution of ȕ-lactone ring can proceed via either acyl C=O 
bond or alkyl C-O bond fission. Regioselective ring opening depends on the choice 
of nucleophile. In general, small or highly polarised hard nucleophiles favour a 
charge-directed interaction, resulting in acyl C=O cleavage. Soft nucleophiles, on 
the other hand, favour an orbital interaction over charge, resulting in alkyl C-O 
cleavage.281 As a soft nucleophile, phenyl selenide anion mediated a nucleophilic 
substitution (SN2) of the carboxylate residue to from the thermodynamically stable 
product.    
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Figure 3-23 0HFKDQLVPRIȕ-lactone ring opening by phenyl selenide anion. 
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Hence, sodium trimethoxyborohydride was added to a solution of diphenyl 
diselenide in dry ethanol under a nitrogen atmosphere. The yellow solution was 
stirred for 30 min. ȕ-Lactone 64 in dry ethanol was then added to this solution and 
the reaction mixture was stirred at room temperature for 2 h. After an aqueous 
work-up, the product was obtained in quantitative yield. 1H NMR spectrum of the 
product showed that only the desired product 65 was formed. MS analysis 
revealing the distinctive selenium isotope patterns centred at m/z 368.0377 (80Se), 
which was assigned as the [M+Na]+ species. The optical rotation of 65 was 
determined, and the obtained value (>Į@D23 = -34 (c = 1.0, MeOH)) is comparable to 
that reported in the literature (>Į@D25 = -36.8 (c = 1.0, MeOH)).150  
3.4.2.3 Deprotection of N-tert-Butyl carbamates group 
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In order to install the N-Fmoc protecting group on phenylselenocysteine which can 
be used for the Fmoc solid phase peptide synthesis, the N-Boc protecting group 
must be removed. Several strategies for the selective removal of N-Boc protecting 
group in the presence of other function groups have been studied extensively in the 
past few years. In general, cleavage of N-Boc protecting group is achieved by using 
acidic conditions, such as HCl in EtOAc or dioxane,282 TFA in DCM, H2SO4 in t-
BuOAc and p-TsOH in t-BuOAc.283 In some highly activated amines, such as 
aromatic heterocycles, cleavage of N-Boc protecting group can also be achieved 
under basic conditions.284 Amongst these N-Boc deprotecting methods, acidolysis 
by TFA in DCM or HCl in dioxane are the mos t commonly used. 284 As shown in 
Figure 3-24, the key step of acidolysis of Boc group is the cleavage of tert-butyl 
carbamate under acidic conditions and the generation of tert-butyl cation. In some 
cases, a scavenger is required to remove the tert-butyl cation, preventing butylation 
of the target molecule. 
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Figure 3-24 Mechanism of N-Boc deprotection via acidolysis. 
Hence, the N-Boc-phenylselenocysteine 65 was treated with a solution of 50 % v/v 
TFA in DCM for 1 h. A successful conversion of 65 to 66 was confirmed by 1H 
NMR analysis, with a loss of a singlet at į = 1.43 ppm being observed which 
corresponded to the t-butyl of N-Boc. Further confirmation was provided by ES-
MS revealing a peak at m/z 246.0019, which was assigned as the [M+H]+ species.  
3.4.2.4 Fmoc-protection of phenylselenocysteine 
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In the final step, phenylselenocysteine 66 was protected with Fmoc by reacting 
with a stoichiometric amount of Fmoc-OSu under basic conditions to afford N-
Fmoc phenylselenocysteine 42 in a yield of 85-95 %. The obtained product was 
identified by MS and NMR analysis.150 In addition, the purity of the final product 
was established using analytical RP-HPLC. The major peak (tR = 10.91 min) 
observed in analytical RP-HPLC showed a purity greater than 98 % (Figure 3-25).  
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 Retention time Area % Area Height 
1 7.633 414945 1.75 53961 
2 10.912 23342684 98.25 2006986 
Figure 3-25 RP-HPLC analysis of N-Fmoc phenylselenocysteine (42). Analysed using 10-60 % 
B over 12 min at 3mL/ min method on an Onyx Monolithic C18 column (100 x 4.6 mm). Eluent 
detection was monitored by UV absorbance at 216 nm.  
3.5 Conclusion 
The synthetic route to the N-Boc-(R)-Ala-Thz-OH dipeptide building block (44) 
was achieved using literature procedures. This four-step reaction enabled a quick 
and efficient process to optically pure product in overall yields of 26–30 %. The 
spectroscopic data of the thiazole dipeptide was identical to those reported in the 
literature.150 In addition, the optical purity of the dipeptide was confirmed by both 
optical rotation and the Mosher’s method.  
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Figure 3-26 Synthesis of N-Boc-(R)-Ala-Thz-OH (44);  Reagents and conditions: (a) DCC, HOBt, 
NH3, CH2Cl2, 0 °C; (b) Lawesson’s reagent, THF, 0°C; (c) i. BrCH2COCO2Et, KHCO3, DME, -15 °
C; ii.TFAA, 2, 6-lutidine, DME, -15 °C; (d) LiOH, THF/ MeOH/ H2O, room temp. 
As summarised in Figure 3-26, the key step in constructing the thiazole dipeptide 
44 was using a modified Hantzsh-thiazole formation. This involved amination of 
the N-Boc protected (R)-Ala-OH to the corresponding amino amide 57 and 
thionation with Lawesson’s reagent. The resulting thioamide 58 was then cyclised 
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using ethyl bromopyruvate to afford thiazoline intermediate, followed by treatment 
of TFAA and 2,6-lutidine to give the desired thiazole dipeptide 44. 
In addition, synthesis of N-Boc-(R)-Ala-oxazole dipeptide analogues also 
attempted by using repor ted methods . The key synthetic in constructing the oxazole 
dipeptide 146 was using Burgess reagent followed by radical oxidation. The 
synthesis involved coupling of N-Boc-(R)-Ala-OH with serine ethyl ester. The 
resulting dipeptide was then reacted with Burgess reagent under microwave 
irradiation to afford the oxazoline intermediate. Finally, treatment of tert-butyl 
perbenzoate and CuBr gave the desired oxazole dipeptide analogue in overall 
yields of 35–38 %. However, extensive epimerisation of the Į-stereogenic centre 
had occurred during the chemical transformation of oxazoline to oxazole. These 
results indicated that both the thiazoline and oxazoline intermediates are liable to 
racemisation. Therefore, in order to provide the optically pure N-Boc-(R)-Ala-
oxazole dipeptide analogue, a reinvestigation of the literature methods is required. 
For the preparation of Įȕ-dehydroalanine, phenylselenocysteine was chosen as a 
reliable precursor of the Įȕ-dehydroalanine building block. As summerised in 
Figure 3-27, the four-step synthesis for the N-Fmoc-protected phenylselenocysteine 
42 was achieved using literature procedures. The formation of the 
phenylselenocysteine was achieved by two chemical transformations. The first step 
involves intramolecular Misunobu reaction to convert N-Boc-VHULQH LQWR D ȕ-
lactone derivative 64. The use of DEAD or DIAD as oxidising azo reagents did not 
influence the product yield. The second step is diphenyl diselenide-mediated ring 
opening to afford N-Boc-phenylselenocysteine 65.  
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Figure 3-27  Synthesis of dehydroalanine precursor, Fmoc-phenylselenocysteine (42). Reagents 
and conditions: (a) DEAD, PPh3, THF, -78 °C to room temp.; (b) PhSeSePh, NaBH(OMe)3, EtOH, 
room temp.; (c) TFA/DCM, room temp.; (d) Fmoc-OSu, NaHCO3, THF/H2O, room temp. (e) ) i. 
NaIO4, CH3CN/H2O; ii. Na2CO3, CH3CN/H2O. 
 
N-Boc-deprotection with 50 % v/v of TFA/DCM followed by N-Fmoc protection 
with Fmoc-OSu afforded the desired N-Fmoc-phenylselenocysteine (42) which is 
suitable for the Fmoc solid phase peptide synthesis. The overall yield over this 
four-step synthesis ranged from 35 to 40 % which was comparable to the yield 
reported in the literature.150 In comparison to the S-aryl protected cysteine 
derivatives, the phenylselenocysteine methodology provided higher efficiency and 
chemoselectivity. Unmasking of the dehydroalanine by oxidative elimination in the 
ultimate step of the synthesis of argyrin is discussed in detail in Section 4.5.  
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Chapter 4  
Fmoc solid-phase 
peptide synthesis and 
biological evaluation of 
argyrin A and analogues     
In the previous three chapters, three unusual amino acid building blocks of argyrin 
A, namely Fmoc-methoxy-(S)-tryptophan (43h), Boc-(R)-Ala-Thz-OH (44) and 
Fmoc-phenylselenocysteine (42) have been prepared. As outlined in Chapter 1.5, 
the ultimate aim of this project is the synthesis of cyclic octapeptide argyrin A and 
analogues thereof. All previous studies into the total synthesis of argyrin analogues 
used traditional solution methods.150-152 In order to enhance the synthesis efficiency 
and to avoid laborious purification procedures after each peptide coupling step, 
Fmoc solid-phase chemistry is exploited for the synthesis of argyrin A and 
analogues thereof.  
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In this chapter, the three existing solution-phase synthesis of argyrin A are 
summarised first, followed by brief introduction of Fmoc-SPPS. Next, attention is 
focused on establishing solid phase peptide synthesis of the title compound and 
analogues thereof. Thus, attachment of the first amino acid residue to the solid 
support is discussed, followed by coupling of subsequent amino acids in the 
peptide chain. Next, cleavage of peptide from the solid supports will be described, 
followed by solution phase head-to-tail cyclisation of linear peptide. Finally, 
unmasking the dehydroalanine precursor by oxidative elimination methods 
afforded the final cyclic peptide argyrin A and analogues.  
In addition, as mentioned in Section 1.4.4, two independent groups have shown 
that argyrin A displays cytotoxic activity as a result of proteasome inhibition. At 
the end of this chapter, in order to further ascertain the importance of an amino acid 
residue in argyrin with regards to the antiproliferative effect and to gain more 
insight into structure-activity relationship, all synthesised argyrin analogues were 
evaluated in cytotoxicity assays. 
4.1 Existing solution-phase approaches for the synthesis of 
argyrin A  
The construction of the amide skeleton of argyrin A and analogues thereof has been 
achieved by traditional solution–phase peptide bond formations. Ley et.al in 2002 
first repor ted the total synthesis of argyrin B using this strategy which required the 
preparation of two tripeptides (170, 172) and the dipeptide (59) fragment as shown 
in Figure 4-1.150 The tripeptides were assembled in four steps by sequential 
condensation of the three N-protected amino acids, and the dipeptide 59 was 
prepared using the method describing in Section 3.1.2.  With the three fragments in 
place, removal of N-Cbz form 170 and coupling with the free acid from 59 afforded 
pentapeptide 171. Similarly, removal of N-Boc protection from 172 and coupling 
with the free acid from 171 afforded the fully assembled octapeptide 46. 
Macrocyclisation was achieved by deprotection of 46 at two termini, followed by 
intramolecular coupling. Finally, phenylselenocysteine was unmasked to reveal a 
dehydroalanine residue to yield argyrin 48. 
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This approach was later adopted by Nickeleit’s group in 2010151 and Jiang’s group 
in 2011152 for the total synthesis of 10 argyrin analogues. However, the synthesis of 
more analogues was hampered by the limitation of this approach, including the 
time-consuming nature of the lengthy process and extensive purification necessary 
after each peptide coupling step. In this thesis, the Fmoc solid-phase peptide 
synthesis approach is introduced for the total synthesis of argyrin A and analogues 
thereof.    
N-Boc-(R)-Ala1-Thz2-OEt
59
N-Cbz-Trp3-(4-MeO)-Trp4-Gly5-OMe
N-Boc-(R)-Ala1-Thz2-Trp3-(4-MeO)-Trp4-Gly5-OMe
N-Boc-(R)-Ala6-Ph(Se)7-Sar8-OEt
N-Boc-(R)-Ala1-Thz2-Trp3-(4-MeO)-Trp4-Gly5-(R)-Ala6-Ph(Se)7-Sar8-OH
Cyclo[(R)-Ala1-Thz2-Trp3-(4-MeO)-Trp4-Gly5-(R)-Ala6-Ph(Se)7-Sar8]
Argyrin A
a
b
c
d
e
f, g
j,k
48
46
47
h, i
170
171
172
Figure 4-1 Solution-phase synthesis of argyrin by Ley et al..150 Reagents and conditions: (a) 
LiOH, THF/MeOH/H2O, room temp.; (b) H2, Pd/C, MeOH, room temp.; (c) EDC, HOBt, DCM, 
room temp.; (d) LiOH, THF/MeOH/H2O, room temp.; (e) TFA/DCM, room temp.; (f) EDC, HOBt, 
DIPEA, DCM; (g) LiOH, THF/MeOH/H2O, room temp.; (h) Anisole/TFA, room temp.; (i) TBTU, 
HOBt, DIPEA, DCM, room temp.; (j) NaIO3, dioxane/H2O, room temp.; (k) NaHCO3, CH3CN/H2O, 
room temp. 
4.2 Principles of solid-phase peptide synthesis 
Solid phase peptide synthesis (SPPS), first reported by Bruce Merrifield,285 is a 
technique for assembling a peptide chain on a polymeric support. The primary 
advantage of SPPS is high yield for each step of coupling compared with solution 
phase coupling, especially in longer sequences. In addition, excess reagents and by-
products could be easily removed by wash and filtration, and intermediates are not 
purified. 
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Fmoc/t-Bu solid-phase peptide synthesis (SPPS) was first reported by Sheppard et 
al. in 1978.286 Compared with original Merrifield SPPS approach, Sheppard’s 
orthogonal approach allowed reactions to be carried out under milder conditions. 
This approach utilises the combinations of the base-labiOH)PRFJURXSIRUĮ-amino 
group protection and the acid-labile group for side-chain protection of amino acids. 
Scheme 4-1 illustrates the principles of Fmoc SPPS. The synthesis proceeds in a C-
terminal to N-terminal fashion, which is opposite to ribosome protein synthesis.  
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Scheme 4-1 The general principles of solid–phase peptide synthesis. 
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The initial step of Fmoc SPPS is the attachment of C-terminus amino acid residue 
to a solid support via a linker. The choice of the suitable linker is discussed in 
detail in Section 4.2.1. Typically, the C-terminal amino acid is attached to a linker 
by forming an ester or an amide bond which can be easily cleaved by acidolysis. 
The Fmoc protecting group is then removed with 20 % v/v piperidine in DMF prior 
to coupling with the next Fmoc-protected amino acid.287 Amide bond formation is 
achieved by activation of the Fmoc-protected amino acid. The three major carboxyl 
activating reagents are discussed in Section 4.2.2. After coupling, excess reagents 
are removed by simple washing procedures. This deprotection-coupling cycle is 
repeated until the target peptide sequence is assembled. In the final step, the desired 
peptide is cleaved from solid support with the simultaneous removal of the side-
chain protections. 
4.2.1   Linker resins used for the solid phase peptide synthesis 
Linker resins, generally refers to the insoluble solid suppor t with a linker which 
enable the attachment of the C-terminal of a peptide chain. The peptide coupling 
reaction can be carried out on the surface or inside of the particles. The ideal 
properties of the resin for efficient SPPS include (1) chemical inertness and ability 
to swell in solvents used in peptide synthesis, such as DMF and DCM, and (2) 
readily functionalised to allow for the attachment of a linker.288 To date, 
polystyrene (PS) is the most commonly used resin in SPPS.288 Some of the newer 
resins, such as polyethylene glycol (PEG)289 and PEG-PS290, have been developed 
for the synthesis of difficult sequences by disruption of aggregation of the growing 
peptide chain. 
Linkers are chemical functional groups to provide a reversible linkage between the 
peptide chain and the solid support, and to protect the C-terminal carboxyl group. 
Ideally, they are designed to be stable throughout the SPPS cycle and to be 
selectively cleaved at the end of the synthesis without damage to the product. A 
serious of linkers have been developed to yield peptide acids, peptides amides or 
sulphonamides upon cleavage. Figure 4-2 lists three linker resins which are 
considered for the Fmoc SPPS of argyrin A and analogues thereof.    
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Figure 4-2 Linker resins considered for the Fmoc SPPS of argyrin 
In order to release peptide acid for the macrocyclisation of linear argyrin precursor, 
Wang resin (173), 4-hydroxymethylphenoxyacetyl (174) and 2-chlorotrityl chloride 
resin (175) were considered.291 Among these three linkers, 173 and 174 using ester 
linkage to the peptide require 90-95 % TFA to release of the assembled peptide. In 
contrast, a hyperacid-labile linker 175, permits the release of peptide acid under 
very mild conditions, typically 1-5 % TFA for 5 min, due to the high stability of  
the trityl cation.292 Since the peptide-ester bond formed with 2-chlorotrityl resin has 
sufficient stability during the conventional coupling conditions, it was chosen as a 
suitable linker for the synthesis of linear argyrin precursor.  
4.2.2   Carboxyl activating reagents 
The carboxyl activation is usually achieved through increasing electrophilicity of 
the carbonyl group by replacement of the hydroxyl with electron withdrawing 
group. As mentioned in Section 3.1.2.1, DCC- and HOBt-mediated carboxyl 
activation is commonly used in solution amide bond formation. However, the 
insolubility of the dicyclohexylurea by-product causes problems during SPPS 
procedures. Therefore, the onium coupling reagents, including phosphonium and 
aminium (or guanidinium) salts are gradually replacing traditional carbodiimide 
reagents in SPPS.293 
The choice of the carboxyl activating reagent is one of the factors that can 
contribute to the success of SPPS.  The ideal carboxyl activating reagent requires 
the following properties: (1) good solubility in numerous organic solvents and can 
be used at high concentration, (2) suppress side reactions, such as racemisation 
caused by direct enolisation or via oxazolone formation (Figure 4-3 (a) and (b)) and 
terminates the peptide chain, caused by reacting with the N-terminal of the peptide 
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(Figure 4-3(c)),291 (3) not toxic, corrosive and does not result in formation of toxic 
by-products, and (4) commercially available and chemically stable. 
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Figure 4-3 (a) Racemisation via oxazolone formation. (b) Racemisation via enolisation. (c) A 
guanidine side product is produced when the aminium coupling reagent is directly reacted to 
the N-terminal of the peptide. 
Phosphonium coupling reagent was the first onium salt used in SPPS in 1975  by 
Castro et al..294 Based on HOAt and HOBt, he developed a new phosphonuam-
based coupling reagent, namely benzotriazol-1-yloxy-tris(dimethylamino)-
phosphonium hexafluorophosphate (BOP) 177. More recently, benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) 178 and (ethyl 
cyano(hydroxyimino)acetato)-tri-(1-pyrrolidinyl)-phosphonium hexafluoro-
phosphate (PyOxim) 179 were introduced, where the dimethylamine subunit was 
replaced by pyrrolidine. 295  This change could avoid the generation of highly toxic 
hexamethylphosphoramide (HMPA) by-product. The mechanism of carboxyl 
activation by the phosphonium reagent is shown in Figure 4-4 (b). 
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Figure 4-4 (a) Three phosphonium reagents for SPPS. (b) Mechanism of carboxyl activation 
by the phosphonium reagent PyBOP (178).  
The carboxylate anion attacks the phosphonium cation generating a highly reactive 
acyloxyphosphonium intermediate 180, which is nucleophilically attacked by the 
liberated hydroxybenzotriazole anion to afford the activated benzotriazolyl ester 
181. The peptide bond is formed by a further nucleophilic acyl substitution with an 
amine, i n a same manner to the DCC/HOBt activation described in Section 3.1.2.1. 
The major advantage of phosphonium reagent to the aminum reagent is that the 
excess unreacted reagent does not guanidate with free amine (Figure 4-3 (c)), 
resulting in termination of peptide chain elongation. Other advantages, such as easy 
handling, storage, and high efficient in the coupling of sterically hindered amino 
acids have been reported in the literature. 296 
Aminium coupling reagents, also known as uronium reagents, are also derived 
from HOAt and HOBt.  Gross et al. introduced HBTU (182) in 1978 as the first 
aminium reagent.297 Since then, a variety of analogues such as HATU (176), TBTU 
(183) having higher coupling efficiency and lower racemisation rate were 
developed. It was established that the choice of counterion have no effect on the 
coupling efficiency. However, it has been shown that 183 having tetrafluorobortate 
is more soluble than 176, allowing preparation of more concentrated solution. 296 
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Thus, three commonly used carboxyl activation reagents have been chosen in this 
project. HATU (176), a well-known aminium based reagent, has been show n to 
have high efficiency in the coupling of sterically hindered amino acids. In addition, 
it is also effective in avoiding epimerisation under a various coupling conditions.298 
Aminium salts which would yield guanidinium by-products with peptidyl amines 
and hence results in termination of peptide elongation.294 
PyBOP (178), a phosphonium based reagent, is easy to handle and store. It also 
shows high efficiency in the coupling of sterically hindered amino acids. PyOxim 
(179), a new PyBOP based reagent, shows superior solubility in solvents employed 
in SPPS, and achieves higher optical purity of peptide products and efficiency of 
reactions in the production of both linear and cyclic peptide sequences.295    
4.3 Synthetic strategies for linear argyrin A 
As shown in Scheme 4-2, Fmoc SPPS was used for the synthesis of the nine linear 
argyrin precursors. In the retrosynthetic analysis of argyrin A, disconnection site of 
the macrostructure is crucial as it could ultimately determine the success of the 
cyclisation. After carefully analysis of the peptide sequences, the sarcosine was 
chosen as the C-terminal end.299 There are three major advantages in the choice of 
sarcosine as the C-terminal end. Firstly, epimerisation of C-terminus during 
backbone macrocyclisation could be avoided as sarcosine is an achiral amino acid. 
Secondly, sarcosine is a non-sterically hindered residue which gives synthetic 
advantage in macrocyclisation. Thirdly, acid-labile N-Boc of the last residue could 
be simultaneously removed while the fully assembled peptide was released from 
the solid support.  
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Scheme 4-2 Fmoc SPPS of linear argyrin precursors (45). 
4.3.1    Condensation of Fmoc-sarcosine with 2-chlorotrityl 
chloride polystyrene 
Assembly of the linear octapeptide precursors started with attachment to the solid 
support through the carboxylic group of a sarcosine residue. In order to release 
peptide acid for the cyclisation, 2-chlorotrityl chloride polystyrene linker resin (40) 
was chosen. The coupling of Fmoc-sarcosine (41) to 2-chlorotrityl chloride 
polystyrene (40) is illustrated in Figure 4-5. 
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184 18540
41
 
Figure 4-5 Esterfication of 2-chlorotrityl chloride resin (40). 
The coupling proceeds via an SN1 mechanism.300 In DCM, 2-chlorotrityl chloride 
undergoes heterolysis to give an equilibrium mixture of the chloride anion and the 
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2-chlorotrityl cation 184. The stabilised tertiary cabocation 184 undergoes 
nucleophilic attack by carboxylate of sarcosine to form an ester bond. Thus, 2-
chlorotrityl chloride resin was swollen in DCM for 1 h, followed by condensation 
with a stoichiometric amount of Fmoc-Sar-OH in the presence of DIPEA (2 eq.) in 
DCM. The reaction mixture was gently stirred at room temperature for 2 h, after 
which the reaction was quenched using a small amount of methanol. The resin 185 
was stored and re-swollen in a suitable solvent prior to use. The efficiency of 
loading was 70%, based on theoretical loading as described in Section 6.5.  
4.3.2   Carboxyl activation and peptide assembly 
Cl
O
O NFmoc peptide elongation
Cl
O
O
N
185 45
Boc-(R)-Ala1-Thz2-Trp3-Trp4(X)-Gly5-(R)-Ala6-Ph(Se)7
 
The second stage of Fmoc-SPPS involves repeated Fmoc deprotection and amino 
acid coupling. Firstly, removal of Fmoc group is achieved using 20 % v/v 
piperidine in DMF. Secondly, the carboxyl group of N-Fmoc protected amino acid 
is activated to promote nucleophilic attack by the amino group of the peptidyl resin 
to form peptide bond.  
Thus, the resin 185 was pre-swollen in DMF/DCM for 16 h. The Fmoc group was 
then removed using 20 % piperidine in DMF. The resin was washed with DMF (10 
min 2.6 mL min-1) and the peptide sequence was assembled manually. For the 
commercially available N-Fmoc amino acids, i.e. Fmoc-(R)-Ala-OH, Fmoc-Gly-
OH and Fmoc-Trp-OH, each coupling reaction was carried out using the mixture of 
N-Fmoc amino acid (2 eq.), activating reagent PyOxim (2 eq.) and DIPEA (4 eq.). 
For the synthesised unusual amino acids, specifically, Fmoc-Ph(Se)-OH (42), 
Fmoc-Trp(X)-OH (43) and Boc-(R)-Ala-Thz-OH (44), each coupling reaction was 
carried out using the mixture of N-Fmoc amino acid (1.5 eq.), activating reagent 
PyOxim (1.5 eq.) and DIPEA (3 eq.). The coupling efficiencies were monitored by 
the effluent of Fmoc deprotections at 290 nm. All acylation reactions were repeated 
twice prior to the coupling the next N-Fmoc amino acid. After repeating six 
Chapter 4 Fmoc-SPPS and biological evaluation of argyrin A and analogues 
-143- 
 
deprotection-coupling cycles, the target linear peptides were assembled. The 
resulting linear peptides then will be cleaved from the linker-support. 
4.3.3   Cleavage of linear peptides and purification 
Cl
O
O
N
45
Boc-(R)-Ala-Thz-Trp-Trp(X)-Gly-(R)-Ala-Ph(Se) TFA
Cl
+
H-(R)-Ala-Thz-Trp-Trp(X)-Gly-(R)-Ala-
Ph(Se)-Sar-OH 46a-g
 
 a b c e f g 
X  = H 5-Br 5-Cl 7-Et 5-Me 5-MeO 
       
Release of the linear peptide 46a-g from the 2-chlorotrityl solid support can be 
accomplished by acidolysis using 1-5% trifluoroacetic acid. However, in order to 
simultaneously deprotect the N-terminus Boc protecting group, 50 % v/v TFA in 
DCM was used. During the acidolysis step, the generation of the tert-butyl 
carbocation could undergo undesired butylation of Trp residues. Therefore, 
scavengers were required to trap the reactive tert-butyl cation. The mixture of 
triisopropylsiliane (TIPS) and water are commonly used as scavengers in the 
cleavage cocktail.291 
Thus, resin-bound linear peptides (45) were treated with TFA/DCM/TIPS/H2O 
(49:49:1:1) for 1 h at room temperature. The crude linear peptides (46) were 
precipitated from ice-cold diethyl ether. The resulting materials were then 
suspended in water and lyophilised overnight to afford orange powders. All crude 
linear peptides were analysised by RP-HPLC and MS. For example, analysis of the 
crude peptide material 46e by RP-HPLC showed one major peak of the desired 
linear peptide at tR = 10.7 min (Figure 4-6 (a)). The elution profiles of all analogues 
are similar in terms of components and retention time. The identities of all 
analogues were confirmed by MS. 
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 Retention time % Area MS 
1 8.86 14.5 841.3278 
2 10.62 84.3 999.2575 
 
Figure 4-6 (a) The crude HPLC analysis of the linear peptide 46e. (b) Major by-product at tR 
= 9.00 min.  Sample was analysised using the method; 1 – 35 % B over 10 min at 3 mL/min. The 
column used was an Onyx Monolithic analytical C18 column (100 x 4.6 mm).  
In addition, the minor peak at tR = 8.86 min was further analysed by MS. The 
observed molecular ion was 158 mass units less than the molecular ion of the 
desired product, which was assigned to the unmasked dehydroalanine-containing 
peptide 186 (Figure 4-6 (b)). Disappearances of the selenium isotopic patterns were 
also observed. It was postulated that during repeated Fmoc deprotection step in 
SPPS, the dissolved oxygen in piperidine/DMF mixture resulted in partial oxidative 
elimination of phenylselenocysteine.  
Table 4-1 summarised the purity of crude peptides and yields. Fortunately, based 
on the observation, it seems dehydroalanine moiety is stable to 50 % TFA 
acidolysis and peptide coupling conditions. The crude linear peptides were used for 
the cyclisation step without further purification.  
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Table 4-1  Summary of the crude yield, purity and MS for the linear peptides 46a, 46b, 46c, 
46e, 46f and 46g. 
# 
 
 
Sequence Yield 
(%) 
Purity a 
(%) 
tR  
(min) b 
MS 
Calculated 
[M+H]+ 
Measured 
46a H-(R)-Ala1-Thz2-Trp3-Trp4-Gly5-
(R)-Ala6-Ph(Se)7-Sar8-OH 
56  90  10.3 971.2777 971.2323 
46b H-(R)-Ala-Thz-Trp-(5-Br)-Trp-
Gly-(R)-Ala-Ph(Se)-Sar-OH 
60  69  10.5 1049.1882 1049.1888 
46c H-(R)-Ala-Thz-Trp-(5-Cl)-Trp-
Gly-(R)-Ala-Ph(Se)-Sar-OH 
56  86  12.1 1005.2388 1005.2287 
46e H-(R)-Ala-Thz-Trp-(7-Et)-Trp-
Gly-(R)-Ala-Ph(Se)-Sar-OH 
54  84  10.6 999.3090 999.2575 
46f H-(R)-Ala-Thz-Trp-(5-Me)-Trp-
Gly-(R)-Ala-Ph(Se)-Sar-OH 
59  79  11.5 985.2943 985.2867 
46g H-(R)-Ala-Thz-Trp-(5-MeO)-
Trp-Gly-(R)-Ala-Ph(Se)-Sar-OH 
64  78  10.4 1001.2883 1001.2643 
 
a.
 Peptide purity determined from integration of RP-HPLC peak. 
b.
 RP-HPLC was performed on Onyx Monolithic analytical C18 column (100 x 4.6 mm). Eluent was 
monitored by UV absorbance at 216 nm. Linear gradient was 1-35 % B over 10 min at 3mL /min.  
 
 
Moreover, in order to confirm that the observed single peaks in the HPLC were 
optically pure, commercially available racemic N-Fmoc-(5-Br)-(S/R)-tryptophan 
was installed by SPPS to afford crude linear peptidic material as a mixture of two 
diastereoisomers. The resulting product was analysed by RP-HPLC and MS. Not 
surprisingly, as shown in Figure 4-7, the two major peaks at tR = 10.2 min and 10.5 
min in HPLC trace were well-resolved and afforded the same m/z 1049.18. This 
result provided the confidence that 46b is exclusively a single component.  
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 Retention time Area % Area MS 
1 10.260 15530099 27.21 1049.1888 
2 10.509 15346703 26.88 1049.1886 
 
Figure 4-7  RP-HPLC analysis of diastereomeric linear peptides derived from the installation 
of (5-Br)-(S/R)-Trp-OH. Sample was analysed using the method; 1–35 % over 10 min at 3 mL 
/min. The column used was an Onyx Monolithic analytical C18 column (100 x 4.6 mm).  
4.4 Macrocyclisation of argyrin A and analogues thereof 
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 a b c e f g 
X = H 5-Br 5-Cl 7-Et 5-Me 5-MeO 
One of the key steps in the synthesis of cyclic octapeptide argyrin A is the 
macrocyclisation. In general, there are two major macrocyclisation strategies: one 
is on-resin head-to-tail cyclisation, and the other is traditional solution-phase 
cyclisation under high dilution conditions. On-resin cyclisation requires linking the 
side chain of the trifunctional amino acid to the resin. Cyclisation thus can be 
performed while peptides remain anchored to the resin. The adva ntage of the on-
resin cyclisation strategy is that intramolecular reaction is favoured which results in 
minimising the formation of cyclodimers and oligomers.301 Although on-resin 
cyclisation strategy appears to be a good choice for the ring closure, the linear 
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argyrin A lacks trifunctional amino acids, such as aspartic acid, lysine or serine, 
which can be attached to the solid support. Therefore, a traditional solution-phase 
cyclisation was used. 
To avoid cyclodimerisation or oligomerisation side reactions during the 
macrocyclisation, the reaction was performed in high dilution conditions (10-3- 10-4 
M). In addition, PyBOP (178) was chosen as the carboxyl-activating reagent to 
avoid the N-guanidylation of the amino terminus. The mechanism of PyBOP-
mediated cyclisation is shown in Figure 4-8.  
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Figure 4-8 Mechanisum of PyBOP-mediated cyclisation. 
Initially, cyclisation of 46 was performed in DCM at a concentration of 0.5 mM in 
the presence of PyBOP (2 eq.) and DIPEA (3 eq.). The reaction mixture was stirred 
at room temperature for 72 h, and the reaction was monitored by RP-HPLC. 
Subsequence MS analysis of the major peak observed by RP-HPLC confirmed the 
identity of the cyclised peptide. However, following work-up, the yield was rather 
unsatisfactory (< 10 %). The reaction condition was then further optimised. 
Optimum results were obtained with the mixture of PyBOP (3 eq.), HOBt (3 eq.) 
and DIPEA (9 eq.) at 0.5 mM peptide concentration. Under these conditions, 
HPLC and MS analysis revealed that reactions were almost complete after 48 h 
with no evidence of oligomeric side products. Figure 4-9 shows the crude  
analytical HPLC of cyclic peptide 47e. The two peaks at tR = 0.8 min and 1.4 min 
were DMSO and coupling reagents, respectively. The major peak at tR = 9.9 min 
was the desired cyclic peptide, whereas the minor peak at tR = 7.9 min was found to 
be the cyclisation of the unmasked dehydroalanine-containing peptide 186.  
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 Retention time Area % Area MS 
1 7.979 9323561 15.11 823.2346 
2 9.913 35425646 56.86 981.2607 
 
Figure 4-9 The crude HPLC trace of cyclic peptide 47e.  Sample was analysed using the method; 
10 –60 % B over 12 min at 3 mL /min. The column used was an Onyx Monolithic analytical C18 
column
 
(100 x 4.6 mm).  
The major peaks of six analogues were purified by preparative RP-HPLC to afford 
cyclic peptides 47a, 47b, 47c, 47e, 47f and 47g in 11-28 % yield (Table 4-2). The 
impure linear peptide 46 is most likely attributable to the low yield of cyclisation 
step. Nevertheless, the purity and yields of the cyclic peptides after preparative 
HPLC were suitable for the final step of synthesis.  
Table 4-2  Summary of the purified yield, RP-HPLC retention time and MS for the cyclic 
peptides 47a, 47b, 47c, 47e,  47f and 47g. 
# 
 
Sequence Yield 
a 
(%) 
tR  
(min) b 
ES-MS  [M+H]+ 
calcd measured 
47a Cyclo [(R)-Ala1-Thz2-Trp3-Trp4-
Gly5-(R)-Ala6-Ph(Se)7-Sar8] 
30  8.5 953.2672 953.2571 
47b Cyclo [(R)-Ala-Thz-Trp-(5-Br)-
Trp-Gly-(R)-Ala-Ph(Se)-Sar] 
17  9.9 1031.1777 1033.1757 
47c Cyclo [(R)-Ala-Thz-Trp-(5-Cl)-Trp-
Gly-(R)-Ala-Ph(Se)-Sar] 
20  9.5 987.2282 987.2104 
47e Cyclo [(R)-Ala-Thz-Trp-(7-Et)-Trp-
Gly-(R)-Ala-Ph(Se)-Sar] 
28  9.9 981.2985 981.2607 
47f Cyclo [(R)-Ala-Thz-Trp-(5-Me)-
Trp-Gly-(R)-Ala-Ph(Se)-Sar] 
27  9.4 967.2828 967.2723 
47g Cyclo [(R)-Ala-Thz-Trp-(5-MeO)-
Trp-Gly-(R)-Ala-Ph(Se)-Sar] 
11  8.5 983.2777 983.2693 
a
  Yield refers to purified yields form preparative RP-HPLC. 
b
 RP-HPLC was performed on Onyx Monolithic analytical C18 column (100 x 4.6 mm). Eluent was 
monitored by UV absorbance at 216 nm. Linear gradient was 10-60 % B over 12 min at 3 mL /min. 
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Analysis of the isolated products using MS revealed all m/z values corresponded to 
the [M+H]+ species of cyclic peptides (Table 4-2). In addition, characterisation of 
47a, 47b, 47c, 47e, 47f and 47g was confirmed by 1H NMR and by 2D 1H-1H 
COSY NMR analysis. Figures 4-10 and 4-11 show the 1H and COSY NMR of 47e, 
respectively. Specifically, the presence of the characteristic NH signals at įH 7.44 
(d, J = 3 Hz, 1H), 7.58 (d, J = 7 Hz, 1H), 8.11 (d, J = 9 Hz, 1H), 8.35 (s, 1H), 8.65 
(d, J = 9 Hz, 1H) and 8.92 (t, J = 5 Hz, 1H) ppm indicated the six secondary 
amides. In addition, the observed correlation of these six amide signals with their 
adjacent Į SURWRQV LQ WKH &26< VSHFWUXP FRQILUPHG WKH unambiguous cyclic 
skeleton. The remaining upfield proton resonances were assigned by detailed 
inspection of the COSY spectrum. 
  
 
Figure 4-10   1H NMR spectrum of cyclic peptide 47e. Amide-1+DUHODEHOOHGUHGĮ-protons 
are blue and others are black. 
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Figure 4-11 1H-1H COSY spectrum of cyclic peptide 47e. 
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4.5 Oxidative elimination of phenylselenocysteine 
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 a b c e f g 
X = H 5-Br 5-Cl 7-Et 5-Me 5-MeO 
The final step of argyrin synthesis was to XQPDVN WKH Įȕ-unsaturated 
dehydroalanine residue. The conversion of the incorporated phenylselenocysteine 
residue to dehydroalanine was achieved through oxidative elimination.270 As 
shown in Figure 4-12, the phenylseleno moiety was firstly oxidised to the 
phenylselenoxide (187) by treatment with a mild oxidising agent, such as hydrogen 
peroxide (H2O2) or sodium periodate (NaIO4). Subsequent syn-elimination of 
phenylselenoxide (187) afforded the exo-methylene moiety (188). 
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Figure 4-12 Oxidative elimination of phenylselenocysteine to dehydroalanine. 
Hence, sodium periodate (4 eq.) was added dropwise to the cyclic peptide 47 in 
water/acetonitrile mixture at room temperature followed by stirring for 2 h. 
Formation of the phenylselenoxide-containing intermediate (187) was seen as a 
major component in RP-HPLC and MS analysis.  The solvent was removed and the 
residual material was extracted with water and DCM/IPA. Isopropyl alcohol (IPA) 
was added due to the low solubility of phenylselenoxide-containing intermediate. 
Subsequently elimination reaction of 187 was initially carried out using saturated 
aqueous NaHCO3 in acetonitrile as described in the literature.150 However, RP-
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HPLC analysis after three days revealed that the elimination was not completed 
(Figure 4-13(a)). In order to reduce the reaction time, the same reaction was carried 
out using saturated Na2CO3 aqueous solution. Gratifyingly, based on RP-HPLC 
analysis, the elimination was almost completed after 48 h (Figure 4-13(b)). The 
main peak at tR = 10 min is the eliminated product and the leading shoulder of the 
main peak is the unreacted phenylselenoxide intermediate.    
 
Figure 4-13 RP-HPLC analysis RIȕ-elimination of phenylselenoxide 187. (a) Using aqueous 
NaHCO3 for 3 days. (b) Using aqueous Na2CO3 for 24 h. Samples were analysed using the 
method; 10 – 60 % B over 12 min at 1 mL /min. The column used was an Onyx Monolithic 
analytical C18 column (100 x 3 mm).  
Successful conversion was confirmed by MS with disappearance of the selenium 
isotopic patterns and molecular ion peak of the product being detected. The major 
peaks were purified by preparative RP-HPLC to afford argyrin A and analogues in 
52-67 % yields (Table 4-3). Using 47e as an example, the successful 
transformation of 47e to 48e was confirmed by 1H NMR analysis, which revealed 
the disappearance of the aromatic protons (į = 7.17 pp m), CH2 (į= 4.33 and 4.37 
pp m) DQG Į-proton (į= 4.60 ppm) in the phenylseleno moiety (Figure 4-10) and 
the appearance of the two singlet protons (į = 4.92 and 5.16 pp m) in the alkene 
moiety (Figure 4-14). A study of the literature for dehydroalanine-containing 
peptides confirmed that no spin-spin splitting was observed for these 2J  germinal 
protons.270 
The assignment of proton resonances was established from 2D COSY spectrum. 
The backbone of cyclic peptide can be derived from cross signals between amide 
SURWRQVDQGWKHLUFRUUHVSRQGLQJĮ-protons. For example, the amide proton (į = 8.12 
ppm) of the (R)-Ala6 moiety which is labeled 6 in red colour in Figure 4-15, 
showed a cross signal WRLWVĮ-proton (į = 4.35 ppm7KLVĮ-proton also displays a 
correlation with the methyl group of (R)-Ala.   
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Figure 4-14  1H NMR spectrum of the argyrin A analogue 48e. Amide-1+DUHODEHOOHGUHGĮ-
protons are blue and others are black. 
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Figure 4-15  1H-1H COSY spectrum of the argyrin A analogue 48e. 
A summary of the retention times, yields and MS analysis of the six purified 
argyrin analogues is listed in Table 4-3. Although the reactions were clean and 
efficient, only moderate yields were obtained. Additionally, the cumulative yields 
from peptide assembling were only 4-11 %. The low cumulative yield may be 
attributed to the several work-up and purification steps. The poor solubility of 
peptides also reduced the yield. Therefore, in order to avoid tedious work-up steps 
and purification processes, an alternative strategy was investigated. 
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Table 4-3  Summary of the yields, RP-HPLC retention times and MS for the argyrin 
analogues 48a, 48b, 48c, 48e, 48f and 48h. 
# 
 
Sequence Yield 
(%) a 
tR 
(min) b 
ES-MS [M+H]+  Cumulative 
yield  
(%) c  
Calculated Measured 
48a Cyclo [(R)-Ala1-Thz2-Trp3-
Trp4-Gly5-(R)-Ala6-Dha7-Sar8] 
66  6.8 795.3037 795.2959 11  
48b Cyclo [(R)-Ala-Thz-Trp-(5-Br)-
Trp-Gly-(R)-Ala-Dha-Sar] 
58  8.0 875.2122 875.1877 6  
48c Cyclo [(R)-Ala-Thz-Trp-(5-Cl)-
Trp-Gly-(R)-Ala-Dha-Sar] 
67  7.5 829.2647 829.2347 8  
48e Cyclo [(R)-Ala-Thz-Trp-(7-Et)-
Trp-Gly-(R)-Ala-Dha-Sar] 
52  7.9 823.3350 823.3311 8  
48f Cyclo [(R)-Ala-Thz-Trp-(5-
Me)-Trp-Gly-(R)-Ala-Dha-Sar] 
66  7.3 809.3193 809.3016 11  
48g Cyclo [(R)-Ala-Thz-Trp-(5-
MeO)-Trp-Gly-(R)-Ala-Dha-
Sar] 
58  6.5 825.3143 825.3056 4  
a
  Yield refers to purified yields after the oxidative elimination step. 
b
 RP-HPLC was performed on Onyx Monolithic analytical C18 column (100 x 4.6 mm). Eluent was 
monitored by UV absorbance at 216 nm. Linear gradient was 10-60 % B over 10 min at 3 mL /min. 
c
 Cumulative yield refers to the accumulation of individual yields from peptide assembly. 
 
 
Inspired by the previous observation that dehydroalanine moiety is stable in 50 % 
TFA acidolysis and peptide coupling processes (Section 4.3.3), it was therefore 
anticipated that oxidative elimination could be achieved while the linear peptide 
was still attached to the solid-support. In other words, instead of releasing the linear 
precursor into solution after peptide assembly, on-resin oxidative elimination was 
effected. The synthesis of 48d, 48h and 48k is outlined in Scheme 4-3 and the 
purification was only required following the final reaction. 
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189
186
48
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45
Boc-(R)-Ala-Thz-Trp-Trp(X)-Gly-(R)-Ala-Ph(Se)
Cl
O
O
N
Boc-(R)-Ala-Thz-Trp-Trp(X)-Gly-(R)-Ala-Dha
H-(R)-Ala-Thz-Trp-Trp(X)-Gly-(R)-Ala-Dha-Sar-OH
(R)-Ala-Thz-Trp-Trp(X)-Gly-(R)-Ala-Dha-Sar
 
 
    d h k 
       X = 6-F  4-MeO (R)-Trp 
Scheme 4-3 Synthetic route for the cyclic peptides argyrin 48d, 48h and 48k. 
After all amino acid residues were coupled to the peptidyl resin as described in 
Section 4.2.2, the resins were suspended in DMF/H2O 0.5:0.2 and an aqueous 
solution of NaIO4 (4 eq.) were added to the SPPS column. The reactions were 
stirred at room temperature for 16 h, after which more than 95 % of the starting 
material were reacted, as determined by RP-HPLC. Unexpectedly, elimination of 
phenylselenoxide occurred spontaneously without further base treatment. The 
reasons for this are unclear, however, analysis by RP-HPLC and MS revealed the 
completion of the elimination. The linear peptides 189d, 189h and 189k were then 
cleaved from the resin and cyclised as previous described in Section 4.3.3 and 
Section 4.4, respectively.  
The results of the three analogues are summarised in Table 4-4. Unfortunately, no 
improvement of yields was obtained using this approach. Nevertheless, this 
approach allows an overall reduction of time and purification efforts. 
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Table 4-4  Summary of the yields, RP-HPLC retention times and MS analysis for the argyrin 
analogues 48d, 48 h and 48k. 
# 
 
Sequence 
Cumulative 
yield 
(%) a 
tR 
(min) 
b 
ES-MS [M+H]+ 
Calculated Measured 
48d Cyclo [(R)-Ala-Thz-Trp-(6-F)-
Trp-Gly-(R)-Ala-Dha-Sar] 
4  7.0 813.2943 813.3016 
48h Cyclo [(R)-Ala-Thz-Trp-(4-
MeO)-Trp-Gly-(R)-Ala-Dha-Sar] 
6  6.6 825.3143 825.3092 
48k Cyclo [(R)-Ala-Thz-Trp-(R)-Trp-
Gly-(R)-Ala-Dha-Sar] 
16  5.9 795.3037 795.3020 
 
a
 RP-HPLC was performed on Onyx Monolithic analytical C18 column (100 x 4.6 mm). Eluent was 
monitored by UV absorbance at 216 nm. Linear gradient was 10-60 % B over 12 min at 3 mL/min. 
b
 Cumulative yield refers to the accumulation of individual yields from peptide assembly. 
 
The structures of all nine argyrin analogues were elucidated by NMR spectroscopy. 
Analysis using solutions of argyrin analogues in DMSO-d6 by 1H NMR provided 
further evidence of their purity. Assignment of proton chemical shifts in argyrins 
was accomplished using 1H and 2D COSY NMR analysis. It was somewhat 
surprising that all nine synthesised argyrin analogues showed poor  solubility in 
CDCl3, the solvent used in the reported literature.152 Therefore, DMSO-d6 was 
chosen as a suitable solvent.   
4.6 Cytotoxicity evaluation of argyrin A and analogues 
As described in Chapter 1, argyrin A exhibited potent inhibition of eukaryotic 
proteasome activity. Based on Nickeleit’s studies, the concentration-dependent 
cytotoxicity effect of argyrin A was observed in several cancer cells of different 
origins, including colon carcinoma (HCT116, SW480), lung cancer (A549), breast 
adenocarcinoma (MCF7) and cervical cancer (Hela).3 In addition, SAR study by 
Stauch et al. revealed that argyrin A and F were the most potent analogues, with 
IC50 values against SW480 up to 3.7 and 4.2 nM, respectively (Table 1-6).155 They 
concluded that the presence of methoxy group in the 4-position of Trp4 was 
essential for their biological activities. This hypothesis can be tested by using 
argyrin analogues incorporating various substituents at different position of the 
Trp4 for further in-depth study.  
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In order to establish SAR of argyrins, the nine synthesised argyrin A and analogues 
(48a-h and 48k) were tested in MTT cell viability assays. A detailed description of 
MTT assay and a discussion of the biological results obtained for the 
aforementioned nine argyrin derivatives are provided in the ensuing sections. 
4.6.1   MTT cell viability assay 
Viability of mammalian cells can be accurately monitored by a variety of viability 
assays. MTT is one of the most common and straightforward technique used to 
assess the cytotoxicity of substances.302 Yellow 3-(4,5-dimethythiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) 190 is reduced to purple formazan 191 by 
succinate dehydrogenase in the mitochondria. Since reduction of MTT can only 
occur in metabolically active cells, the viability of the cells can be quantified by 
measuring of absorbance of this purple formazan solution. 
N
N
NN
S
N N
NH
N N
S
N
mitochondrial reductase
Tetrazolium salt (yellow) Formazan salt (purple)
190 191
 
 
Colon carcinoma cells have previously been reported to be sensitive to argyrin A 
treatment.3, 151 Therefore, the cytotoxicity of synthetic argyrin A and analogues 
reported in this thesis was performed using an MTT assay against the HCT-116 
human colon cancer cell line. Specifically, HCT-116 cells were seeded at a density 
of 2.5 x 103 cells per mL in 96-well plates and allowed to adhere overnight. The 
cells were treated with argyrins at various concentrations, from of 0.1 nM to 100 
ȝM and incubated at 37 °C for 72 h. Proliferation activity was determined by 
treating the cells with MTT. It is anticipated that viable cells with active 
mitochondria would reduce the tetrazolium into purple formazan. The purple 
IR UPD]DQ FU\VWDOV ZHUH GLVVROY HG LQ    ȝ/ '062 2S WLFDO G HQVLWLHV R I WKH
solutions were measured by absorbance at 500 nm in an ELISA plate reader. The 
GI50 values were determined according to an established methodology as described 
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in Section 6.5. All measurements were performed in triplicate and the results are 
reported as mean ± standard error of the mean.  
4.6.2   Results from the MTT cell viability assay 
The results of the GI50 values obtained from MTT cell viability assay with argyrin 
A and analogues are summarised in Table 4-5. The clinically used proteasome 
inhibitor bortezomib58 was used as a positive control. GI50 values represent the 
concentration of argyrin analogue that inhibit the growth of cancer cells by 50 %.  
Table 4-5  Inhibition of HCT-116 cell proliferation by argyrin analogues 
S
N
H
NO
N
O
HN
O
N
H
O HN
O
HN O
HN
O
N
H
NH
X
48
(R)
(R)
1 2
3
4
5
6
7
8
 
# Argyrin analogues GI50 (nM) a 
48a Cyclo [(R)-Ala1-Thz2-Trp3-Trp4-Gly5-(R)-Ala6-Dha7-Sar8] / Argyrin E 227 ± 10.8 
48b Cyclo [(R)-Ala-Thz-Trp-(5-Br)-Trp-Gly-(R)-Ala-Dha-Sar] 26  ± 4.1 
48c Cyclo [(R)-Ala-Thz-Trp-(5-Cl)-Trp-Gly-(R)-Ala-Dha-Sar] 20  ± 1.3 
48e Cyclo [(R)-Ala-Thz-Trp-(7-Et)-Trp-Gly-(R)-Ala-Dha-Sar] 133  ± 91 
48f Cyclo [(R)-Ala-Thz-Trp-(5-Me)-Trp-Gly-(R)-Ala-Dha-Sar] 26 ± 0.2 
48g Cyclo [(R)-Ala-Thz-Trp-(5-MeO)-Trp-Gly-(R)-Ala-Dha-Sar] 3.8  ± 2.7 
48d Cyclo [(R)-Ala-Thz-Trp-(6-F)-Trp-Gly-(R)-Ala-Dha-Sar] 40  ± 6.0 
48h Cyclo [(R)-Ala-Thz-Trp-(4-MeO)-Trp-Gly-(R)-Ala-Dha-Sar] / Argyrin A 1.8 ± 0.6 
48k Cyclo [(R)-Ala-Thz-Trp-(R)-Trp-Gly-(R)-Ala-Dha-Sar] 335 ± 7 
 
Bortezomib b 2.5 ± 0.8 
a
 Concentration needed to inhibit cell growth by 50% as determined from the dose-response curve. 
Determinations were made at 6 different concentrations of argyrins using MTT cell proliferation 
assays.  
b
 This clinically used drug was purchased from Sigma-Aldrich. 
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The results show that all nine synthetic argyrin analogues display antiproliferative 
activity in the nanomolar range. The potency is comparable with those results 
reported from the other groups.3, 151 Although the GI50 value determined for argyrin 
A with HCT116 cell line was 1.8 nM, which is slightly lower than the literature 
IC50 value of 2.8 nM,3 this difference is presumably due to the cell line variability 
and experimental error.  
Argyrin E (48a), which lack subs titution in Trp4, is less potent than other analogues. 
In addition, argyrin A (48h) and 48g, which contain the methoxy substitution on 
Trp4 residue are more potent than other analogues. As was discussed in Chapter 
1.4.2, this observation is in agreement with the literature hypothesis that the 
methoxy substitution of Trp4 is essential for activity. In fact, to investigate the 
influence of the key methoxy substituent at 4-position of Trp4 on the potency, the 
methoxy group of argyrin 48g was moved from the 4- to 5-postion. The results 
indicated that both 48h and 48g showed nearly equal potency. To the best of our 
knowledge, this is the first unique synthetic analogue of argyrin A, that displayed 
such high potency. 
In contrast, replacement of the 4-methoxy group (48g) with a methyl group (48f) 
resulted in significant decreased in potency, by some 10-fold. Previous studies have 
suggested that the 4-methoxy group on Trp4 residue is involved in electrostatic 
interaction with proteasome.155 As illustrated in Figure 1-23, the methoxy oxygen 
atom participates in a hydrogen bond to the hydroxyl group of S118 in the C-L and 
CT-L pockets. Thus, this decrease in activity could be explained by the inability of 
the 4-Me to participate in a hydrogen bond. 
Expectedly, another argyrin analogue 48e with a 7-ethyl substituent on Trp4 
displayed even poorer activity than that of 48f. It is postulated that, in addition to a 
lack of hydrogen bond, the introduction of an ethyl group at the 7-position of Trp4 
would sterically clash with the proteasome backbone (Figure 4-16). It is possible 
that this protrusion results in poorer binding affinity to the areas of the proteasome 
subunit. 
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Figure 4-16 Proposed binding pose of argyrin 48e to the CT-L pocket. 
Next, in order to investigate the electrostatic effect of the methoxy group on the 
potency, methoxy group (48g) was further replaced with an electron-withdrawing 
group. Argyrin 48b bearing a bromine atom at 5-position of Trp4 showed a GI50 
value of 26 nM. The result showed a 10-fold less in potency compared to argyrin A. 
Incorporation of other halogen groups in the 5- and 6-postion of Trp4 also resulted 
in diminished po tency, as shown by argyrin 48b, 48c and 48d. In addition, it seems 
that all halogenated argyrin analogous displayed similar degrees of potency. This is 
presumably due to hydrophobic characteristic of the halogen groups matches the 
hydrophobic side pocket of proteasome active site. However, good potency was 
maintained which is likely due to pos sible halogen bond interactions.  
In fact, studies in the medicinal chemistry field have shown that the insertion of 
halogen atoms could provide two major interactions to their target proteins.303 One 
of the most recognised interactions is the attachment of these bulky halogen atoms 
could occupy all the active site of target pockets, resulting in superior binding 
affinities to target proteins. For example, nemonapride (192), a chlorobenzamide, is 
a potent dopa minergic antagonist. The removal of the chlorine in this drug was 
found to be deleterious for the potency and reduce selectivity to the dopaminergic 
receptors.304 Another effect of halogen atoms is the ability to contribute an 
intermolecular halogen bond in a fashion resembling the hydrogen bonds. The 
formation of halogen bonds provides favourable electrostatic interactions between 
ligand and protein. For example, the activity of 4,5,6,7,-tetrabromobenzotriazole 
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(193), an ATP competitive inhibitor of cyclin A-CDK2, was attributed to  the 
involvement of three halogen bonds  (Figure 4-17(b)).305   
(a) (b)
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O O N
192
193
 
Figure 4-17 (a) Structure of nemonapride (192) and 4,5,6,7,-tetrabromobenzotriazole (193). (b) 
The 2.2 Å structure of cyclin A/CDK2 in complex with the inhibitor 184. The inhibitor is shown 
with three bromine halogen bonds to peptide carbonyl oxygens of the protein.305 
On the basis of these experimental results, it can be concluded that the presence of 
methoxy group in the 4-position of Trp4 is essential for biological activity. 
However, the methoxy group at 5-position of Trp4 is also tolerated. Conversely, 
Argyrin E which lacked of subs titution on Trp4 showed considerable lost of activity. 
Other derivatives lacking the methoxy group on Trp4 displayed less activity. The 
activities shown by halogenated compounds 48b, 48c and 48d were not 
significantly different, but were typically 10-fold less potent than that of argyrin A.   
In summary, the above  results clearly demonstrate that argyrin A which contains 4-
methoxy group on Trp4 displayed the greatest degree of potency within the nine 
argyrin analogous. Both diastereoisomers of argyrin E which lack substitution on 
Trp4 displayed the lowest activity.    
4.7 Conclusion 
A practical and robust solid-phase approach for the synthesis of argyrin A and 
analogues thereof has been developed. The described approaches enabled the 
production of linear precursors and the target cyclic peptides within a week. As a 
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result, the synthesis of nine argyrin A derivatives incorporating a wide range of 
functional group in an tryptophan residue was achieved. The high efficiency and 
reproducibility of the synthetic approach could be applied for the synthesis of other 
argyrin A analogues. 
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Route A a b c e f g Route B d h k 
X = H 5-Br 5-Cl 7-Et 5-Me 5-MeO X = 6-F 4-MeO (R)-Trp 
Scheme 4-4 Synthesis of argryin A and analogues thereof (48). Reagents and conditions: (a) i. 
piperidine/DMF (1:4); ii.Fmoc-amino acids, PyOxim or HATU, DIPEA; (b) TFA/DCM, H2O, 
TIPS.; (c) PyBOP, HOBt, DIPEA; (d) i. NaIO4, CH3CN/H2O; ii. Na2CO3, CH3CN/H2O; (e) NaIO4, 
DMF/H2O. 
In summary, Fmoc-Sar (41) was chosen as the C-terminus amino acid residue 
which was tethered to the resin linker 2-chlorotrityl chloride polystyrene (40). All 
subsequent amino acids, including Fmoc-Ph(Se)-OH (42), Fmoc-(R)-Ala-OH, 
Fmoc-Gly-OH, Fmoc-Trp(X)-OH (43), Fmoc-Trp-OH and Boc-(R)-Ala-Thz-OH 
(44)  were then coupled to the peptidyl resin using HATU- (176) or PyOxim- 
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mediated (179) carboxyl-activation to afford resin-bound linear peptides which 
were universally deprotected and cleaved form the resin by acidolysis using 50 % 
TFA to afford linear precursors 46 (Route A, Scheme 4-4). Cyclisation were then 
undertaken on high diluted solutions by treatment with PyBOP (178), HOBt and 
DIPEA to afford cyclic peptides 47. RP-HPLC and MS confirmed the success of 
the cyclisation without oligomeric side-products being observed. Finally, 
conversion of phenylseleno moiety to the exo-methylene was achieved by oxidative 
elimination. Preparative RP-HPLC was used to purify the argyrin analogues in 
purity of > 95% and overall yields of 4-11 % (Table 4-5). As an alternative, on-
resin oxidative elimination of the phenylselenocysteine residue was evaluated 
(Route B, Scheme 4-4). Unfortunately, the results showed that no significant 
improvements in yield were obtained in this approach (Table 4-4). However, this 
approach facilitated an overall reduction of time and purification efforts required to 
obtain the final desired products. 
The purity and identity of nine synthesised argyrin analogues were established by 
RP-HPLC, MS and NMR. The purity and yield following RP-HPLC purification 
for each analogue are summarised in Table 4-5. The successful synthesis of argyrin 
A and eight analogues therefore allowed for further structure-activity studies. 
The nine argyrin A and analogues described above were tested in a cell viability 
assay. HCT-116 human colon cancer cell line was chosen for the preliminary 
cytotoxicity study. The cells were treated with nine argyrin analogues for 72 h. The 
cytotoxic experiment was carried out using the MTT colorimetric assay. The 
results indicated that the synthesised argyrin analogues exhibited GI50 values in 
nanomolar range. The two most potent argyrins, argyrin A (48h) and argyrin 48g, 
possessed GI50 values in 1.8 nM and 3.8 nM, respectively. It was found that 
replacing the 4-methoxy group with other groups greatly reduced the potency. Such 
results provide valuable evidence that the presence of the methoxy group on Trp4 is 
crucial for biological activities of argyrin.   
 
 
 
Chapter 4 Fmoc-SPPS and biological evaluation of argyrin A and analogues 
-165- 
 
Table 4-5     Argyrin derivatives synthesised and purified by RP-HPLC with corresponding 
isolation yields  and purity.  
# 
 
Sequence Cumulative yield  
(%) a  
Purity 
(%) b 
tR  
(min) c 
GI50 
(nM) d 
48a Cyclo [(R)-Ala1-Thz2-Trp3-Trp4-Gly5-
(R)-Ala6-Dha7-Sar8]/ Argyrin E 
11  > 95 6.8 227 ± 10.8 
48b Cyclo [(R)-Ala-Thz-Trp-(5-Br)-Trp-
Gly-(R)-Ala-Dha-Sar] 
6  > 95 8.0 26  ± 4.1 
48c Cyclo [(R)-Ala-Thz-Trp-(5-Cl)-Trp-
Gly-(R)-Ala-Dha-Sar] 
8  > 95 7.5 20  ± 1.3 
48e Cyclo [(R)-Ala-Thz-Trp-(7-Et)-Trp-
Gly-(R)-Ala-Dha-Sar] 
8  > 95 7.9 133  ± 91 
48f Cyclo [(R)-Ala-Thz-Trp-(5-Me)-Trp-
Gly-(R)-Ala-Ph(Se)-Sar] 
11  > 95 7.3 26 ± 0.2 
48g Cyclo [(R)-Ala-Thz-Trp-(5-MeO)-Trp-
Gly-(R)-Ala-Dha-Sar] 
4  > 95 6.5 3.8  ± 2.7 
48d Cyclo [(R)-Ala-Thz-Trp-(6-F)-Trp-
Gly-(R)-Ala-Dha-Sar] 
4 > 95 7.0 40  ± 6.0 
48h Cyclo [(R)-Ala-Thz-Trp-(4-MeO)-Trp-
Gly-(R)-Ala-Dha-Sar] / Argyrin A 
6 > 90 6.6 1.8 ± 0.6 
48k Cyclo [(R)-Ala-Thz-Trp-(R)-Trp-Gly-
(R)-Ala-Dha-Sar] 
16 > 90 5.9 335 ± 7 
a.
 Cumulative yield refers to the accumulation of individual yields from peptide assembly. 
b.
 Peptide purity was determined from integration of RP-HPLC peaks. 
c.
 RP-HPLC was performed on Onyx Monolithic analytical C18 column (100 x 4.6 mm). Eluent was 
monitored by UV absorbance at 216 nm. Linear gradient was 10-60 % B over 12 min at 3 mL/min. 
d. Concentration needed to inhibit HCT-116 cell growth by 50% as determined from the dose-
response curve. Determinations were made at 6 different concentrations of argyrins using MTT cell 
proliferation assays.  
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Chapter 5   
General conclusion and 
further studies 
Argyrin A is a cyclic octapeptide comprised of four natural amino acids and three 
unusual amino acids. To date, the total synthesis of argyrin A and its analogues 
have been achieved by three independent laboratories. In 2002, Ley et al. first 
described a total synthesis of argyrin B in 17 steps. After argyrin A was identified 
as a potent proteasome inhibitor by Nickeleit et al. in 2008, this natural occurring 
cyclic peptide has attracted the attention of chemists and biologists.3 Preliminary 
studies also demonstrated that the dehydroalanine and 4-methoxy-tryptophan 
residues in this sequence are essential for their biological activities. In order to 
understand the structure-activity relationships of this complex molecule, %ȨORZet 
al. synthesised argyrin F and its eight Gly5-modified analogues.151 Wu et al. further 
modified the convergent strategy to achieve the total synthesis of argyrin A and 
E.152   
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However, the complexity of these syntheses limits both its availability and the 
scope for preparing structural analogues. In this thesis, the synthesis of three key 
unusual amino acid building blocks of argyrin A has been established, in particular 
a novel generic route for the synthesis of optically pure N-Fmoc tryptophan 
analogues. Additionally, the first solid-phase-based synthesis of the cyclic 
octapeptide argyrin A and analogues thereof was also established. This solid-phase 
strategy enabled the rapid and efficient synthesis of various argyrin analogues. 
Therefore, argyrin analogues obtained by this strategy provide valuable SAR 
concerning the key role played by the methoxy group in Trp4. 
5.1 Synthesis of (S)-tryptophan and analogues 
The development of a novel synthetic route for the synthesis of N-Fmoc tryptophan 
analogues provided a key building block necessary for the synthesis of argyrin. As 
outlined in Scheme 5-1, a series of Fmoc tryptophan derivatives 43 were obtained 
from the corresponding indoles 49 in eight steps. 
Commercially available indoles 49 were subjected to Vilsmeier formylation to give 
aldehydes 50, which were then homologated via Wittig reaction followed by acid 
hydrolysis of the enol ether intermediates to afford aldehydes 51. A practical one-
pot diastereoselective Strecker amino acid synthesis using a chiral auxiliary amine 
in the presence of sodium cyanide led to the straightforward synthesis of a 
diastereoisomeric mixture of (S,R) and (R,RĮ-aminonitriles 52 in 3:1 ratio. For the 
non-halogen substituted indoles, (R)-2-phenylglycinol (R’ = OH, R’’ = H) was 
used as a chiral auxiliary. In contrast, for the chlorine and bromine substituted 
indoles, 4-methoxy-Į-methylbenzylamine (PMB) (R’ = H, R’’= OCH3) was 
introduced as a chiral auxiliary reagent.  
A number of acidic and basic conditions were found to be unsuccessful in their 
ability to effect hydrolysis of amino nitriles 52 to amino amides 53; decomposition 
was the main observation. Thus, the mild peroxide hydrolysis was employed for 
WKH FRQYHUVLRQ RI DFLG ODELOH Į-aminonitriles 52 to the FRUUHVSRQGLQJ Į-amino 
amides 53. Consequent separation of the desired (S,R Į-aminoa mides 54 was 
readily achieved by silica chromatography or RP-HPLC. 
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Scheme 5-1 Synthesis Fmoc-tryptophan derivatives (43); Reagents and conditions: (a) POCl3, 
DMF, 0 °C then 45 °C; (b) i. Ph3PCH2OCH3, n-BuLi; ii. HCl, THF, reflux; (c) Chiral auxiliary, 
NaCN, AcOH, MeOH; (d) H2O2, Na2CO3, DMSO; (e) Recrystallisation or HPLC; (f1) Pd/ C, 
NH4HCO2, MeOH, reflux; (f2) TFA, TIPS, 60 °C; (g) 1 M HCl, reflux; (h) Fmoc-OSu, NaHCO3, 
THF/H2O. 
Having obtained the desired diastereomeric pure (S,R Į-aminoa mides 54, the 
chiral auxiliary was removed by two difference conditions: For the non-halogen 
substituted aminoamides (54a, d-h), removal of the N-benzyl group was achieved 
by catalytic transfer hydrogenation to afford (S)-tryptophan amide derivatives 55. 
In contrast, for the chlorine and bromine substituted aminoamides (54b and 54c), 
removal of the PMB group was achieved by TFA-mediated acidolysis. Subsequent 
hydrolysis of (S)-tryptophan amide derivatives 55 to the corresponding (S)-
tryptophan derivatives 56 was accomplished in good yield (> 80 %) by refluxing in 
1 M aqueous hydrochloric acid without causing decomposition. Finally, the N-
terminal of amino acids was protected with Fmoc to afford 43 which were suitable 
for the Fmoc solid phase peptide synthesis. 
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The method described above was used for the synthesis of eight Fmoc-tryptophan 
derivatives with a broad range of substitutions in the indole ring. The overall yields 
over this eight-step synthesis ranged from 2 to 5 %. The low yield was due to 
sensitivity of indole moiety, especially for the indole with electron-donating 
substitutions.  
In summary, a new generic method for the synthesis of optically pure N-Fmoc-
tryptophan derivatives was established. This method employed inexpensive  
commercially available reagents, and avoided using expensive chiral auxiliaries or 
resolving reagents. 
5.2  Synthesis of N-Boc-(R)-Ala-Thz-OH 
The second unusual building block for the total synthesis of argyrin A is the 
thiazole-containing dipeptide. Therefore, N-Boc-(R)-Ala-Thz-OH dipeptide 
building block (44) was obtained using known procedures. As depicted in Scheme 
5-2, N-Boc-(R)-Ala-Thz-OH (44) was prepared in four steps starting from N-Boc-
(R)-Ala-OH.   
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Scheme 5-2 Synthesis of N-Boc-(R)-Ala-Thz-OH (44);  Reagents and conditions: (a) DCC, HOBt, 
NH3, CH2Cl2, 0 °C; (b) Lawesson’s reagent, THF, 0°C; (c) i. BrCH2COCO2Et, KHCO3, DME, -15 °
C; ii.TFAA, 2, 6-lutidine, DME, -15 °C; (d) LiOH, THF/ MeOH/ H2O, room temp. 
The key synthetic strategy of thiazole unit was achieved by using a modified 
Hantzsh-thiazole formation. Thioamide (58) was cyclised using ethyl 
bromopyruvate to afford thiazoline intermediate, followed by treatment of TFAA 
and 2,6-lutidine to give the desired thiazole dipeptide.  
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The overall yields over this four-step synthesis ranged from 26 to 30 %. The 
characterisation data of the thiazole dipeptide 44 was identical to that reported in 
the literature.150 In addition, the specific rotation obtained for 44 indicated that 
thiazole formation occurred without racemisation. The optical purity of 44 was 
further confirmed by the Mosher’s method. However, further modification of the 
thiazole subunit to oxazole derivative was unsuccessful, due to the epimerisation 
during the cyclisation step. 
5.3 Synthesis of Fmoc-phenylselenocysteine, a dehydroalanine 
precursor 
The third building block necessary for the total synthesis of argyrin A is the 
dehydroalanine precursor, phenylselenocysteine. It has been described that 
phenylselenocysteine can be incorporated into growing peptide chain via standard 
Fmoc SPPS procedure.270 Therefore, Fmoc protected phenylselenocysteine was 
chosen as a masked precursor to the labile dehydroalanine building block. As 
outlined in Scheme 5-3, Fmoc-phenylselenocysteine (42) was prepared in four 
steps starting from N-Boc-Serine. 
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Scheme 5-3 Synthesis of a dehydroalanine precursor, Fmoc-phenylselenocysteine (42). 
Reagents and conditions: (a) DEAD, PPh3, THF, -78 °C to room temp.; (b) PhSeSePh, 
NaBH(OMe)3, EtOH, room temp.; (c) TFA/DCM, room temp.; (d) Fmoc-OSu, NaHCO3, THF/H2O, 
room temp. 
N-Boc-6HULQH ZDV ILUVWO\ FRQYHUWHG WR LWV ȕ-lactone (64) via intramolecular 
Misunobu reaction. This was followed by ring opening with phenylselenide anion 
which was generated by the reaction of diphenyl diselenide with sodium 
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trimethoxyborohydride. The resulting Boc-protected 65 was converted to its Fmoc 
derivatives 42 via standard conditions. 
The overall yields over this four-step synthesis ranged from 35 to 40 %. The 
spectroscopic data of the N-Boc-phenylselenocysteine (65) was identical to that 
reported in the literature.150 It should be  noted that Fmoc-phenylselenocysteine (42) 
is stable to storage at room temperature without noticeable decomposition over at 
least several months. Unmasking of the dehydroalanine by oxidative elimination 
would be carried out in the ultimate step of the synthesis of argyrin. 
5.4 Fmoc solid-phase synthesis of proteasome inhibitors argyrin A 
and analogues thereof 
Having obtained the three unique amino acid building blocks, the work continued 
with the synthesis the cyclic peptide argyrin A. As outlined in Scheme 5-4, the 
strategy involved Fmoc solid phase peptide synthesis and in a solution-based head-
to-tail cyclisation. 
Fmoc SPPS was used for the synthesis of the linear argyrin precursors. Sarcosine 
was chosen as the C-terminal end to attach to the resin linker 2-chlorotrityl chloride 
polystyrene (40). Having determined the resin loading, all subsequent amino acids  
were coupled to the peptidyl resin manually. Sequential acylation reactions were 
carried out using appropriately N-protected amino acids, N-Fmoc amino acids (3-4 
eq.) and carboxyl-activating reagent PyOxim or HATU (3-4 eq.) in the presence of 
DIPEA (6-8 eq.). Repetitive N-Fmoc deprotection was achieved by using 20 % v/v 
piperidine in DMF. 
  
 
Chapter 5 General conclusion and further studies 
-172- 
 
OH
O
N
O
HN
Se
O
NH
HN
O
O
NH
NH
O
HN
HN
O
N
S
TFA
.
H2N
X
46
Fmoc-Sar-OH
Fmoc-Ph(Se)-OH
Fmoc-(R)-Ala-OH
Fmoc-Gly-OH
Fmoc-Trp-OH
Boc-(R)-Ala-Thz-OH
Cl
Cl
Fmoc-Trp(X)-OH
(42)
(44)
(43)
+
40
(41)
S
N
H
NO
N
O
HN
O
N
H
O HN
O
HN O
HN
O
N
H
NHSe
X
47
S
N
H
NO
N
O
HN
O
N
H
O HN
O
HN O
HN
O
N
H
NH
R
48
(a)
(b)
(c)
(d)
(e)
(b), (c)
Route ARoute B
Cl
O
O
N
45
Boc-(R)-Ala-Thz-Trp-Trp(X)-Gly-(R)-Ala-Ph(Se)
O
N
O
HN
O
NH
HN
O
O
NH
NH
O
HN
HN
O
N
S
BocHN
X
189
O
Cl
1
2
3
4
56
7
8
 
Route A a b c e f g Route B d h k 
X = H 5-Br 5-Cl 7-Et 5-Me 5-MeO  6-F 4-MeO (R)-Trp 
Yield 
(%) 11 6  8 8  11   4   4  6  16  
Scheme 5-4 Synthesis of argryin A and analogues thereof (48). Reagents and conditions: (a) i. 
piperidine /DMF (1:4); ii.Fmoc-amino acids, PyOxim or HATU, DIPEA; (b) TFA/DCM, H2O, 
TIPS.; (c) PyBOP, HOBt, DIPEA; (d) i. NaIO4, CH3CN/H2O; ii. Na2CO3, CH3CN/H2O; (e) NaIO4, 
DMF/H2O. 
In route A, the assembled 45 were universal deprotected and cleaved form the resin 
using 50 % v/v TFA in DCM. Subsequent cyclisation in high diluted solution for 3 
days results in the cyclic peptides 47. Finally, oxidative elimination of the 
phenylselenocysteine residue to exo-methylene afforded the final argyrin and 
analogues thereof in an overall yield of 4-11 %. 
Alternatively, in route B, instead of releasing the linear precursor into solution after 
peptide assembly, on-resin oxidative elimination was employed to afford 180. 
Subsequent cleavage of the resin followed by cyclisation in high diluted solution 
resulted in the final argyrin analogues in an overall yield of 4-16 %. 
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In summary, the first solid-phase-based synthesis of the cyclic octapeptide argyrin 
A and analogues was established. However, both route A and route B gave 
relatively low yields. Nevertheless, the purity and quantity achieved after 
preparative HPLC were suitable for preliminary biological test. All synthetic 
argyrin analogues were characterised by MS, 1H and 2D COSY NMR spectrometry.  
5.5 SAR study of argyrins 
Synthetic argyrin A, argyrin E and seven novel argyrin analogues were tested in a 
cell viability assay using HCT-116 human colon cancer cell line. The obtained GI50 
values are listed in Table 5-1. 
 Table 5-1 Inhibition of HCT-116 cell proliferation by argyrins. 
# Argyrin analogues GI50 (nM) a 
48a Cyclo [(R)-Ala1-Thz2-Trp3-Trp4-Gly5-(R)-Ala6-Dha7-Sar8] / Argyrin E 227 ± 10.8 
48b Cyclo [(R)-Ala-Thz-Trp-(5-Br)-Trp-Gly-(R)-Ala-Dha-Sar] 26  ± 4.1 
48c Cyclo [(R)-Ala-Thz-Trp-(5-Cl)-Trp-Gly-(R)-Ala-Dha-Sar] 20  ± 1.3 
48e Cyclo [(R)-Ala-Thz-Trp-(7-Et)-Trp-Gly-(R)-Ala-Dha-Sar] 133  ± 91 
48f Cyclo [(R)-Ala-Thz-Trp-(5-Me)-Trp-Gly-(R)-Ala-Dha-Sar] 26 ± 0.2 
48g Cyclo [(R)-Ala-Thz-Trp-(5-MeO)-Trp-Gly-(R)-Ala-Dha-Sar] 3.8  ± 2.7 
48d Cyclo [(R)-Ala-Thz-Trp-(6-F)-Trp-Gly-(R)-Ala-Dha-Sar] 40  ± 6.0 
48h Cyclo [(R)-Ala-Thz-Trp-(4-MeO)-Trp-Gly-(R)-Ala-Dha-Sar] / Argyrin A 1.8 ± 0.6 
48k Cyclo [(R)-Ala-Thz-Trp-(R)-Trp-Gly-(R)-Ala-Dha-Sar] 335 ± 7 
 
Bortezomib b 2.5 ± 0.8 
a
 Concentration needed to inhibit cell growth by 50% as determined from the dose-response curve. 
Determinations were made at 6 different concentrations of argyrins using MTT cell proliferation 
assays.  
b
 This clinically used drug was purchased from Sigma-Aldrich. 
The results showed that most synthetic argyrin derivatives displayed growth 
inhibitory effects on HCT-116 human colon cancer cell line at nanomolar 
concentrations. These results are comparable to that reported by Nickeleit et al. It 
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has been proposed that the cytotoxic effect is due to inhibition of proteasomal 
activity. Among the nine argyrins, argyrin A which comprised 4-methoxy-Trp4 
displayed the greatest activity with GI50 value at 1.8 nM. Significantly, a 
comparable GI50 value was observed for argyrin 48g which indicate 4-methoxy 
group on Trp4 is tolerated at the 5-position. 
However, other derivatives lacking the methoxy group on Trp4 displayed less 
activity; the activity show n by halogenated compounds 48b, 48c and 48d were not 
significantly different, but was 10-fold less potent when compared with argyrin A. 
Both isomers of argyrin E which lack substitution on Trp4 displayed low activities. 
In summary, the preliminary cytotoxicity study of argyrin A and analogues 
confirmed that a methoxy group at 4- or 5-position of Trp4 showed the best 
cytotoxic activity. This finding is in agreement with the hypothesis that the 
methoxy moiety of Trp4 is required to form a hydrogen bond with the active site of 
proteasome. Such result provided valuable information with respect to structure-
activity relationship studies. 
5.6 Further studies 
The major goal of this thesis was the total synthesis of argyrin A and analogues 
thereof. This has been achieved by developing a generic route to the synthesis of N-
Fmoc tryptophan analogues which is required for the argyrin synthesis. In addi tion, 
a convenient and efficient methodology to synthesise argyrin A has been 
established. 
The ultimate goal of this project was to derive a library of rationally designed 
analogues of argyrin A. It is clear now that argyrin A and the eight analogues 
thereof have displayed anti-proliferative effect against HCT-116 tumour cell line. It 
is envisaged that these compounds will also show cytotoxic activity on other 
human tumour cell lines. Thus, further work in evaluating the biological properties 
would include  (1) screening of a wider panel of human tumour cell lines against 
argyrin analogues to determine the sensitivity of individual cell line to the 
treatment of argyrin analogues, and (2) testing whether the cytotoxic effect is due 
to proteasome inhibition. 
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Besides HCT-116, a variety of cell lines, such as SW480 (colon adenocarcinoma), 
A549 (lung cancer), MCF7 (breast cancer), HeLa (cervical cancer) and human 
fibroblast cell lines could be tested against the nine synthetic argyrin analogues. 
The preliminary findings reported by Nickeleit et al. suggested that all these cell 
lines are sensitive to argyrin A with IC50 values in the low nanomolar range.3  As 
revealed by the measurement of the sub-G1 DNA fraction in flow cytometry 
histograms, they suggested that argyrin A exhibits two different cellular 
phenotypes. Primary human fibroblast and A549 cells ceased to proliferate, 
whereas WS480, MDF7 and Hela cells underwent apoptosis.3 Further time course 
experiments with these cell lines found that argyrin A treatment resulted in 
stabilisation of cellular p27 levels by preventing the turnover of the protein.3 
Thus, in order to determine if proteasome inhibition is responsible for the cytotoxic 
effect of argyrin A and analogues, it is crucial to establish their proteasome 
inhibitory activity. To date, there are two available methods to monitor  proteasome 
activity. One utilised purified human 20S proteasome from cell lysates.104 20S 
proteasome incubated with the argyrin analogues, and the CT-L, C-L and T-L 
activities of proteasome could be measured using fluorogenic peptide substrates 
specific for the three catalytic subunits The increase in fluorescence is proportional 
to the remaining proteasome activity. The other method is to assess proteasome 
activity in whole cells using site-specific proteasome probes.306 Experiments are 
conducted using cell-permeable, fluorophore labelled proteasome inhibitors which 
specifically bind to and eventually label the active sites of the proteasome. The 
amount of fluorophore generated is proportional to the remaining proteasome 
activity. 
In addition to the biological studies, further investigation into the structural 
modification of the other amino acid residues will be undertaken. Having 
established the SPPS of argyrin A, the main efforts towards the total synthesis of 
argyrin analogues are the preparation of the three unusual amino acid building 
blocks. Thus, a possible avenue for further investigation is to simplify the structure 
of argyrin A without compromising biological activities. 
Since the methoxy group in Trp4 was found to be crucial for the biological activity 
of argyrin A, the first logical progression is the synthesis of O-methyl-Tyr4-argyrin 
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194 and 195, in which the 4-methoxy-trypop han residue is respectively replaced by 
the O-methyl tyrosine and O-methyl-m-tyrosine (Figure 5-1).  
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Figure 5-1 Chemical structure of two proposed (O-methyl-Tyr4)-argyrin analogues. 
It is anticipated that theses analogues would preserve the aryl methoxy group and 
physicochemical properties of the aromatic side-chain. The use of tyrosine as a 
Trp-mimetic residue is not only to avoid laborious preparation of tryptophan 
derivatives, but also to facilitate the derivatisation of 4-hydroxyphenyl side chain 
into a various different functional subs titutions which are deemed suitable for 
further SAR studies.  
Having examined the structural modifications of the unusual amino acid 4-
methoxy-Trp4, attention could now be focused on optimisation of the dipeptide (R)-
Ala1-Thz2-OH. The computational docking studies of argyrin A bound to the 
proteasome revealed that the three active sites of proteasome were not involved in 
any interaction with the dipeptide, particularly with the thiazole moiety.155 In order 
to test this hypothesis and to simplify the synthesis, analogues 196 and 197 can be 
respectively prepared using Ala2 and Dha2 in place of the Thz2 residue. This 
modification is not expected to change the conformation of the argyrin backbone 
significantly.  
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Based on previous SAR studies, absence of the dehydroalanine residue displayed 
significantly less activity due to reduction of conformational rigidity of the peptide 
backbone.155 Nevertheless, as reported in the thesis, dehydroalanine moiety is 
stable in 50 % TFA acidolysis and other basic conditions during peptide coupling 
processes, it is therefore envisioned that it might not be necessary to prepare Fmoc-
phenylselenocysteine as a precursor. Thus, an efficient method of introducing 
dehydroalanine into argyrin could be achieved using Fmoc-S-benzylcysteine (198), 
followed by oxidation and elimination to yield the Dha7 residue.307  
The proposed method for the synthesis of Dha7 is outlined in Scheme 5-5. 
Sequential coupling of seven amino acid building blocks yields the on-resin linear 
precursor, which is then subjected to oxidation of the side chain of S-benzyl-Cys7, 
followed by elimination, to yield the linear argyrin 199. Subsequent cleavage from 
resin followed by cyclisation in high dilution affords argyrin A. The advantages of 
using this strategy are: (1) Fmoc-S-benzylcysteine (198) is commercially available, 
(2) S-benzylcysteine is stable in standard Fmoc deprotection conditions and (3) it is 
less toxic than selenocysteine.    
FmocHN
O
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Scheme 5-5 Proposed scheme for the synthesis of argyrin A utilising N-Fmoc-S-benzylcysteine 
(198) as a dehydroalanine precursor. Reagents and conditions: (a) i. Piperidine /DMF (1:4); 
ii.Fmoc-amino acids, PyOxim or HATU, DIPEA; (b) i. m-CPBA, DCM, 0 °C; ii. DBU, MeOH or 
dioxane, reflux; (c) TFA/DCM, H2O, TIPS; (d) PyBOP, HOBt, DIPEA. 
As illustrated in Chapter 3.3, several attempts of obtaining the dipeptide analogue 
(R)-Ala-oxazole suitable for SPPS were unsuccessful, yielding a racemic mixture 
of (R)-Ala-oxazole and (S)-Ala-oxazole. It is deemed necessary either to optimise 
the conditions of the described processes or to investigate a different approach. As 
an alternative approach, oxazole derivatives could be accessed following a one-step 
oxazole synthesis established by Williams et al..308 They utilised bis(2-
methoxyethyl)aminosulfur trifluoride (Deoxo-Fluor) (200) for the cyclo-
GHK\GUDWLYH FRQYHUVLRQ RI ȕ-hydroxy amides to oxazole derivatives with no 
evidence of epimerisation.308 Optically pure (R)-Ala-oxazole-OEt therefore could 
be synthesised following the proposed synthetic route shown in Scheme 5-6. 
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Scheme 5-6  Synthesis of N-Boc-(R)-Ala-oxazole-OEt (146) via Mitsunobu reaction. Reagents 
and conditions: (a) DCC, HOBt, DIPEA, DCM; (b) 200, -20 °C; then BrCCl3, DBU, 2-3 °C, 8 h.   
As shown above, N-Boc-(R)-Ala-OH is first coupled with serine ethyl ester under 
standard conditions to give the amide 148. Subsequent fluorination with Deoxo-
Fluor (200) at -20 °C followed by oxidation, gives the desired (R)-Ala-oxazole-OEt 
146. The significance of this approach is the cyclisation and the oxidation 
performed under mild conditions, avoiding the potential epimerisation and hence 
giving a high optical purity (e.e. > 97 %) and good yields (> 60 %).308  
In conclusion, the SPPS strategy established in this thesis has given access to 
argyrin A and a wide range of analogues. 
       
   
Chapter 6 Experimental 
-180- 
 
 
 
 
 
Chapter 6  
Experimental 
6.1 Materials and instrumentation 
Reagents which were used in the experiments were obtained from Sigma-Aldrich, 
Fisher scientific, Acros and TCI. 2-Chlorotrityl chloride resins were purchased 
from Novabiochem (100-200 mesh, 1% DVB, loading 1.2 mmol /g). The silica gel 
(sorbsil®, Group Rhone Poulene, UK) or ISOLUTE® scaffold (international sorbent 
technology, UK) were used for the column and flash chromatography respectively. 
Dried solvents such as DME, ethanol and THF, were used as supplied. All 
glassware was oven-dried overnight prior to use. TLC was carried out on Merck 60 
Chapter 6 Experimental 
-181- 
 
F254 silica gel plates and visualised by UV irradiation 254 nm or by staining with 
KMnO4 or ninhydrin solution if appropriate.  
The identification of the prepared compound was done by using melting point 
apparatus, infrared spectra, polarimeter, nuclear magnetic resonance spectra and 
mass spectroscopy. 
Melting points were measured on a Gallenkamp melting point apparatus and are 
uncorrected. Infrared spectra were obtained from an Avatar 360 Nicolet FT-IR 
spectrophotometer in the range of 4000-500 cm-1 using KBr discs. Absorption 
PD[LPD ȣmax) are reported in wave numbers (cm-1). Only signals representing 
functional groups are reported. Absorptions from the fingerprint region are not 
listed.  Optical rotations were measured on an $'3 PRGHO SRODULPHWHU >Į@D 
values are reported in 10-1 deg. cm-2. g-1, concentration (c) is in gram per 100 mL.  
Proton nuclear magnetic resonance (į H), carbon nuclear magnetic resonance (į C) 
and fluorine nuclear magnetic resonance (į F) spectra were obtained at room 
temperature on a Bruker 400 Ultrashield operating at 400.13 MHz, 101.62 MHz 
and 400.13 MHz, respectively. Deuterated solvents used were deuterium oxide, 
CDCl3, acetone-d6, CD3OD and DMSO-d6. Chemical shifts (į) were recorded in 
ppm relative to TMS and coupling constants (J) were recorded in Hz. 
Abbreviations used in the description of spectra are: s, singlet; d, doublet; t, triplet; 
q, quartet and m, multiplet. 1H and 13C assignments were typically achieved using 
COSY, HSQC, DEPT 90 & 135. Mass spectra were recorded on a Waters 2759 
spectrometer with both the positive and negative electrospray ionisation.  
Analytical reverse-phase high performance liquid chromatography (RP-HPLC) was 
performed on an Onyx monolithic-C18 column (100 x 4.6 mm) at 3.0 mL min-1. 
Eluent de tection was monitored by UV absorbance at 214 nm. Solvent A was 100 
% water + 0.06 % TFA and solvent B was 80 % aqueous acetonitrile + 0.06 % TFA. 
Preparative RP-HPLC was performed on an Onyx monolithic-C18 semi-preparative 
column (100 x 10 mm) at 9 mL min-1.   
Peptide synthesis was carried out using a NOVASYN® GEM manual peptide 
synthesiser with DMF to remove excess amino acid and coupling reagents. Fmoc 
deprotection was achieved by 20 % piperidine in DMF. The reaction progress was 
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monitored by UV absorbance at 344 nm. N-Fmoc deprotection profiles were 
recorded using a LKB Bromma 2210 recorder. 
6.2 Experimental for Chapter 2 
6.2.1   Preparation of indole-3-carbaldehyde derivatives 
General procedure for the preparation of 6-fluoro-1H-indole-3-carbaldehyde 
(50d) 
N
H
H
O
F
 
Phosphoryl chloride (1.2 mL, 13.4 mmol) was added dropwise to dry DMF (10 mL) 
at 0 °C. The mixture was stirred for 10 min. Then the solution of 5-fluoroindole 
(1.2 g, 9.0 mmol) in DMF (8 mL) was added dropwise to the mixture. The solution 
was heated to 45 °C and was stirred for 2 h. The reaction was poured onto ice water 
(50 mL), extracted with Et2O (2 x 30 mL). The aqueous layer was treated with 1 M 
NaOH to pH = 9 and extracted with EtOAc (2 x 50 mL). The organic layers were 
combined, washed with brine, dried and concentrated to give 50d as yellow 
crystals (0.9 g, 66 % yield) m.p. 174-178 °C; Rf = 0.2 (Hexane/EtOAc, 2:1); IR 
(KBr): v = 2933, 1641, 1530, 1448, 1149 cm-1. 1H NMR (400 MHz, acetone-d6): į 
= 7.08 (td, J = 8, 2 Hz, 1H, H-5 or H-7), 7.31 (dd, J = 8 ,2 Hz, H-5 or H-7), 8.22 
(dd, J = 8, 2 Hz,1H,  H-4), 8.24 (s, 1H, H-2), 10.03 (s, 1H, CHO), 11.28 (br, 1H, 
NH) ppm. 13C NMR (100 MHz, acetone-d6): į = 98.46 (d, J = 26 Hz, CH), 110.41 
(d, J = 24 Hz, CH), 119.08 (C), 121.19 (C), 122.42 (d, J = 10 Hz, CH), 137.85 
(CH), 159.18 (C), 161.54 (C), 184.43 (CHO) ppm; MS: m/z (+ESI) calcd for 
C9H7FNO 164.0512, found 164.0430 [MH+]. 
7-Ethyl-1H-indole-3-carbaldehyde (50e) 
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Procedure as described in the general procedure using phosphoryl chloride (1 mL, 
10.9 mmol), 7-ethylindole (1 mL, 7.3 mmol) and DMF (8 mL) gave 50e as brown 
powder (1.1 g, 95 % yield) m.p. 92-94 °C; Rf  = 0.2 (Hexane/EtOAc, 2:1). IR (KBr): 
v = 3166, 3054, 1628, 1456, 1228 cm-1. 1H NMR (400 MHz, CDCl3): į = 1.38 (t, J 
= 7.5 Hz, 3H, CH2CH3), 2.98 (q, J = 7.5 Hz, 2H, CH2CH3), 7.18 (d, J = 7 Hz, 1H, 
H-5 or H-6), 7.29 (t, J = 7 Hz, 1H, H-5 or H-6), 7.90 (d, J = 1 Hz,1H, H-2), 8.19 (d, 
J =7 Hz, 1H, H-4), 9.95 (br, 1H, NH), 10.05 (s, 1H, CHO) ppm. 13C NMR (100 
MHz, CDCl3): į = 14.11 (CH3), 23.97 (CH2), 119.33 (C), 119.70 (CH), 
123.06(CH), 123.36 (CH), 127.63 (C), 135.91 (C), 136.31 (C), 146.54 (CH), 
185.68 (CHO) ppm. MS: m/z (+ESI) calcd for C11H12NO 174.0919, found 
174.0805 [MH+]. 
5-Methyl-1H-indole-3-carbaldehyde (50f) 
N
H
H
O
 
Procedure as described in the general procedure using phosphoryl chloride (1 mL, 
11.3 mmol), 5-methylindole (1 g, 7.58 mmol) and DMF (10 mL) gave 50f as 
yellow crystals (0.8 g, 65 % yield) m.p. 150- 151 °C; Rf = 0.2 (Hexane/EtOAc, 2:1). 
IR (KBr): v = 3214, 1636, 1437, 1388 cm-1. 1H NMR (400 MHz, acetone-d6): į = 
2.45 (s, 3H, CH3), 7.12 (dd, J = 8, 2 Hz, 1H, H-6 or H-7), 7.44 (dd, J = 8 ,2 Hz, H-
6 or H-7), 8.06 (d, J = 2 Hz, 1H,  H-4), 8.15 (s, 1H, H-2), 10.02 (s, 1H, CHO), 
11.08 (br, 1H, NH) ppm. 13C NMR (100 MHz, acetone-d6): į = 20.71 (CH3), 
111.74 (CH), 118.90 (C), 121.11 (CH), 124.92 (C), 125.12 (CH), 131.47 (CH), 
135.72 (C), 137.20 (C), 184.39 (CHO) ppm. MS: m/z (+ESI) calcd for C10H10NO 
160.0762, found 160.0667 [MH+]. 
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5-Methoxyl-1H-indole-3-carbaldehyde (50g) 
N
H
H
O
H3CO
 
Procedure as described in the general procedure using phosphoryl chloride (2.87 
mL, 30.6 mmol), 5-methoxylindole (3 g, 20.4 mmol) and DMF (10 mL) gave 50g 
as yellow crystals (1.9 g, 54 % yield) m.p. 179-183 °C; Rf = 0.2 (Hexane/EtOAc, 
2:1) IR (KBr): v = 3170, 1641, 1432, 1263, 790 cm-1. 1H NMR (400 MHz, CDCl3): 
į = 3.89 (s, 3H, OCH3), 6.95 (dd, J = 7, 2 Hz, 1H, H-6), 7.34 (d, J = 7 Hz, 1H, H-7), 
7.78 (s, 1H, H-2), 7.79 (d, J = 2 Hz, 1H, H-4), 9.99 (s, 1H, CHO) ppm. 13C NMR 
(100 MHz, CDCl3): į = 55.81 (OCH3), 103.11 (CH), 112.50 (CH), 114.83 (CH), 
119.42 (C), 125.23 (C), 131.60 (C), 136.31 (CH), 156.57 (C), 185.23 (CHO) ppm. 
MS: m/z (+ESI) calcd for C10H10NO2 176.0712, found 176.0650 [MH+]. 
4-Methoxyl-1H-indole-3-carbaldehyde (50h) 
N
H
H
O
H3CO
 
Procedure as described in the general procedure using phosphoryl chloride (0.9 mL, 
10.2 mmol), 4-methoxylindole (1 g, 6.8 mmol) and DMF (10 mL) gave 50h as a 
yellow powder (0.8 g, 70 % yield) m.p. 148-150 °C; Rf = 0.2 (Hexane/EtOAc, 2:1). 
IR (KBr): v = 3250, 1642, 1361, 1323, 790 cm-1.  1H NMR (400 MHz, CDCl3): į = 
4.01 (s, 3H, OCH3), 6.77 (dd, J = 7, 2 Hz, 1H, H-6), 7.19 (d, J = 7 Hz, 1H, H-7), 
7.19 (s, 1H, H-5), 8.04 (s, 1H, H-2), 10.51 (s, 1H, CHO) ppm. 13C NMR (100 MHz, 
acetone-d6): į = 54.81(OCH3), 102.09 (CH), 105.67 (CH), 116.16 (C), 119.08 (C), 
123.73 (CH), 128.45 (CH), 138.22 (C), 154.43 (C), 186.72 (CHO) ppm. MS: m/z 
(+ESI) calcd for C10H10NO2 176.0712, found 176.0672 [MH+]. 
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1-Methyl-indole-3-carbaldehyde (50i) 
N
H
O
1 2
3
4
5
6
7 7a
4a
 
Procedure as described in the general procedure using phosphoryl chloride (2.1 mL, 
23 mmol), 1-methylindole (1 g, 7.4 mmol) and DMF (10 mL) gave 50i as purple 
crystals (2.07 g, 83 % yield); m.p. 67-70 °C;  Rf = 0.2 (Hexane/EtOAc, 2:1); IR 
(KBr): v = 3438, 1640, 1535, 1381, 1074 cm-1. 1H NMR (400 MHz, CDCl3): į = 
3.66 (s, 3 H, CH3), 7.27 (m, 3H, H-5, 6, 7), 7.46 (s, 1H, H-2), 8.27 (dd, J = 7.2, 1 
Hz, H-4), 9.84 (s, 1 H, CHO) ppm. 13C NMR (100 MHz, CDCl3): į = 33.51 (CH3), 
110.04 (C-7), 117.78 (C-3), 121.78 (C-4), 122.82 (C-5), 123.93 (C-6), 125.07 (C-
4a), 137.83 (C-7a), 139.81 (C-2), 184.46 (CHO) ppm. MS: m/z (+ESI) calcd for 
C10H10NO 160.0762, found 160.0650 [MH+]. 
2-Methyl-1H-indole-3-carbaldehyde (50j) 
N
H
H
O
 
Procedure as described in the general procedure using phosphoryl chloride (2.1 mL, 
22.8 mmol), 2-methylindole (2 g, 15.2 mmol) and DMF (10 mL) gave 50j as a 
brown powder (1.8 g, 77 % yield) m.p. 204-205 °C; Rf = 0.2 (Hexane/EtOAc, 2:1); 
IR (KBr): v = 3267, 1636, 1469, 1378, 1243 cm-1. 1H NMR (400 MHz, CDCl3): į = 
2.77 (s, 3H, CH3), 7.28 (m, 2H, H-5, 6), 7.35 (dd, 1H, J = 7.2, 1 Hz, H-7), 8.27 (dd, 
J = 7.2, 1 Hz, H-4), 8.70 (br, 1H, NH), 10.22 (s, 1 H, CHO) ppm. 13C NMR (100 
MHz, CDCl3): į = 12.28 (CH3), 110.65 (CH), 114.83 (C), 120.88 (CH), 122.82 
(CH), 123.46 (CH), 126.07 (C), 134.91 (C), 146.54 (C), 184.58 (CHO) ppm. MS: 
m/z (+ESI) calcd for C10H10NO 160.0762, found 160.0592 [MH+]. 
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6.2.2   Preparation of 2-(2-hydroxy-1-phenylehtylamino)-3-(1H-
indol-3-yl)propanenitrile derivatives 
General procedure for the preparation of 2-(2-hydroxy-1-phenylehtylamino)-
3-(1H-indol-3-yl)propanenitrile (52a) 
       
N
H
H
O
51a
N
H
HN
CN
OH
52a
 
A white suspension of (methoxymethyl)triphenylphosphonium chloride (2.3 g, 6.9 
mmol) in dry THF (18 mL) was cooled to 0 °C under nitrogen, and treated with 2.5 
M n-butyllithium in hexane (3.3 mL, 8.28 mmol). The reaction was stirred for 15 
min then 50a (500 mg, 3.45 mmol) in dry THF (15 mL) was added and stirred at 
room temperature for 2 h. Excess butyllithium was quenched by adding a few 
drops of MeOH. The mixture was acidified with 3 M HCl to pH = 7. The solvent 
was removed in vacuo. The residue was partitioned between EtOAc (100 mL) and 
brine (100 mL). The organic layer was dried and concentrated. The resultant 
residue was subjected to column chromatography (hexane/EtOAc, 1:1) to afford 
the enol ether intermediate. The enol ether intermediate was subsequently treated 
with THF (18 mL) and 1M HCl (12 mL). After being heated at reflux for 3 h, the 
solution was cooled and partitioned between Et2O (80 mL) and brine (80 mL). The 
organic layer was dried and concentrated to afford 51a. 
(R)-2-SKHQ\OJO\FLQROPJPPRODQGDFHWLFDFLGȝ/PPROZDV
added to a solution of 51a (435 mg, 2.74 mmol) in MeOH (20 mL) at 0 °C. Sodium 
cyanide (160 mg, 3.28 mmol) was added to the solution immediately. The mixture 
was allowed to warm to room temperature and stirred for 16 h. The solvent was 
removed under reduced pressure, and the residue was partitioned between DCM (2 
x 40 mL) and brine (80 mL). The organic layers were combined dried and 
concentrated. Purification of the residue by column chromatography 
(CHCl3/MeOH, 30:1) gave 52a as orange amorphous solid (307 mg, 29 % yield 
from 50a); Rf = 0.3 (Hexane/EtOAc, 1:1); RP-HPLC 10-60 % B in 12 min, tR 5.7 
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min for  (R,R) isomer and 6.7 min for (S,R) isomer; IR (KBr): v = 3413, 2924, 2873, 
1455, 1356, 744 cm-1. 1H NMR (400 MHz, CDCl3): į =  2.58 (br, 1 H, NH), 3.23 
(d, J = 4 Hz, 1H , CHAHB), 3.24 (d, J = 4 Hz, 1H , CHAHB), 3.52 (dd, J = 12, 8 Hz, 
1H, CHAHBOH), 3.67 (dd, J     +] + Į-H), 3.70 (dd, J = 12, 8 Hz, 1H, 
CHAHBOH), 4.05 (dd, J = 8, 4 Hz, 1H, CHCH2OH), 7.10- 7.59 (m, 10 H, arom. H), 
8.30 (br, 1 H, NH) ppm. 13C NMR (100 MHz, CDCl3): į = 29.47 (CH2), 49.02 
(CH), 63.03 (CH), 67.22 (CH2), 109.13, 111.49, 118.60, 119.68, 120.53, 122.27, 
123.75, 127.28, 127.63, 128.26, 128.87, 136.17, 138.31 ppm. MS: m/z (+ESI) calcd 
for C19H20N3O 306.1606, found 306.1680 [MH+]. 
3-(5-Bromo-indol-3-yl)-2-[1-(4-methoxy-phenyl)-ethylamino]-propanenitrile 
(52b)  
         
N
H
H
OBr
N
H
HN
CN
Br
OCH3
51b 52b
 
Procedure as described in the general procedure using 
(methoxymethyl)triphenylphosphonium chloride (2.14 g, 6.3 mmol), 2.5 M n-
butyllithium in hexane (3 mL, 7.5 mmol) and 50b (700 mg, 3.1 mmol) afforded 
51b. 
Procedure as described in the general procedure using 51b (486 mg, 2.1 mmol), 
(S)-4-methoxy-Į-methylbenzylamine (ȝ/PPRO DFHWLFDFLGȝ/
mmol) and sodium cyanide (120 mg, 2.5 mmol)  gave 52b as a yellow oil (442 mg, 
39 % yield from 50b); Rf  = 0.4 (Hexane/EtOAc, 2:1); RP-HPLC 10-60 % B in 12 
min, tR 7.0 min for (R,R) isomer and 7.6 min for (S,R) isomer; IR (KBr): v = 3418, 
2960, 1459, 1244, 755 cm-1. 1H NMR (400 MHz, CDCl3): į =  1.35 (d, J = 6 Hz, 
3H, CH3), 1.68 (br, 1H, NH), 3.13 (d, J = 6 Hz, 2 H, CH2), 3.56 (t, J  +]+Į-
H), 3.85 (s, 3H, OCH3), 4.02 (q, J = 6 Hz, 1H, CHCH3), 6.90- 7.30 (m, 7H, arom. 
H), 7.66 (d, J = 2 Hz, 1H, arom. H), 8.43 (br, 1H, NH) ppm. 13C NMR (100 MHz, 
CDCl3): į = 24.85 (CH3), 29.52 (CH2), 49.27 (CH), 55.36 (OCH3), 56.00 (CH), 
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109.19, 112.88, 113.01, 114.20, 120.64, 121.32, 124.76, 125.15, 127.89, 129.15, 
134.80, 135.09, 159.10 ppm. 
3-(5-Chloro-indol-3-yl)-2-[1-(4-methoxy-phenyl)-ethylamino]-propanenitrile 
(52c) 
          
N
H
H
OCl
N
H
HN
CN
Cl
OCH3
51c 52c
 
Procedure as described in the general procedure using 
(methoxymethyl)triphenylphosphonium chloride (2.68 g, 7.8 mmol), 2.5 M n-
butyllithium in hexane (3.7 mL, 9.4 mmol) and 50c (700 mg, 3.9 mmol) afforded 
51c. 
Procedure as described in the general procedure using 51c (54 mg, 3.9 mmol), (S)-
4-methoxy-Į-methylbenzylamine (ȝ/PPRODQGDFHWLFDFLGȝ/
mmol) and sodium cyanide (229 mg, 4.7 mmol) to give 52c as a yellow oil (611 
mg, 45 % yield from 50c); Rf  = 0.4 (Hexane/EtOAc, 2:1); RP-HPLC 10-60 % B in 
12 min, tR 7.0 min for (R,R) isomer and 7.6 min for (S,R) isomer;  IR (KBr): v = 
3419, 2963, 1609, 1457, 756 cm-1. 1H NMR (400 MHz, CDCl3): į = 1.35 (d, J = 6 
Hz, 3H, CH3), 1.70 (br, 1H, NH), 3.14 (d, J = 6 Hz, 2 H, CH2), 3.56 (t, J = 6 Hz, 
+Į-H), 3.84 (s, 3H, OCH3), 4.02 (q, J = 6 Hz, 1H, CHCH3), 6.90- 7.30 (m, 7H, 
arom. H), 7.50 (d, J = 2 Hz, 1H, arom. H), 8.41 (br, 1H, NH) ppm. 13C NMR (100 
MHz, CDCl3): į = 24.82 (CH3), 29.51 (CH2), 49.26 (CH), 55.33 (OCH3), 55.99 
(CH), 109.28, 112.41, 114.17, 118.22, 120.63, 122.63, 124.91, 125.49, 127.90, 
128.50, 134.51, 135.10, 159.10 ppm.  
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3-(6-Fluoro-1H-indol-3-yl)-2-(2-hydroxy-1-phenyl-ethyamino)-propanenitrile 
(52d) 
  
N
H
H
O
F NH
HN
CN
OH
F
51d 52d
 
Procedure as described in the general procedure using 
(methoxymethyl)triphenylphosphonium chloride (2.9 g, 8.6 mmol), 2.5 M n-
butyllithium in hexane (4 mL, 10.2 mmol) and 50d (700 mg, 4.3 mmol) afforded 
51d. 
Procedure as described in the general procedure using 51d (759 mg, 4.3 mmol), 
(R)-2-phenylglycinol (704 mg, 5.1 mmol), DFHWLF DFLG  ȝ/  PPRO DQG
sodium cyanide (251 mg, 5.1 mmol) gave 52d as yellow amorphous solid (614 mg, 
44 % yield from 50d);  Rf  = 0.3 (Hexane/EtOAc, 1:1); RP-HPLC 10-60 % B in 12 
min, tR 6.0 min for (R,R) isomer and 7.2 min for (S,R) isomer; IR (KBr): v = 3425, 
3025, 2925, 1627, 758 cm-1. 1H NMR (400 MHz, CDCl3): į = 2.58 (br, 1 H, NH), 
3.17 (d, J = 4 Hz, 1H, CHAHB), 3.19 (d, J = 4 Hz, 1H, CHAHB), 3.51 (dd, J = 12, 8 
Hz, 1H, CHAHBOH), 3.64 (dd, J  +]+Į-H), 3.71 (dd, J = 12, 8 Hz, 1H, 
CHAHBOH), 4.04 (dd, J = 8, 4 Hz, 1H, CHCH2OH), 7.10- 7.59 (m, 9 H, arom. H), 
8.30 (br, 1 H, NH) ppm. 13C NMR (100 MHz, CDCl3): į =  29.41 (CH2), 48.89 
(CH), 63.03 (CH), 67.20 (CH2), 97.69 (d, J = 26 Hz), 108.75 (d, J = 24 Hz), 109.32, 
119.39 (d, J = 11 Hz), 120.41, 123.87, 123.92 (d, J = 4 Hz), 127.58, 128.33, 128.89, 
136.09 (d, J = 13 Hz), 138.15, 160.03 (d, J = 237 Hz) ppm. MS: m/z (+ESI) calcd 
for C19H19FN3O 324.1512, found 324.1248 [MH+]. 
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3-(7-Ethyl-1H-indol-3-yl)-2-(2-hydroxy-1-phenyl-ethyamino)-propanenitrile 
(52e) 
    
N
H
H
O
N
H
HN
CN
OH
51e 52e
 
Procedure as described in the general procedure using 
(methoxymethyl)triphenylphosphonium chloride (2.7 g, 8.0 mmol), 2.5 M n-
butyllithium in hexane (3.8 mL, 9.7 mmol) and 50e (700 mg, 4.04 mmol) afforded 
51e. 
Procedure as described in the general procedure using 51e (700 mg, 3.74 mmol), 
(R)-2-phenylglycinol (613 mg, 4.5 mmol), DFHWLF DFLG  ȝ/  PPRO DQG
sodium cyanide (219 mg, 4.48 mmol) gave 52e as brown amorphous solid (444 mg, 
33 % yield from 50e); Rf  = 0.3 (Hexane/EtOAc, 1:1); RP-HPLC 10-60 % B in 12 
min, tR 7.0 min for (R,R) isomer and 8.1 min for (S,R) isomer; IR (KBr): v = 3415, 
2964, 2930, 1453, 753 cm-1. 1H NMR (400 MHz, CDCl3): į = 1.37 (t, J = 8 Hz, 3H, 
CH2CH3), 2.52 (br, 1 H, NH), 2.85 (q, J = 8 Hz, 2H, CH2CH3), 3.26 (d, J = 4 Hz, 
1H, CHAHB), 3.27 (d, J = 4 Hz, 1H, CHAHB), 3.57 (dd, J = 12, 8 Hz, 1H, 
CHAHBOH), 3.70 (dd, J     +] + Į-H), 3.74 (dd, J = 12, 8 Hz, 1H, 
CHAHBOH), 4.09 (dd, J = 8, 4 Hz, 1H, CHCH2OH), 7.10- 7.59 (m, 9 H, arom. H), 
8.28 (br, 1 H, NH) ppm. 13C NMR (100 MHz, CDCl3): į = 13.84 (CH3), 23.96 
(CH2), 29.71 (CH2), 49.17 (CH), 63.10 (CH), 67.31 (CH2), 109.72, 116.27, 120.03, 
120.50, 120.81, 123.27, 126.87, 127.05, 127.64, 128.26, 128.87, 135.07, 138.35 
pp m. MS: m/z (+ESI) calcd for C21H24N3O 334.1919, found 334.1843 [MH+]. 
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3-(5-Methyl-1H-indol-3-yl)-2-(2-hydroxy-1-phenyl-ethyamino)-propanenitrile 
(52f) 
         
N
H
H
O
N
H
HN
CN
OH
51f 52f
 
Procedure as described in the general procedure using 
(methoxymethyl)triphenylphosphonium chloride (3 g, 8.8 mmol), 2.5 M n-
butyllithium in hexane (4.2 mL, 10.5 mmol) and 50f (700 mg, 4.4 mmol) afforded 
51f. 
Procedure as described in the general procedure using 51f (600 mg, 3.5 mmol), 
(R)-2-phenylglycinol (570 mg, 4.2 mmol), DFHWLF DFLG  ȝ/  PPRO DQG
sodium cyanide (203 mg, 4.2 mmol) gave 52f as a brown oil (496 mg, 35 % yield 
from 50f); Rf  = 0.4 (Hexane/EtOAc, 1:1); RP-HPLC 10-60 % B in 12 min, tR 6.5 
min for  (R,R) isomer and 7.2 min for (S,R) isomer; IR (KBr): v = 3405, 3017, 2922, 
1450, 756 cm-1. 1H NMR (400 MHz, CDCl3): į = 2.38 (br, 1 H, NH), 2.44 (s, 3H, 
CH3), 3.22 (d, J = 4 Hz, 1H , CHAHB), 3.23 (s, 1H , CHAHB), 3.55 (dd, J = 12, 8 Hz, 
1H, CHAHBOH), 3.68 (dd, J     +] + Į-H), 3.74 (dd, J = 12, 8 Hz, 1H, 
CHAHBOH),  4.08 (dd, J = 8, 4 Hz, 1H, CHCH2OH), 7.03- 7.36 (m, 9 H, arom. H), 
8.12 (br, 1H, NH) ppm. 13C NMR (100 MHz, CDCl3): į = 21.52 (CH3), 29.70 
(CH2), 48.91 (CH), 63.05 (CH), 67.29 (CH2), 108.77, 111.08, 118.17, 120.51, 
123.68, 123.93, 127.41, 127.62, 128.23, 128.83, 128.94, 134.52, 138.33 ppm. MS: 
m/z (+ESI) calcd for C20H22N3O 320.1763, found 320.1711 [MH+]. 
 
 
 
 
Chapter 6 Experimental 
-192- 
 
3-(5-Methoxyl-1H-indol-3-yl)-2-(2-hydroxy-1-phenyl-ethyamino)-
propanenitrile (52g) 
      
N
H
H
OH3CO
N
H
HN
CN
OH
H3CO
51g 52g
 
Procedure as described in the general procedure using 
(methoxymethyl)triphenylphosphonium chloride (2.74 g, 8 mmol), 2.5 M n-
butyllithium in hexane (3.8 mL, 9.6 mmol) and 50g (700 mg, 4 mmol) afforded 
51g. 
Procedure as described in the general procedure using 51g (500 mg, 2.6 mmol), 
(R)-2-phenylglycinol (434 mg, 3.1 mmol), DFHWLF DFLG  ȝ/  PPRO DQG
sodium cyanide (155 mg, 3.2 mmol) gave 52g as a brown oil (177 mg, 13 % yield 
from 50g); Rf = 0.5 (Hexane/EtOAc, 1:1), RP-HPLC 10-60 % B in 12 min, tR 5.5 
min for  (R,R) isomer and 6.4 min for (S,R) isomer; IR (KBr): v = 3405, 3011, 2938, 
1480, 757 cm-1. 1H NMR (400 MHz, CDCl3): į = 2.11 (br, 1 H, NH), 3.21 (d, J = 4 
Hz, 1H , CHAHB), 3.22 (s, 1H , CHAHB), 3.55 (dd, J = 12, 8 Hz, 1H, CHAHBOH), 
3.67 (dd, J  +]+Į-H), 3.75 (dd, J = 12, 8 Hz, 1H, CHAHBOH), 3.81 (s, 
3H,OCH3), 4.08 (dd, J = 8, 4 Hz, 1H, CHCH2OH), 6.86- 7.34 (m, 9 H, arom. H), 
8.11 (br, 1H, NH) ppm. 13C NMR (100 MHz, CDCl3): į = 29.75 (CH2), 48.88 (CH), 
55.85 (OCH3), 63.05 (CH), 67.33 (CH2), 100.22, 109.09, 112.14, 112.77, 120.42, 
124.31, 127.59, 128.24, 128.82, 131.29, 138.32, 154.15 ppm. MS: m/z (+ESI) calcd 
for C20H22N3O2 336.1712, found 336.1786 [MH+]. 
 
 
 
 
Chapter 6 Experimental 
-193- 
 
3-(4-Methoxyl-1H-indol-3-yl)-2-(2-hydroxy-1-phenyl-ethyamino)-
propanenitrile (52h) 
      
N
H
H
O
OCH3
N
H
HN
CN
OHOCH3
51h 52h
 
Procedure as described in the general procedure using 
(methoxymethyl)triphenylphosphonium chloride (2.74 g, 8 mmol), 2.5 M n-
butyllithium in hexane (3.8 mL, 9.6 mmol) and 50h (700 mg, 4 mmol) afforded 
51h. 
Procedure as described in the general procedure using 51h (756 mg, 4.0 mmol), 
(R)-2-phenylglycinol (657 mg, 4.8 mmol), DFHWLF DFLG  ȝ/  PPRO DQG
sodium cyanide (235 mg, 4.8 mmol) gave 52h as a brown oil (258 mg, 19 % yield 
from 50h); Rf = 0.5 (Hexane/EtOAc, 1:1); RP-HPLC 10-60 % B in 12 min, tR 5.8 
min for  (R,R) isomer and 6.2 min for (S,R) isomer; IR (KBr): v = 3401, 2924, 1357, 
1255, 733 cm-1. 1H NMR (400 MHz, CDCl3): į = 2.51 (br, 1 H, NH), 3.18 (dd, J = 
14, 8 Hz, 1H , CHAHB), 3.47 (dd, J = 14, 8 Hz,1H , CHAHB), 3.58 (dd, J = 9, 8 Hz, 
1H, CHAHBOH), 3.65 (s, 3H, OCH3), 3.77 (dd, J  +]+Į-H), 3.93 (dd, J 
= 9, 6 Hz, 1H, CHAHBOH), 4.15 (dd, J = 9, 4 Hz, 1H, CHCH2OH),  6.42 (d, J = 8 
Hz, 1 H, arom. H), 6.97- 7.28 (m, 8 H, arom. H), 8.25 (br, 1H, NH) ppm. 13C NMR 
(100 MHz, CDCl3): į = 31.60 (CH2), 50.39 (CH), 54.75 (OCH3), 63.11 (CH), 
67.25 (CH2), 99.42, 104.74, 109.86, 116.87, 120.88, 122.67, 123.05, 127.60, 
128.00, 128.66, 138.06, 138.63, 154.15 ppm. MS: m/z (+ESI) calcd for C20H22N3O2 
336.1712, found 336.1656 [MH+]. 
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2-(2-Hydroxy-1-phenyl-ethylamino)-3-(1-methyl-1H-indol-3-yl)propanenitirle 
(52i) 
     
N
H
O
CH3
N
HN
CN
OH
CH3
51i 52i
 
Procedure as described in the general procedure using 
(methoxymethyl)triphenylphosphonium chloride (3 g, 8.8 mmol), 2.5 M n-
butyllithium in hexane (4.2 mL, 10.5 mmol) and 50i (700 mg, 4.4 mmol) afforded 
51i. 
Procedure as described in the general procedure using 51i (717 mg, 4.1 mmol), (R)-
2-phenylglycinol (671 mg, 4.9 mmol), DFHWLFDFLGȝ/PPRODQGVRGLum 
cyanide (240 mg, 4.9 mmol) gave 52i as a brown oil (430 mg, 31 % yield from 50i); 
Rf = 0.3 (Hexane/EtOAc, 2:1); RP-HPLC 10-60 % B in 12 min, tR 6.8 min for (R,R) 
isomer and 7.8 min for (S,R) isomer;  IR (KBr): v = 3322, 3020, 2927, 1470, 751 
cm-1. 1H NMR (400 MHz, CDCl3): į = 2.58 (br, 1 H, NH), 3.25 (d, J = 4 Hz, 1H , 
CHAHB), 3.26 (d, J = 4 Hz, 1H , CHAHB), 3.56 (dd, J = 12, 8 Hz, 1H, CHAHBOH), 
3.67 (dd, J  +]+Į-H), 3.75 (dd, J = 12, 8 Hz, 1H, CHAHBOH), 3.78 (s, 
3H, CH3),  4.10 (dd, J = 8, 4 Hz, 1H, CHCH2OH), 7.08- 7.57 (m, 10 H, arom. H) 
ppm. 13C NMR (100 MHz, CDCl3): į = 29.55 (CH2), 32.78 (CH3), 49.29 (CH), 
63.10 (CH), 67.33 (CH2), 107.82, 109.45, 118.71, 119.27, 120.42, 121.97, 127.65, 
127.83, 128.17, 128.24, 128.84, 136.97, 138.42 ppm; MS: m/z (+ESI) calcd for 
C20H22N3O 320.1763, found 320.1357 [MH+]. 
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2-(2-Hydroxy-1-phenyl-ethylamino)-3-(2-methyl-1H-indol-3-yl)propanenitirle 
(52j) 
      
N
H
H
O
N
H
HN
CN
OH
51j 52j
 
Procedure as described in the general procedure using 
(methoxymethyl)triphenylphosphonium chloride (2.1 g, 6.3 mmol), 2.5 M n-
butyllithium in hexane (3 mL, 7.5 mmol) and 50j (500 mg, 3.1 mmol) afforded 51j. 
Procedure as described in the general procedure using 51j (500 mg, 2.9 mmol), 
(R)-2-phenylglycinol (474 mg, 3.5 mmol), DFHWLF DFLG  ȝ/  PPRO DQG
sodium cyanide (69 mg, 3.5 mmol) gave 52j as brown amorphous solid (388 mg, 
39 % yield from 50j); Rf = 0.5 (Hexane/EtOAc, 1:1), RP-HPLC 10-60 % B in 12 
min, tR 5.9 min for (R,R) isomer and 7.2 min for (S,R) isomer; IR (KBr): v = 3399, 
3016, 2923, 1456, 1219, 754 cm-1. 1H NMR (400 MHz, CDCl3): į =  2.38 (br, 1 H, 
NH), 2.41 (s, 3H, CH3), 3.19 (d, J = 4 Hz, 1H , CHAHB), 3.21 (s, 1H , CHAHB), 
3.53 (dd, J = 12, 8 Hz, 1H, CHAHBOH), 3.64 (dd, J  +]+Į-H), 3.73 (dd, J 
= 12, 8 Hz, 1H, CHAHBOH), 4.05 (dd, J = 8, 4 Hz, 1H, CHCH2OH), 7.07- 7.42 (m, 
9 H, arom. H), 7.99 (br, 1H, NH) ppm. 13C NMR (100 MHz, CDCl3): į = 11.98 
(CH3), 28.76 (CH2), 49.02 (CH), 62.96 (CH), 67.38 (CH2), 105.22, 110.44, 117.76, 
119.57, 120.62, 121.36, 127.45, 128.22, 128.48, 128.84, 133.62, 135.22, 138.33 
pp m. MS: m/z (+ESI) calcd for C20H22N3O 320.1763, found 320.1670 [MH+]. 
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6.2.3   Preparation of (S)-2-((R)-2-Hydroxy-1-phenylethylamino)-3-
(1H-indol-3-yl)-propanamide derivatives 
General procedure for the preparation of (S)-2-((R)-2-Hydroxy-1-
phenylethylamino)-3-(1H-indol-3-yl)-propanamide, (S,R)-54a 
             
N
H
HN
CONH2
OH
N
H
HN
CONH2
OH
(R,R)-53a (S,R)-54a
 
7R D VROXWLRQ RI Į-aminonitrile 52a (257 mg, 0.8 mmol) in DMSO (3.5 mL), 
K2CO3 (138 mg, 1.3 mmol) and 30 % aqueous H2O2 (0.6 mL, 6.3 mmol) were 
added at 20 °C. After stirring at room temperature for 2 h, another portion of 30 % 
aqueous H2O2 (0.4 mL, 4.7 mmol) was added and stirred for a further hour. The 
resultant mixture was extracted with Et2O (50 mL x 3) and brine (50 mL). The 
organic layers were combined, dried and concentrated. Purification of residue by 
column chromatography ( CHCl3/MeOH, 10:1) gave (R,R)-53a as a yellow oil (first 
eluting diastereoisomer, 35 mg, 13 % yield) and (S,R)-54a as a white foam (second 
eluting diastereoisomer, 101 mg, 38 % yield). 
(R,R)-53a Rf  = 0.5 (CHCl3/MeOH, 6 :1), IR (KBr): v = 3412, 2917, 1662, 744 cm-1. 
1H NMR (400 MHz, acetone-d6): į = 3.13 (br, 1 H, NH), 3.24 (dd, J = 12, 8 Hz, 1H, 
CHAHB), 3.32 (dd, J = 12, 8 Hz, 1H, CHAHB), 3.36 (dd, J = 8, 8 +]+Į-H), 3.52 
(dd, J = 12, 8 Hz, 1H, CHAHBOH), 3.60 (dd, J = 12, 8 Hz, 1H, CHAHBOH), 3.96 
(dd, J = 8, 4 Hz, 1H, CHCH2OH), 6.40 (br, 1H, NH), 6.98 (t, 1H, arom. H), 7.01 (t, 
1H, arom. H), 7.08- 7.68 (m, 7H, arom. H), 7.70 (d, 1H, arom. H), 10.18 (br, 1H, 
NH) ppm. 13C NMR (100 MHz, acetone-d6): į = 26.62 (CH2), 59.46 (CH), 63.63 
(CH), 66.74 (CH2), 110.39, 111.14, 118.53, 119.17, 121.16, 124.28, 127.30, 127.95, 
128.02, 128.23, 136.76, 141.25, 176.26 ppm. MS: m/z (+ESI) calcd for C19H22N3O2 
324.1712, found 324.1638 [MH+]. 
(S,R)-54a Rf  = 0.4 (CHCl3/MeOH, 6:1), IR (KBr): v = 3412, 2917, 1662, 744 cm-1. 
1H NMR (400 MHz, acetone-d6): į = 2.97 (dd, J = 16, 8 Hz, 1H, CHAHB), 3.22 (dd, 
Chapter 6 Experimental 
-197- 
 
J = 16, 8 Hz, 1H, CHAHB), 3.31 (dd, J = 8, 4 Hz, 1H, Į-H), 3.46 (dd, J = 12, 8 Hz, 
1H, CHAHBOH), 3.60 (dd, J = 12, 8 Hz, 1H, CHAHBOH), 3.77 (dd, J = 8, 4 Hz, 1H, 
CHCH2OH), 6.71 (br, 1H, NH), 6.92- 7.15 (m, 7H, arom. H), 7.42- 7.48 (m, 3H, 
arom. H), 10.17 (br, 1H, NH) ppm. 13C NMR (100 MHz, acetone-d6): į = 30.00 
(CH2), 60.36 (CH), 63.50 (CH), 67.18 (CH2), 111.06, 111.27, 118.61, 121.25, 
123.64, 126.82, 127.22, 127.81, 127.94, 136.84, 140.93, 177.15 ppm. MS: m/z 
(+ESI) calcd for C19H22N3O2 324.1712, found 324.1365 [MH+]. 
(S)-3-(5-Bromo-indol-3-yl)-2-[(S)-1-(4-methoxy-phenyl)ethylamino]-
propanamide, (S,S)-125b 
N
H
HN
CONH2
Br
OCH3(S,S)-125b
 
Procedure as described in the general procedure used Į-aminonitrile 52b (356 mg, 
0.9 mmol) in DMSO (3.5 mL), K2CO3 (172 mg, 1.2 mmol) and 30 % H2O2 (0.8 
mL, 7.3 mmol), 30 % H2O2 (0.4 mL, 2.3 mmol). Purification of residue by column 
chromatography (Hexane/EtOAc, 1 : 4) followed by RP-HPLC (Onyx Monolithic 
C18, 100 x 10 mm) gave (S,S)-125b as yellow foam (196 mg, 53 %);  Rf = 0.2 
(Hexane/EtOAc, 1 : 4) IR (KBr): v = 3267, 3006, 2961, 1669, 1244, 755 cm-1. 1H 
NMR (400 MHz, CDCl3): į = 1.24 (d, J = 6 Hz, 3H, CH3), 1.83 (br, 1H, NH), 2.79 
(dd, J = 14, 9 Hz, 1H, CHAHB), 3.22 (m, 2H, CHAHBĮ-H), 3.55 (q, J = 6 Hz, 1H, 
CHCH3), 3.76 (s, 3H, OCH3), 6.10 (br, 1H, NH), 6.53 (d, J = 8 Hz, 2H, arom. H), 
6.63 (d, J = 8 Hz, 2H, arom. H), 6.90 (d, J = 2 Hz, 1H, arom. H), 7.21 (s, 1H, arom. 
H), 7.23 (d, J = 2 Hz, 1H, arom.H), 7.48 (d, J = 2 Hz, 1H, arom. H), 8.75 (br, 1H, 
NH) ppm. 13C NMR (100 MHz CDCl3): į = 24.14 (CH3), 29.55 (CH2), 55.18 
(OCH3), 56.38 (CH), 59.82 (CH), 110.86, 112.69, 112.77, 113.53, 121.45, 124.34, 
125.00, 127.03, 128.92, 135.11, 135.73, 158.42, 178.18 ppm. MS: m/z (+ESI) calcd 
for C20H23BrN3O2 416.0974, found 416.0773 [MH+]. 
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(S)-3-(5-Chloro-indol-3-yl)-2-[(S)-1-(4-methoxy-phenyl)-ethylamino]-
propanamide, (S,S)-125c 
N
H
HN
CONH2
Cl
OCH3(S,S)-125c
 
Procedure as described in the general procedure used Į-aminonitrile 52c (542 mg, 
1.5 mmol) in DMSO (3.5 mL), K2CO3 (275 mg, 2.0 mmol) and 30 % H2O2 (1.1 
mL, 11.6 mmol), 30 % H2O2 (0.4 mL, 2.3 mmol). Purification of residue by 
column chromatography (Hexane/EtOAc, 1 : 4) followed by RP-HPLC (Onyx 
Monolithic C18, 100 x 10 mm) gave (S,S)-125c as yellow foam (406 mg, 71 %);  Rf 
= 0.4 (Hexane/EtOAc, 2:1) IR (KBr): v = 3269, 2961, 2928, 1670, 1279, 755 cm-1. 
1H NMR (400 MHz, CDCl3): į = 1.24 (d, J = 6 Hz, 3H, CH3), 1.85 (br, 1H, NH), 
2.79 (dd, J = 14, 9 Hz, 1H, CHAHB), 3.22 (m, 2H, CHAHBĮ-H), 3.54 (q, J = 6 Hz, 
1H, CHCH3), 3.75 (s, 3H, OCH3), 6.12 (br, 1H, NH), 6.52 (d, J = 8 Hz, 2H, arom. 
H), 6.62 (d, J = 8 Hz, 2H, arom. H), 6.91 (d, J = 2 Hz, 1H, arom. H), 7.09- 7.31 (m, 
3H, arom. H), 8.75 (br, 1H, NH) ppm. 13C NMR (100 MHz CDCl3): į = 24.12 
(CH3), 29.57 (CH2), 55.14 (OCH3), 56.38 (CH), 59.82 (CH), 110.93, 112.23, 
113.51, 118.38, 121.45, 124.51, 125.17, 127.04, 128.26, 134.83, 135.76, 158.42, 
178.24 ppm. MS: m/z (+ESI) calcd for C20H23ClN3O2 372.1479, found 372.1255 
[MH+]. 
(S)-3-(6-Fluoro-1H-indol-3-yl)-2-((R)-2-hydroxy-1-phenylethyamino)-
propanamide, (S,R)-54d 
      
N
H
HN
CONH2
OH
F NH
HN
CONH2
OH
F
(R,R)-53d (S,R)-54d
 
Procedure as described in the general procedure using Į-aminonitrile 52d (557 mg, 
1.7 mmol) in DMSO (4 mL), K2CO3 (308 mg, 2.2 mmol) and 30 % H2O2 (1.3 mL, 
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13 mmol), 30 % H2O2 (0.4 mL, 4.7 mmol) gave (R,R)-53d  as yellow foam (first 
eluting diastereoisomer, 71 mg, 12 % yield) and (S,R)-54d as white foam (second 
eluting diastereoisomer, 207 mg, 35 % yield). 
(R,R)-53d Rf = 0.5 (CHCl3/MeOH, 6:1), IR (KBr): v = 3423, 3311, 2919, 1664, 759 
cm-1. 1H NMR (400 MHz, acetone-d6): į = 3.24 (dd, J = 12, 8 Hz, 1H, CHAHB), 
3.34 (dd, J = 12, 8 Hz, 1H, CHAHB), 3.35 (dd, J = 8, 8 +]+Į-H), 3.52 (dd, J = 
12, 8 Hz, 1H, CHAHBOH), 3.62 (dd, J = 12, 8 Hz, 1H, CHAHBOH), 3.97 (dd, J = 8, 
4 Hz, 1H, CHCH2OH), 6.58 (br, 1H, NH), 6.80 (td, J = 4, 2 Hz, 1H, arom. H), 7.14 
(dd, J = 8, 2 Hz, 1H, arom. H), 7.25- 7.66 (m, 6H, arom. H), 7.66 (dd, J = 8, 4 Hz, 
1H, arom. H), 10.29 (br, 1H, NH) ppm. 13C NMR (100 MHz, acetone-d6): į = 
26.50 (CH2), 59.32 (CH), 63.60 (CH), 66.89 (CH2), 97.13 (d, J = 26 Hz), 106.92 (d, 
J = 24 Hz), 110.65, 120.24 (d, J = 10 Hz), 124.78, 124.90 (d, J = 3 Hz), 127.34, 
127.92, 128.28, 136.65 (d, J = 13 Hz), 140.30, 159.66 (d, J = 233 Hz), 176.83 ppm. 
MS: m/z (+ESI) calcd for C19H21FN3O2 342.1618, found 342.1321 [MH+]. 
(S,R)-54d Rf = 0.4 (CHCl3/MeOH, 6:1), IR (KBr): v = 3423, 3311, 2919, 1664, 759 
cm-1. 1H NMR (400 MHz, acetone-d6): į = 2.96 (dd, J = 16, 8 Hz, 1H, CHAHB), 
3.22 (dd, J = 16, 8 Hz, 1H, CHAHB), 3.31 (dd, J = 8, 4 +]+Į-H), 3.48 (dd, J = 
12, 8 Hz, 1H, CHAHBOH), 3.62 (dd, J = 12, 8 Hz, 1H, CHAHBOH), 3.77 (dd, J = 8, 
4 Hz, 1H, CHCH2OH), 6.73 (td, J = 4, 2 Hz, 1H, arom. H), 6.76 (br, 1H, NH), 
6.76- 7.17 (m, 7H, arom. H), 7.40 (td, J = 4, 2 Hz, 1H, arom. H), 8.02 (br, 1H, NH), 
10.29 (br, 1H, NH) ppm. 13C NMR (100 MHz, acetone-d6): į = 29.97 (CH2), 60.23 
(CH), 63.53 (CH), 67.12 (CH2), 97.24 (d, J = 26 Hz), 106.96 (d, J = 24 Hz), 111.32, 
119.59 (d, J = 10 Hz), 124.27 (d, J = 3 Hz), 124.53, 126.88, 127.21, 127.95, 136.73 
(d, J = 13 Hz), 140.93, 159.68 (d, J = 233 Hz), 177.37 ppm. MS: m/z (+ESI) calcd 
for C19H21FN3O2 342.1618, found 342.1298 [MH+]. 
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(S)-3-(7-Ethyl-1H-indol-3-yl)-2-((R)-2-hydroxy-1-phenylethyamino)-
propanamide, (S,R)-54e 
               
N
H
HN
CONH2
OH
N
H
HN
CONH2
OH
(R,R)-53e (S,R)-54e
 
Procedure as described in the general procedure using Į-aminonitrile 52e (396 mg, 
1.1 mmol) in DMSO (3 mL), K2CO3 (172 mg, 1.4 mmol) and 30 % H2O2 (0.8 mL, 
8.4 mmol), 30 % H2O2 (0.4 mL, 4.7 mmol) gave (R,R)-53e as a yellow oil (first 
eluting diastereoisomer, 71 mg, 17 % yield) and (S,R)-54e as yellow foam (second 
eluting diastereoisomer, 196 mg, 47 % yield). 
(R,R)-53e Rf = 0.5 (CHCl3/MeOH, 6:1), IR (KBr): v = 3417, 3311, 2929, 1665, 749 
cm-1. 1H NMR (400 MHz, acetone-d6): į = 1.32 (t, J = 8 Hz, 3H, CH2CH3), 2.91 (q, 
J = 8 Hz, 2H, CH2CH3 ), 3.24 (dd, J = 12, 8 Hz, 1H, CHAHB), 3.34 (dd, J = 12, 8 
Hz, 1H, CHAHB), 3.35 (dd, J = 8, 8 +] + Į-H), 3.51 (dd, J = 12, 8 Hz, 1H, 
CHAHBOH), 3.61 (dd, J = 12, 8 Hz, 1H, CHAHBOH), 3.98 (dd, J = 8, 4 Hz, 1H, 
CHCH2OH), 6.49 (br, 1H, NH), 6.96 (d, J = 4 Hz, 2H, arom. H), 7.24- 7.40 (m, 6H, 
arom. H), 7.55 (dd, J = 4, 4 Hz, 1H, arom. H), 10.18 (br, 1H, NH) ppm. 13C NMR 
(100 MHz, acetone-d6): į = 13.80 (CH3), 23.88 (CH2), 26.71 (CH2), 59.51 (CH), 
63.61 (CH), 66.85 (CH2), 110.81, 116.94, 118.95, 119.90, 123.94, 126.61, 127.28, 
127.95, 127.98, 128.23, 135.39, 141.42, 176.60 ppm. MS: m/z (+ESI) calcd for 
C21H26N3O2 352.1947, found 352.1683 [MH+]. 
(S,R)-54e Rf = 0.4 (CHCl3/MeOH, 6:1), IR (KBr): v = 3417, 3311, 2929, 1665, 749 
cm-1. 1H NMR (400 MHz, acetone-d6): į = 1.35 (t, J = 8 Hz, 3H, CH2CH3), 2.93 (q, 
J = 8 Hz, 2H, CH2CH3), 2.96 (dd, J = 16, 8 Hz, 1H, CHAHB), 3.23 (dd, J = 16, 8 Hz, 
1H, CHAHB), 3.30 (dd, J = 8, 4 +] + Į-H), 3.45 (dd, J = 12, 8 Hz, 1H, 
CHAHBOH), 3.61 (dd, J = 12, 8 Hz, 1H, CHAHBOH), 3.76 (dd, J = 8, 4 Hz, 1H, 
CHCH2OH), 6.73 (br, 1H, NH), 6.89- 7.12 (m, 8H, arom. H), 7.32 (d, J = 8 Hz, 1H, 
arom. H), 7.45 (br, 1H, NH), 10.15 (br, 1H, NH) ppm. 13C NMR (100 MHz, 
acetone-d6): į = 13.93 (CH3), 23.96 (CH2), 30.09 (CH2), 60.49 (CH), 63.56 (CH), 
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67.21 (CH2), 111.52, 116.37, 119.03, 120.04, 123.22, 126.80, 127.19, 127.75, 
127.92, 135.45, 140.96, 177.24 ppm. MS: m/z (+ESI) calcd for C21H26N3O2 
352.1947, found 352.1595 [MH+]. 
(S)-3-(5-Methyl-1H-indol-3-yl)-2-((R)-2-hydroxy-1-phenylethyamino)-
propanamide, (S,R)-54f 
   
N
H
HN
CONH2
OH
N
H
HN
CONH2
OH
(R,R)-53f (S,R)-54f
 
Procedure as described in the general procedure using Į-aminonitrile 52f (468 mg, 
1.5 mmol) in DMSO (3 mL), K2CO3 (261 mg, 1.9 mmol) and 30 % H2O2 (1.3 mL, 
11.1 mmol), 30 % H2O2 (0.4 mL, 4.7 mmol) gave (R,R)-53f as a yellow oil (first 
eluting diastereoisomer, 12 mg, 2 % yield) and (S,R)-54f as yellow foam (second 
eluting diastereoisomer, 48 mg, 10 % yield). 
(R,R)-53f  Rf = 0.6 (CHCl3/MeOH, 6:1), IR (KBr): v = 3310, 2919, 1662, 756 cm-1. 
1H NMR (400 MHz, acetone-d6): į = 2.39 (s, 3H, CH3), 3.20 (dd, J = 12, 8 Hz, 1H, 
CHAHB), 3.22 (dd, J = 12, 8 Hz, 1H, CHAHB), 3.32 (dd, J = 8, 8 +]+Į-H), 3.49 
(dd, J = 12, 8 Hz, 1H, CHAHBOH), 3.58 (dd, J = 12, 8 Hz, 1H, CHAHBOH), 3.93 
(dd, J = 8, 4 Hz, 1H, CHCH2OH), 6.32 (br, 1H, NH), 6.94 (dd, 1H, arom. H), 7.22- 
7.44 (m, 8H, arom. H), 9.95 (br, 1H, NH) ppm. 13C NMR (100 MHz, acetone-d6): į 
= 20.82 (CH3), 26.83 (CH2), 59.49 (CH), 63.56 (CH), 66.84 (CH2), 110.10, 110.82, 
118.75, 122.78, 124.22, 127.20, 127.22, 127.94, 128.19, 128.26, 135.15, 141.49, 
176.27 ppm. MS: m/z (+ESI) calcd for C20H24N3O2 338.1869, found 338.1823 
[MH+]. 
(S,R)-54f Rf = 0.5 (CHCl3/MeOH, 6:1), IR (KBr): v = 3310, 2919, 1662, 756 cm-1. 
1H NMR (400 MHz, acetone-d6): į = 2.33 (s, 3H, CH3), 2.91 (dd, J = 16, 8 Hz, 1H, 
CHAHB), 3.18 (dd, J = 16, 8 Hz, 1H, CHAHB), 3.29 (dd, J = 8, 4 +]+Į-H), 3.45 
(dd, J = 12, 8 Hz, 1H, CHAHBOH), 3.59 (dd, J = 12, 8 Hz, 1H, CHAHBOH), 3.75 
(dd, J = 8, 4 Hz, 1H, CHCH2OH), 6.63 (br, 1H, NH), 6.90- 7.30 (m, 9H, arom. H), 
7.36 (br, 1H, NH), 10.02 (br, 1H, NH) ppm. 13C NMR (100 MHz, acetone-d6): į = 
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20.79(CH3), 30.08 (CH2), 60.22 (CH), 63.51 (CH), 67.12 (CH2), 110.53, 110.95, 
118.29, 122.90, 123.71, 126.77, 127.24, 127.29, 127.88, 127.98, 135.26, 140.98, 
176.97 ppm. MS: m/z (+ESI) calcd for C20H24N3O2 338.1869, found 338.1942 
[MH+]. 
(S)-3-(5-Methoxyl-1H-indol-3-yl)-2-((R)-2-hydroxy-1-phenylethyamino)-
propanamide, (S,R)-54g 
      
N
H
HN
CONH2
OH
H3CO
N
H
HN
CONH2
OH
H3CO
(R,R)-53g (S,R)-54g
 
Procedure as described in the general procedure using Į-aminonitrile 52g (266 mg, 
0.8 mmol) in DMSO (3 mL), K2CO3 (141 mg, 1.0 mmol) and 30 % H2O2 (0.6 mL, 
5.9 mmol), 30 % H2O2 (0.4 mL, 4.7 mmol) gave (R,R)-53g as a yellow oil (first 
eluting diastereoisomer, 17 mg, 6 % yield) and (S,R)-54g as yellow foam (second 
eluting diastereoisomer, 30 mg, 10 % yield). 
(R,R)-53g Rf = 0.6 (CHCl3/MeOH, 6:1), IR (KBr): v = 3331, 2931, 1661, 1481, 
1216, 756 cm-1. 1H NMR (400 MHz, acetone-d6): į = 2.93 (br, 1H, NH), 3.18 (dd, 
J = 16, 8 Hz, 1H, CHAHB), 3.29 (dd, J = 16, 8 Hz, 1H, CHAHB), 3.30 (dd, J = 8, 8 
+]+Į-H), 3.50 (dd, J = 8, 8 Hz, 1H, CHAHBOH), 3.60 (dd, J = 12, 4 Hz, 1H, 
CHAHBOH), 3.78 (s, 3H, OCH3), 3.98 (dd, J = 8, 4 Hz, 1H, CHCH2OH), 6.31 (br, 
1H, NH), 6.74 (dd, 1H, arom. H), 7.20- 7.40 (m, 8H, arom. H), 9.95 (br, 1H, NH) 
ppm. 13C NMR (100 MHz, acetone-d6): į = 26.52 (CH2), 54.92 (OCH3), 59.20 
(CH), 63.54 (CH), 66.89 (CH2), 100.84, 110.21, 111.65, 111.67, 124.99, 127.27, 
127.92, 128.21, 128.35, 131.86, 141.41, 153.77, 176.22 ppm. MS: m/z (+ESI) calcd 
for C20H24N3O3 354.1818, found 354.1886 [MH+]. 
(S,R)-54g Rf = 0.4 (CHCl3/MeOH, 6:1), IR (KBr): v = 3331, 2931, 1661, 1481, 
1216, 756 cm-1. 1H NMR (400 MHz, acetone-d6): į = 2.93 (dd, J = 16, 8 Hz, 1H, 
CHAHB), 3.15 (dd, J = 16, 8 Hz, 1H, CHAHB), 3.28 (dd, J = 8, 4 +]+Į-H), 3.45 
(dd, J = 12, 8 Hz, 1H, CHAHBOH), 3.59 (dd, J = 12, 8 Hz, 1H, CHAHBOH), 3.70 (s, 
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3H, OCH3) 3.76 (dd, J = 8, 4 Hz, 1H, CHCH2OH), 6.56 (br, 1H, NH), 6.76 (dd, J = 
8, 4 Hz, 1H, arom. H), 6.76-7.30 (m, 8H, arom. H), 7.33 (br, 1H, NH), 9.98 (br, 1H, 
NH) ppm. 13C NMR (100 MHz, acetone-d6): į = 30.09 (CH2), 54.92 (OCH3), 60.14 
(CH), 63.55 (CH), 67.16 (CH2), 100.30, 110.83, 111.72, 111.86, 124.27, 126.80, 
127.26, 127.91, 128.01, 131.95, 141.06, 153.77, 176.80 ppm. MS: m/z (+ESI) calcd 
for C20H24N3O3 354.1818 found 354.1914 [MH+]. 
(S)-3-(4-Methoxyl-1H-indol-3-yl)-2-((R)-2-hydroxy-1-phenylethyamino)-
propanamide, (S,R)-54h 
           
N
H
HN
CONH2
OHOCH3
N
H
HN
CONH2
OHOCH3
(R,R)-53h (S,R)-54h
 
Procedure as described in the general procedure using Į-aminonitrile 52h (213 mg, 
0.6 mmol) in DMSO (3 mL), K2CO3 (113 mg, 0.8 mmol) and 30 % H2O2 (0.5 mL, 
4.7 mmol), 30 % H2O2 (0.4 mL, 4.7 mmol) gave (R,R)-53h as a yellow oil (first 
eluting diastereoisomer, 16 mg, 7 % yield) and (S,R)-54h as yellow foam (second 
eluting diastereoisomer, 25 mg, 11 % yield). 
(R,R)-53h Rf = 0.6 (CHCl3/MeOH, 6 :1), IR (KBr): v = 3317, 2932, 1665, 1086, 
755 cm-1. 1H NMR (400 MHz, acetone-d6): į = 2.90 (br, 2H, NH), 3.16 (ddd, J = 
12, 8, 8 Hz, 1H, CHAHB), 4.16 (m, 4 H, CHAHB, Į-H, CHAHBOH, CHAHBOH), 
3.69 (dd, , J = 8, 4 Hz, 1H), 3.86 (s, 3H, OCH3), 6.22 (br, 1H, NH), 6.49 (dd, 6,1 
Hz, 1H, arom. H), 7.00- 7.06 (m, 3H, arom. H), 7.11 (br, 1H, NH), 7.21- 7.27 (m, 5 
H, arom. H), 10.07 (br, 1H, NH) ppm. 13C NMR (100 MHz, acetone-d6): į = 29.91 
(CH2), 54.34 (CH), 60.97 (OCH3), 63.59 (CH), 66.44 (CH2), 98.83, 104.85, 111.57, 
117.74, 122.01, 122.53, 126.97, 127.88, 128.00, 138.44, 141.90, 154.66, 176.52 
pp m. MS: m/z (+ESI) calcd for C20H24N3O3 354.1818, found 354.1598 [MH+]. 
(S,R)-54h Rf = 0.5 (CHCl3/MeOH, 6 :1), IR (KBr): v = 3317, 2932, 1665, 1086, 
755 cm-1. 1H NMR (400 MHz, acetone-d6): į = 2.90 (br, 1H, NH), 3.01 (dd, J = 12, 
8 Hz, 1H, CHAHB), 3.29 (dd, J = 16, 8 Hz, 1H, CHAHB), 3.32 (dd, J = 16, 4 Hz, 1H, 
Į-H), 3.44 (dd, J = 12, 8 Hz, 1H, CHAHBOH), 3.59 (dd, J = 12, 8 Hz, 1H, 
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CHAHBOH), 3.70 (s, 3H, OCH3), 3.71 (dd, J = 8, 4 Hz, 1H, CHCH2OH), 6.40 (dd, 
J = 4, 1 Hz, 1H, arom. H), 6.51 (br, 1H, NH), 6.04- 7.09 (m, 8 H, arom. H), 7.22 
(br, 1H, NH), 10.10 (br, 1H, NH) ppm. 13C NMR (100 MHz, acetone-d6): į = 31.39 
(CH2), 54.24 (CH), 61.15 (CH), 63.60 (OCH3), 67.20 (CH2), 98.97, 104.78, 111.45, 
117.65, 122.09, 122.57, 126.66, 127.23, 127.83, 138.57, 141.27, 154.56, 177.22 
pp m. MS: m/z (+ESI) calcd for C20H24N3O3 354.1818, found 354.1441 [MH+]. 
(S)-2-((R)-2-Hydroxy-1-phenylethylamino)-3-(1-methylindol-3-yl)-
propanamide, (S,R)-54i 
        
N
HN
CONH2
OH
CH3
N
HN
CONH2
OH
CH3
(R,R)-53i (S,R)-54i
 
Procedure as described in the general procedure using Į-aminonitrile 52i (391 mg, 
1.2 mmol) in DMSO (3.5 mL), K2CO3 (220 mg, 1.6 mmol) and 30 % H2O2 (1.0 
mL, 9.3 mmol), 30 % H2O2 (0.4 mL, 4.7 mmol) gave (R,R)-53i as a yellow oil (first 
eluting diastereoisomer, 48 mg, 11 % yield) and (S,R)-54i as white foam (second 
eluting diastereoisomer, 122 mg, 29 % yield). 
(R,R)-53i Rf = 0.5 (CHCl3/MeOH, 20 :1), IR (KBr): v = 3424, 3314, 2925, 1673, 
752 cm-1. 1H NMR (400 MHz, acetone-d6): į = 2.98 (br, 1 H, NH), 3.21 (dd, J = 12, 
8 Hz, 1H, CHAHB), 3.29 (dd, J = 12, 8 Hz, 1H, CHAHB), 3.31 (dd, J = 8, 8 Hz, 1H, 
Į-H), 3.50 (dd, J = 12, 8 Hz, 1H, CHAHBOH), 3.60 (dd, J = 12, 8 Hz, 1H, 
CHAHBOH), 3.75 (s, 3H, CH3), 3.96 (dd, J = 8, 4 Hz, 1H, CHCH2OH), 6.40 (br, 1H, 
NH), 7.01 (t, 1H, arom. H), 7.04 (t, 1H, arom. H), 7.14- 7.68 (m, 7H, arom. H), 
7.70 (d, 1H, arom. H) ppm. 13C NMR (100 MHz, acetone-d6): į = 26.28 (CH2), 
31.84 (CH3), 59.34 (CH), 63.56 (CH), 66.92 (CH2), 109.05, 109.59, 118.44, 119.46, 
121.15, 127.27, 127.91, 128.23, 128.48, 128.69, 137.17, 141.42, 176.33 ppm. MS: 
m/z (+ESI) calcd for C20H24N3O2 338.1869, found 338.1843 [MH+]. 
(S,R)-54i Rf = 0.4 (CHCl3/MeOH, 20 :1), IR (KBr): v = 3424, 3314, 2925, 1673, 
752 cm-1. 1H NMR (400 MHz, acetone-d6): į = 2.93 (dd, J = 16, 8 Hz, 1H, CHAHB), 
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3.17 (dd, J = 16, 8 Hz, 1H, CHAHB), 3.27 (dd, J = 8, 4 +]+Į-H), 3.47 (dd, J = 
12, 8 Hz, 1H, CHAHBOH), 3.59 (dd, J = 12, 8 Hz, 1H, CHAHBOH), 3.73 (dd, J = 8, 
4 Hz, 1H, CHCH2OH), 3.75 (s, 3H, CH3), 6.63 (br, 1H, NH), 6.95- 6.69 (m, 4H, 
arom. H), 7.05- 7.18 (m, 4H, arom. H), 7.36 (d, J = 8 Hz, 1H, arom. H), 7.40 (br, 
1H, NH), 7.48 (d, J = 8 Hz, 1H, arom. H) ppm. 13C NMR (100 MHz, acetone-d6): į 
= 29.75 (CH2), 31.85 (CH3), 60.54 (CH), 63.64 (CH), 67.09 (CH2), 109.17, 110.34, 
118.51, 118.80, 121.22, 126.86, 127.29, 127.84, 127.93, 128.29, 137.20, 141.09, 
176.95 ppm. MS: m/z (+ESI) calcd for C20H24N3O2 338.1869, found 338.1441 
[MH+]. 
(S)-2-((R)-2-Hydroxy-1-phenylethylamino)-3-(2-methyl-1H-indol-3-yl)-
propanamide, (S,R)-54j 
    
N
H
HN
CONH2
OH
N
H
HN
CONH2
OH
(R,R)-53j (S,R)-54j
 
Procedure as described in the general procedure using Į-aminonitrile 52j (355 mg, 
1.1 mmol) in DMSO (3 mL), K2CO3 (199 mg, 1.4 mmol) and 30 % H2O2 (0.9 mL, 
8.4 mmol), 30 % H2O2 (0.4 mL, 4.7 mmol) to give (R,R)-53j as a yellow foam 
(first eluting diastereoisomer, 18 mg, 5 % yield) and (S,R)-54j as a yellow foam 
(second eluting diastereoisomer, 150 mg, 40 % yield). 
(R,R)-53j Rf = 0.6 (CHCl3/MeOH, 6 :1), IR (KBr): v = 3311, 2926, 1667, 1453, 752 
cm-1. 1H NMR (400 MHz, acetone-d6): į = 2.44 (s, 3H, CH3), 2.98 (br, 1 H, NH), 
3.10 (dd, J = 12, 8 Hz, 1H, CHAHB), 3.22 (dd, J = 12, 8 Hz, 1H, CHAHB), 3.35 (dd, 
J = 8, 8 +]+Į-H), 3.45 (dd, J = 12, 8 Hz, 1H, CHAHBOH), 3.48 (dd, J = 12, 8 
Hz, 1H, CHAHBOH), 3.75 (dd, J = 8, 4 Hz, 1H, CHCH2OH), 6.38 (br, 1H, NH), 
6.93 (t, 1H, arom. H), 7.02 (t, 1H, arom. H), 7.14- 7.68 (m, 6H, arom. H), 7.49 (d, J 
= 8 Hz ,1H, arom. H), 9.95 (br, 1H, NH) ppm. 13C NMR (100 MHz, acetone-d6): į 
= 11.00 (CH3), 27.60 (CH2), 60.01 (CH), 63.69 (CH), 66.54 (CH2), 106.99, 110.17, 
118.10, 118.39, 120.25, 127.11, 127.88, 128.09, 128.99, 133.26, 135.85, 141.59, 
176.64 ppm. MS: m/z (+ESI) calcd for C20H24N3O2 338.1869, found 338.1766 
[MH+]. 
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(S,R)-54j Rf = 0.5 (CHCl3/MeOH, 6 :1),  IR (KBr): v = 3311, 2926, 1667, 1453, 
752 cm-1. 1H NMR (400 MHz, acetone-d6): į = 2.31 (s, 3H, CH3), 2.95 (dd, J = 16, 
8 Hz, 1H, CHAHB), 3.17 (dd, J = 16, 8 Hz, 1H, CHAHB), 3.24 (dd, J = 8, 4 Hz, 1H, 
Į-H), 3.39 (dd, J = 12, 8 Hz, 1H, CHAHBOH), 3.58 (dd, J = 12, 8 Hz, 1H, 
CHAHBOH), 3.74 (dd, J = 8, 4 Hz, 1H, CHCH2OH), 6.76 (br, 1H, NH), 6.84- 7.09 
(m, 6H, arom. H), 7.31- 7.40 (m, 3H, arom. H), 10.02 (br, 1H, NH) ppm. 13C NMR 
(100 MHz, acetone-d6): į = 10.86 (CH3), 29.62 (CH2), 60.64 (CH), 63.47 (CH), 
67.33 (CH2), 106.87, 110.30, 117.65, 118.55, 120.34, 126.76, 127.10, 127.93, 
129.15, 133.08, 135.76, 140.96, 177.00 ppm. MS: m/z (+ESI) calcd for C20H24N3O2 
338.1869, found 338.1903 [MH+]. 
6.2.4   Preparation of (S)-2-Amino-3-(indol-3-yl)-propanamide 
derivatives 
General procedure for the preparation of (S)-2-Amino-3-(indol-3-yl)-
propanamide, (55a) 
N
H
NH2HCl
NH2O
55a
 
To a stirred solution of 54a (101 mg, 0.3 mmol), 10 % Pd/C (50 mg, 50 % w/w) in 
MeOH (10 mL) and ammonium formate (98 mg, 1.56 mmol) were added under 
nitrogen. The resulting mixture was stirred at reflux for 4 h. The catalyst was 
removed by filtration through a celite pad and washed with MeOH (5 mL). The 
filtrate was dried and concentrated. Purification of the residue by column 
chromatography (CH2Cl2/MeOH, 4:1) gave amino amide. The amino amide was 
acidified with 1M HCl to give 55a hydrochloric salt as a white solid (30 mg, 41 %) 
m.p. 256-257 °C; Rf = 0.2 (CHCl3/MeOH, 4:1). IR (KBr): v = 3388, 3247, 2914, 
1693, 1492, 751 cm-1. 1H NMR (400 MHz, D2O): į = 3.23 (dd, J = 14, 7 Hz, 1H, 
CHAHB), 3.30 (dd, J = 14, 7 Hz, 1H, CHAHB), 4.20 (t, J  +]+Į-H), 7.10 (td, 
J = 8, 1 Hz, 1H, arom. H), 7.22 (s, 1H, C2H), 7.18 (td, J = 8, 1 Hz, 1H, arom. H), 
7.44 (d, J = 8 Hz, 1H, arom. H), 7.60 (d, J = 8 Hz, 1H, arom. H) ppm. 13C NMR 
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(100 MHz, D2O): į = 26.83 (CH2), 53.21 (CH), 106.26, 111.99, 118.24, 119.50, 
122.15, 125.36, 126.53, 136.22, 171.84 ppm. MS: m/z (+ESI) calcd for C11H14N3O 
204.1137, found 204.1016 [MH+]. 
(S)-2-Amino-3-(5-bromo-indol-3-yl)propanamide, (55b) 
N
H
NH2.HCl
NH2O
Br
55b
 
A solution of 125b (510 mg, 1.2 mmol) and triisopropylsilane (252 µL, 1.2 mmol) 
in trifluoroacetic acid (4 mL) was stirred at 60 °C for 42 h. The crude mixture was 
triturated with cold ether. The crude  55b was use used directly to the acid 
hydrolysis. 
(S)-2-Amino-3-(5-chloro-indol-3-yl)propanamide, (55c) 
N
H
NH2.HCl
NH2O
Cl
55c
 
A solution of 125c (446 mg, 1.2 mmol) and triisopropylsilane (246 µL, 1.2 mmol) 
in trifluoroacetic acid (4 mL) was stirred at 60 °C for 40 h. The crude mixture was 
triturated with cold ether. The crude  55c was use used directly to the acid 
hydrolysis. 
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(S)-2-Amino-3-(6-fluoro-indol-3-yl)-propanamide, (55d) 
N
H
NH2.HCl
NH2O
F
55d
 
Procedure as described in the general procedure using 54d (207 mg, 0.6 mmol), 10 
% Pd/C (62 mg, 35 % w/w) in MeOH (8 mL), ammonium formate (190 mg, 3.0 
mmol) gave 55d hydrochloric salt as a pale orange solid (102 mg, 65 %). m.p. 232-
233 °C;  Rf = 0.2 (CHCl3/MeOH, 4:1), IR (KBr): v = 3472, 3271, 2983, 1658, 1451 
cm-1. 1H NMR (400 MHz, D2O): į = 3.13 (dd, J = 14, 7 Hz, 1H, CHAHB), 3.20 (dd, 
J = 14, 7 Hz, 1H, CHAHB), 4.17 (t, J  +]+Į-H), 6.81 (m, 1H, arom. H), 7.04 
(dd, J = 10, 4 Hz, 1H, arom. H), 7.12 (s, 1H, C2H), 7.43 (dd, 10, 4 Hz, 1H, arom. H) 
ppm. 13C NMR (100 MHz, D2O): į = 26.75 (CH2), 53.12 (CH), 97.76 (d, J = 26 
Hz), 106.34, 107.91 (d, J = 25 Hz), 118.97 (d, J = 10 Hz), 123.19, 125.54 (d, J = 3 
Hz), 136.10 (d, J = 12 Hz), 159.58 (d, J = 233 Hz), 171.76 ppm. MS: m/z (+ESI) 
calcd for C11H12FN3O 222.1043, found 222.0912 [MH+]. 
(S)-2-Amino-3-(7-ethyl-indol-3-yl)propanamide, (55e) 
N
H
NH2.HCl
NH2O
55e
 
Procedure as described in the general procedure using 54e (275 mg, 0.8 mmol), 10 
% Pd/C (90 mg, 35 % w/w) in MeOH (10 mL), ammonium formate (246 mg, 3.9 
mmol) gave 55e hydrochloric salt  as a pale purple solid (102 mg, 65 %). m.p. 160-
161 °C; Rf = 0.2 (CHCl3/MeOH, 4:1), IR (KBr): v = 3411, 3154, 3045, 1687, 1413 
cm-1. 1H NMR (400 MHz, D2O): į = 1.12 (t, J = 8 Hz, 3H, CH2CH3), 2.68 (q, J = 8 
Hz, 2H, CH2CH3), 3.15 (dd, J = 14, 7 Hz, 1H, CHAHB), 3.20 (dd, J  = 14, 7 Hz, 1H, 
CHAHB), 4.17 (t, J  +]+Į-H), 6.88 (d, J = 6 Hz, 1H, arom. H), 6.98 (t, J = 7 
Hz, 1H, arom. H), 7.18 (s, 1H, C2H), 7.40 (d, J = 8 Hz, 1H, arom. H) ppm. 13C 
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NMR (100 MHz, D2O): į = 13.45 (CH3), 23.64 (CH2), 26.93 (CH2), 53.21 (CH), 
106.68, 115.98, 119.90, 120.51, 125.01, 126.50, 128.22, 134.86, 171.76 ppm. MS: 
m/z (+ESI) calcd for C13H18N3O 232.1450, found 232.1390 [MH+]. 
(S)-2-Amino-3-(5-indol-3-yl)propanamide, (55f) 
N
H
NH2.HCl
NH2O
55f
 
Procedure as described in the general procedure using 54f (94 mg, 0.3 mmol), 10 % 
Pd/C (32 mg, 35 % w/w) in MeOH (6 mL), ammonium formate (88 mg, 1.4 mmol)  
gave 55f hydrochloric salt as a colourless film (26 mg, 37 %) m.p. 82-84 °C;  Rf = 
0.2 (CHCl3/MeOH, 4:1). IR (KBr): v = 3402, 2916, 1668, 1431 cm-1. 1H NMR (400 
MHz, D2O): į = 2.33 (s, 3H, CH3), 3.04 (dd, J = 15, 6 Hz, 1H, CHAHB), 3.12 (dd, J 
= 15, 6 Hz, 1H, CHAHB), 3.83 (t, J  +]+Į-H), 7.00 (dd, J = 8, 1 Hz, 1H, 
arom. H), 7.12 (s, 1H, C-2H), 7.30 (d, J = 8 Hz, 1H, arom. H), 7.38 (s, 1H, arom. H) 
ppm. 13C NMR (100 MHz, D2O): į = 20.41 (CH3), 28.64 (CH2), 54.05 (CH), 
107.50, 111.69, 117.71, 123.46, 125.01, 127.03, 129.00, 134.45, 176.44 ppm. MS: 
m/z (+ESI) calcd for C12H16N3O 218.1293, found 218.1220 [MH+]. 
(S)-2-amino-3-(5-methoxyl-indol-3-yl)propanamide, (55g) 
N
H
NH2.HCl
NH2O
H3CO
55g
 
Procedure as described in the general procedure using 54g (80 mg, 0.2 mmol), 10 
% Pd/C (30 mg, 35 % w/w) in MeOH (8 mL), ammonium formate (71 mg, 1.1 
mmol) gave 55g hydrochloric salt  as a pale purple solid (38 mg, 64 %). m.p. 247-
249 °C; Rf = 0.2 (CHCl3/MeOH, 4:1). IR (KBr): v = 3354, 3167, 2954, 1687, 1462 
cm-1. 1H NMR (400 MHz, D2O): į = 3.17 (dd, J = 15, 7 Hz, 1H, CHAHB), 3.23 (dd, 
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J = 15, 7 Hz, 1H, CHAHB), 3.75 (s, 3H, OCH3), 4.18 (t, J  +]+Į-H), 6.78 
(dd, J = 8, 2 Hz, 1H, C6H), 7.05 (d, J = 2 Hz, 1H, C4H), 7.17 (s, 1H, C2H), 7.29 (d, 
J = 8 Hz, 1H, C7H) ppm. 13C NMR (100 MHz, D2O): į = 26.80 (CH2), 53.08 (CH), 
56.03 (OCH3), 100.59, 106.02, 111.74, 112.78, 126.19, 126.93, 131.62, 152.90, 
171.88 ppm. MS: m/z (+ESI) calcd for C12H16N3O2 234.1243 found 234.1187 
[MH+]. 
(S)-2-Amino-3-(4-methoxyl-indol-3-yl)propanamide, (55h) 
N
H
NH2.HCl
NH2O
OCH3
55h
 
Procedure as described in the general procedure using 54h (55 mg, 0.2 mmol), 10 
% Pd/C (20 mg, 35 % w/w) in MeOH (8 mL), ammonium formate (49 mg, 0.8 
mmol) gave 55h hydrochloric salt as a pale yellow solid (28 mg, 68 %) m.p. 231-
233 °C; Rf = 0.2 (CHCl3/MeOH, 4:1). IR (KBr): v = 3354, 3168, 2955, 1687, 1463 
cm-1. 1H NMR (400 MHz, D2O): į = 3.22 (dd, J = 15, 7 Hz, 1H, CHAHB), 3.35 (dd, 
J = 15, 7 Hz, 1H, CHAHB), 3.84 (s, 3H, OCH3), 4.24 (t, J  +]+Į-H), 6.53 
(dd, J = 8, 1 Hz, 1H, arom. H), 7.02 (dd, J = 8, 1 Hz, 1H, arom. H), 7.04 (s, 1H, 
C2H), 7.06 (d, J = 8 Hz, 1H, arom. H) ppm. 13C NMR (100 MHz, D2O): į = 
28.21(CH2), 54.37 (CH), 55.12 (OCH3), 99.74, 105.41, 106.26, 116.19, 123.11, 
124.24, 138.02, 153.51, 171.88 ppm. MS: m/z (+ESI) calcd for C12H16N3O2 
234.1243 found 234.1096 [MH+]. 
(S)-2-Amino-3-(1-methyl-indol-3-yl)propanamide, (55i) 
N
NH2.HCl
NH2O
CH3
55i
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To a stirred solution of 54i (122 mg, 0.3 mmol) and 10 % Pd/C (42 mg, 35 % w/w) 
in MeOH (8 mL), ammonium formate (113 mg, 1.8 mmol) were added under 
nitrogen. The resulting mixture was stirred at reflux for 4 h. Another 10 % Pd/C 
(42 mg, 35 % w/w) and ammonium formate (113 mg, 1.8 mmol) were added and 
stirred for 16 h. The catalyst was removed by filtration through a celite pad and 
washed with MeOH (5 mL). The filtrate was dried and concentrated. Purification 
of the residue by column chromatography (CH2Cl2/MeOH, 4:1) gave amino amide. 
The amino amide was acidified with 1M HCl to give 55i hydrochloric salt as a 
white solid (46 mg, 53 %) m.p. 260-261 °C;  Rf = 0.4 (CHCl3/MeOH, 9:1) IR (KBr): 
v = 3376, 3175, 1687, 1480, 742 cm-1. 1H NMR (400 MHz, acetone-d6): į = 2.93 
(dd, J = 14, 9 Hz, 1H, CHAHB), 3.37 (dd, J = 14, 3 Hz, 1H, CHAHB), 3.77 (s, 3H, 
CH3), 4.10 (dd, J  +]+Į-H), 6.65 (br, 1H, NH), 6.97 (s, 1H, C2H), 7.04 
(td, J = 8, 1 Hz, 1H, arom. H), 7.15 (td, J = 8, 1 Hz, 1H, arom. H), 7.33 (d, J = 8 Hz, 
1H, arom. H), 7.60 (d, J = 8 Hz, 1H, arom. H) ppm. 13C NMR (100 MHz, acetone-
d6): į = 29.97 (CH2), 31.77 (CH3), 65.68 (CH), 109.13, 110.95, 118.40, 118.99, 
121.14, 127.96, 128.39, 137.02, 175.22 ppm. MS: m/z (+ESI) calcd for C12H16N3O 
218.1293, found 218.1318 [MH+]. 
(S)-2-Amino-3-(2-methyl-indol-3-yl)propanamide, (55j) 
N
H
NH2.HCl
NH2O
55j
 
To a stirred solution of 54j (150 mg, 0.4 mmol) and 10 % Pd/C (52 mg, 35 % w/w) 
in MeOH (8 mL) and ammonium formate (138 mg, 2.2 mmol) were added under 
nitrogen. The resulting mixture was stirred at reflux for 4 h. Another 10 % Pd/C 
(32 mg, 20 % w/w) and ammonium formate (138 mg, 2.2 mmol) were added and 
stirred for 16 h. The catalyst was removed by filtration through a celite pad and 
washed with MeOH (5 mL). The filtrate was dried and concentrated. Purification 
of the residue by column chromatography (CH2Cl2/MeOH, 4:1) gave amino amide. 
The amino amide was acidified with 1M HCl to give 55j hydrochloric salt  as a 
purple solid (90 mg, 81 %). m.p. 210-211°C;  Rf = 0.4 (CHCl3/MeOH, 4:1), IR 
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(KBr): v = 3397, 3174, 1687, 1461, 749 cm-1. 1H NMR (400 MHz, D2O): į = 2.18 
(s, 3H, CH3), 3.02 (dd, J = 11, 7 Hz, 1H, CHAHB), 3.06 (dd, J = 11, 7 Hz, 1H, 
CHAHB), 4.04 (t, J  +]+Į-H), 7.01 (td, J = 8, 1 Hz, 1H, arom. H), 7.05 (td, J 
= 8, 1 Hz, 1H, arom. H), 7.27 (d, J = 8 Hz, 1H, arom. H), 7.41 (d, J = 8 Hz, 1H, 
arom. H) ppm. 13C NMR (100 MHz, D2O): į = 10.47 (CH3), 25.87 (CH2), 53.09 
(CH), 102.22, 110.98, 117.25, 119.26, 121.10, 127.60, 135.17, 135.42, 171.76 ppm. 
MS: m/z (+ESI) calcd for C12H16N3O 218.1293, found 218.1079 [MH+]. 
6.2.5   Preparation of (S)-2-Amino-3-(indol-3-yl)propanic acid 
derivatives 
General procedure for the preparation of (S)-2-Amino-3-(indol-3-yl)propanic 
acid, (56a) 
N
H
NH2.HCl
OHO
56a
 
To a two neck round bottom flask containing the Į-aminoa mide 55a (86 mg, 0.4 
mmol) was added a solution of 1M HCl (6 mL). The reaction mixture was heated at 
reflux for 5 h and was cooled to room temperature. The residue was lyophilised to 
give 56a as a white solid (100 mg, 83 % yield). m.p. 246-247 °C; IR (KBr): v = 
3386, 2941, 1735 cm-1. 1H NMR (400 MHz, D2O): į = 3.23 (dd, J = 15, 7 Hz, 1H, 
CHAHB), 3.32 (dd, J = 15, 5 Hz, 1H, CHAHB), 4.13 (dd, J  +]+Į-H), 7.04 
(td, J = 8, 1 Hz, 1H, arom. H), 7.13 (td, J = 8, 1 Hz, 1H, arom. H), 7.16 (s, 1H, C-
2H), 7.39 (d, J = 8 Hz, 1H, arom. H), 7.51 (d, J = 8 Hz, 1H, arom. H) ppm. 13C 
NMR (100 MHz, D2O): į = 25.65 (CH2), 53.19 (CH), 106.17, 111.97, 118.16, 
119.48, 122.12, 125.31, 126.44, 136.24, 171.80 ppm. MS: m/z (+ESI) calcd for 
C11H13N2O2 205.0977, found 205.0953 [MH+]. 
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(S)-2-Amino-3-(5-bromo-indol-3-yl)propanic acid, (56b) 
N
H
NH2.HCl
OHO
Br
56b
 
7RDWZRQHFNURXQGERWWRPIODVNFRQWDLQLQJĮ-aminoa mide 55b (90 mg, 0.2 mmol) 
was added a solution of 1M HCl (5 mL). The reaction mixture was heated at reflux 
for 18 h and was cooled to room temperature. The residue was lyophilised to give 
56b as a yellow solid (78 mg, 99 % yield). m.p. 220-221 °C; 1H NMR (400 MHz, 
D2O): į = 3.20 (dd, J = 15, 7 Hz, 1H, CHAHB), 3.28 (dd, J = 15, 5 Hz, 1H, CHAHB), 
4.18 (dd, J  +]+Į-H), 7.17 (dd, J = 8, 2 Hz, 1H, arom. H), 7.17 (s, 1H, C-
2H), 7.25 (d, J = 8 Hz, 1H, arom. H), 7.63 (d, J = 2 Hz, 1H, arom. H) ppm. 13C 
NMR (100 MHz, D2O): į = 25.64 (CH2), 53.31 (CH), 106.03, 112.01, 113.46, 
120.52, 124.55, 126.46, 128.19, 134.91, 172.00 ppm. MS: m/z (+ESI) calcd for 
C11H12BrN2O2 283.0082, found 283.0150 [MH+]. 
(S)-2-Amino-3-(5-chloro-indol-3-yl)propanic acid, (56c) 
N
H
NH2.HCl
OHO
Cl
56c
 
7RDWZRQHFNURXQGERWWRPIODVNFRQWDLQLQJĮ-aminoa mide 55c (62 mg, 0.3 mmol) 
was added a solution of 1M HCl (5 mL). The reaction mixture was heated at reflux 
for 18 h and was cooled to room temperature. The residue was lyophilised to give 
56c as a yellow solid (59 mg, 95 % yield). m.p. 230-233 °C; IR (KBr): v = 3456, 
3138, 3037, 1730, 1407 cm-1. 1H NMR (400 MHz, D2O): į = 3.16 (dd, J = 15, 7 Hz, 
1H, CHAHB), 3.23 (dd, J = 15, 5 Hz, 1H, CHAHB), 4.16 (dd, J  +]+Į-H), 
7.00 (dd, J = 8, 2 Hz, 1H, arom. H), 7.16 (s, 1H, C-2H), 7.25 (d, J = 8 Hz, 1H, 
arom. H), 7.41 (d, J = 2 Hz, 1H, arom. H) ppm. 13C NMR (100 MHz, D2O): į = 
25.59 (CH2), 53.24 (CH), 106.02, 113.00, 117.34, 121.95, 124.41, 126.59, 127.49, 
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134.61, 171.88 ppm. MS: m/z (+ESI) calcd for C11H12ClN2O2 239.0587, found 
239.0587 [MH+]. 
(S)-2-Amino-3-(6-fluoro-indol-3-yl)propanic acid, (56d) 
N
H
NH2.HCl
OHO
F
56d
 
7R D WZR QHFN URXQG ERW WRP IODVN FRQWDLQLQJ Į-aminoa mide 55d (102 mg, 0.4 
mmol) was added a solution of 1M HCl (6 mL). The reaction mixture was heated at 
reflux for 5 h and was cooled to room temperature. The residue was lyophilised to 
give 56d as a white solid (92 mg, 90 % yield). m.p. 218-220 °C; IR (KBr): v = 
3458, 3015, 1732, 1412 cm-1. 1H NMR (400 MHz, D2O): į = 3.26 (dd, J = 15, 7 Hz, 
1H, CHAHB), 3.33 (dd, J = 15, 5 Hz, 1H, CHAHB), 4.13 (dd, J  +]+Į-H), 
6.84 (ddd, J = 10, 9, 2 Hz, 1H, arom. H), 7.10 (dd, J = 10, 2 Hz, 1H, arom. H), 7.15 
(s, 1H, C-2H), 7.45 (dd, J = 9, 5 Hz, 1H, arom. H) ppm. 13C NMR (100 MHz, D2O): 
į = 25.66 (CH2), 53.24 (CH), 97.81 (d, J = 26 Hz), 106.43, 108.00 (d, J = 25 Hz), 
118.95 (d, J = 10 Hz), 123.11, 125.54 (d, J = 3 Hz), 136.17 (d, J = 13 Hz), 159.64 
(d, J = 234 Hz), 171.92 ppm. MS: m/z (+ESI) calcd for C11H12FN2O2 223.0883, 
found 223.0752 [MH+]. 
(S)-2-Amino-3-(7-ethyl-indol-3-yl)propanic acid, (56e) 
N
H
NH2HCl
OHO
56e
 
7R D WZR QHFN URXQG ERWWRP IODVN FRQWDLQLQJ Į-aminoa mide 55e (151 mg, 0.6 
mmol) was added a solution of 1M HCl (8 mL). The reaction mixture was heated at 
reflux for 5 h and was cooled to room temperature. The residue was lyophilised to 
give 56e as a white solid (151 mg, 99 % yield). m.p. 216-218 °C; IR (KBr): v = 
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3393, 3137, 3041, 1728, 1407 cm-1. 1H NMR (400 MHz, D2O): į =  1.14 (t, J = 8 
Hz, 3H, CH2CH3), 2.71 (q, J = 8 Hz, 2H, CH2CH3), 3.22 (dd, J = 15, 7 Hz, 1H, 
CHAHB), 3.31 (dd, J = 15, 5 Hz, 1H, CHAHB), 4.20 (dd, J  +]+Į-H), 6.93 
(t, J = 8 Hz, 1H, arom. H), 6.98 (t, J = 8 Hz, 1H, arom. H), 7.17 (s, 1H, C-2H), 7.36 
(d, J = 8 Hz, 1H, arom. H) ppm. 13C NMR (100 MHz, D2O): į = 13.44 (CH3), 
23.65 (CH2), 25.81 (CH2), 53.28 (CH), 106.68, 115.91, 119.91, 120.55, 125.02, 
126.42, 128.29, 134.90, 171.88 ppm. MS: m/z (+ESI) calcd for C13H17N2O2 
233.1290, found 233.1174 [MH+]. 
(S)-2-Amino-3-(5-methoxyl-indol-3-yl)propanic ac id, (56f) 
N
H
NH2.HCl
OHO
56f
 
To a WZRQHFNURXQGERWWRPIODVNFRQWDLQLQJĮ-aminoa mide 55f (28 mg, 0.1 mmol) 
was added a solution of 1M HCl (5 mL). The reaction mixture was heated at reflux 
for 16 h and was cooled to room temperature. The residue was lyophilised to give 
56f as a white solid (27 mg, 96 % yield). m.p. 112-114 °C; IR (KBr): v = 3406, 
2918, 1736, 1485 cm-1. 1H NMR (400 MHz, D2O): į = 2.32 (s, 3H, CH3), 3.25 (dd, 
J = 15, 7 Hz, 1H, CHAHB), 3.35 (dd, J = 15, 5 Hz, 1H, CHAHB), 4.21 (dd, J = 7, 5 
+]+Į-H), 7.00 (dd, J = 8, 1 Hz, 1H, arom. H), 7.16 (s, 1H, arom. H), 7.30 (d, J 
= 8 Hz, 1H, arom. H), 7.36 (s, 1H, arom. H) ppm. 13C NMR (100 MHz, D2O): į = 
20.42 (CH3), 25.76 (CH2), 53.25 (CH), 105.74, 111.79, 117.60, 123.65, 125.45, 
126.70, 129.21, 134.57, 171.96 ppm. MS: m/z (+ESI) calcd for C12H15N2O2 
219.1134, found 219.1036 [MH+]. 
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(S)-2-Amino-3-(5-methoxyl-indol-3-yl)propanic ac id, (56g) 
N
H
NH2.HCl
OHO
H3CO
56g
 
7RDWZRQHFNURXQGERWWRPIODVNFRQWDLQLQJĮ-aminoa mide 55g (38 mg, 0.1 mmol) 
was added a solution of 1M HCl (4 mL). The reaction mixture was heated at reflux 
for 5 h and was cooled to room temperature. The residue was lyophilised to give 
56g as a white solid (38 mg, 99 % yield). m.p. 224-225 °C; IR (KBr): v = 3358, 
2909, 1728, 1478, 1214 cm-1. 1H NMR (400 MHz, D2O): į = 3.22 (dd, J = 15, 7 Hz, 
1H, CHAHB), 3.30 (dd, J = 15, 5 Hz, 1H, CHAHB), 3.74 (s, 3H, OCH3), 4.21 (dd, J 
 +]+Į-H), 6.78 (dd, J = 8, 2 Hz, 1H, arom. H), 7.02 (d, J = 2 Hz, 1H, 
arom. H), 7.15 (s, 1H, C-2H), 7.28 (d, J = 8 Hz, arom. H) ppm. 13C NMR (100 
MHz, D2O): į = 25.81 (CH2), 53.28 (CH), 55.97 (OCH3), 100.44, 106.04, 111.82, 
112.81, 126.14, 126.82, 131.67, 152.91, 171.97 ppm. MS: m/z (+ESI) calcd for 
C12H15N2O3 235.1083, found 235.1068 [MH+]. 
(S)-2-Amino-3-(4-methoxyl-indol-3-yl)propanic ac id, (56h) 
N
H
NH2.HCl
OHO
OCH3
56h
 
7RDWZRQHFNURXQGERWWRPIODVNFRQWDLQLQJĮ-aminoa mide 55h (28 mg, 0.1 mmol) 
was added a solution of 1M HCl (4 mL). The reaction mixture was heated at reflux 
for 5 h and was cooled to room temperature. The residue was lyophilised to give 
56h as a white solid (36 mg, 99 % yield). m.p. 220-222 °C; IR (KBr): v = 3358, 
2906, 1728, 1480, 1215 cm-1. 1H NMR (400 MHz, D2O): į = 3.24 (dd, J = 15, 7 Hz, 
1H, CHAHB), 3.37 (dd, J = 15, 7 Hz, 1H, CHAHB), 3.86 (s, 3H, OCH3), 4.28 (t, J = 
+]+Į-H), 6.55 (dd, J = 8, 1 Hz, 1H, arom. H), 7.04 (dd, J = 8, 1 Hz, 1H, 
arom. H), 7.06 (s, 1H, C2H), 7.09 (d, J = 8 Hz, 1H, arom. H) ppm. 13C NMR (100 
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MHz, D2O): į = 28.21(CH2), 54.37 (CH), 55.13 (OCH3), 99.74, 105.41, 106.26, 
116.20, 123.09, 124.24, 138.02, 153.56, 171.84 ppm. MS: m/z (+ESI) calcd for 
C12H15N2O3 235.1083, found 235.1068 [MH+]. 
(S)-2-Amino-3-(1-methyl-indol-3-yl)propanic ac id, (56i) 
N
NH2.HCl
OHO
CH3
56i
 
7RDWZRQHFNURXQGERWWRPIODVNFRQWDLQLQJĮ-aminoamide 55i (42 mg, 0.2 mmol) 
was added a solution of 1M HCl (6 mL). The reaction mixture was heated at reflux 
for 5 h and was cooled to room temperature. The residue was lyophilised to give 
56i as a white solid (41 mg, 97 % yield). m.p. 210-212 °C;  IR (KBr): v = 3420, 
3127, 3047, 1731, 1412 cm-1. 1H NMR (400 MHz, D2O): į = 3.25 (dd, J = 16, 7 Hz, 
1H, CHAHB), 3.32 (dd, J = 16, 5 Hz, 1H, CHAHB), 3.62 (s, 3H, CH3), 4.20 (dd, J = 
+]+Į-H), 7.06 (s, 1H, C-2H), 7.08 (dd, J = 8, 1 Hz, 1H, arom. H), 7.19 (td, 
J = 8, 1 Hz, 1H, arom. H), 7.33 (d, J = 8 Hz, 1H, arom. H), 7.53 (d, J = 8 Hz, 1H, 
arom. H) ppm. 13C NMR (100 MHz, D2O): į = 25.54 (CH2), 32.10 (CH3), 53.34 
(CH), 105.12, 110.05, 118.36, 119.31, 121.94, 126.90, 129.55, 136.92, 171.92 ppm. 
MS: m/z (+ESI) calcd for C12H15N2O2 219.1134, found 219.1115 [MH+]. 
(S)-2-amino-3-(2-methyl-indol-3-yl)propanic acid, (56j) 
N
H
NH2.HCl
OHO
56j
 
7RDWZRQHFNURXQGERWWRPIODVNFRQWDLQLQJĮ-aminoa mide 55j (68 mg, 0.4 mmol) 
was added a solution of 1M HCl (6 mL). The reaction mixture was heated at reflux 
for 5 h and was cooled to room temperature. The residue was lyophilized to give 
Chapter 6 Experimental 
-218- 
 
56j as a purple solid (68 mg, 99 % yield). m.p. 200-202 °C; IR (KBr): v = 3397, 
3033, 1730, 1422 cm-1. 1H NMR (400 MHz, D2O): į = 2.19 (s, 3H, CH3), 3.08 (dd, 
J = 16, 7 Hz, 1H, CHAHB), 3.19 (dd, J = 16, 6 Hz, 1H, CHAHB), 4.13 (t, J = 6 Hz, 
+Į-H), 7.00 (td, J = 7, 1 Hz, 1H, arom. H), 7.05 (td, J = 7, 1 Hz, 1H, arom.), 
7.27 (d, J = 8 Hz, 1H, arom. H), 7.38 (d, J = 8 Hz, 1H, arom. H) ppm. 13C NMR 
(100 MHz, D2O): į = 10.49 (CH3), 24.85 (CH2), 53.29 (CH), 102.10, 111.01, 
117.17, 119.29, 121.15, 127.53, 135.23, 135.37, 171.65 ppm. MS: m/z (+ESI) calcd 
for C12H15N2O2 219.1134, found 219.1122 [MH+]. 
6.2.6   Preparation of N-[(fluoren-9-
ylmethoxy)carbonyl]tryptophan derivatives 
General procedure for the preparat ion of N-[(fluoren-9-
ylmethoxy) carbonyl]tryptophan, (43a) 
N
H
NHFmoc
OHO
43a
 
Tryptophan hydrochloric salt 56a (100 mg, 0.42 mmol) was added to an aqueous 
solution of sodium carbonate (89 mg, 0.84 mmol) 10 mL. 9-Fluorenylmethyl 
succinimidyl carbonate (141 mg, 0.42 mmol) in THF (3 mL) was added to the 
solution. The mixture was stirred for 2 h at room temperature. THF was removed in 
vacuo and the crude was poured into water (15 mL) and extracted with Et2O (15 
mL x 2).  The pH of the aqueous layer was adjusted to 2 using 3 M HCl and was 
extracted with DCM (20 mL x 2). The organic layer were combined, washed with 
brine, dried and concentrated to give 43a as a pale yellow solid (114 mg, 44 % 
yield). m.p. 182- &  >Į@24D = -29 (c 1, MeOH);  IR (KBr): v = 3416, 3057, 
2950, 1710, 743 cm-1. 1H NMR (400 MHz, acetone-d6): į = 3.31 (dd, J = 15, 8 Hz, 
1H, CHAHB), 3.46 (dd, J = 15, 5 Hz, 1H, CHAHB), 4.20 (t, J = 8 Hz, 1H, Fmoc CH), 
4.31 (m, 2H, Fmoc CH2P+Į-H), 6.68 (d, J = 8 Hz, 1H, NH), 7.07 (t, J 
= 7 Hz, 1H, arom. H), 7.14 (t, J = 7 Hz, 1H, arom. H), 7.28 (s, 1H, C-2H), 7.30 (m, 
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2H, arom. H), 7.41 (m, 3H, arom. H), 7.69 (m, 3H, arom. H), 7.84 (d, J = 7 Hz, 2H. 
arom. H), 10.10 (br, 1H, NH) ppm. 13C NMR (100 MHz, acetone-d6): į = 27.52 
(CH2), 47.09 (CH), 54.83 (CH), 66.36 (CH2), 110.30, 111.41, 118.39, 118.88, 
119.91, 121.38, 123.63, 125.29, 125.33, 127.08, 127.64, 127.79, 136.75, 141.18, 
144.11, 144.15, 156.07, 173.04 ppm. MS: m/z (+ESI) calcd for C26H23N2O4 
427.1658, found 427.1743 [MH+]. 
N-[(fluoren-9-ylmethoxy)carbonyl]-5-bromo-tryptophan, (43b) 
N
H
NHFmoc
OHO
Br
43b
 
Procedure as described in the general procedure using 56b (66 mg, 0.21 mmol), 
sodium carbonate (65 mg, 0.62 mmol) and 9-fluorenylmethyl succinimidyl 
carbonate (71 mg, 0.21 mmol) gave 43b as a white solid (23 mg, 20 % yield). m.p. 
130-132 &>Į@24D = -23 (c 1, MeOH);  IR (KBr): v = 3411, 3060, 2950, 1709, 737 
cm-1. 1H NMR (400 MHz, acetone-d6): į = 3.25 (dd, J = 16, 8 Hz, 1H, CHAHB), 
3.41 (dd, J = 16, 5 Hz, 1H, CHAHB), 4.20 (t, J = 8 Hz, 1H, Fmoc CH), 4.31 (m, 2H, 
Fmoc CH2P+Į-H), 6.70 (d, J = 8 Hz, 1H, NH), 7.23 (dd, J = 8, 2 Hz, 
1H, arom. H), 7.30 (m, 3H, arom. H), 7.40 (m, 3H, arom. H), 7.66 (dd, J = 8, 2 Hz, 
2H, arom. H), 7.86 (m, 3H, arom. H), 10.34 (br, 1H, NH) ppm. 13C NMR (100 
MHz, acetone-d6): į = 27.13 (CH2), 47.07 (CH), 54.67 (CH), 66.32 (CH2), 110.25, 
111.77, 113.15, 119.87, 120.96, 123.92, 125.14, 125.25, 125.33, 127.05, 127.60, 
129.66, 135.17, 141.15, 141.17, 144.11, 144.15, 155.94, 172.64 ppm. MS: m/z 
(+ESI) calcd for C26H22BrN2O4 505.0763, found 505.0978 [MH+]. 
N-[(fluoren-9-ylmethoxy)carbonyl]-5-chloro-tryptophan, (43c) 
N
H
NHFmoc
OHO
Cl
43c
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Procedure as described in the general procedure using 56c (59 mg, 0.25 mmol), 
sodium carbonate (79 mg, 0.75 mmol) and 9-fluorenylmethyl succinimidyl 
carbonate (84 mg, 0.25 mmol) gave 43c as a white solid (23 mg, 20 % yield). m.p. 
98-&>Į@24D = -16 (c 1, MeOH);  IR (KBr): v = 3414, 3058, 2953, 1710, 748 cm-
1
. 
1H NMR (400 MHz, acetone-d6): į = 3.27 (dd, J = 15, 8 Hz, 1H, CHAHB), 3.42 
(dd, J = 15, 5 Hz, 1H, CHAHB), 4.20 (t, J = 8 Hz, 1H, Fmoc CH), 4.31 (m, 2H, 
Fmoc CH2P+Į-H), 6.73 (d, J = 8 Hz, 1H, NH), 7.12 (dd, J = 8, 2 Hz, 
1H, arom. H), 7.27- 7.42 (m, 6H, arom. H), 7.66 (dd, J = 8, 4 Hz, 2H, arom. H), 
7.71 (m, 1H, arom. H), 7.85 (d, J = 8 Hz, 2H, arom. H), 10.31 (br, 1H, NH) ppm. 
13C NMR (100 MHz, acetone-d6): į = 27.17 (CH2), 47.07 (CH), 54.65 (CH), 66.32 
(CH2), 100.30, 112.69, 117.84, 119.87, 119.88, 121.36, 124.19, 125.24, 125.31, 
127.05, 127.60, 128.95, 134.93, 141.15, 141.17, 144.11, 144.14, 155.95, 172.65 
ppm. MS: m/z (+ESI) calcd for C26H22ClN2O4 461.1268, found 461.1317 [MH+]. 
N-[(fluoren-9-ylmethoxy)carbonyl]-6-fluoro-tryptophan, (43d) 
N
H
NHFmoc
OHO
F
43d
 
Procedure as described in the general procedure using 56d (90 mg, 0.35 mmol), 
sodium carbonate (74 mg, 0.70 mmol) and 9-fluorenylmethyl succinimidyl 
carbonate (117 mg, 0.35 mmol) gave 43d as a white solid (77 mg, 50 % yield). m.p. 
102-&>Į@24D = -19 (c 1, MeOH);  IR (KBr): v =3419, 3064, 2952, 1710, 745 
cm-1. 1H NMR (400 MHz, acetone-d6): į = 3.26 (dd, J = 14, 8 Hz, 1H, CHAHB), 
3.41 (dd, J = 14, 5 Hz, 1H, CHAHB), 4.20 (t, J = 8 Hz, 1H, Fmoc CH), 4.31 (m, 2H, 
Fmoc CH2P+Į-H), 6.68 (d, J = 8 Hz, NH), 6.89 (td, J = 10, 2 Hz, 1H, 
arom. H), 7.15 (dd, J = 10, 2 Hz, 1H, arom. H), 7.27 (s, 1H, C-2H), 7.30 (m, 2H, 
arom.H), 7.41 (t, J = 7 Hz, 2H, arom. H), 7.66 (m, 3H, arom. H), 7.85 (d, J = 8 Hz, 
2H, arom. H), 10.19 (br, 1H, NH) ppm. 13C NMR (100 MHz, acetone-d6): į = 
27.41 (CH2), 47.08 (CH), 54.74 (CH), 66.30 (CH2), 97.33 (d, J = 26 Hz), 107.22 (d, 
J = 25 Hz), 110.63, 119.89, 119.35 (d, J = 10 Hz), 124.16(d, J = 3 Hz), 124.56, 
125.26, 125.29, 127.04, 127.62, 136.60 (d, J = 13 Hz), 141.18, 144.11, 144.15, 
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156.00, 159.70 (d, J = 233 Hz), 172.82 ppm. MS: m/z (+ESI) calcd for 
C26H22FN2O4 445.1564, found 445.1790 [MH+]. 
N-[(fluoren-9-ylmethoxy)carbonyl]-7-ethyl-tryptophan, (43e) 
N
H
NHFmoc
OHO
43e
 
Procedure as described in the general procedure using 56e (102 mg, 0.38 mmol), 
sodium carbonate (80 mg, 0.76 mmol) and 9-fluorenylmethyl succinimidyl 
carbonate (128 mg, 0.38 mmol) gave 43e as a white solid (83 mg, 50 % yield). m.p. 
146-148 &>Į@24D = -26 (c 1, MeOH);  IR (KBr): v = 3422, 3057, 2964, 1711, 746 
cm-1. 1H NMR (400 MHz, acetone-d6): į = 1.31 (t, J = 8 Hz, 3H, CH2CH3), 2.91 (q, 
J = 8 Hz, 2H, CH2CH3), 3.27 (dd, J = 15, 8 Hz, 1H, CHAHB), 3.43 (dd, J = 15, 5 Hz, 
1H, CHAHB), 4.20 (t, J = 7 Hz, 1H, Fmoc CH), 4.29 (m, 2H, Fmoc CH2), 4.66 (m, 
+Į-H), 6.65 (d, J = 8 Hz, 1H, NH), 7.01 (m, 2H, arom. H), 7.27 (s, 1H, C-2H), 
7.30 (m, 2H, arom. H), 7.40 (t, J = 7 Hz, 2H, arom. H), 7.54 (d, J = 7 Hz, 1H, arom. 
H), 7.66 (m, 2H, arom. H), 7.85 (d, J = 7 Hz, 2H, arom. H), 10.08 (br, 1H, NH) 
ppm. 13C NMR (100 MHz, acetone-d6): į = 13.72 (CH3), 23.85 (CH2), 27.62 (CH2), 
47.07 (CH), 54.79 (CH), 66.34 (CH2), 110.73, 116.16, 119.26, 119.88, 120.13, 
123.19, 125.29, 125.33, 126.87, 127.05, 127.61, 135.37, 141.16, 144.14, 156.01, 
172.95 ppm. MS: m/z (+ESI) calcd for C28H27N2O4 455.1971, found 455.2142 
[MH+]. 
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N-[(fluoren-9-ylmethoxy)carbonyl]-5-methyl-tryptophan, (43f) 
N
H
NHFmoc
OHO
43f
 
Procedure as described in the general procedure using 56f (48 mg, 0.19 mmol), 
sodium carbonate (40 mg, 0.38 mmol) and 9-fluorenylmethyl succinimidyl 
carbonate (64 mg, 0.19 mmol) gave 43f as a colourless film (55 mg, 66 % yield). 
PS&  >Į@24D = -15 (c 1, MeOH);  IR (KBr): v = 3424, 3038, 2920, 1708, 
1448 cm-1. 1H NMR (400 MHz, acetone-d6): į = 2.42 (s, 3H, CH3), 3.25 (dd, J = 15, 
8 Hz, 1H, CHAHB), 3.43 (dd, J = 15, 5 Hz, 1H, CHAHB), 4.20 (t, J = 7 Hz, 1H, 
Fmoc CH), 4.29 (m, 2H, Fmoc CH2P+ Į-H), 6.65 (d, J = 8 Hz, 1H, 
NH), 6.97 (dd, J = 8, 1 Hz, 1H, arom. H), 7.23 (d, J = 2 Hz, 1H, arom. H), 7.28 (s, 
1H, C-2H), 7.30 (m, 2H, arom. H), 7.40 (t, J = 7 Hz, 2H, arom. H), 7.48 (s, 1H, 
arom. H), 7.66 (d, J = 7 Hz, 2H, arom. H), 7.85 (d, J = 7 Hz, 2H, arom. H), 9.97 (br, 
1H, NH) ppm. 13C NMR (100 MHz, acetone-d6): į = 20.88 (CH3), 27.47 (CH2), 
47.08 (CH), 54.80 (CH), 66.34 (CH2), 109.75, 111.11, 117.98, 119.89, 122.99, 
123.69, 125.27, 127.06, 127.59, 127.62, 128.03, 135.13, 141.16, 144.14, 156.03, 
173.02 ppm. MS: m/z (+ESI) calcd for C27H25N2O4 441.1814, found 441.2083 
[MH+]. 
N-[(fluoren-9-ylmethoxy)carbonyl]-5-methoxyl-tryptophan, (43g) 
N
H
NHFmoc
OHO
H3CO
43g
 
Procedure as described in the general procedure using 56g (300 mg, 1.28 mmol), 
sodium carbonate (271 mg, 2.56 mmol) and 9-fluorenylmethyl succinimidyl 
carbonate (431 mg, 1.28 mmol) gave 43g as a white powder (479 mg, 82 % yield). 
PS&  >Į@24D = -23 (c 1, MeOH);  IR (KBr): v = 3415, 2949, 1703, 1493, 
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1218 cm-1. 1H NMR (400 MHz, acetone-d6): į = 3.25 (dd, J = 15, 8 Hz, 1H, 
CHAHB), 3.39 (dd, J = 15, 5 Hz, 1H, CHAHB), 3.82 (s, 3H, OCH3), 4.20 (t, J = 7 Hz, 
1H, Fmoc CH), 4.29 (m, 2H, Fmoc CH2P+Į-H), 6.63 (d, J = 8 Hz, 1H, 
NH), 6.79 (dd, J = 8, 1 Hz, 1H, arom. H), 7.21 (m, 1H, arom. H), 7.30 (m, 4H, 
arom. H), 7.40 (t, J = 7 Hz, 2H, arom. H), 7.66 (d, J = 7 Hz, 2H, arom. H), 7.85 (d, 
J = 7 Hz, 2H, arom. H), 9.96 (br, 1H, NH) ppm. 13C NMR (100 MHz, acetone-d6): 
į = 27.45 (CH2), 47.07 (CH), 54.65 (CH), 54.97 (OCH3), 66.32 (CH2), 100.18, 
110.01, 111.60, 111.92, 119.87, 124.06, 125.28, 125.32, 127.05, 127.60, 128.14, 
131.66, 141.15, 144.12, 144.15, 153.98, 155.93, 172.83 ppm. MS: m/z (+ESI) 
calcd for C27H25N2O5 457.1763, found 457.1913 [MH+]. 
N-[(fluoren-9-ylmethoxy)carbonyl]-4-methoxyl-tryptophan, (43h) 
N
H
NHFmoc
OHO
OCH3
43h
 
Procedure as described in the general procedure using 56h (38 mg, 0.14 mmol), 
sodium carbonate (29 mg, 0.28 mmol) and 9-fluorenylmethyl succinimidyl 
carbonate (47 mg, 0.14 mmol) gave 43h as a white powder (39 mg, 62 % yield). 
m.p. 168 & >Į@24D = -27 (c 1, MeOH);  IR (KBr): v = 3415, 2949, 1703, 1494, 
1218 cm-1. 1H NMR (400 MHz, acetone-d6): į = 3.26 (dd, J = 15, 8 Hz, 1H, 
CHAHB), 3.41 (dd, J = 15, 5 Hz, 1H, CHAHB), 3.82 (s, 3H, OCH3), 4.20 (t, J = 7 Hz, 
1H, Fmoc CH), 4.29 (m, 2H, Fmoc CH2P+Į-H), 6.59 (d, J = 8 Hz, 1H, 
NH), 6.56 (dd, J = 8, 1 Hz, 1H, arom. H), 7.25 (m, 1H, arom. H), 7.26 (m, 4H, 
arom. H), 7.41 (t, J = 7 Hz, 2H, arom. H), 7.66 (d, J = 7 Hz, 2H, arom. H), 7.85 (d, 
J = 7 Hz, 2H, arom. H), 9.96 (br, 1H, NH) ppm. 13C NMR (100 MHz, acetone-d6): 
į = 27.45 (CH2), 47.07 (CH), 54.63 (CH), 54.95 (OCH3), 66.33 (CH2), 99.76, 
110.11, 111.65, 116.20, 119.85, 121.34, 123.41, 125.26, 125.29, 127.06, 127.61, 
137.94, 141.15, 144.12, 144.15, 154.98, 156.02, 172.83 ppm. MS: m/z (+ESI) 
calcd for C27H25N2O5 457.1763, found 457.1781 [MH+]. 
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N-[(fluoren-9-ylmethoxy)carbonyl]-1-methyl-tryptophan, (43i) 
N
NHFmoc
OHO
CH3
43i
 
Procedure as described in the general procedure using 56i (300 mg, 1.37 mmol), 
sodium carbonate (290 mg, 2.75 mmol) and 9-fluorenylmethyl succinimidyl 
carbonate (461 mg, 1.37 mmol) gave 43i as a white powder (447 mg, 74 % yield). 
m.p. 92-& >Į@24D = -24 (c 1, MeOH);  IR (KBr): v = 3416, 3058, 2937, 1708, 
741 cm-1. 1H NMR (400 MHz, DMSO-d6): į = 3.04 (dd, J = 14, 10 Hz, 1H, 
CHAHB), 3.20 (dd, J = 14, 5 Hz, 1H, CHAHB), 3.71 (s, 3H, CH3P+Į-H, 
Fmoc CH, CH2), 7.03 (t, J = 6 Hz, 1H, arom. H), 7.14 (s, 1H, C-2H), 7.14 (t, J = 8 
Hz, arom. H), 7.25- 7.43 (m, 5H, arom. H), 7.60 (d, J = 8 Hz, 1H, arom. H), 7.69 
(m, 2H, arom. H), 7.89 (d, J = 8 Hz, 2H, arom. H), 12.7 (br, 1H, NH) ppm. 13C 
NMR (100 MHz, DMSO-d6): į = 27.25 (CH2), 32.75 (CH), 40.05 (CH3), 55.47 
(CH), 66.12 (CH2), 110.06, 118.89, 118.98, 120.57, 121.52, 125.76, 127.51, 127.93, 
128.09, 128.47, 137.01, 141.15, 144.24, 156.46, 174.11 ppm. MS: m/z (+ESI) calcd 
for C27H25N2O4 441.1814, found 441.1994 [MH+]. 
N-[(fluoren-9-ylmethoxy)carbonyl]-2-methyl-tryptophan, (43j) 
N
H
NHFmoc
OHO
43j
 
Procedure as described in the general procedure using 56j (68 mg, 0.31 mmol), 
sodium carbonate (65 mg, 0.62 mmol) and 9-fluorenylmethyl succinimidyl 
carbonate (104 mg, 0.31 mmol) gave 43j as a white solid (53 mg, 40 % yield). m.p. 
182-&>Į@24D = -15 (c 1, MeOH);  IR (KBr): v =3412, 3057, 2924, 1712, 743 
cm-1. 1H NMR (400 MHz, acetone-d6): į =  2.43 (s, 3H, CH3), 3.26 (dd, J = 14, 7 
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Hz, 1H, CHAHB), 3.37 (dd, J = 14, 6 Hz, 1H, CHAHB), 4.19 (t, J = 8 Hz, 1H, Fmoc 
CH), 4.29 (d, J = 8 Hz, 2H, Fmoc CH2P+Į-H), 6.57 (d, J = 8 Hz, NH), 
7.03 (m, 2H, arom. H), 7.30 (m, 3H, arom. H), 7.40 (t, J = 7 Hz, 2H, arom. H), 7.62 
(d, J = 7 Hz, 1H, arom. H), 7.67 (m, 2H, arom. H), 7.85 (d, J = 8 Hz, 2H, arom. H), 
9.91 (br, 1H, NH) ppm. 13C NMR (100 MHz, acetone-d6): į = 10.88 (CH3), 26.88 
(CH2), 47.06 (CH), 54.92 (CH), 66.39 (CH2), 106.11, 110.35, 117.68, 118.71, 
119.89, 120.41, 125.32, 125.33, 127.06, 127.62, 129.02, 133.31, 135.81, 141.17, 
144.10, 144.19, 155.92, 172.97 ppm. MS: m/z (+ESI) calcd for C27H25N2O4 
441.1814, found 441.2033 [MH+]. 
6.3 Experimental for Chapter 3 
6.3.1   Synthesis of (R)-Ala-Thz-OH 
(R)-tert-Butyl 1-amino-1-oxopropan-2-ylcarbamate, (57) 
O
H
N
O
NH2
O
57
 
DCC (6.57 g, 31.9 mmol) was added to a suspension of Boc-(R)-alanine (5.03 g, 
26.6 mmol) and 1-hydroxybenzotriazole (4.3 g, 31.9 mmol) in CH2Cl2 (80 mL) at 
0°C. The solution was warmed to room temperature and stirred for 1 h. The 
solution was cooled to 0 °C again and 0.5 M ammonia in dioxane (69 mL) was 
added into the solution, The reaction mixture was warmed to room temperature, 
stirred for 1 h and then filtered. The mother liquor was concentrated and purified 
by column chromatography (CHCl3/ MeOH, 96:4) to give the amide 57 as a white 
solid (4.81 g, 96 % yield); m.p. 100-104 °C (ref.309 m.p. 120-121 °C); Rf  = 0.25 
(CHCl3/ MeOH, 96:4). IR (KBr): v = 3390, 3353, 3200, 1682, 1644, 1522, 1325, 
1251, 1167 cm-1. 1H NMR (400 MHz, CDCl3): į = 1.37 (d, J = 7 Hz, 3H, CHCH3), 
1.43 (s, 9H, C(CH3)3), 4.23 (br, 1H, CHCH3), 5.29 EU+Į-NH), 6.07 (br, 1H, 
NHAHB), 6.56 (br, 1H, NHAHB) ppm. 13C NMR (100 MHz, CDCl3): į = 18.45 
(CHCH3), 28.31 (C(CH3)), 49.71 (CHCH3), 80.14 (C(CH3)), 155.62 (CO), 176.03 
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(CO) ppm. MS: m/z (+ESI) calcd for C8H16N2O3Na+ 211.1161, found 
211.1191[MNa+]. 
tert-Butyl -(R)-(1-thiocarbamoylethyl)carbamate, (58) 
O
H
N
O
NH2
S
58
 
Lawesson’s reagent (3.1 g, 7.6 mmol) was added to a solution of the amide 57 (2.4 
g, 12.7 mmol) in THF (50 mL) cooled at 0 °C. The mixture was stirred at room 
temperature for 40 min. The solution was poured into a separating funnel which 
contains ice (50 mL) and saturated aqueous NaHCO3 (50 mL), and the mixture was 
extracted with Et2O (50 mL × 3). The organic layers were combined, washed with 
brine (100 mL), dried with MgSO4 and concentrated. The residue was purified by 
column chromatography (n-hexane/EtOAc) to give 58 as a white solid (1.71 g, 66 
% yield); m.p. 64- 66 °C (ref.150 m.p. 104- 105 °C); Rf = 0.30 (n-hexane/EtOAc, 
3:2). IR (KBr): v = 3378, 3288, 3181, 1675, 1523, 1241, 1158 cm-1. 1H NMR (400 
MHz, CDCl3): į = 1.44 (s, 9H, C(CH3)3), 1.47 (d, J = 7 Hz, 3H, CHCH3), 4.58 (br, 
1H, CHCH3EU+Į-NH), 7.85 (br, 1H, NHAHB), 8.23 (br, 1H, NHAHB) 
ppm. 13C NMR (100 MHz, CDCl3): į = 21.73 (CHCH3), 28.34 (C(CH3)), 55.14 
(CHCH3), 80.56 (C(CH3)), 155.57 (CO), 210.58 (CS) ppm. 
Ethyl-2-(1-(tert-butoxycaronylamino)ethyl)-4-hydroxy-4,5-dihydrothiazole-4-
carboxylate, (138) 
O
H
N
O
N
S
COOEt
OH
138
 
Thioamide 58 (100 mg, 0.5 mmol) was dissolved in DME (5mL). After stirring 
vigorously for 10 min at -15 °C, the ground KHCO3 (400 mg, 4 mmol) fine powder 
was added to a suspension solution. The mixture was stirred for 30 min and then 
ethyl bromopyruvate (0.2 mL, 1.5 mmol) was added. The solution was poured into 
water (10 mL) and was extracted with Et2O (10 mL × 3). The combined dry with 
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MgSO4 and concentrated. The residue was purified by column chromatography (n-
hexane/EtOAc, 1:1) to give hydroxythiazoline 138 as a colourless oil (60 mg, 38 % 
yield), Rf  = 0.10 (n-hexane/EtOAc, 3:1). 1H NMR (400 MHz, CDCl3, isomer ratio 
= 1:1,  the asterisk denotes isomer peak): į =1.33 and 1.34* (t, J = 7 Hz, 3H, 
OCH2CH3), 1.46 (d, J = 7 Hz, 3H, CHCH3) 1.47 (s, 9H, C(CH3)3), 3.41 (d, J = 12 
Hz, SCHAHB), 3.87 (d, J = 12 Hz, SCHAHB), 4.31 and 4.32* (q, J = 7.2 Hz, 2H, 
OCH2CH3), 4.63 (br, 1H, CHCH3EU+Į-NH) ppm. 13C NMR (100 MHz, 
CDCl3): į = 14.04 (CH2CH3), 20.24 and 20.61* (CHCH3), 28.23 and 28.31* 
(C(CH3)3), 40.8 (C5-+  DQG  Į-CH), 62.90 and 62.99* (CH2CH3), 
79.92 (C(CH3)3), 105.35 (C-OH), 154.83 (C=O), 170.71 (C=O), 179.90 (C=N) 
pp m. 
Ethyl (R)-2-(1-tert-butoxycarbonylaminoethyl)thiazole-4-carboxylate, (59) 
O
H
N
O
N
S
OEt
O
59
 
Thioamide 58 (500 mg, 2.45 mmol) was dissolved in DME (12 mL). After stirring 
vigorously at -15 °C for 10 min, finely ground KHCO3 (1.96 g, 19.6 mmol) was 
added to a suspension solution. The mixture was stirred for 30 min and ethyl 
bromopyruvate (0.2 mL, 1.5 mmol) was added. After 5 min, the solution of 2,6-
lutidine (2.43 mL, 20.8 mmol) and trifluoroacetic anhydride (1.37 mL, 9.8 mmol) 
in DME (2 mL) was added at -15 °C. After stirring at -15 °C for 1 h, the mixture 
was poured into water (20 mL) and extracted with Et2O (10 mL × 3). The organic 
layers were combined, dried (MgSO4) and concentrated. The residue was purified 
by column chromatography (n-hexane/EtOAc, 4:1) to give thiazole 59 as a light 
yellow solid (361 mg, 49 % yield), m.p. 80-82 °C (ref.150 85-86 °C); Rf  = 0.5 (n-
KH[DQH(W2$F>Į@D21 = +32 (c =1.0, CHCl3). IR (KBr): v = 3368, 3114, 1717, 
1687, 1494, 1229, 1059 cm-1. 1H NMR (400 MHz, CDCl3): į = 1.40 (t, J = 7 Hz, 
3H, CH2CH3), 1.44 (s, 9H, C(CH3)3), 1.62 (d, J = 6.4 Hz, 3H, CHCH3), 4.40 (q, J = 
7 Hz, 2H, CH2CH3EUV+Į-&+EUV+Į-NH), 8.08 (s, 1H, 
C5H) ppm. 13C NMR (100 MHz, CDCl3): į = 14.36 (CH2CH3), 21.79 (CHCH3), 
28.31 (C(CH3)3Į-CH), 61.43 (CH2CH3), 80.25 (C(CH3)3), 127.14 (C5-H), 
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147.21 (C=C), 154.88 (C=O), 161.35 (C=O), 174.90 (C=N) ppm. MS: m/z (+ESI) 
calcd for C13H20N2O4SNa+ 323.1144, found 323.0970 [MNa+]. 
(R)-2-(1-tert-Butoxycarbonylaminoethyl)thiazole-4-carboxylic acid, (44) 
O
H
N
O
N
S
OH
O
44
 
Boc-(R)-Ala-Thz-OEt (59) (1.24 g, 4.1 mmol) was dissolved in solution of THF/ 
MeOH/ H2O 9:6:6 mL. Lithium hydroxide (118 mg, 4.9 mmol) in water (2 mL) 
was added at 0 °C. The mixture was warmed to room temperature and stirred 
overnight. The solvent was removed in vacuo. The residue was dissolved in H2O 
(40 mL) and extracted with EtOAc (20 mL × 2). The aqueous layer was acidified 
with saturated aqueous KHSO4 to pH = 2 and extracted with DCM (40 mL × 3). 
The organic layers were washed with brine, dried and concentrated. The residue 
was recrystallised with DCM/ Hexane to give the carboxylic acid 44 as a pale 
yellow solid (986 mg, 88 % yield), m.p. 58-61 °C; >Į@D26 = + 31 (c = 1.0, CHCl3). 
IR (Solid): v = 3362, 3105, 2979, 1692, 1517, 1366, 1242, 1058 cm-1. 1H NMR 
(400 MHz, CDCl3): į = 1.47 (s, 9H, C(CH3)3), 1.66 (d, J = 6 Hz, 3H, CHCH3), 5.10 
EUV+Į-&+EUV+Į-NH), 8.23 (s, 1H, C5H) ppm. 13C NMR (100 
MHz, CDCl3): 21.7 (CH3), 28.4 (C(CH3)3  Į-CH), 80.2 (C(CH3)3), 128.7 
(C5-H), 146.6 (C=C), 155.0 (C=O), 164.1 (C=O), 171.4 (C=N) ppm. MS: m/z 
(+ESI) calcd for C11H17N2O4SNa+ 295.0562, found 295.0352 [MNa+]. 
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Ethyl-2-((R)-1-((S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanamido)ethyl)-
thiazole-4-carboxylate, (R,S)-145 
Ethyl-2-((S)-1-((S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanamido)ethyl)-
thiazole-4-carboxylate, (S,S)-145 
CF3H3CO
O
H
N N
S O
O
CF3H3CO
O
H
N N
S O
O
(R,S)-145 (S,S)-145
 
Recemic Boc-(R)-Ala-Thz-OEt (59) (20 mg, 0.06 mmol) was treated with 
TFA/DCM (1 mL/ 1 mL). The reaction mixture was stirred at room temperature for 
1 h. The solvent was removed in vacuo. The residue oil was treated with (R)-(í-Į-
Methoxy-Į-WULIOXRURPHWK\OSKHQ\ODFHW\O FKORULGH  ȝ/  PPRO DQG
',3($ȝ/ PPRO LQ'&0P/ and was stirred at room temperature 
for 1 h. The solvent was removed in vacuo to give the Mosher’s derivatives (R,S)-
145 and (R,R)-145 as colourless oils (27 mg, 96 % yield).  
(R,S)-145: 1H NMR (400 MHz, CDCl3): į = 1.41 (t, J = 7 Hz, 3H, OCH2CH3), 1.75 
(d, J  +]+ Į-CH3), 3.41 (t, J = 1 Hz, 3H, OCH3), 4.43 (q, J = 7 Hz, 3H, 
OCH2CH3), 5.49 (td, J  +]+Į-H ),  7.38-7.53 (m, 5 H, arom. H), 8.09 (s, 
1H, C-5H) ppm. 19F NMR (375 MHz, CDCl3): į = - 68.94 ppm. 
(R,R)-145: 1H NMR (400 MHz, CDCl3): į = 1.41 (t, J = 7 Hz, 3H, OCH2CH3), 1.69 
(d, J  +]+ Į-CH3), 3.47 (t, J = 1 Hz, 3H, OCH3), 4.42 (q, J = 7 Hz, 3H, 
OCH2CH3), 5.49 (td, J  +]+Į-H),  7.38-7.53 (m, 5 H, arom. H), 8.13 (s, 
1H, C-5H) ppm. 19F NMR (375 MHz, CDCl3): į = - 68.57 ppm. 
 
 
 
 
 
Chapter 6 Experimental 
-230- 
 
6.3.2   Synthesis of (R)-Ala-oxazole-OH 
(S)-Ethyl 2-((R)-2-(tert-butoxycarbonylamino)propanamido)-3-
hydropropanoate, (148)   
O
H
N
O
N
H
O
OEt
O
HO
148
 
Boc-(R)-Alanine (1.23 g, 6.5 mmol) and serine ethyl ester hydrochloride were 
dissolved in CH2Cl2 (15 mL). N,N-diisopropylethylamine (1.70 mL, 9.7 mmol) was 
added into the solution and cooled to 0 °C. Then hydroxybenzotriazole (0.878 g, 
6.5 mmol) and N,N'-dicyclohexylcarbodiimide (1.34 g, 6.5 mmol) were added. The 
reaction mixture was warmed to room temperature and stirred for 2 h. The solution 
was partitioned with 0.1 N HCl (10 mL) and CH2Cl2 (10 mL × 3). The organic 
layer was washed with saturated NaHCO3 (10 mL), dried (MgSO4) and 
concentrated. The residue was purified by column chromatography (CHCl3/MeOH, 
96:4) to give Boc-(R)-Ala-Ser-OEt (148) as a white solid (1.37 g, 69 % yield); m.p. 
86-87 °C; Rf  = 0.25 (CHCl3/MeOH, 96:4). IR (KBr): v = 3510, 3363, 3263, 1706, 
1678, 1530, 1327 cm-1. 1H NMR (400 MHz, CDCl3): į = 1.30 (t, J = 7 Hz, 3H, 
CH2CH3), 1.40 (d, J = 7 Hz, 3H, CHCH3), 1.45 (s, 9H, C(CH3)3), 2.82 (t, J = 6 Hz, 
1H, OH), 3.96 (br, 1H, CHAHBOH), 4.04 (br, 1H, CHAHBOH), 4.18 (t, J = 6 Hz, 
1H, CHCH2), 4.26 (q, J = 7 Hz, 2H, CH2CH3), 4.61 (br, 1H, CHCH3), 5.04 (d, J =  
4 Hz, 1H, NH), 7.08 (d, J = 4 Hz, 1H, NH). 13C NMR (100 MHz, CDCl3 į  
14.10 (CH2CH3), 18.23 (CHCH3), 28.28 (C(CH3  Į-C+  Į-CH), 
61.80 (OCH2), 62.70 (OCH2), 80.48 (C(CH3)), 155.81 (CO), 170.38 (CO), 172.92 
(CO) ppm. MS: m/z (+ESI) calcd for C13H24N2O6Na+ 305.0634, found 305.0638 
[MNa+]. 
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Ethyl 2-((R)-1-(tert-butoxycarbonylamino)ethyl)-4,5-dihydrooxazole-4-
carboxylate, (149) 
O
H
N
O
N
O
OEt
O
149
 
Burgess reagent (methoxycarbonylsulphamoyl-triethylammoniumm hydroxide) 
was added to a solution of Boc-(R)-Ala-Ser-OEt (148) (200 mg, 0.66 mmol) in dry 
THF (5 mL) in 7 mL microwave tube. The tube was capped; the mixture was 
stirred for 10 min and was microwaved (100 W) for 30 min at 70 °C under 250 psi 
pressure. The solution was allowed to cool to room temperature. The pale yellow 
solution was concentrated and purified  by column chromatography (n-
Hexane/EtOAc, 2:3) to give Boc-(R)-Ala-dehydrooxazole 149 as a yellow oil (145 
mg, 77 % yield), Rf = 0.5 (n-Hexane/EtOAc, 2:3).  1H NMR (400 MHz, CDCl3): į 
= 1.32 (t, J = 7 Hz, 3H, OCH2CH3), 1.41 (d, J = 7 Hz, 3H, CHCH3), 1.45 (s, 9H, 
C(CH3)3), 4.25 (q, J = 7 Hz, 2H, OCH2CH3), 4.47 (br, 1H, CHCH3), 4.48 (t, J = 8 
Hz, 1H, OCHAHB), 4.57 (t, J = 8 Hz, 1H, OCHAHB), 4.74 (dd, J = 4, 8 Hz, 1H, 
NCH), 5.21 (br, 1H, NH). 13C NMR (100 MHz, CDCl3, isomer ratio = 1:1, the 
DVWHULVNGHQRWHVLVRPHUSHDNį= 14.12 (OCH2CH3), 19.57 and 19.63* (CHCH3), 
28.31 (C(CH3)), 44.78 (CHCH3), 61.76 (OCH2CH3), 67.98 (NCH), 70.21 (CH2CH), 
79.73 (C(CH3)), 154.89 (CO), 170.8 (CO), 170.78 (CN) ppm. 
(R)-Ethyl 2-(1-(tert-butoxycarbonylamino)ethyl)oxazole-4-carboxylate, (150)  
O
H
N
O
N
O
OEt
O
150
 
tert-Butyl perbenzoate (74.6 µL, 0.65 mmol) was added dropwise to a boiling 
solution, which is a mixture  of the Boc-(R)-Ala-dehydrooxazole (149) and CuBr 
(74.6 mg, 0.52 mmol) in benzene (4 mL) over 1 h. The solution was further 
refluxed for 1 h. Then the reaction mixture was poured into saturated aqueous 
NaHCO3 (10 mL) and extracted with ether (10 mL × 2), dried with MgSO4 and 
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concentrated. The residue oil was purified by column chromatography (n-
Hexane/EtOAc, 7:3) to give oxazole 150 as a colourless oil (86 mg, 72 % yield), Rf 
= 0.4 (n-Hexane/EtOAc, 7:3>Į@D21 = + 13 (c = 1.0, CHCl3). IR (KBr): v =3346, 
3016, 1716, 1683, 1523, 1110, 1063 cm-1. 1H NMR (400 MHz, CDCl3): į = 1.39 (t, 
J = 7 Hz, 3H, CH2CH3), 1.46 (s, 9H, C(CH3)3), 1.60 (d, J = 7.2 Hz, 3H, CHCH3), 
4.41 (q, J = 7 Hz, 2H, CH2CH3), 5.03 (br, 1H, CHCH3), 5.23 (br, 1H, NH), 8.18 (s, 
1H, C=CH). 13C NMR (100 MHz, CDCl3): į = 14.32 (OCH2CH3), 20.25 (CHCH3), 
28.30 (C(CH3)), 44.80 (CHCH3),  61.30 (OCH2CH3), 80.17 (C(CH3)), 133.48 
(C=CH), 143.86 (C=CH), 161.14 (CO), 165.87 (CO) ppm. MS: m/z (+ESI) calcd 
for C13H20N2O5Na+ 307.1372, found 307.1220 [MNa+]. 
Ethyl-2-((R)-1-((S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanamido)ethyl)-
oxazole-4-carboxylate, (R,S)-155 
Ethyl-2-((S)-1-((S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanamido)ethyl)-
oxazole-4-carboxylate, (S,S)-155 
CF3H3CO
O
H
N N
O O
O
CF3H3CO
O
H
N N
O O
O
(R,S)-155 (S,S)-155
 
Boc-Ala-oxazole-OEt (150) (4 mg, 0.014 mmol) was treated with TFA/DCM (1 
mL/ 1mL). The reaction mixture was stirred at room temperature for 1 h. The 
solvent was removed in vacao. The residue oil was treated with (R)-(í-Į-
Methoxy-Į-(trifluoromethyl)phenylacetyl FKORULGH  ȝ/  PPRO DQG
',3($ȝ/PPROLQ'&0P/DQGZDVVWLUUHGDWURRPWHPSHUDWXUH
for 1 h. The solvent was removed in vacao to give the Mosher’s derivatives (R,S)-
155 and (S,S)-155 as a colourless oil (5 mg, 90 % yield). 1H NMR (400 MHz, 
CDCl3, isomer ratio = 2:1, the asterisk denotes isomer peak ): į = 1.39 and 1.40* (t, 
J = 7 Hz, 3H, OCH2CH3), 1.61* and 1.67 (d, J  +]+Į-CH3), 3.93* and 3.48 
(t, J = 1 Hz, 3H, OCH3), 4.42 (q, J = 7 Hz, 3H, OCH2CH3P+Į-H ), 
7.41-7.45 (m, 5 H, arom. H), 8.17* and 8.20(s, 1H, C-5H) ppm. 19F NMR (375 
MHz, CDCl3): į= -68.99 and -68.74* ppm. 
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6.3.3   Synthesis of N-Fmoc-phenylselenocysteine 
N-(tert-Butoxycarbonyl)-(S)-VHULQHȕ-lactone, (64)  
O
H
N
O
O
O
64
 
Two-Neck round-bottom flask was equipped with a stir bar, nitrogen bubbler and a 
rubber septum. The flask was charged with dry THF (8 mL) and 
triphenylphosphine (257 mg, 0.98 mmol). The triphenylphosphine was dissolved 
by stirring and was cooled to -78 °C. Diethyl D]RGLFDUER[\ODWHȝ/PPRO
was added to the solution. The result pale solution was stirred at -78 °C for 10 min. 
The rubber septum was quickly replaced by a dropping funnel containing a solution 
of Boc-(S)-serine (200 mg, 0.98 mmol) in THF (2 mL) which was further added 
dropwise to the mixture over more than 30 min. After completion of addition, the 
mixture was stirred at -78 °C for 20 min. The cooling bath was removed, and the 
mixture was slowly warmed to room temperature over 2.5 h, then concentrated. 
The yellow residual oil was suspended in n-hexane/EtOAc (1:1, 20 mL) and 
filtered. The filtrate was concentrated and further purified by column 
chromatography (n-hexane/EtOAc, 7:3) to give 64 as a white solid (76 mg, 42 % 
yield). Rf = 0.25 (n-Hexane/EtOAc, 7:3>Į@D23 = -17 (c 1.0, CHCl3). IR (KBr): v = 
3358, 3011, 2977, 1842, 1680, 1531, 1289 cm-1. 1H NMR (400 MHz, CDCl3į = 
1.45 (s, 9H, C(CH3)3), 4.43 (br, 2H, CH2), 5.09 (br, 1H, NCH), 5.58 (d, J = 8 Hz, 
1H, NH) ppm. 13C NMR (100 MHz, CDCl3): į = 28.18 (C(CH3)), 59.44 (CH), 
66.55 (CH2), 81.30 (C(CH3)), 154.66 (CO), 169.71 (CO) ppm. 
N-(tert-Butoxycarbonyl)-(R)-phenylselenocysteine, (65) 
O
H
N
O
OH
O
SePh
65
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Sodium trimethylborohydride (358 mg, 2.8 mmol) was added to a solution of 
diphenyl diselenide (437 mg, 1.4 mmol) in dry ethanol (12 mL) at room 
temperature under nitrogen. The resulting yellow solution was stirred for 30 min 
WKHQ D VROXWLRQ RI ȕ-lactone (64) (374 mg, 2 mmol) in dry ethanol (5 mL) was 
added. The reaction mixture was stirred for 2 h and concentrated. The residue was 
partitioned between saturated NaHCO3 (20 mL) and Et2O (20 mL). The aqueous 
layer was washed by Et2O (5 mL × 2) to remove excess diphenyl diselenide. The 
aqueous layer was acidified with 3M aqueous HCl to pH = 2, extracted with EtOAc 
(20 mL × 3). The organic layers were combined, washed with brine, dried (MgSO4) 
and concentrated to give 65 as a white solid (685 mg, 99 % yield). m.p. 87-90 °C 
(ref.150 m.p. 94-95 °C); Rf  = 0.4 (CHCl3/MeOH, 9:1 with 1 drop AcOH). >Į@D23 = -
34 (c = 1.0, MeOH). 1H NMR (400 MHz, CDCl3): į = 1.43 (s, 9H, C(CH3)3), 3.38 
(br, 2H, CH2EU+Į-CH), 5.37 (br, 1H, NH), 7.28 (br, 3H, arom. CH), 
7.57 (br, 2H, arom. CH) ppm. 13C NMR (100 MHz, CDCl3): į = 28.27 (C(CH3)), 
30.16 (CH2Į-CH), 80.43 (C(CH3)), 127.61 (arom. CH), 129.02 (arom. C), 
133.62 (arom. CH), 155.27 (CO), 175.43 (CO) ppm. MS: m/z (+ESI) calcd for 
C14H19NNaO4Se+ 368.0377, found  368.0130 [MNa+]. 
(R)-ȕ-Phenylselenocysteine, (66) 
H2N OH
O
SePh
66
 
Trifluroroacetic acid (15 mL) was added dropwise to a solution of Boc-
phenyselenocycsteine (65) (3.65 g, 10.6 mmol) in CH2Cl2 (15 mL) at room 
temperature. The reaction mixture was stirred for 1 h and concentrated. The white 
solid was wash with n-hexane to give 66 trifluoroacetate salt as a white solid (3.7 g, 
97 % yield). m.p. 166-170 °C. 1H NMR (400 MHz, MeOD): į = 3.11 (dd, J = 16, 4 
Hz, 1H, CHAHB), 3.29 (dd, J = 16, 4 Hz, 1H, CHAHB), 3.91 (dd, J  +]+Į-
H), 7.13 (m, 3H, arom. CH), 7.42 (m, 3H, arom. CH) ppm. MS: m/z (+ESI) calcd 
for C9H12NO2Se+ 246.0033, found 246.0019 [MH+]. 
 
Chapter 6 Experimental 
-235- 
 
N-(9-Fluorenylmethoxyc arbonyl)-(R)-ȕ-phenylselenocysteine, (67) 
O
O
N
H
OH
O
SePh
67
 
N-(9-Fluorenylmethyoxycarbonyloxy) succinimide (2.77 g, 8.2 mmol) was 
dissolved in THF (20 mL) and was added to a stirred solution of 
phenyselenocycsteine (66) (2.87 g, 8 mmol) and NaHCO3 (2.3 g, 28 mmol) in 
water (25 mL) over 10 min. The reaction mixture was stirred overnight at room 
temperature. The solvent was removed in vacuo. The residue was dissolved in H2O 
(40 mL), acidified with saturated aqueous KHSO4 (30 mL), extracted with ethyl 
acetate (3 × 40 mL), washed with brine, dried and concentrated. The oil residue 
was purified by column chromatography (CHCl3/MeOH, 19:1) to give Fmoc-
phenylselenocysteine (67) as a white solid (3.49 g, 93 % yield); m.p. 98-99 °C;  Rf 
= 0.5 (CHCl3/ MeOH, 9:1 + 1 % AcOH). IR (KBr): v = 3358, 3063, 1727, 1711, 
1682, 1522, 1449, 1248 and 758 cm-1. 1H NMR (400MHz, CDCl3): į = 3.37 (dd, J 
= 4, 16 Hz, 1H, CHAHB), 3.45 (dd, J = 4, 16 Hz, 1H, CHAHB), 4.20 (t, J = 8 Hz, 1H, 
OCH2CH), 4.36 (m, 2H, OCH2&+EU+Į-H), 5.58 (d, J = 8 Hz, 1H, NH), 
7.26 (m, 4H, arom. CH), 7.34 (m, 2H, arom. CH), 7.43 (m, 2H, arom. CH), 7.54 (m, 
3H, arom. CH), 7.79 (m, 2H, arom. CH) ppm. 13C NMR (100MHz, CDCl3): į = 
29.73 (SeCH2Į-CH), 53.91 (CHCH2), 67.38 (CHCH2), [120.03, 125.14, 
127.12, 127.79, 127.86, 128.58, 129.30, 133.79, 141.31, 143.66, 143.71] 
(arom.CH), 155.75 (CO), 174.93 (CO) ppm. MS: m/z (+ESI) calcd for 
C24H22NO4Se+ 468.0636 found 468.0135 [MH+]. 
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6.4 Experimental for Chapter 4 
(S)-2-Chlorotrityl[N-(fluoren-9-ylmethoxycarbonyl)methyl-amino]-acetic acid 
polystyrene, (185) 
O
O
N O
OCl
185
 
2-Chlorotrityl chloride resin (1 g, 1.2 mmol, theoretical loading 1.2 mmol g-1) was 
swollen in DCM (6 mL) for 1 h. Fmoc-sarcosine (373 mg, 1.2 mmol) and DIPEA 
 ȝ/  PPRO LQ '&0  P/ WKHQ DGGHG WR WKH UHVLQ suspension. The 
UHDFWLRQ PL[WXUHZDVJHQWO\VWLUUHGDW URRPWHPSHUDWXUH IRUK 0H2+ȝ/
was added and the suspension was stirred for another 15 min. The derivatised resin 
was collected in a Buchner funnel, washed with DMF, DCM and hexane and dried 
in vacuo to give the desired product 185 (1.363 g, Fmoc substitution 0.84 mmol g-1, 
70 %). 
An accurately weighted sample of the dry Fmoc-substituted resin (ca.1-2 mg) was 
exposed to a solution of 20 % v/v peperidine in DMF (3 mL) for 1 h, with 
occasional agitation. Te UV absorbance reading at 290 nm was taken and used in 
the Beer-Lamber’s law. 
Determination of resin substation based on the Fmoc-substitution. 
A290  İFO 
A = absorbance wavelength at 209 nm 
İ PRODUH[WLQFWLRQFRHIILFLHQWPRO-1 cm-1 for Fmoc piperidine           adduct) 
c = concentration (mol-1) 
 l = path length (1 cm) 
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6LQFH ODQG İDUHNQRZn and A can be measured, the concentration of the Fmoc-
piperidein adduct released from the resin can be determined. 
 
The theoretical loading can be calculated using the follow equation  
Theoretical loading = x /(1+( xy / 1000)) mmol g-1 
X = initial loading of resin (mmol) 
Y = molecular weight added on to resin 
The percentage efficiency of resin loading can then be evaluated from the 
following equation: 
 % loading efficiency = (actual loading / theoretical loading) x 100 
The derivatised resin 185 (1 eq.) was placed in a reaction column, swollen with 
DMF/DCM (1 mL) for 12 h, and Fmoc-deprotection was carried out on a 
continuous flow of 20 % v/v piperidein in DMF (2.8 mL min-1, 10 min) using 
NOVA SYN® GEM manual peptide synthesiser. The reaction was monitored post-
column at 355 nm. The resin was then washed with DMF (2.8 mL min-1, 5 min), 
and the peptide sequence (R)-Ala1-Thz2-Trp3-Trp4(X)–Gly5-(R)-Ala6-Ph(Se)7-Sar8-
OH was assembled manually using NOVA SYN® GEM manual peptide synthesiser. 
Standard Protocal A for linear peptide synthesis 
Sequential acylation reactions were carried out at ambient temperature for 4 h 
using appropriate NĮ-Fmoc-protected amino acids (4 eq.) [Fmoc-Ph(Se)-OH (42), 
Fmoc-(R)-Ala-OH, Fmoc-Gly-OH, Fmoc-Trp(X)-OH (43), Fmoc-Trp-OH, Boc-
(R)-Ala-Thz-OH (44)] and carboxylated-activating reagent, PyOxim (4 eq.)  or 
HATU (3.9 eq.) and DIPEA (8 eq.) in DMF (0.5 mL). Sequential Fmoc-
deprotection was achieved using 20 % v/v piperidine in DMF (2.8 mL min-1, 10 
min). 
After final acylation reaction, the peptidyl-resin was filtered, washed successively 
with DMF, DCM and hexane, and dr ied in vacuo. 
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The resin product was suspended in a mixture of water (0.025 mL), TIPS (0.025 
mL) and DCM (1 mL), followed by the addition of TFA (1 mL). The reaction 
mixture was allowed to stand at ambient temperature for 1 h. The suspension was 
filtered, washed with DCM (3 mL), and the filterate was evaporated in vacuo. 
The residual material was triturated with diethyl ether (2 mL) to result an off-white 
sold. The desired linear peptide was dissolved in water (2 mL) and lyophilized 
overnight.  
(R)-Ala1-Thz2-Trp3-Trp4-Gly5-(R)-Ala6-Ph(Se)7-Sar8-OH, (46a) 
Using Standard protocol A and the Fmoc-Trp-OH (43a) the title peptide was 
assembled as a white solid (54 mg, 56 %, yield, 90 % purity). The linear peptide 
was used di rectly in the next cyclisation step without further purification. 
RP-HPLC 1-35 % B in 10 min, tR 10.3 min. 
ES-MS m/z calcd for C45H51N10O8SSe 971.2777, found 971.2313 [MH+]. 
(R)-Ala-Thz-Trp-(5-Br)-Trp-Gly-(R)-Ala-Ph(Se)-Sar-OH, (46b)  
Using Standard protocol A and the Fmoc-(5-Br)-Trp-OH (43b) the title peptide 
was assembled as a white solid (63 mg, 60 % yield, 69 % purity). The linear 
peptide was used di rectly in the next cyclisation step without further purification. 
RP-HPLC 1-35 % B in 10 min, tR 10.6 min. 
ES-MS m/z calcd for C45H50BrN10O8SSe 1049.1882, found 1049.1888 [MH+]. 
(R)-Ala-Thz-Trp-(5-Cl)-Trp-Gly-(R)-Ala-Ph(Se)-Sar-OH, (46c) 
Using Standard protocol A and the Fmoc-(5-Cl)-Trp-OH (43c) the title peptide was 
assembled as a white solid (56 mg, 56 % yield, 86 % purity). The linear peptide 
was used di rectly in the next cyclisation step without further purification. 
RP-HPLC 1-35% B in 10 min, tR 12.1 min. 
ES-MS m/z calcd for C45H50ClN10O8SSe 1005.2388, found 1005.2287 [MH+]. 
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(R)-Ala-Thz-Trp-(5-Et)-Trp-Gly-(R)-Ala-Ph(Se)-Sar-OH, (46e)  
Using Standard protocol A and the Fmoc-(5-Et)-Trp-OH (43e) the title peptide was 
assembled as a white solid (53 mg, 54% yield, 84 % purity). The linear peptide was 
used di rectly in the next cyclisation step without further purification. 
RP-HPLC 1-35 % B in 10 min, tR 10.6 min. 
ES-MS m/z calcd for C47H55N10O8SSe 999.3090, found 999.2575 [MH+]. 
(R)-Ala-Thz-Trp-(5-Me)-Trp-Gly-(R)-Ala-Ph(Se)-Sar-OH, (46f)  
Using Standard protocol A and the Fmoc-(5-Me)-Trp-OH (43f), the title peptide 
was assembled as a white solid (58 mg, 59 % yield, 79 % purity). The linear 
peptide was used di rectly in the next cyclisation step without further purification. 
RP-HPLC 1-35 % B in 10 min, tR 11.5 min. 
ES-MS m/z calcd for C46H53N10O8SSe 985.2934, found 985.2867 [MH+]. 
(R)-Ala-Thz-Trp-(5-OMe)-Trp-Gly-(R)-Ala-Ph(Se)-Sar-OH, (46g)  
Using Standard protocol A and the Fmoc-(5-Me)-Trp-OH (43g) the title peptide 
was assembled as a white solid (64 mg, 64 % yield, 78 % purity). The linear 
peptide was used di rectly in the next cyclisation step without further purification. 
RP-HPLC 1-35 % B in 10 min, tR 10.4 min. 
ES-MS m/z calcd for C46H53N10O9SSe 1001.2883, found 1001.2643 [MH+]. 
(R)-Ala-Thz-Trp-(1-Me)-Trp-Gly-(R)-Ala-Ph(Se)-Sar-OH, (46i)   
Using Standard protocol A and the Fmoc-(1-Me)-Trp-OH (43i) the title peptide 
was assembled as a white solid (84 mg, 86 % yield, 86 % purity). The linear 
peptide was used di rectly in the next cyclisation step without further purification. 
RP-HPLC 1-35 % B in 10 min, tR 10.8 min. 
ES-MS m/z calcd for C46H53N10O8SSe 985.2934, found 985.2985 [MH+]. 
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The derivatised resin 185 (1 eq.) was placed in a reaction column, swollen with 
DMF/DCM (1 mL) for 12 h, and Fmoc-deprotection was carried out on a 
continuous flow of 20 % v/v piperidine in DMF (2.8 mL min-1, 10 min) using 
NOVA SYN® GEM manual peptide synthesizer. The reaction was monitored post-
column at 355 nm. The resin was then washed with DMF (2.8 mL min-1, 5 min), 
and the peptide sequence (R)-Ala1-Thz2-Trp3-Trp4(X)-Gly5-(R)-Ala6-Ph(Se)7-Sar8-
OH was assembled manually using NOVA SYN® GEM manual peptide 
synthesizer. 
Standard Protocol B for linear peptide synthesis 
Sequential acylation reactions were carried out at ambient temperature for 4 h 
using appropriate NĮ-Fmoc-protected amino acids (4 eq.) [Fmoc-Ph(Se)-OH (42), 
Fmoc-(R)-Ala-OH, Fmoc-Gly-OH, Fmoc-Trp(X)-OH (43), Fmoc-Trp-OH, Boc-
(R)-Ala-Thz-OH (44)] and carboxylated-activating reagent, PyOxim(4 eq.) or 
HATU (3.9 eq.) and DIPEA (8 eq.) in DMF (0.5 mL). Repetitive Fmoc-
deprotection was achieved using 20 % v/v piperidine in DMF (2.8 mL min-1, 10 
min). 
After final acylation reaction, the peptidyl-resin directly treated with NaIO4 (4 eq.) 
in DMF/H2O (0.5:0.2 mL) and stirred at room temperature for 6 h. The final 
assembled peptidyl-resin was filtered, washed successively with H2O, DMF, DCM 
and hexane, and dr ied in vacuo. 
The resin product was suspended in a mixture of water (0.1 mL) and DCM (1 mL), 
followed by the addition of TFA (1 mL). The reaction mixture was allowed to 
stand at ambient temperature for 1 h. The suspension was filtered, washed with 
DCM (3 mL), and the filterate was evaporated in vacuo. 
The residual material was triturated with diethyl ether (2 mL) to result an off-white 
sold. The desired linear peptide was dissolved in water (2 mL) and lyophilized 
overnight.  
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(R)-Ala-Thz-Trp-(6-F)-Trp-Gly-(R)-Ala-Dha-Sar-OH, (46d)  
Using Standard protocol B and the Fmoc-(6-F)-Trp-OH (43d) the title peptide was 
assembled as a red solid (54 mg, 65 %). The linear peptide was used directly in the 
next cyclisation step without further purification. 
RP-HPLC 1-35 % B in 10 min, tR 8.2 min. 
ES-MS m/z calcd for C39H44FN10O8S 831.3048, found 831.2910 [MH+]. 
(R)-Ala-Thz-Trp-(4-MeO)-Trp-Gly-(R)-Ala-Dha-Sar-OH, (46h) 
Using Standard protocol B and the Fmoc-(4-MeO)-Trp-OH (43h) the title peptide 
was assembled as a brown solid (63 mg, 75 %). The linear peptide was used 
directly in the next cyclisation step without further purification. 
RP-HPLC 1-35 % B in 10 min, tR 7.9 min. 
ES-MS m/z calcd for C40H47N10O9S 843.3248, found 843.3193 [MH+]. 
(R)-Ala-Thz-Trp-(R)-Trp-Gly-(R)-Ala-Dha-Sar-OH, (46k) 
Using Standard protocol B and the Fmoc-(R)-Trp-OH, the title peptide was 
assembled as a brown solid (39 mg, 48 %). The linear peptide was used directly in 
the next cyclisation step without further purification. 
RP-HPLC 1-35 % B in 10 min, tR 8.3 min. 
ES-MS m/z calcd for C39H45N10O8S 813.3143, found 813.3288 [MH+]. 
Cyclo[(R)-Ala1-Thz2-Trp3-Trp4-Gly5-(R)-Ala6-Ph(Se)7-Sar8], (47a)   
'LLVRSURS\OHWK\ODPLQHȝ/ PPRODQG3\%23 PJ PPROZHUH
added successively to a solution of the linear peptide 46a (70 mg, 0.07 mmol) and 
HOBt (29 mg, 0.2 mmol) in CH2Cl2 (144 mL) at room temperature. The reaction 
mixture was stirred for 1 day, concentrated and purified by RP-HPLC (Onyx 
Monolithic C18, 100 x 10 mm) to afford the cyclic peptide 47a as a white powder 
(20 mg, 30 % yield). 
RP-HPLC 10-60 % B in 12 min, tR 8.5 min. 
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ES-MS m/z calcd for C45H49N10O7SSe 953.2672, found 953.2571 [MH+]. 
Cyclo[(R)-Ala1-Thz2-Trp3-(5-Br)-Trp4-Gly5-(R)-Ala6-Ph(Se)7-Sar8], (47b)  
S
N
H
NO
N
O
HN
O
N
H
O HN
O
HN O
HN
O
N
H
NHSe
1
2
3
4
56
7
Br
47b
8
 
DiisopropyleWK\ODPLQHȝ/PPRO PyBOP (88 mg, 0.17 mmol) and HOBt 
(22 mg, 0.1 mmol) were added successively to a solution of the linear peptide 46b 
(62 mg, 0.06 mmol) in CH2Cl2 (120 mL) at room temperature. The reaction 
mixture was stirred for 3 days, concentrated and purified by preparative RP-HPLC 
(Onyx Monolithic C18, 100 x 10 mm) to afford the cyclic peptide 47b as a white 
powder (10 mg, 17 % yield). 
RP-HPLC 10-60 % B in 12 min, tR 9.9 min. 
1H NMR (400 MHz, DMSO-d6): į = 0.65 (d, J = 7 Hz, 3H, 6-CH3), 1.56 (d, J = 7 
Hz, 3H, 1-CH3), 3.13 (dd, J = 14, 8 Hz, 1H, 4-CHAHB), 3.22 (s, 3H. 8-CH3), 3.24 
(m, 1H, 4-CHAHB), 3.31 (m, 1H, 5-CHAHB), 3.34 (m, 1H, 7-CHAHB), 3.45 (m, 1H, 
7-CHAHB), 3.49 (m, 1H, 8-CHAHB), 3.50 (m, 1H, 3-CHAHB), 3.67 (m, 1H, 3- 
CHAHB), 3.74 (m, 1H, 5-CHAHB), 4.13 (q, J = 7 Hz, 1H, 6-Į-CH), 4.18 (t, J = 8 Hz, 
1H, 4-Į-CH), 4.35 (d, J = 17 Hz, 1H, 8-CHAHB), 4.60 (td, J = 7, 4 Hz, 1H, 7-Į-CH), 
4.78 (td, J = 12, 4 Hz, 1H, 3-Į-CH), 5.32 (m, 1H, 1-Į-CH), 7.01-7.32 (m, 12H, 
arom. H), 7.43 (d, J = 3 Hz, 7-NH), 7.56 (m, 2H, arom. H), 7.58 (d, J = 7 Hz, 1H, 
1-NH), 7.95 (s, 1H, 2-CH), 8.06 (d, J = 9 Hz, 1H, 6-NH), 8.30 (s, 1H, 4-NH), 8.64 
(d, J = 9 Hz, 1H, 3-NH), 8.88 (t, J = 5 Hz, 1H, 5-NH), 10.81 (d, J = 2 Hz, indole-
NH), 11.16 (d, J = 2 Hz, indole-NH) ppm. 
ES-MS m/z calcd for C45H48N10O7SSe 1031.1777, found 1033.1757 [MH+]. 
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Cyclo[(R)-Ala-Thz-Trp-(5-Cl)-Trp-Gly-(R)-Ala-Ph(Se)-Sar], (47c)  
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'LLVRSURS\OHWK\ODPLQHȝ/PPRO, PyBOP (86 mg, 0.17 mmol) and HOBt 
(22 mg, 0.17 mmol) were added successively to a solution of the linear peptide 46c 
(56 mg, 0.05 mmol) in CH2Cl2 (120 mL) at room temperature. The reaction 
mixture was stirred for 3 days, concentrated and purified by preparative RP-HPLC 
(Onyx Monolithic C18, 100 x 10 mm) to afford the cyclic peptide 47c as a white 
powder (11 mg, 20 % yield). 
RP-HPLC 10-60 % B in 12 min, tR 9.5 min. 
1H NMR (400 MHz, DMSO-d6): į = 0.65 (d, J = 7 Hz, 3H, 6-CH3), 1.56 (d, J = 7 
Hz, 3H, 1-CH3), 3.12 (dd, J = 14, 8 Hz, 1H, 4-CHAHB), 3.22 (s, 3H. 8-CH3), 3.24 
(m, 1H, 4-CHAHB), 3.31 (m, 1H, 5-CHAHB), 3.34 (m, 1H, 7-CHAHB), 3.45 (m, 1H, 
7-CHAHB), 3.49 (m, 1H, 8-CHAHB), 3.50 (m, 1H, 3-CHAHB), 3.67 (m, 1H, 3- 
CHAHB), 3.74 (m, 1H, 5-CHAHB), 4.13 (q, J = 7 Hz, 1H, 6-Į-CH), 4.18 (t, J = 8 Hz, 
1H, 4-Į-CH), 4.35 (d, J = 17 Hz, 1H, 8-CHAHB), 4.60 (td, J = 7, 4 Hz, 1H, 7-Į-CH), 
4.78 (td, J = 12, 4 Hz, 1H, 3-Į-CH), 5.32 (m, 1H, 1-Į-CH), 6.97-7.32 (m, 12H, 
arom. H), 7.43 (d, J = 3 Hz, 7-NH), 7.56 (m, 2H, arom. H), 7.58 (d, J = 7 Hz, 1H, 
1-NH), 7.95 (s, 1H, 2-CH), 8.06 (d, J = 9 Hz, 1H, 6-NH), 8.30 (s, 1H, 4-NH), 8.64 
(d, J = 9 Hz, 1H, 3-NH), 8.88 (t, J = 5 Hz, 1H, 5-NH), 10.81 (d, J = 2 Hz, indole-
NH), 11.17 (d, J = 2 Hz, indole-NH) ppm. 
ES-MS m/z calcd for C45H48N10O7SSe 987.2282, found 987.2104 [MH+]. 
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Cyclo[(R)-Ala-Thz-Trp-(7-Et)-Trp-Gly-(R)-Ala-Ph(Se)-Sar], (47e)  
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DiisopropyleWK\ODPLQHȝ/PPRO PyBOP (81 mg, 0.17 mmol) and HOBt 
(21 mg, 0.16 mmol) were added successively to a solution of the linear peptide 46e 
(52 mg, 0.05 mmol) in CH2Cl2 (120 mL) at room temperature. The reaction 
mixture was stirred for 3 days, concentrated and purified by preparative RP-HPLC 
(Onyx Monolithic C18, 100 x 10 mm) to afford the cyclic peptide 47e as a white 
powder (14 mg, 28 % yield). 
RP-HPLC 10-60 % B in 12 min, tR 9.9 min. 
1H NMR (400 MHz, DMSO-d6): į = 0.65 (d, J = 7 Hz, 3H, 6-CH3), 1.26 (t, J = 7 
Hz, 3H, 4-CH2CH3), 1.56 (d, J = 7 Hz, 3H, 1-CH3), 2.86 (q, J = 7 Hz, 2H, 4-
CH2CH3), 3.12 (dd, J = 14, 8 Hz, 1H, 4-CHAHB), 3.22 (s, 3H, 8-CH3), 3.24 (m, 1H, 
4-CHAHB), 3.31 (m, 1H, 5-CHAHB), 3.34 (m, 1H, 7-CHAHB), 3.45 (m, 1H, 7-
CHAHB), 3.49 (m, 1H, 8-CHAHB), 3.50 (m, 1H, 3-CHAHB), 3.67 (m, 1H, 3- 
CHAHB), 3.74 (m, 1H, 5-CHAHB), 4.14 (q, J = 7 Hz, 1H, 6-Į-CH), 4.22 (t, J = 8 Hz, 
1H, 4-Į-CH), 4.35 (d, J = 17 Hz, 1H, 8-CHAHB), 4.60 (td, J = 7, 4 Hz, 1H, 7-Į-CH), 
4.78 (td, J = 12, 4 Hz, 1H, 3-Į-CH), 5.32 (m, 1H, 1-Į-CH), 6.97-7.32 (m, 12H, 
arom. H), 7.44 (d, J = 3 Hz, 7-NH), 7.56 (m, 2H, arom. H), 7.58 (d, J = 7 Hz, 1H, 
1-NH), 7.95 (s, 1H, 2-CH), 8.11 (d, J = 9 Hz, 1H, 6-NH), 8.35 (s, 1H, 4-NH), 8.65 
(d, J = 9 Hz, 1H, 3-NH), 8.92 (t, J = 5 Hz, 1H, 5-NH), 10.83 (d, J = 2 Hz, indole-
NH), 10.95 (d, J = 2 Hz, indole-NH) ppm. 
ES-MS m/z calcd for C47H53N10O7SSe 981.2985, found 981.2607 [MH+]. 
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Cyclo[(R)-Ala-Thz-Trp-(5-Me)-Trp-Gly-(R)-Ala-Ph(Se)-Sar], (47f) 
S
N
H
NO
N
O
HN
O
N
H
O HN
O
HN O
HN
O
N
H
NHSe
1
2
3
4
56
7
47f
8
 
DiisopropyleWK\ODPLQHȝ/PPRO PyBOP (90 mg, 0.17 mmol) and HOBt 
(22 mg, 0.17 mmol) were added successively to a solution of the linear peptide 46f 
(57 mg, 0.06 mmol) and in CH2Cl2 (120 mL) at room temperature. The reaction 
mixture was stirred for 3 days, concentrated and purified by preparative RP-HPLC 
(Onyx Monolithic C18, 100 x 10 mm) to afford the cyclic peptide 47f as a white 
powder (15 mg, 27 % yield). 
RP-HPLC 10-60 % B in 12 min, tR 9.4 min. 
1H NMR (400 MHz, DMSO-d6): į = 0.65 (d, J = 7 Hz, 3H, 6-CH3), 1.56 (d, J = 7 
Hz, 3H, 1-CH3), 2.41 (s, 3H, 4-CH3), 3.11 (dd, J = 14, 8 Hz, 1H, 4-CHAHB), 3.22 (s, 
3H, 8-CH3), 3.27 (m, 1H, 4-CHAHB), 3.31 (m, 1H, 5-CHAHB), 3.34 (m, 1H, 7-
CHAHB), 3.45 (m, 1H, 7-CHAHB), 3.49 (m, 1H, 8-CHAHB), 3.67 (dd, J = 14, 4 Hz, 
1H, 3-CHAHB), 3.75 (dd, J =  17, 4 Hz,1H, 3-CHAHB), 3.76 (m, 1H, 5-CHAHB), 
4.13 (q, J = 7 Hz, 1H, 6-Į-CH), 4.20 (t, J = 8 Hz, 1H, 4-Į-CH), 4.35 (d, J = 17 Hz, 
1H, 8-CHAHB), 4.60 (td, J = 7, 4 Hz, 1H, 7-Į-CH), 4.78 (td, J = 12, 4 Hz, 1H, 3-Į-
CH), 5.32 (m, 1H, 1-Į-CH), 6.94-7.56 (m, 12H, arom. H), 7.44 (d, J = 3 Hz, 7-NH), 
7.56 (m, 2H, arom. H), 7.58 (d, J = 7 Hz, 1H, 1-NH), 7.95 (s, 1H, 2-CH), 8.09 (d, J 
= 9 Hz, 1H, 6-NH), 8.28 (s, 1H, 4-NH), 8.64 (d, J = 9 Hz, 1H, 3-NH), 8.85 (t, J = 5 
Hz, 1H, 5-NH), 10.78 (d, J = 2 Hz, indole-NH), 10.81 (d, J = 2 Hz, indole-NH) 
pp m. 
ES-MS m/z calcd for C46H51N10O7SSe 967.2828, found 967.2723 [MH+]. 
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Cyclo[(R)-Ala-Thz-Trp-(5-OMe)-Trp-Gly-(R)-Ala-Ph(Se)-Sar], (47g)   
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DiisopropyleWK\ODPLQH  ȝ/  PPRO PyBOP and (185 mg, 0.36 mmol) 
HOBt (48 mg, 0.36 mmol) were added successively to a solution of the linear 
peptide 46g (119 mg, 0.12 mmol) and in CH2Cl2 (220 mL) at room temperature. 
The reaction mixture was stirred for 3 days, concentrated and purified by 
preparative RP-HPLC (Onyx Monolithic C18, 100 x 10 mm) to afford the cyclic 
peptide 47g as a white powder (12 mg, 11 % yield). 
RP-HPLC 10-60 % B in 12 min, tR 8.5 min. 
1H NMR (400 MHz, DMSO-d6): į = 0.65 (d, J = 7 Hz, 3H, 6-CH3), 1.56 (d, J = 7 
Hz, 3H, 1-CH3), 3.13 (dd, J = 14, 8 Hz, 1H, 4-CHAHB), 3.22 (s, 3H. 8-CH3), 3.24 
(m, 1H, 4-CHAHB), 3.31 (m, 1H, 5-CHAHB), 3.34 (m, 1H, 7-CHAHB), 3.45 (m, 1H, 
7-CHAHB), 3.49 (m, 1H, 8-CHAHB), 3.50 (m, 1H, 3-CHAHB), 3.67 (m, 1H, 3-
CHAHB), 3.74 (m, 1H, 5-CHAHB), 3.80 (s, 3H, 4-OCH3), 4.13 (q, J = 7 Hz, 1H, 6-
Į-CH), 4.20 (t, J = 8 Hz, 1H, 4-Į-CH), 4.40 (d, J = 17 Hz, 1H, 8-CHAHB), 4.60 (td, 
J = 7, 4 Hz, 1H, 7-Į-CH), 4.79 (td, J = 12, 4 Hz, 1H, 3-Į-CH), 5.32 (m, 1H, 1-Į-
CH), 6.75-7.28 (m, 12H, arom. H), 7.42 (d, J = 3 Hz, 7-NH), 7.56 (m, 2H, arom. 
H), 7.58 (d, J = 7 Hz, 1H, 1-NH), 7.95 (s, 1H, 2-CH), 8.11 (d, J = 9 Hz, 1H, 6-NH), 
8.36 (s, 1H, 4-NH), 8.65 (d, J = 9 Hz, 1H, 3-NH), 8.85 (t, J = 5 Hz, 1H, 5-NH), 
10.79 (d, J = 2 Hz, indole-NH), 10.82 (d, J = 2 Hz, indole-NH) ppm. 
ES-MS m/z calcd for C46H51N10O8SSe 983.2777, found 983.2693 [MH+]. 
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Cyclo[(R)-Ala-Thz-Trp-(1-Me)-Trp-Gly-(R)-Ala-Ph(Se)-Sar], (47i) 
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DiisopropyletK\ODPLQH  ȝ/  PPRO PyBOP (130 mg, 0.25 mmol) and 
HOBt (33 mg, 0.25 mmol) were added successively to a solution of the linear 
peptide 46i (84 mg, 0.08 mmol) and in CH2Cl2 (120 mL) at room temperature. The 
reaction mixture was stirred for 3 days, concentrated and purified by RP-HPLC 
(Onyx Monolithic C18, 100 x 10 mm) to afford the cyclic peptide 47i as a white 
powder (14 mg, 17 % yield). 
RP-HPLC 10-60 % B in 12 min, tR 8.0 min. 
1H NMR (400 MHz, DMSO-d6): į = 0.65 (d, J = 7 Hz, 3H, 6-CH3), 1.56 (d, J = 7 
Hz, 3H, 1-CH3), 3.13 (dd, J = 14, 8 Hz, 1H, 4-CHAHB), 3.22 (s, 3H. 8-CH3), 3.24 
(m, 1H, 4-CHAHB), 3.31 (m, 1H, 5-CHAHB), 3.34 (m, 1H, 7-CHAHB), 3.45 (m, 1H, 
7-CHAHB), 3.49 (m, 1H, 8-CHAHB), 3.50 (m, 1H, 3-CHAHB), 3.67 (m, 1H, 3- 
CHAHB), 3.74 (m, 1H, 5-CHAHB), 3.77 (s, 3H, 4-CH3), 4.14 (q, J = 7 Hz, 1H, 6-Į-
CH), 4.19 (t, J = 8 Hz, 1H, 4-Į-CH), 4.33 (d, J = 17 Hz, 1H, 8-CHAHB), 4.61 (td, J 
= 7, 4 Hz, 1H, 7-Į-CH), 4.79 (td, J = 12, 4 Hz, 1H, 3-Į-CH), 5.32 (m, 1H, 1-Į-CH), 
6.75-7.32 (m, 13H, arom. H), 7.42 (d, J = 3 Hz, 7-NH), 7.56 (m, 2H, arom. H), 
7.58 (d, J = 7 Hz, 1H, 1-NH), 7.96 (s, 1H, 2-CH), 8.07 (d, J = 9 Hz, 1H, 6-NH), 
8.19 (s, 1H, 4-NH), 8.66 (d, J = 9 Hz, 1H, 3-NH), 8.91 (t, J = 5 Hz, 1H, 5-NH), 
10.86 (d, J = 2 Hz, indole-NH) ppm. 
ES-MS m/z calcd for C46H51N10O7SSe 967.2828, found 967.2866 [MH+]. 
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General procedure for the preparat ion of Cyclo[(R)-Ala1-Thz2-Trp3-Trp4-
Gly5-(R)-Ala6-Dha7-Sar8], Argyrin E, (48a) 
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6RGLXPSHULRGDWHPJȝPROZDVDGGHGWRDVROXWLRQRIF\FOLFSHSWLGH47a 
PJȝPROLQZDWHUP/DQGDFHWRQLWULOHP/DWURRPWHPSHUDWXUH7KH
solution was stirred for 2 h. The solvent was removed and the residue was extracted 
with water (2 mL) and DCM/IPA (7 mL / 2 mL x 2). The organic layers were 
combined and concentrated. The residue was dissolved in acetonitiles (4 mL) then 
water (2 mL) and saturated aqueous Na2CO3 (2 mL) were added successively. The 
reaction mixture was stirred for 2 days, diluted with water (4mL) and extracted 
with DCM/IPA (7 mL/ 2 mL x2). The organic layers were combined, washed with 
water (5 mL), dried (MgSO4) and concentrated. The residue was purified by 
preparative RP-HPLC (Onyx Monolithic C18, 100 x 10 mm) to afford the argyrin 
48a as a pale yellow powder (2 mg, 66 % yield). 
RP-HPLC 10-60 % B in 12 min, tR 6.8 min. 
1H NMR (400 MHz, DMSO-d6): į = 0.87 (d, J = 7 Hz, 3H, 6-CH3), 1.54 (d, = 7 Hz, 
3H, 1-CH3), 3.08 (s, 3H, 8-CH3), 3.15 (m, 2H, 4-CH2), 3.21 (m, 1H, 3-CHAHB), 
3.22(m, 1H, 8-CHAHB), 3.39 (m, 1H, 5-CHAHB), 3.44 (m, 1H, 3-CHAHB), 3.80 (d, 
J = 16 Hz, 1H, 8-CHAHB), 3.88 (dd, J = 16, 8 Hz, 5-CHAHB), 4.24 (m, 1H, 4-Į-
CH), 4.35 (m, 1H, 6-Į-CH), 4.78 (td, J = 12, 4 Hz, 1H, 3-Į-CH), 4.89 (s, 1H, 7-
CHAHB), 5.20 (s, 1H, 7-CHAHB), 5.39 (m, 1H, 1-Į-CH), 6.90-7.75 (m, 10H, armo. 
H), 8.03 (s, 1H, 2-CH), 8.12 (d, J = 9 Hz, 1H, 6-NH), 8.29 (d, J = 9 Hz, 1H, 1-NH), 
8.52 (d, J = 9 Hz, 1H, 3-NH), 8.57 (s, 1H, 4-NH), 8.79 (t, J = 4 Hz, 1H, 5-NH), 
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9.39 (s, 1H, 7-NH), 10.84 (d, J = 2 Hz, indole-NH), 11.05 (d, J = 2 Hz, indole-NH) 
pp m. 
ES-MS m/z calcd for C39H43N10O7S 795.3037, found 795.2959 [MH+]. 
Cyclo[(R)-Ala-Thz-Trp-(5-Br)-Trp-Gly-(R)-Ala-Dha-Sar], (48b) 
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Procedure as described in the general procedure using cyclic peptide 47b (4 mg, 4 
ȝPROWRDIIRUGDUJ\ULQ48b as a sticky solid (2 mg, 58 % yield). 
RP-HPLC 10-60 % B in 12 min, tR 8.0 min. 
1H NMR (400 MHz, DMSO-d6): į = 0.87 (d, J = 7 Hz, 3H, 6-CH3), 1.54 (d, J = 7 
Hz, 3H, 1-CH3), 3.13 (s, 3H, 8-CH3), 3.15 (m, 2H, 4-CH2), 3.21 (m, 1H, 3-CHAHB), 
3.22 (m, 1H, 8-CHAHB), 3.39 (m, 1H, 5-CHAHB), 3.44 (m, 1H, 3-CHAHB), 3.80 (d, 
J = 16 Hz, 1H, 8-CHAHB), 3.88 (dd, J = 16, 8 Hz, 5-CHAHB), 4.24 (m, 1H, 4-Į-
CH), 4.35 (m, 1H, 6-Į-CH), 4.78 (td, J = 12, 4 Hz, 1H, 3-Į-CH), 4.92 (s, 1H, 7-
CHAHB), 5.16 (s, 1H, 7-CHAHB), 5.39 (m, 1H, 1-Į-CH), 6.95-7.77 (m, 9H, arom. 
H), 8.00 (s, 1H, 2-CH), 8.09 (d, J = 9 Hz, 1H, 6-NH), 8.27 (d, J = 9 Hz, 1H, 1-NH), 
8.40 (s, 1H, 4-NH), 8.56 (d, J = 9 Hz, 1H, 3-NH), 8.73 (t, J = 4 Hz, 1H, 5-NH), 
9.22 (s, 1H, 7-NH), 10.76 (d, J = 2 Hz, indole-NH), 11.15 (d, J = 2 Hz, indole-NH) 
pp m. 
ES-MS m/z calcd for C39H42N10BrO7S 875.2122, found 875.1877 [MH+]. 
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Cyclo[(R)-Ala-Thz-Trp-(5-Cl)-Trp-Gly-(R)-Ala-Dha-Sar], (48c)  
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Procedure as described in the general procedure using cyclic peptide 47c (5 mg, 5 
ȝPROWRDIIRUGDUJ\ULQ48c as a sticky solid (3 mg, 67 % yield). 
RP-HPLC 10-60 % B in 12 min, tR 7.5 min 
1H NMR (400 MHz, DMSO-d6): į = 0.87 (d, J = 7 Hz, 3H, 6-CH3), 1.54 (d, J = 7 
Hz, 3H, 1-CH3), 3.13 (s, 3H, 8-CH3), 3.15 (m, 2H, 4-CH2), 3.21 (m, 1H, 3-CHAHB), 
3.22 (m, 1H, 8-CHAHB), 3.39 (m, 1H, 5-CHAHB), 3.44 (m, 1H, 3-CHAHB), 3.80 (d, 
J = 16 Hz, 1H, 8-CHAHB), 3.88 (dd, J = 16, 8 Hz, 5-CHAHB), 4.24 (m, 1H, 4-Į-
CH), 4.35 (m, 1H, 6-Į-CH), 4.78 (td, J = 12, 4 Hz, 1H, 3-Į-CH), 4.92 (s, 1H, 7-
CHAHB), 5.16 (s, 1H, 7-CHAHB), 5.39 (m, 1H, 1-Į-CH), 6.95-7.77 (m, 9H, arom. 
H), 8.00 (s, 1H, 2-CH), 8.09 (d, J = 9 Hz, 1H, 6-NH), 8.27 (d, J = 9 Hz, 1H, 1-NH), 
8.40 (s, 1H, 4-NH), 8.56 (d, J = 9 Hz, 1H, 3-NH), 8.73 (t, J = 4 Hz, 1H, 5-NH), 
9.22 (s, 1H, 7-NH), 10.76 (d, J = 2 Hz, indole-NH), 11.15 (d, J = 2 Hz, indole-NH) 
pp m. 
ES-MS m/z calcd for C39H42ClN10O7S 829.2647, found 829.2347 [MH+]. 
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Cyclo[(R)-Ala-Thz-Trp-(6-F)-Trp-Gly-(R)-Ala-Dha-Sar], (48d) 
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Diisopropylethylamine (101 ȝ/  PPRO PyBOP (101 mg, 0.19 mmol) and 
HOBt (26 mg, 0.19 mmol) were added successively to a solution of the linear 
peptide 46d (54 mg, 0.06 mmol) in CH2Cl2 (120 mL) at room temperature. The 
reaction mixture was stirred for 3 days, concentrated and purified by preparative 
RP-HPLC (Onyx Monolithic C18, 100 x 10 mm) to afford argyrin 48d as a orange 
solid (2 mg, 4 % yield). 
RP-HPLC 10-60 % B in 12 min, tR 7.0 min. 
1H NMR (400 MHz, DMSO-d6): į = 0.87 (d, J = 7 Hz, 3H, 6-CH3), 1.54 (d, J = 7 
Hz, 3H, 1-CH3), 3.13 (s, 3H, 8-CH3), 3.15 (m, 2H, 4-CH2), 3.21 (m, 1H, 3-CHAHB), 
3.22 (m, 1H, 8-CHAHB), 3.39 (m, 1H, 5-CHAHB), 3.44 (m, 1H, 3-CHAHB), 3.80 (d, 
J = 16 Hz, 1H, 8-CHAHB), 3.88 (dd, J = 16, 8 Hz, 5-CHAHB), 4.24 (m, 1H, 4-Į-
CH), 4.35 (m, 1H, 6-Į-CH), 4.78 (td, J = 12, 4 Hz, 1H, 3-Į-CH), 4.92 (s, 1H, 7-
CHAHB), 5.16 (s, 1H, 7-CHAHB), 5.39 (m, 1H, 1-Į-CH), 6.95-7.77 (m, 9H, arom. 
H), 8.00 (s, 1H, 2-CH), 8.09 (d, J = 9 Hz, 1H, 6-NH), 8.27 (d, J = 9 Hz, 1H, 1-NH), 
8.40 (s, 1H, 4-NH), 8.56 (d, J = 9 Hz, 1H, 3-NH), 8.69 (t, J = 4 Hz, 1H, 5-NH), 
9.21 (s, 1H, 7-NH), 10.74 (d, J = 2 Hz, indole-NH), 10.99 (d, J = 2 Hz, indole-NH) 
pp m. 
ES-MS m/z calcd for C39H42FN10O7S 813.2943, found 813.3016 [MH+]. 
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Cyclo[(R)-Ala-Thz-Trp-(7-Et)-Trp-Gly-(R)-Ala-Dha-Sar], (48e)  
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Procedure as described in the general procedure using cyclic peptide 47e (4 mg, 4 
ȝPROWRDIIRUGDUJ\ULQ48e as a sticky solid (2 mg, 52 % yield). 
RP-HPLC 10-60 % B in 12 min, tR 7.9 min. 
1H NMR (400 MHz, DMSO-d6): į= 0.87 (d, J = 7 Hz, 3H, 6-CH3), 1.27 (t, J = 7 
Hz, 3H, 4-CH2CH3), 1.55 (d, J = 7 Hz, 3H, 1-CH3), 2.85 (q, J = 7 Hz, 2H, 4-
CH2CH3), 3.12 (s, 3H, 8-CH3), 3.15 (m, 2H, 4-CH2), 3.21 (m, 1H, 3-CHAHB), 3.22 
(m, 1H, 8-CHAHB), 3.39 (m, 1H, 5-CHAHB), 3.44 (m, 1H, 3-CHAHB), 3.80 (d, J = 
16 Hz, 1H, 8-CHAHB), 3.88 (dd, J = 16, 8 Hz, 5-CHAHB), 4.24 (td, J = 12, 4 Hz, 
1H, 4-Į-CH), 4.35 (m, 1H, 6-Į-CH), 4.78 (td, J = 12, 4 Hz, 1H, 3-Į-CH), 4.92 (s, 
1H, 7-CHAHB), 5.16 (s, 1H, 7-CHAHB), 5.39 (m, 1H, 1-Į-CH), 6.93-7.76 (m, 9H, 
arom. H), 8.00 (s, 1H, 2-CH), 8.12 (d, J = 9 Hz, 1H, 6-NH), 8.27 (d, J = 9 Hz, 1H, 
1-NH), 8.41 (d, J = 2 Hz, 1H, 4-NH), 8.55 (d, J = 9 Hz, 1H, 3-NH), 8.72 (t, J = 4 
Hz, 1H, 5-NH), 9.23 (s, 1H, 7-NH), 10.74 (d, J = 2 Hz, indole-NH), 10.89 (d, J = 2 
Hz, indole-NH) ppm. 
ES-MS m/z calcd for C41H47N10O7S 823.3350, found 823.3311 [MH+]. 
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Cyclo[(R)-Ala-Thz-Trp-(5-Me)-Trp-Gly-(R)-Ala-Dha-Sar], (48f) 
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Procedure as described in the general procedure using cyclic peptide 47f (5 mg, 5 
ȝPROWRDIIRUGDUJ\ULQ48f as a sticky solid (3 mg, 66 % yield). 
RP-HPLC 10-60 % B in 12 min, tR 7.3 min 
1H NMR (400 MHz, DMSO-d6): į = 0.87 (d, J = 7 Hz, 3H, 6-CH3), 1.54 (d, J = 7 
Hz, 3H, 1-CH3), 2.43 (s, 3H, 4-CH3), 3.13 (s, 3H, 8-CH3), 3.15 (m, 2H, 4-CH2), 
3.21 (m, 1H, 3-CHAHB), 3.22(m, 1H, 8-CHAHB), 3.39 (m, 1H, 5-CHAHB), 3.44 (m, 
1H, 3-CHAHB), 3.80 (d, J = 16 Hz, 1H, 8-CHAHB), 3.88 (dd, J = 16, 8 Hz, 5-
CHAHB), 4.24 (m, 1H, 4-Į-CH), 4.35 (m, 1H, 6-Į-CH), 4.78 (td, J = 12, 4 Hz, 1H, 
3-Į-CH), 4.92 (s, 1H, 7-CHAHB), 5.16 (s, 1H, 7-CHAHB), 5.39 (m, 1H, 1-Į-CH), 
6.93-7.74 (m, 9H, arom. H), 8.00 (s, 1H, 2-CH), 8.09 (d, J = 9 Hz, 1H, 6-NH), 8.27 
(d, J = 9 Hz, 1H, 1-NH), 8.37 (s, 1H, 4-NH), 8.56 (d, J = 9 Hz, 1H, 3-NH), 8.70 (t, 
J = 4 Hz, 1H, 5-NH), 9.22 (s, 1H, 7-NH), 10.75 (d, J = 2 Hz, indole-NH), 10.76 (d, 
J = 2 Hz, indole-NH) ppm. 
ES-MS m/z calcd for C40H45N10O8S 809.3193, found 809.3016 [MH+]. 
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Cyclo[(R)-Ala-Thz-Trp-(5-OMe)-Trp-Gly-(R)-Ala-Dha-Sar], (48g)   
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Procedure as described in the general procedure using cyclic peptide 47g (4 mg, 4 
ȝPROWRDIIRUGDUJ\ULQ 48g as a sticky solid (2 mg, 58 % yield). 
RP-HPLC 10-60 % B in 12 min, tR 6.5 min. 
1H NMR (400 MHz, DMSO-d6): į= 0.87 (d, J = 7 Hz, 3H, 6-CH3), 1.54 (d, J = 7 
Hz, 3H, 1-CH3), 3.08 (s, 3H, 8-CH3), 3.15 (m, 2H, 4-CH2), 3.21 (m, 1H, 3-CHAHB), 
3.22 (m, 1H, 8-CHAHB), 3.39 (m, 1H, 5-CHAHB), 3.44 (m, 1H, 3-CHAHB), 3.79 (s, 
3H, 4-OCH3), 3.80 (d, J = 16 Hz, 1H, 8-CHAHB), 3.88 (dd, J = 16, 8 Hz, 5-CHAHB), 
4.22 (m, 1H, 4-Į-CH), 4.34 (m, 1H, 6-Į-CH), 4.78 (td, J = 12, 4 Hz, 1H, 3-Į-CH), 
4.93 (s, 1H, 7-CHAHB), 5.16 (s, 1H, 7-CHAHB), 5.39 (m, 1H, 1-Į-CH), 6.90-7.75 
(m, 9H, arom. H), 8.00 (s, 1H, 2-CH), 8.12 (d, J = 9 Hz, 1H, 6-NH), 8.27 (d, J = 9 
Hz, 1H, 1-NH), 8.42 (s, 1H, 4-NH), 8.56 (d, J = 9 Hz, 1H, 3-NH), 8.69 (t, J = 4 Hz, 
1H, 5-NH), 9.24 (s, 1H, 7-NH), 10.75 (d, J = 2 Hz, indole-NH), 10.76 (d, J = 2 Hz, 
indole-NH) ppm. 
ES-MS m/z calcd for C40H45N10O8S 825.3143, found 825.3056 [MH+]. 
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Cyclo[(R)-Ala-Thz-Trp-(4-OMe)-Trp-Gly-(R)-Ala-Dha-Sar], Argyrin A (48h)   
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DiisopropyleWK\ODPLQH  ȝ/  PPRO  PyBOP (93 mg, 0.18 mmol) and 
HOBt (24 mg, 0.18 mmol) were added successively to a solution of the linear 
peptide 46h (60 mg, 0.06 mmol) in CH2Cl2 (120 mL) at room temperature. The 
reaction mixture was stirred for 3 days, concentrated and purified by preparative 
RP-HPLC (Onyx Monolithic C18, 100 x 10 mm) to afford argyrin 48h as a sticky 
solid (2 mg, 6 % yield). 
RP-HPLC 10-60 % B in 12 min, tR 6.6 min 
1H NMR (400 MHz, DMSO-d6): į = 0.87 (d, J = 7 Hz, 3H, 6-CH3), 1.54 (d, J = 7 
Hz, 3H, 1-CH3), 3.08 (s, 3H, 8-CH3), 3.18 (m, 2H, 4-CH2), 3.22 (m, 1H, 3-CHAHB), 
3.22(m, 1H, 8-CHAHB), 3.39 (m, 1H, 5-CHAHB), 3.44 (m, 1H, 3-CHAHB), 3.77 (s, 
3H, 4-OCH3), 3.80 (d, J = 16 Hz, 1H, 8-CHAHB), 3.88 (dd, J = 16, 8 Hz, 5-CHAHB), 
4.22 (m, 1H, 4-Į-CH), 4.34 (m, 1H, 6-Į-CH), 4.78 (td, J = 12, 4 Hz, 1H, 3-Į-CH), 
4.93 (s, 1H, 7-CHAHB), 5.16 (s, 1H, 7-CHAHB), 5.39 (m, 1H, 1-Į-CH), 6.88-7.70 
(m, 9H, arom. H), 8.00 (s, 1H, 2-CH), 8.12 (d, J = 9 Hz, 1H, 6-NH), 8.28 (d, J = 9 
Hz, 1H, 1-NH), 8.42 (s, 1H, 4-NH), 8.56 (d, J = 9 Hz, 1H, 3-NH), 8.70 (t, J = 4 Hz, 
1H, 5-NH), 9.24 (s, 1H, 7-NH), 10.75 (d, J = 2 Hz, indole-NH), 10.78 (d, J = 2 Hz, 
indole-NH) ppm. 
ES-MS m/z calcd for C40H45N10O8S 825.3143, found 825.3092 [MH+]. 
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Cyclo[(R)-Ala-Thz-Trp-(R)-Trp-Gly-(R)-Ala-Dha-Sar], (48k)  
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DiisopropyleWK\ODPLQHȝ/PPRO PyBOP (49 mg, 0.09 mmol) and HOBt 
(12 mg, 0.09 mmol) were added successively to a solution of the linear peptide 46k 
(39 mg, 0.05 mmol) in CH2Cl2 (80 mL) at room temperature. The reaction mixture 
was stirred for 3 days, concentrated and purified by preparative RP-HPLC (Onyx 
Monolithic C18, 100 x 10 mm) to afford argyrin 48k as a sticky solid (5 mg, 14 % 
yield). 
RP-HPLC 10-60 % B in 12 min, tR 5.9 min. 
1H NMR (400 MHz, DMSO-d6): į = 0.73 (d, J = 7 Hz, 3H, 6-CH3), 1.48 (d, J = 7 
Hz, 3H, 1-CH3), 3.08 (s, 3H, 8-CH3), 3.10 (m, 4H, 2-CH2, 4-CH2), 3.19 (m, 1H, 8-
CHAHB), 3.40 (m, 1H, 5-CHAHB), 3.95 (dd, J = 16, 8 Hz, 5-CHAHB), 4.06 (m, 1H, 
4-Į-CH), 4.49 (m, 1H, 8-CHAHB), 4.61 (s, 1H, 7-CHAHB), 5.00 (s, 1H, 7-CHAHB), 
5.11 (m, 1H, 3-Į-CH), 5.43 (m, 1H, 1-Į-CH), 6.13-7.46 (m, 8H, arom. H), 7.48 (m, 
1H, 6-NH), 7.71 (d, J = 9 Hz, 1H, 3-NH), 7.77 (d, J = 8 Hz, arom. H), 8.27 (s, 1H, 
2-CH), 8.32 (d, J = 9 Hz, 1H, 1-NH), 8.85 (m, 2H, 4-NH, 5-NH), 9.75 (s, 1H, 7-
NH), 10.67 (d, J = 2 Hz, indole-NH), 11.00 (d, J = 2 Hz, indole-NH) ppm. 
ES-MS m/z calcd for C39H43N10O7S 795.3037, found 795.3020 [MH+]. 
HCT-116 human colon carcinoma cells were grown in RPMI 1640 medium 
containing 10% fetal bovine serum and 2 mM glutamine. For the cytotoxicity 
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screening experiment, cells were inoculated into 96 well microtiter plates in 180 µL 
at plating densities at 2500 cells per well. Additionally two rows of wells on a 
separate microtiter plate (‘Time 0’ plate) received cells as above. After inoculation, 
both plates were incubated at 37° C, 5 % CO2, 95 % air and 100 % relative 
humidity for 24 h prior to T-zero determination and addition of experimental 
compounds.  
At 24 h, MTT assay was performed on the ‘Time 0’ plate to represent a 
measurement of the cell population for the cell line at the time of compound 
addition (Tz). This was done by DGGLWLRQRIȝ/RI 077VROXWLRQ PJP/LQ
PBS). After incubation for 2 h the supernatant was aspired from each well and the 
resultant formazan crystals were dissolved in '062  ȝ/ 7KH DEVRUEDQFH
intensity was measured by a micro-plate reader at 550 nm. 
Experimental compounds were solubilised in DMSO to achieve a stock 
concentration of 10 mM and stored frozen prior to use. At the time of compound 
DGGLWLRQ  ȝ/ DOLTXRW RI IUR ]HQ VR OXWLRQ ZDV WKDZHG DQG G LOXWHG ZLWK    ȝ/
media to achieve a 10 fold the desired final maximum test concentration. 
Additional five, 10-fold serial dilutions were made to provide a total of six drug 
concentrations plus control. Aliquots of 20 µl of these different compound dilutions 
were added to the appropriate microtiter wells already containing 180 µl of 
medium in quadruplicate, resulting in the required final drug concentrations 
ranging from 0.1 nM – ȝ0The final concentration of DMSO in each well is 
not more than 1%.  
Following compound addition, the plates were incubated for an additional 72 h at 
37 °C, 5 % CO2, 95 % air, and 100 % relative humidity. The assay was terminated 
by the addition of ȝ/RI077VROXWLRQPJP/LQ3%6$fter incubation for  
2 h the supernatant was aspired from each well and the resultant formazan crystals 
ZHUHGLVVROYHG LQ'062ȝ/7KHDEVRUEDQFH LQWHQVLW\ZDVPHDsured by a 
micro-plate reader at 550 nm. 
Using the eight absorbance measurements [time zero, (Tz), control growth, (C), 
and test growth in the presence of compounds at the six concentration levels (Ti)], 
Determination of GI50  
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the percentage growth was calculated at each of the drug concentration levels. 
Percentage growth inhibition was calculated as: 
[(Ti-Tz)/(C-Tz)] x 100 for concentrations for which Ti  >/= Tz 
[(Ti-Tz)/Tz] x 100 for concentrations for which Ti < Tz. 
50 % Growth inhibition (GI50) was calculated from [(Ti-Tz)/(C-Tz)] x 100 = 50.  
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